KR100720766B1 - Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation - Google Patents

Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation Download PDF

Info

Publication number
KR100720766B1
KR100720766B1 KR1020027000678A KR20027000678A KR100720766B1 KR 100720766 B1 KR100720766 B1 KR 100720766B1 KR 1020027000678 A KR1020027000678 A KR 1020027000678A KR 20027000678 A KR20027000678 A KR 20027000678A KR 100720766 B1 KR100720766 B1 KR 100720766B1
Authority
KR
South Korea
Prior art keywords
mmol
mixture
delete delete
compound
alkyl
Prior art date
Application number
KR1020027000678A
Other languages
Korean (ko)
Other versions
KR20020040754A (en
Inventor
릭스마이클죤
덴트윌리암헌터3세
로져스리챠드브루워
야오쳉글린
나더바삼사림
미젤죤루이스
피쯔패트릭지나마리
메이어케빈제럴드
니야즈누르모하메드모하메드
모리슨이렌마에
헨리매튜제임스
아담스키부쯔제니퍼린
가져스키로버트피터
Original Assignee
다우 아그로사이언시즈 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/620,662 external-priority patent/US6521622B1/en
Application filed by 다우 아그로사이언시즈 엘엘씨 filed Critical 다우 아그로사이언시즈 엘엘씨
Publication of KR20020040754A publication Critical patent/KR20020040754A/en
Application granted granted Critical
Publication of KR100720766B1 publication Critical patent/KR100720766B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

하기식 (Ⅰ)에 의한 헤테로 사이클릭 방향족 아미드(HAA)가 제공된다. 이 발명은 그 수화물, 염 및 복합체를 포함한다. Heterocyclic aromatic amides (HAA) are provided by the following formula (I). This invention includes its hydrates, salts and complexes.

이들 화합물은 살균제로서 유용하다.These compounds are useful as fungicides.

[식1][Equation 1]

Figure 112006089133699-pct00202
Figure 112006089133699-pct00202

단, X1-X4,M,Z 및 A는 정의되어 있다.Provided that X 1 -X 4 , M, Z and A are defined.

살균제, 헤테로 고리 방향족 아미드Fungicides, Heterocyclic Aromatic Amides

Description

살균성 헤테로사이클릭 방향족 아미드 및 그 조성물, 이용 및 제조방법{FUNGICIDAL HETEROCYCLIC AROMATIC AMIDES AND THEIR COMPOSITIONS, METHODS OF USE AND PREPARATION}Fungicidal Heterocyclic Aromatic Amides and Compositions, Uses and Preparations of the Invention {FUNGICIDAL HETEROCYCLIC AROMATIC AMIDES AND THEIR COMPOSITIONS, METHODS OF USE AND PREPARATION}

본 발명은 살균조성물 및 살균방법에 관한 것이며, 보다 상세히는 새로운 살균성 헤테로사이클릭 방향족 아미드 화합물 및 이같은 화합물을 살균적으로 효과적인 량으로 식물 병원체의 서식지에 적용함을 포함하는 살균방법에 관한 것이다.FIELD OF THE INVENTION The present invention relates to sterilization compositions and methods of sterilization, and more particularly to sterilization methods comprising the application of new bactericidal heterocyclic aromatic amide compounds and such compounds to the habitat of plant pathogens in bactericidal effective amounts.

본 발명은 또한 헤테로사이클릭 방향족 아미드 제조방법 및 그 살균 조성물에 관한 것이다.The present invention also relates to a process for preparing heterocyclic aromatic amides and their sterilizing compositions.

다양한 항균조성물 및 항균방법이 이 기술분야에 알려져 있다. 예를들어 안티마이신은 스트렙토마이세스종(streptomyces ssp)에 의해 생성되고 항생효능을 갖는 자연발생 물질인 것으로 인식되고 있다(Barrow, C. J; et al., Journal of Antibiotics, 1997, 50(9), 729). 이들 물질들은 또한 효과적인 살균제(fungicides)인 것으로 밝혀졌다(The Merck Index, Twelfth Edition, S. Budavari, Ed., Merck and Co., Whitehouse Station, N.J., 1996, p.120).Various antimicrobial compositions and antimicrobial methods are known in the art. For example, antimycin is recognized as a naturally occurring substance produced by Streptomyces ssp and has antimicrobial activity (Barrow, C. J; et al., Journal of Antibiotics, 1997, 50 (9). , 729). These substances have also been found to be effective fungicides (The Merck Index, Twelfth Edition, S. Budavari, Ed., Merck and Co., Whitehouse Station, N.J., 1996, p.120).

WO97/08135는 살충제(농약)으로서 유용한 아실아미노 살리실산 아미드에 대하여 기술하고 있다. WO97 / 08135 describes acylamino salicylic acid amides useful as insecticides (pesticides).                 

EP-A-O-661269는 의약품으로 유용한 치환된 헤테로사이클릭 카복실산 아미드에 대하여 개시하고 있다.EP-A-O-661269 discloses substituted heterocyclic carboxylic acid amides useful as pharmaceuticals.

JP-A-7-233165는 항진균성 활성을 갖는 3-하이드록시피리딘카복실기를 갖는 항균성 디락톤에 대하여 개시하고 있다.JP-A-7-233165 discloses an antimicrobial dilactone having a 3-hydroxypyridinecarboxyl group with antifungal activity.

다음 자료들에는 상기 화합물의 이소-부티릴, 티크로일, 이소-발레릴 및 2-메틸부티릴 유도체에 대하여 기술하고 있다;The following data describe iso-butyryl, ticroyl, iso-valeryl and 2-methylbutyryl derivatives of the compounds;

Tetrahedron 1998, 54, 12745-12774; J. Antibiot. 1997, 50(7), 551; J. Antibiot. 1996, 49(7), 639; J.Antibiot. 1996, 49(12), 1226; 및 Tetrahedron Lett. 1998, 39, 4363-4366.
Tetrahedron 1998, 54, 12745-12774; J. Antibiot. 1997, 50 (7), 551; J. Antibiot. 1996, 49 (7), 639; J.Antibiot. 1996, 49 (12), 1226; And Tetrahedron Lett. 1998, 39, 4363-4366.

그러나 여전히 새로운 살균제가 필요한 것이다. 본 발명은 높은 잔류활성, 낮은 적용율에서의 높은 활성, 치료 활성 및 보다 광범위한 효능을 갖는 살균제를 제공한다.But new fungicides are still needed. The present invention provides fungicides having high residual activity, high activity at low application rates, therapeutic activity and broader efficacy.

본 발명의 일견지에 의하면 하기 식Ⅰ의 헤테로사이클릭 방향족 아미드(hetrocyclic aromatic amides, 이하 "HAA"라고도 한다)를 포함하여 구성되는 화합물이 제공된다.According to one aspect of the invention there is provided a compound comprising a heterocyclic aromatic amides of the formula (I) (hereinafter also referred to as "HAA").

[식 1][Equation 1]

Figure 112002001377712-pct00001
Figure 112002001377712-pct00001

단, 상기 식에서 X1-X4, M, Z 및 A는 후술되는 바와같다.In the above formula, X 1 -X 4 , M, Z and A are as described later.

본 발명은 또한 상기 화합물의 수화물, 염 및 복합체를 포함한다.The invention also includes hydrates, salts and complexes of the compounds.

본 발명은 또한 식물론적으로 수용가능한 운반체 및/또한 희석제와 함께 HAA를 포함하는 살균조성물을 제공한다. The present invention also provides a sterile composition comprising HAA with a botanically acceptable carrier and / or diluent.

헤테로 사이클릭 방향족 아미드 화합물과 그 조성물의 이용방법 또한 개시된다.
Also disclosed are heterocyclic aromatic amide compounds and methods of using the compositions.

본 발명의 목적은 살균제로서 유용한 HAA 및 그 조성물을 제공하는데 있다.
It is an object of the present invention to provide HAA and compositions thereof useful as fungicides.

본 발명의 다른 목적은 HAA와 이를 함유한 조성물을 적용함을 포함하는, 진균 감염을 제어 및/또는 예방하는 방법을 제공하는데 있다.Another object of the present invention is to provide a method for controlling and / or preventing fungal infection, comprising applying HAA and a composition containing the same.

본 발명의 다른 목적 및 잇점등은 후술되는 바에 따라 명확할 것이다.
Other objects and advantages of the present invention will be apparent from the following description.

이하 본 발명에 대하여 상세히 설명한다.
Hereinafter, the present invention will be described in detail.

본 발명은 항균제로서 활성적인 여러가지 HAA 화합물에 관한 것이다. 또한 포함되는 것은 HAA 화합물을 포함한 제제형(製劑刑) 및 이들의 사용방법이다.The present invention relates to various HAA compounds active as antibacterial agents. Also included are formulations containing HAA compounds and methods of use thereof.

HAA 화합물의 제조방법이 또한 개시되며, 살균제로서의 이용이 또한 개시된다. Also disclosed are methods of making HAA compounds, and also use as bactericides.                 

HAA 화합물HAA Compound

본 발명의 새로운 살균성 HAA 화합물은 다음식 Ⅰ에 의해 기술된다.The novel bactericidal HAA compounds of the present invention are described by the following formula (I).

[식 1][Equation 1]

Figure 112002001377712-pct00002
Figure 112002001377712-pct00002

단, 상기 식에서In the above formula

a)

Figure 112002001377712-pct00003
은 5-혹은 6-멤버 헤테로사이클릭 방향족링을 나타내는 것으로서,a)
Figure 112002001377712-pct00003
Is a 5- or 6-membered heterocyclic aromatic ring,

(ⅰ) X1∼X4 각각은 독립적으로 O, S, NR′, N, CR″ 혹은 본드(bond)이 (Iii) each of X 1 to X 4 independently represents O, S, NR ′, N, CR ″ or bond;

며;       ;

(ⅱ) X1∼X4 의 하나이하는 O, S 또는 NR′이며;(Ii) at least one of X 1 to X 4 is O, S or NR ′;

(ⅲ) X1∼X4의 하나이하는 본드이며;(Iii) at least one of X 1 to X 4 is a bond;

(ⅳ) X1∼X4 중 어느 하나가 S, O, NR′인 경우, 인접한 X1∼X4 중 하나는 (Iii) when any one of X 1 to X 4 is S, O, or NR ′, one of adjacent X 1 to X 4 is

본드를 나타내어야 하며;       Must represent a bond;

(ⅴ) X1∼X4중 최소 하나는 O, S, NR′ 또는 N이며;
(Iii) at least one of X 1 to X 4 is O, S, NR ′ or N;

여기서, R′는 H, C1-C3알킬, C2-C3알케닐, C2-C3알키닐, 히드록시, 아실옥시,Wherein R ′ is H, C 1 -C 3 alkyl, C 2 -C 3 alkenyl, C 2 -C 3 alkynyl, hydroxy, acyloxy,

C1-C6알콕시메틸, CHF2, 시클로프로필 또는 C1-C4알콕시이며; C 1 -C 6 alkoxymethyl, CHF 2 , cyclopropyl or C 1 -C 4 alkoxy;

R″는 독립적으로 H, 할로겐, 시아노, 히드록시, C1-C3알킬, C1-C3 할로알킬,R ″ is independently H, halogen, cyano, hydroxy, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl,

시클로프로필, C1-C3알콕시, C1-C3할로알콕시, C1-C 3알킬티오, 아릴, Cyclopropyl, C 1 -C 3 alkoxy, C 1 -C 3 haloalkoxy, C 1 -C 3 alkylthio, aryl,

C1-C3 NHC(O)알킬, NHC(O)H, C1-C3할로알킬티오, C2-C 4알케닐,C 1 -C 3 NHC (O) alkyl, NHC (O) H, C 1 -C 3 haloalkylthio, C 2 -C 4 alkenyl,

C2-C4할로알케닐, C2-C4알키닐,C 2 -C 4 haloalkenyl, C 2 -C 4 alkynyl,

C2-C4할로알키닐, 또는 니트로이며, 인접한 R″치환체는 링(ring)을 이루거나 C 2 -C 4 haloalkynyl, or nitro, adjacent R ″ substituents form a ring or

혹은 인접한 R′및 R″치환체가 링을 이룰수 있다.Or adjacent R ′ and R ″ substituents may form a ring.

b) Z는 O, S 또는 NOR2 이며, Rz는 H 또는 C1-C3알킬이며; b) Z is O, S or NOR 2 and R z is H or C 1 -C 3 alkyl;

c) A는 다음을 나타내며,c) A represents

(ⅰ) 모두가 분지되었거나 분지되지 않았으며, 치환되지 않았거나,   (Iii) all are branched or unbranched, unsubstituted,

알로겐, 히드록시, 니트로, 아로일, 아릴옥시, C1-C8아실옥시, Allogenes, hydroxy, nitro, aroyl, aryloxy, C 1 -C 8 acyloxy,

C1-C6알킬티오, 아릴티오, 아릴, 헤테로아릴, 헤테로 아릴티오,C 1 -C 6 alkylthio, arylthio, aryl, heteroaryl, hetero arylthio,

헤테로아릴옥시, C1-C6아실, C1-C6할로알킬, C1 -C6알콕시 혹은 Heteroaryloxy, C 1 -C 6 acyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or

C1-C6할로알콕시 치환될수있는, C1-C14알킬, C2 -C14알케닐 혹은 C 1 -C 6 haloalkoxy group which can be substituted, C 1 -C 14 alkyl, C 2 -C 14 alkenyl or

C2-C14알키닐C 2 -C 14 alkynyl

(ⅱ) 치환되지 않았거나, 할로겐, 히드록시, C1-C6알킬, C1-C6할로알킬, (Ii) unsubstituted, halogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl,

시아노, 니트로, 아로일, 아릴옥시, 헤테로아릴옥시, C1-C6알킬티오, Cyano, nitro, aroyl, aryloxy, heteroaryloxy, C 1 -C 6 alkylthio,

아릴티오, 헤테로아릴티오, C1-C6알콕시, C1-C6할로알콕시, Arylthio, heteroarylthio, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy,

C1-C8아실옥시, 아릴, 헤테로아릴, C1-C6아실, 카보아릴옥시, C 1 -C 8 acyloxy, aryl, heteroaryl, C 1 -C 6 acyl, carboaryloxy,

카보헤테로아릴옥시, C1-C6카보알콕시 또한 치환되지 않았거나 1또는Carboheteroaryloxy, C 1 -C 6 carboalkoxy also is unsubstituted or 1 or

2의 C1-C6알킬기로 치환된 아미도로 치환될수 있으며, 0∼3 헤테로원자It may be substituted with an amido substituted with a C 1 -C 6 alkyl group of 2, 0 to 3 heteroatoms

와 0∼2 불포화기를 함유한 C3-C14시클로알킬And C 3 -C 14 cycloalkyl containing 0 to 2 unsaturated groups

(ⅲ) 치환되지 않았거나, 할로겐, 히드록시, C1-C6알킬, C1-C6할로알킬, (Iii) unsubstituted, halogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl,

시아노, 니트로, 아로일, 아릴옥시, 헤테로아릴옥시, C1-C6알킬티오,Cyano, nitro, aroyl, aryloxy, heteroaryloxy, C 1 -C 6 alkylthio,

아릴티오, 헤테로아릴티오, C1-C6알콕시, C1-C6할로알콕시, Arylthio, heteroarylthio, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy,

C1-C8아실옥시, 아릴, 헤테로아릴, C1-C6아실, 카보아릴옥시, C 1 -C 8 acyloxy, aryl, heteroaryl, C 1 -C 6 acyl, carboaryloxy,

카보헤테로아릴옥시, C1-C6카보알콕시 혹은 치환되지 않았거나 1또는Carboheteroaryloxy, C 1 -C 6 carboalkoxy or unsubstituted or 1 or

2의 C1-C6알킬기로 치환된 아미도로 치환될수 있는, 0∼3 헤테로원자0 to 3 heteroatoms, which may be substituted with an amido substituted with a C 1 -C 6 alkyl group of 2

및 0∼2 불포화기를 함유한, C6-C14 2(bi)또는 3(tri)-사이클릭링시스템,And a C 6 -C 14 2 (bi) or 3 (tri) -cycling system, containing 0-2 unsaturated groups,

(ⅳ) 치환되지 않았거나 혹은 니트로, C1-C6알킬, C1-C6할로알킬, (Iii) unsubstituted or nitro, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl,

C3-C6시클로알킬, C2-C6알케닐, C2-C6 알키닐, 아릴, 헤테로 아릴, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, hetero aryl,

할로겐, 히드록시, C1-C6알콕시, C1-C6할로알콕시, 카보아릴옥시, Halogen, hydroxy, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, carboaryloxy,

카보헤테로아릴옥시, C1-C6카보알콕시 혹은 치환되지 않았거나 1 또는 Carboheteroaryloxy, C 1 -C 6 carboalkoxy or unsubstituted or 1 or

2의 C1-C6알킬기, C1-C6알킬티오, C1 -C6알킬술포닐, C1-C6알킬술피닐, C 1 -C 6 alkyl group of 2, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylsulfinyl,

C1-C6 OC(O)알킬, OC(O)아릴, C3-C6NHC(O) 시클로알킬, C1-C6 NHC(O)알킬, C 1 -C 6 OC (O) alkyl, OC (O) aryl, C 3 -C 6 NHC (O) cycloalkyl, C 1 -C 6 NHC (O) alkyl,

C3-C6 NHC(O)시클로알킬, NHC(O)아릴, NHC(O) 헤테로아릴, C 3 -C 6 NHC (O) cycloalkyl, NHC (O) aryl, NHC (O) heteroaryl,

C3-C6시클로알킬티오, C3-C6시클로알킬술포닐, C 3 -C 6 cycloalkylthio, C 3 -C 6 cycloalkylsulfonyl,

C3-C6시클로알킬술피닐, 아릴옥시, 헤테로아릴옥시, 헤테로아릴티오, C 3 -C 6 cycloalkylsulfinyl, aryloxy, heteroaryloxy, heteroarylthio,

헤테로아릴술피닐, 헤테로아릴술포닐, 아릴티오, 아릴술피닐,    Heteroarylsulfinyl, heteroarylsulfonyl, arylthio, arylsulfinyl,

아릴술포닐, C(O)RY, C(NORX)RY로 치환된 아미도로 치환될 수 있으며,
Arylsulfonyl, C (O) R Y , Amido substituted with C (NOR X ) R Y , and

상기 알킬 또는 시클로 알킬 함유 치환체는 1이상의 할로겐으로 치환    The alkyl or cycloalkyl-containing substituent is substituted with one or more halogens

될수 있으며,    Can be,

상기 아릴 또는 헤테로아릴 함유 치환체 역시 치환되지 않았거나,     The aryl or heteroaryl containing substituents are also unsubstituted,

할로겐, 시아노, 니트로, 아로일, 아릴옥시, 아릴, 헤테로아릴,    Halogen, cyano, nitro, aroyl, aryloxy, aryl, heteroaryl,

C1-C6아실, C1-C6할로알킬, C1-C6알콕시, C1-C6할로알콕시, C1-C6카보알콕시C 1 -C 6 acyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 carboalkoxy

또는 치환되지 않았거나 1 또는 2 C1-C6알킬기로 치환된 아미도로 치환될Or unsubstituted or substituted with amido substituted with 1 or 2 C 1 -C 6 alkyl groups

수 있으며,
Can and

상기 RY 및 RX는 독립적으로 H, C1-C6알킬, C3-C6알케닐, C3-C6시클로알킬, R Y and R X are independently H, C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 6 cycloalkyl,

아릴 또는 헤테로아릴인,
Aryl or heteroaryl,

아릴 또는 헤테로아릴
Aryl or heteroaryl

(Ⅴ)

Figure 112002001377712-pct00004
단, 상기 식에서 *는 부착점이며,(Ⅴ)
Figure 112002001377712-pct00004
Where * is the attachment point,

Q1, Q2는 O 또는 S 이며;Q 1 , Q 2 is O or S;

W는 O, CH2, CHR6, 또는 본드이며;W is O, CH 2 , CHR 6 , or a bond;

R1은 C1-C8알킬, C2-C8알케닐, C2-C 8알키닐, C3-C8시클로알킬, 아릴 또는 R 1 is C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, aryl or

헤테로아릴이며;Heteroaryl;

R2는 H, C1-C3알킬, C2-C5알케닐 또는 C2-C 5알키닐이며;R 2 is H, C 1 -C 3 alkyl, C 2 -C 5 alkenyl or C 2 -C 5 alkynyl;

R3는 H, R1, OR1, OC(O)R2, OC(O)OR1 또는 CO(O)NR 1R6 이며;R 3 is H, R 1 , OR 1 , OC (O) R 2 , OC (O) OR 1 or CO (O) NR 1 R 6 ;

R4와 R5는 독립적으로 H, C1-C6알킬, 또는 C2-C 6알케닐이나, R4와 R5의 전체 R 4 and R 5 are independently H, C 1 -C 6 alkyl, or C 2 -C 6 alkenyl, but the total of R 4 and R 5

탄소수는 6이하이며, R4와 R5는 합하여 C3-C6링을 형성할 수 있다.The number of carbon atoms is 6 or less, and R 4 and R 5 may be combined to form a C 3 -C 6 ring.

R6와 R7은 독립적으로 H, C1-C6알킬, C3-C5 시클로알킬, C2-C5알케닐 혹은 R 6 and R 7 are independently H, C 1 -C 6 alkyl, C 3 -C 5 cycloalkyl, C 2 -C 5 alkenyl or

C2-C5알키닐이나 R6와 R7중 최소하나는 H 이다. C 2 -C 5 alkynyl or at least one of R 6 and R 7 is H.

그리고

Figure 112002001377712-pct00005
Figure 112002001377712-pct00006
일때, And
Figure 112002001377712-pct00005
end
Figure 112002001377712-pct00006
when,

(단, R″는 H 또는 OCH3이다)(Where R ″ is H or OCH 3 )

R1은 아소부티릴, 티그로일, 이소발레릴 또는 2-메틸부타노일이 아니다.R 1 is not asobutyryl, tigroyl, isovaleryl or 2-methylbutanoyl.

(d) M은 H, Si(t-Bn)Me2, Si(Ph)Me2, SiEt3, SiMe3, C(Z)R8 , SO2R9을 나타내며,(d) M represents H, Si (t-Bn) Me 2 , Si (Ph) Me 2 , SiEt 3 , SiMe 3 , C (Z) R 8 , SO 2 R 9 ,

여기서 R8은 H, C1-C6알킬, C2-C6알케닐, C2 -C6알키닐, C3-C6시클로알킬, 알콕시알킬, 할로알킬, 알콕시알케닐, 할로알케닐, 알콕시알키닐, 할로알키닐, 치환된 그리고 치환되지 않은 아릴알킬, 치화된 그리고 치환되지 않은 아릴알케닐, 치환된 그리고 치환되지 않은 아릴알키닐, 치화된 그리고 치환되지 않은 아릴, 치환된 그리고 치환되지 않은 헤테로아릴, C1-C6알콕시, C3-C6시클로알콕시, C1-C6할로알콕시, C2-C6알케닐옥시, C2-C6할로알케닐옥시, C2-C6 알키닐옥시, C2-C6할로알키닐옥시, C1-C6티오알콕시, 치환된 그리고 치환되지 않은 아릴알콕시, 치환된 그리고 치환되지 않은 아릴알케닐옥시, 치환된 그리고 치환되지 않은 아릴알키닐옥시, 치환된 그리고 치환되지 않은 아릴옥시, 치환된 그리고 치환되지 않은 헤테로아릴옥시, 치환되지 않았거나 하나이상의 C1-C6알킬기도 치환된 아미노이며,
Wherein R 8 is H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, alkoxyalkyl, haloalkyl, alkoxyalkenyl, haloalkenyl , Alkoxyalkynyl, haloalkynyl, substituted and unsubstituted arylalkyl, substituted and unsubstituted arylalkenyl, substituted and unsubstituted arylalkynyl, substituted and unsubstituted aryl, substituted and substituted Unsubstituted heteroaryl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkoxy, C 1 -C 6 haloalkoxy, C 2 -C 6 alkenyloxy, C 2 -C 6 haloalkenyloxy, C 2- C 6 alkynyloxy, C 2 -C 6 haloalkynyloxy, C 1 -C 6 thioalkoxy, substituted and unsubstituted arylalkoxy, substituted and unsubstituted arylalkenyloxy, substituted and unsubstituted Arylalkynyloxy, substituted and unsubstituted aryloxy, substituted and unsubstituted heteroaryloxy, And also substituted amino not ring, or one or more C 1 -C 6 alkyl group,

R9은 C1-C6알킬, C2-C6알케닐, C3-C 6알키닐, C3-C6시클로알킬, 아릴 또는 헤테로아릴이다.
R 9 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 alkynyl, C 3 -C 6 cycloalkyl, aryl or heteroaryl.

여기서 사용되는 용어 알킬, 알케닐, 알키닐등은 그 범주에 드는 직선형 및 분지형 그룹 모두를 포함하는 것으로 해석되며; 용어 알케닐, 알케닐렌 등은 하나이상의 2중결합을 갖는 그룹을 포함하며; 용어 알키닐, 알키닐렌 등은 하나이상의 3중결합을 갖는 그룹을 포함하는 것으로 해석된다.
As used herein, the terms alkyl, alkenyl, alkynyl and the like are to be interpreted to include both straight and branched groups falling within the scope; The terms alkenyl, alkenylene, and the like include groups having one or more double bonds; The terms alkynyl, alkynylene and the like are to be understood to include groups having one or more triple bonds.

용어 시클로알킬은 0∼3 헤테로원자와 0∼2 불포화기를 갖는 C3-C14시클로알킬기를 의미한다.The term cycloalkyl means a C 3 -C 14 cycloalkyl group having 0-3 heteroatoms and 0-2 unsaturated groups.

2(Bi)-또는 3(tri)-사이클릭 링시스템은 0∼3 헤테로원자와 0∼2 불포화기를 갖는 C6-C14지방족 링시스템을 의미한다.2 (Bi)-or 3 (tri) -cyclic ring system means a C 6 -C 14 aliphatic ring system having 0-3 heteroatoms and 0-2 unsaturated groups.

상기 용어등은 나아가 치환되었거나 치환되지 않은 것들을 모두 가르킨다.The term further refers to both substituted and unsubstituted.

별도로 정의 하지 않는한, 치환된 것이란 할로겐, 하이드록시, 시아노, 니트로, 아로일, 아릴옥시, 아릴, 아릴티오, 헤테로아릴, 헤테로아릴옥시, 헤테로아릴티오, C1-C8아실, C1-C6할로알킬, C1-C6알콕시, C1-C6할로알콕시, C1-C6알킬티오, C1-C6할로알킬티오, 카보아릴옥시, 카보헤테로아릴옥시, C1-C6카보알콕시 또는 치환되지 않았거나 1 또는 2의 C1-C6알킬기로 치환된 아미도로 구성된 그룹에서 선택된 것과 치환된 것을 의미한다.
Unless defined otherwise, substituted are halogen, hydroxy, cyano, nitro, aroyl, aryloxy, aryl, arylthio, heteroaryl, heteroaryloxy, heteroarylthio, C 1 -C 8 acyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 haloalkylthio, carboaryloxy, carboheteroaryloxy, C 1- Substituted with C 6 carboalkoxy or those selected from the group consisting of unsubstituted or amido substituted with 1 or 2 C 1 -C 6 alkyl groups.

여기서 사용된 용어 아릴이란 치환된 페닐 또는 나프틸기를 의미한다.The term aryl, as used herein, means a substituted phenyl or naphthyl group.

용어 헤테로아릴은 하나이상의 헤테로원자를 갖는 5혹은 6멤버 방향족고리를 의미하며, 이들 헤테로 방향족링은 다른 방향족 시스템에 접합될 수도 있다.
The term heteroaryl means a 5 or 6 membered aromatic ring having one or more heteroatoms, which heteroaromatic rings may be conjugated to other aromatic systems.

상기 용어들은 나아가 치환되었거나 치환되지 않은 형태를 포함한다. 치환된 형태는 니트로, C1-C6알킬, C1-C6할로알킬, C3-C 6시클로알킬, C2-C6알케닐, C2-C6알키닐, 아릴, 헤테로아릴, 할로겐, 히드록시, C1-C6알콕시, C1-C6할로알콕시, C1-C6알킬티오, C1-C6알키술포닐, C1-C6알킬술피닐, C1-C 6 OC(O)알킬, OC(O)아릴, C3-C6 OC(O)시클로알킬, C1-C6 NHC(O)알킬, C3-C6 NHC(O)시클로알킬, NHC(O)아릴, NHC(O)헤테로아릴, C3-C6시클로알킬티오, C3-C6시클로알킬술포닐, C3 -C6시클로알킬술피닐, 아릴옥시, 헤테로아릴옥시, 헤테로아릴티오, 헤테로아릴술피닐, 헤테로아릴술포닐, 아릴티오, 아릴술피닐, 아릴술포닐, C(O)RY, C(NORX)RY로 부터 선택된 1이상의 기와의 치환을 의미하며, The terms further include substituted or unsubstituted forms. Substituted forms include nitro, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, Halogen, hydroxy, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkoxysulfonyl, C 1 -C 6 alkylsulfinyl, C 1 -C 6 OC (O) alkyl, OC (O) aryl, C 3 -C 6 OC (O) cycloalkyl, C 1 -C 6 NHC (O) alkyl, C 3 -C 6 NHC (O) cycloalkyl, NHC ( O) aryl, NHC (O) heteroaryl, C 3 -C 6 cycloalkylthio, C 3 -C 6 cycloalkylsulfonyl, C 3 -C 6 cycloalkylsulfinyl, aryloxy, heteroaryloxy, heteroarylthio , Heteroarylsulfinyl, heteroarylsulfonyl, arylthio, arylsulfinyl, arylsulfonyl, C (O) R Y , C (NOR X ) R Y It is substituted with at least one group selected from,

상기에서 RY와 RX는 독립적으로 H, C1-C6알킬, C2-C 6알케닐, C3-C6시클로알킬, 아릴 혹은 헤테로아릴이며, 상기 알킬 또는 시클로알킬 함유 치환체는 하나이상의 할로겐으로 치환될 수 있으며, 화학결합 및 변형에너지 법칙은 만족된다. Wherein R Y and R X are independently H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 6 cycloalkyl, aryl or heteroaryl, wherein the alkyl or cycloalkyl containing substituent is one It can be substituted with the above halogen, the chemical bond and strain energy law is satisfied.

여기서 사용되는 용어 할로겐 및 할로는 염소, 브롬, 불소 및 요오드를 포함한다. 용어 할로알킬 등은 하나이상의 할로겐 원자로 치환된 기를 의미한다.
As used herein, the terms halogen and halo include chlorine, bromine, fluorine and iodine. The term haloalkyl and the like means a group substituted with one or more halogen atoms.

용어 Me는 메틸기를 가르키며, Et는 에틸기를 가르킨다. Pr은 프로필기를 의미하며, Bu는 부틸기를 의미한다. Ph는 페닐기를 가르키며 EtOAc는 에틸아세테이트를 의미한다.
The term Me refers to a methyl group and Et refers to an ethyl group. Pr means a propyl group, Bu means a butyl group. Ph refers to a phenyl group and EtOAc refers to ethyl acetate.

용어 알콕시는 직선 또는 분지된 사슬 알콕시기를 의미하며, 할로알콕시는 하나이상의 할로겐 원자를 치환된 알콕시기를 의미한다.
The term alkoxy means a straight or branched chain alkoxy group and haloalkoxy means an alkoxy group substituted with one or more halogen atoms.

용어 헤테로원자는 O, S 및 N을 의미한다.
The term heteroatom means O, S and N.

Figure 112002001377712-pct00007
을 갖는 바람직한 5- 또는 6-멤버 헤테로사이클릭 방향족링은 피리딘, 피리다진, 피리미딘, 피라진, 피롤, 피라졸, 이미다졸, 퓨란, 티오펜, 옥사졸, 이소옥사졸, 티아졸, 이소티아졸 및 티아디아졸의 적절한 이성체를 포함한다. 가장 바람직한 헤테로사이클릭 방향족링은 피리딘, 피리미딘, 피라진, 피리다진, 티아졸, 이소티아졸, 티아디아롤 및 옥사졸이다.
Figure 112002001377712-pct00007
Preferred 5- or 6-membered heterocyclic aromatic rings having pyridine, pyridazine, pyrimidine, pyrazine, pyrrole, pyrazole, imidazole, furan, thiophene, oxazole, isoxazole, thiazole, isothia Suitable isomers of sol and thiadiazole. Most preferred heterocyclic aromatic rings are pyridine, pyrimidine, pyrazine, pyridazine, thiazole, isothiazole, thiadirol and oxazole.

식Ⅰ의 특히 바람직한 화합물은 2-아미도-3-히드록시피리딘, 2-아미도-3-히드록시-4-메톡시피리딘, 2-아미도-3-히드록시피라진 및 4-아미도-5-히드록시피리미 딘에 근거한 것이다.
Particularly preferred compounds of formula I are 2-amido-3-hydroxypyridine, 2-amido-3-hydroxy-4-methoxypyridine, 2-amido-3-hydroxypyrazine and 4-amido- Based on 5-hydroxypyrimidine.

여기에 정의한 범주에 드는 화합물에 대한 치환기의 특정 조합은 입체 및/또는 화학적 이유로 제조하는 것이 불가능하며, 이같은 화합물은 본 발명의 범주에 들지 않는 것으로 이해된다.
It is understood that certain combinations of substituents for compounds falling within the scope defined herein cannot be prepared for steric and / or chemical reasons, and such compounds are not within the scope of the present invention.

식Ⅰ의 화합물의 여러가지 수화물, 염 및 복합물은 통상의 방법에 따라 제조될 수 있다.Various hydrates, salts and complexes of the compounds of formula I can be prepared according to conventional methods.

예를들어, 염은 히드록실 수소원자(M=H)를 NH4 +, +N(Bi)4,

Figure 112002001377712-pct00008
,등과 같은 양이온과 교체 시킴으로써 형성될 수 있다. 이들 유도체 역시 본 발명에 따라 유용하다.
For example, salts may represent hydroxyl hydrogen atoms (M = H) with NH 4 + , + N (Bi) 4 ,
Figure 112002001377712-pct00008
It can be formed by replacing with a cation such as. These derivatives are also useful according to the invention.

본 명세서를 통하여, 별도로 언급하지 않은 한 모든 온도는 ℃(섭씨)를 가르키며, 모든 퍼어센트는 중량기준이다.Throughout this specification, unless stated otherwise, all temperatures refer to degrees Celsius (Celsius) and all percentages are by weight.

용어 ppm은 부/백만(parts per million)을 의미하며, psi는 파운드/인치2(pounds per square inch)를 의미하며, m.p는 융점 그리고 b.p는 비등점을 각각 의미한다.
The term ppm refers to parts / million (parts per million), and, psi; means pounds / inch 2 (pounds per square inch), mp is melting point, and bp means boiling point, respectively.

화합물의 제조Preparation of the compound

본 발명의 화합물은 공지의 화학 공정을 이용하여 제조된다. 요구되는 출발물질은 상업적으로 구입 가능한 것이거나 표준절차를 이용하여 쉽게 형성될 수 있다.
Compounds of the present invention are prepared using known chemical processes. The required starting materials are either commercially available or can be readily formed using standard procedures.

(피리딘-2-카보옥사이드(pyridine-2-carboxamides)의 일반제법)(General method of pyridine-2-carboxamides)

요구되는 HAA들(2)은 적절한 오르소-히드록시헤테르 방향족 카복실산(1)을 커플링제(포스겐 혹은 1-[3-디메틸아미노프로필]-3-에틸카보디이미드 하이드로클로라이드(EDCI)) + 1-히드록시벤조트리아졸(HOBt) 혹은 1-히드록시-7-아자벤조트리아졸(HOAt)와 산 스캐빈저, 예를들어 N-메틸모포린(NMM), 트리에틸아민, 4-(디메틸아미노)피리딘(DMAP) 혹은 디이소프로필에틸아민의 존재하에 아민과 반응시켜 제조된다(방법 1).The required HAAs (2) are selected from a suitable ortho-hydroxyheteroaromatic carboxylic acid (1) as coupling agent (phosgene or 1- [3-dimethylaminopropyl] -3-ethylcarbodiimide hydrochloride (EDCI)) + 1-hydroxybenzotriazole (HOBt) or 1-hydroxy-7-azabenzotriazole (HOAt) and acid scavengers such as N-methylmorpholine (NMM), triethylamine, 4- ( Prepared by reaction with an amine in the presence of dimethylamino) pyridine (DMAP) or diisopropylethylamine (method 1).

몇몇 경우에는 (3)과 같이 보호된 히드록시기를 갖는 산염화물을 적절한 아민과 반응시켜 중간체 아미드(4)를 제조할 수 있다. 파라듐(Pd) 촉매의 존재하에 수소화를 통해 그 보호기를 제거하면 필요한 산물(2×)을 얻을 수 있다.In some cases, the intermediate amide (4) can be prepared by reacting an acid chloride having a protected hydroxy group as in (3) with a suitable amine. Removal of the protecting group through hydrogenation in the presence of a palladium (Pd) catalyst yields the required product (2x).

화합물 2내의 헤테로사이클의 히드록실기를 아실, 술포닐, 혹은 실린기(M)으로 캐핑(capping)하는 것은 적절한(2)를, DMAP같은 아실화촉매를 사용하여, 피리딘 같은 적절한 용매 내에서 카복실산 클로라이드, 술포닐클로라이드 또는 실릴클로라이드(MCl)와 반응시켜 상응하는 0-아실, 0-술포닐, 혹은 0-실릴 유도체(2Y)를 제공 함으로서 쉽게 이루어질 수 있다.Capping a heterocycle hydroxyl group in compound 2 with an acyl, sulfonyl, or silin group (M) is appropriate for (2) carboxylic acid in a suitable solvent such as pyridine, using an acylation catalyst such as DMAP. It can be readily accomplished by reacting with chloride, sulfonylchloride or silylchloride (MCl) to provide the corresponding 0-acyl, 0-sulfonyl, or 0-silyl derivatives (2Y).

Figure 112002001377712-pct00009
Figure 112002001377712-pct00009

(오르소-히드록시 헤테로 방향족 카복실산 1의 제조)(Preparation of ortho-hydroxy heteroaromatic carboxylic acid 1)

카복실산 1

Figure 112002001377712-pct00010
독립적으로 C-Me, C-SMe, C-Cl)의 제조방법이 방법2에 도시되어 있다.
Carboxylic acid 1
Figure 112002001377712-pct00010
Independently, a process for preparing C-Me, C-SMe, C-Cl) is shown in Method 2.

디메틸포름아미드(DMF)-테트라하이드로퓨란(THF)의 1:1 혼합물내에서 염기로서 포타슘 tert-부톨사이드를 이용하여 3-히드록시-2-브로모피리딘(5)과 2-(트리메틸실릴)에톡시메틸클로라이드(SEM-Cl)을 반응시켜 요구되는 에테르 6을 얻었다.3-hydroxy-2-bromopyridine (5) and 2- (trimethylsilyl) using potassium tert-butoxide as a base in a 1: 1 mixture of dimethylformamide (DMF) -tetrahydrofuran (THF) Ethoxymethylchloride (SEM-Cl) was reacted to give the required ether 6.

리튬 디이소프로필아미드(LDA)로 6을 탈양자화한후 적절한 친전자체(요오드메탄, 디미틸디술파이드, 혹은 헥사클로로에탄)와 축합시켜 4-치환 피리딘 7을 얻 었다.Deprotonated 6 with lithium diisopropylamide (LDA) and then condensed with an appropriate electrophile (iodinemethane, dimityldisulfide, or hexachloroethane) to give 4-substituted pyridine 7.

4-치환 피리딘 7과 n-부틸리튬(n-BuLi)사이의 브롬/리튬 교환후 이산화탄소(CO2)로 카복실화하고 산가수분해하여 필요한 4-치환-3-히드록시피콜린산 1×를 얻었다.After bromine / lithium exchange between 4-substituted pyridine 7 and n-butyllithium (n-BuLi), carboxylation with carbon dioxide (CO 2 ) and acid hydrolysis to remove 1 × of the required 4-substituted-3-hydroxypicolinic acid. Got it.

Figure 112002001377712-pct00011
Figure 112002001377712-pct00011

선택적으로, 3-히드록시피리딘(8)을 SEM-Cl와 축합하여 9를 얻을수 있다(방법3).Optionally, 9 can be obtained by condensation of 3-hydroxypyridine (8) with SEM-Cl (method 3).

3차(tert)-부틸리튬(t-BuLi)으로 9를 탈양자한 후 N-플루오로벤젠술폰이미드와 축합하여 4-플루오로 유도체 10을 얻었다.Dequantization of 9 with tert-butyllithium (t-BuLi) followed by condensation with N-fluorobenzenesulfonimide gave 4-fluoro derivative 10.

10을 소디움 에톡사이드로 축합하여 디에테르 11을 얻었다.10 was condensed with sodium ethoxide to give dieter 11.

디에테르 11을 t-BuLi로 탈양자화한후 카복실화 및 산가수분해하여 필요한 4-에톡시피리딘 1×를 얻었다(X-OEt).Deether 11 was deprotonated with t-BuLi, followed by carboxylation and acid hydrolysis to afford the required 4-ethoxypyridine 1 × (X-OEt).

Figure 112002001377712-pct00012
Figure 112002001377712-pct00012

산클로라이드 3의 제조를 방법4에 간략하게 나타내었다. The preparation of acid chloride 3 is briefly shown in process 4.

이와같이, 3-히드록시 피콜린산(12)를 촉매로서 3불화붕소를 사용하여 환류 메탄올내에서 메틸 에스테르 13으로 변환시킨 다음 염기수용액내에서 브롬을 이용하여 브롬화시켜 디브로마이드 14를 얻었다. 그후 디브로마이드 14를 소디움 하이드리드의 존재하에 벤질클로라이드로 축합시켜 벤질에테르 15를 제조하였다.Thus, 3-hydroxy picolinic acid (12) was converted to methyl ester 13 in reflux methanol using boron trifluoride as a catalyst and then brominated with bromine in a basic aqueous solution to obtain dibromide 14. Dibromide 14 was then condensed with benzylchloride in the presence of sodium hydride to produce benzylether 15.

벤질에테르15를 메탄올/포타슘카보네이트 내에서 주의깊게 메탄올첨가 분해(methanolysis)하여 4-메톡시 피콜린산 유도체 16을 얻었다.Benzyl ether 15 was carefully methanololyzed in methanol / potassium carbonate to give 4-methoxy picolinic acid derivative 16.

화합물 16의 산클로라이트로의 변환은 용매로서 벤젠 및 촉매량이 DMF를 사 용하여 옥살릴클로라이드로서 성취되었다.The conversion of compound 16 to acid chlorite was achieved as oxalylchloride using benzene and catalytic amounts of DMF as solvent.

Figure 112002001377712-pct00013
Figure 112002001377712-pct00013

<4-에톡시-3-히드록시피콜린산

Figure 112002001377712-pct00014
의 제조 (방법 1 및 3 참조)> <4-ethoxy-3-hydroxypicolinic acid
Figure 112002001377712-pct00014
Preparation (see methods 1 and 3)>

Figure 112002001377712-pct00015

Figure 112002001377712-pct00015

a. 3-(2-(트리메틸실릴)에톡시메톡시)-피리딘(9)의 제조 a. Preparation of 3- (2- (trimethylsilyl) ethoxymethoxy) -pyridine (9)

DMF(100mL)와 THF(100mL)의 교반 혼합물에 고체상 포타슘 tert-부톡사이드(17.96g, 0.16mol)를 첨가하였다.To a stirred mixture of DMF (100 mL) and THF (100 mL) was added solid potassium tert-butoxide (17.96 g, 0.16 mol).

모든 고체가 용해된 후, 그 용액을 5℃ 이하로 냉각시키고 3-히드록시피리딘(14.25g, 0.15mol)을 한꺼번에 첨가하였다. 10분간 교반후, 그 혼합물을 -10℃로 냉각시키고 내부온도를 -5℃ 이하로 유지하면서 SEM-Cl(25g, 0.15mol)을 적정 첨가하였다. After all the solids had dissolved, the solution was cooled down to 5 ° C. and 3-hydroxypyridine (14.25 g, 0.15 mol) was added all at once. After stirring for 10 minutes, the mixture was cooled to −10 ° C. and SEM-Cl (25 g, 0.15 mol) was appropriately added while maintaining the internal temperature at −5 ° C. or lower.                 

첨가한 후, 그 혼합물을 0℃에서 1시간 교반하고 실온에서 2시간더 교반하였다. 그 혼합물을 물 60mL에 첨가한 후 에테르(3×150mL)로 추출하였다.After addition, the mixture was stirred at 0 ° C. for 1 hour and at room temperature for 2 hours. The mixture was added to 60 mL of water and then extracted with ether (3 × 150 mL).

그 에테르 추출물을 합하고 2N NaOH(100mL), 물(50mL) 및 포화 NaCl용액(100mL)로 순차적으로 세척한 후 건조(MgSO4) 및 농축시켜 갈색액체를 얻었다. 증류하여 무색액체이며, b.p 95∼99℃(0.3mmHg)인 요구되는 에테르 9를 얻었다.
The ether extracts were combined, washed sequentially with 2N NaOH (100 mL), water (50 mL) and saturated NaCl solution (100 mL), dried (MgSO 4 ) and concentrated to give a brown liquid. Distillation gave the desired ether 9 which was a colorless liquid and was bp 95-99 占 폚 (0.3 mmHg).

b. 4-플루오로-3-(2-(트리메틸실릴)에톡시메톡시)피리딘(10)의 제조b. Preparation of 4-fluoro-3- (2- (trimethylsilyl) ethoxymethoxy) pyridine (10)

아르곤 대기하에 -70℃ 이하까지 냉각된 에테르(200mL)내에 상기 화합물 9(12.39g, 0.055mol)을 용해시킨 교반용액에 t-BuLi(40mL, 1.5M 펜탄용액)을 천천히 첨가하였다.T-BuLi (40 mL, 1.5 M pentane solution) was slowly added to the stirred solution in which Compound 9 (12.39 g, 0.055 mol) was dissolved in ether (200 mL) cooled to -70 ° C or lower under an argon atmosphere.

첨가동안 반응온도는 -68℃ 이하로 유지하였다.The reaction temperature was kept below -68 ° C during the addition.

첨가 완료후 그 혼합물을 -70℃ 이하에서 60분간 더 교반하였으며 그후 캐뉼러를 통해, 역시 아르곤하에 -70℃이하로 냉각된 무수 THF(200mL)내에 N-플루오로벤젠술폰이미드(18.92g)을 용해시킨 교반용액에 옮겼다.After the addition was complete the mixture was stirred for a further 60 min at -70 ° C or less and then via cannula, N-fluorobenzenesulfonimide (18.92 g) in dry THF (200 mL), also cooled to -70 ° C under argon. It was transferred to the stirred solution in which it was dissolved.

첨가완료후 냉각조를 제거하고 그 반응 혼합물을 실온까지 상승되게 하였다.After the addition was completed the cooling bath was removed and the reaction mixture was allowed to rise to room temperature.

물(100mL)을 첨가하고 유기상을 분리하고, 건조후 (MgSO4) 농축시켜 갈색오일을 얻었다.Water (100 mL) was added and the organic phase was separated, dried (MgSO 4 ) and concentrated to give a brown oil.

크로마토그라피(실라카겔, 헥산-아세톤, 9:1) 분석결과 15% 출발물질을 함유 한 오렌지 오일같은 요구되는 산물10을 얻었다. 이 조질혼합물은 다음 반응에 바로 사용되었다.
Chromatography (silica gel, hexane-acetone, 9: 1) gave the desired product 10, such as an orange oil containing 15% starting material. This crude mixture was used directly in the next reaction.

c. 4-에톡시-3-(2-(트리메틸실릴)에톡시메톡시)피리딘(11)의 제조c. Preparation of 4-ethoxy-3- (2- (trimethylsilyl) ethoxymethoxy) pyridine (11)

에탄올(10mL)내에 소디움에톡사이드(0.9g, 13mmol)을 용해시킨 교반용액에 화합물10(1.07g, 4.4mmol)을 한꺼번에 첨가하였다. 그 결과물인 혼합물을 실온에서 48시간 교반한 후 물(100mL)에 옮겼다.Compound 10 (1.07 g, 4.4 mmol) was added all at once to a stirring solution in which sodium ethoxide (0.9 g, 13 mmol) was dissolved in ethanol (10 mL). The resulting mixture was stirred for 48 hours at room temperature and then transferred to water (100 mL).

그 결과 혼합물을 에테르(3×50mL)로 추출하였다.그 에테르 추출물을 합하고, 건조시킨후(MgSO4) 농축시켰다. 그 결과물인 호박색 오일을 크로마토그래피 분석(실리카겔, 헥산-아세톤 4:1)하여 황색오일로서 화합물 11(0.6g)을 얻었다.
The resulting mixture was extracted with ether (3 × 50 mL). The ether extracts were combined, dried (MgSO 4 ) and concentrated. The resulting amber oil was chromatographed (silica gel, hexane-acetone 4: 1) to give compound 11 (0.6 g) as a yellow oil.

d. 4-에톡시-3-히드록시피리딘-2-카복실산

Figure 112002001377712-pct00016
d. 4-ethoxy-3-hydroxypyridine-2-carboxylic acid
Figure 112002001377712-pct00016

아르곤 대기하에 THF(50mL)에 용해시킨 화합물 11(2.9g)의 교반용액을 -70℃이하까지 냉각시켰다.The stirred solution of Compound 11 (2.9 g) dissolved in THF (50 mL) was cooled to -70 ° C or lower under argon atmosphere.

여기에 반응온도를 -66℃ 이하로 유지하면서 t-BuLi(8mL, 1.5M 펜탄용액)을 천천히 부가하였다.T-BuLi (8 mL, 1.5 M pentane solution) was slowly added thereto while maintaining the reaction temperature at -66 ° C or lower.

반응완료후 그 혼합물을 -70℃ 이하에서 45분간 교반하였으며, 그후 에테르내에 조각 드라이아이스를 넣은 슬러리에 부었다. 그 결과 혼합물을 실온에서 도달할때까지 교반한 후 용매를 증발시켰다. After completion of the reaction, the mixture was stirred for 45 minutes at -70 DEG C or lower, and then poured into a slurry containing flake dry ice in ether. As a result, the mixture was stirred until reaching room temperature and the solvent was evaporated.                 

THF(25mL)과 4NHCl(15mL)을 잔류물에 첨가하였으며 그 결과 혼합물을 실온에서 2시간동안 교반하였다,THF (25 mL) and 4NHCl (15 mL) were added to the residue and the resulting mixture was stirred at room temperature for 2 hours,

이 시기의 끝에 불용성물질을 여과하고, 소량의 THF로 세척한후 공기건조시켜 백색고체로서 상기 화합물(1.05g)을 얻었다.
At the end of this period the insoluble material was filtered off, washed with a small amount of THF and air dried to afford the above compound (1.05 g) as a white solid.

<6-브로모-3-벤질옥시-4-메톡시피리딘-2-카복실산 (16) 및 그 산 클로라이드(3)의 제조>(방법4 참조)<Preparation of 6-bromo-3-benzyloxy-4-methoxypyridine-2-carboxylic acid (16) and its acid chloride (3)> (see method 4)

Figure 112002001377712-pct00017

Figure 112002001377712-pct00017

a. 메틸 4,6-디브로모-3-히드록시 피리딘-2-카복시레이트(14)의 제조a. Preparation of Methyl 4,6-dibromo-3-hydroxy pyridine-2-carboxylate (14)

적정핀넬과 기계적 교반기가 달린 2L 3-목달린 플라스크에 물(800mL) 및 메틸3-히드록시피리딘-2-카복실레이트(15.3g)을 첨가하였다. 이 교반용액에 브롬(32g)을 천천히 첨가하였다.To a 2L 3-necked flask with a titration pinnel and a mechanical stirrer was added water (800 mL) and methyl3-hydroxypyridine-2-carboxylate (15.3 g). Bromine (32 g) was slowly added to this stirred solution.

반응이 전개됨에 따라, 용액에서 분리된 고체와 반응 혼합물은 교반하기 어렵게 되었다.As the reaction developed, the solids and reaction mixture separated from the solution became difficult to stir.

첨가완료후 브롬색상이 사라질때까지 상기 혼합물을 격렬하게 교반하였다.After the addition was completed, the mixture was stirred vigorously until the bromine color disappeared.

소량의 조질산물 시료에 대한 1H-NMR(CDCl3)결과 모노 : 디브롬화 산물의 3:1 혼합물인 것으로 나타났다. 1 H-NMR (CDCl 3 ) on small amounts of crude product samples showed a 3: 1 mixture of mono: dibrominated products.

상기 반응 혼합물에 소디움 카보네이트(31.8g)을 주의 깊게 첨가한후 추가적인 브롬(12g)을 적정첨가 하였다.Sodium carbonate (31.8 g) was carefully added to the reaction mixture, followed by titration of additional bromine (12 g).

브롬색상이 사라진후 진한 HCl로서 반응 혼합물의 pH를 pH5까지 조절하였으며, 그 결과 혼합물을 CH2Cl2(3×150mL)로서 추출하였다. 그 유기 추출물을 합하고 건조한후 (MgSO4) 농축시켜 오렌지색 고체(14g)을 얻었다.이 물질은 메틸시클로헥산으로부터(숯처리후) 재결정화되어 m.p 181∼183℃인 백색고체로서 화합물 14를 얻을 수 있다.
After the bromine disappeared, the pH of the reaction mixture was adjusted to pH 5 with concentrated HCl, and the mixture was extracted as CH 2 Cl 2 (3 × 150 mL). The organic extracts were combined, dried (MgSO 4 ) and concentrated to give an orange solid (14 g). This material was recrystallized from methylcyclohexane (after charcoal treatment) to give compound 14 as a white solid at mp 181 to 183 ° C. have.

b. 메틸 4,6-디브로모-3-벤질옥시피리딘-2-카복실레이트(15)의 제조b. Preparation of Methyl 4,6-dibromo-3-benzyloxypyridine-2-carboxylate (15)

DMF(50mL)내에 소디움 하이드리드(0.6g)를 용해시킨 교반 혼합물에 화합물 14(7.1g)를 첨가하였다. 첨가완료후, 혼합물을 실온에서 15분간 교반한후 벤질클로라이드(3.05g)를 단번에 첨가 하였다.Compound 14 (7.1 g) was added to the stirred mixture in which sodium hydride (0.6 g) was dissolved in DMF (50 mL). After the addition was completed, the mixture was stirred at room temperature for 15 minutes, and then benzyl chloride (3.05 g) was added at once.

그후 상기 혼합물을 6시간동안 90℃로 가열한 후, 냉각시키고, 물(500mL)에 붓고 에테르(2×200mL)로 추출하였다.The mixture was then heated to 90 ° C. for 6 hours, then cooled, poured into water (500 mL) and extracted with ether (2 × 200 mL).

그 에테르 추출물을 합하고, 2N NaOH(50mL)로 세척하고, 건조(MgSO4)시켰으며, 용매를 증발시켜 옅은 황색고체(8.3g)로서 화합물 15를 얻었다.The ether extracts were combined, washed with 2N NaOH (50 mL), dried (MgSO 4 ) and the solvent was evaporated to afford compound 15 as a pale yellow solid (8.3 g).

소량의 메탄올로 부터 재결정화하여 m.p 75∼76℃인 분석시료를 얻었다.
Recrystallization from a small amount of methanol yielded an analytical sample with mp 75-76 ° C.

c. 6-브로모-3-벤질옥시-4-메톡시피리딘-2-카복실산(16)c. 6-Bromo-3-benzyloxy-4-methoxypyridine-2-carboxylic acid (16)

화합물 15(25.5g)과 포타슘 카보네이트(75g) 및 메탄올(300mL)의 격렬하게 교반된 혼합물을 환류하면서 30분간 가열하였다.A vigorously stirred mixture of compound 15 (25.5 g), potassium carbonate (75 g) and methanol (300 mL) was heated to reflux for 30 minutes.

그 혼합물을 냉각시키고, 물(800ml)내에 붓고, 진한 HCl을 부가하여 pH를 2로 조정하였다. 결과물인 혼합물을 CH2Cl2(3×150mL)로서 추출하였다. The mixture was cooled, poured into water (800 ml) and the pH was adjusted to 2 by addition of concentrated HCl. The resulting mixture was extracted as CH 2 Cl 2 (3 × 150 mL).

그 유기 추출물을 합하고, 건조시킨 다음(MgSO4), 용제를 증발시켜 방치시 천천히 고화되는 거의 무색인 오일(20.5g)을 얻었다.The organic extracts were combined, dried (MgSO 4 ) and the solvent was evaporated to yield an almost colorless oil (20.5 g) that solidified slowly upon standing.

이를 메탄올(125mL)/물(40mL)로부터 재결정화하여 m.p 134∼135℃인 요구되는 산16(11.6g)을 얻었다.
This was recrystallized from methanol (125 mL) / water (40 mL) to give the required acid 16 (11.6 g) with mp 134-135 ° C.

d. 6-브로모-3-벤질옥시-4-메톡시피리딘-2-카보닐클로라이드(3)의 제조d. Preparation of 6-bromo-3-benzyloxy-4-methoxypyridine-2-carbonylchloride (3)

DMF(3방울)를 함유한 벤젠(30mL)에 화합물 16(2.54g, 7.5mmol)을 용해시킨 교반용액에 옥살릴 클로라이드(1.90g, 15mmol)을 첨가하였다.Oxalyl chloride (1.90 g, 15 mmol) was added to a stirred solution in which compound 16 (2.54 g, 7.5 mmol) was dissolved in benzene (30 mL) containing DMF (3 drops).

가스휘발이 중단된후(약 45분), 이제 균질인 상기 용액을 15분간 더 교반한 다음 용매을 증발시켰다.After the gas volatilization was stopped (about 45 minutes), the now homogeneous solution was further stirred for 15 minutes before the solvent was evaporated.

1,2-디클로로에탄(30mL)을 첨가하고 다시 상기 용매를 증발시켜 거의 무색 오일인 상기 화합물 3을 얻었다. 1,2-dichloroethane (30 mL) was added and the solvent was evaporated again to afford compound 3, which was an almost colorless oil.

이물질을 CH2Cl2(10mL) 혹은 THF(10mL)에 용해시키고 다음 커플링 반응에 직접 사용하였다. The foreign material was dissolved in CH 2 Cl 2 (10 mL) or THF (10 mL) and used directly for the next coupling reaction.

< 6-브로모-3-히드록시 피콜린 산(17) >6-bromo-3-hydroxy picolinic acid (17)

Figure 112002001377712-pct00018
Figure 112002001377712-pct00018

메틸 3-히드록시피콜리네이트(30.6g)을 물(800mL)에 용해시킨 기계적으로 교반한 용액에 브롬(32g)을 30분에 걸쳐 천천히 첨가하였다. 첨가완료후 1시간더 교반하였다.Bromine (32 g) was slowly added over 30 minutes to a mechanically stirred solution in which methyl 3-hydroxypicolinate (30.6 g) was dissolved in water (800 mL). After the addition was completed, the mixture was stirred for 1 hour.

에테르(300mL)를 첨가하고 모든 고체가 용해될때까지 교반을 계속하였다. 유기층을 분리하고 에테르(200mL)로 수상을 추출하였다. 유기상을 합하고, 건조하였으며(MgSO4), 용매를 증발시켜 회백색 고체로서 메틸 6-브로모-3-히드록시피콜리네이트 32.8g을 얻었다. 메탄올/물로부터 재결정화하여 m.p 115∼117℃인 분석시료를 얻었다.Ether (300 mL) was added and stirring continued until all solids dissolved. The organic layer was separated and the aqueous phase was extracted with ether (200 mL). The organic phases were combined, dried (MgSO 4 ) and the solvent evaporated to give 32.8 g of methyl 6-bromo-3-hydroxypicolinate as off-white solid. Recrystallization from methanol / water gave an analytical sample of mp 115-117 ° C.

THF(15mL)에 용해시킨 이 에스테르(2.32g)의 교반용액에 물(7mL)에 LiOH.H2O(1g)을 용해시킨 용액을 단번에 첨가하였다.To a stirring solution of this ester (2.32 g) dissolved in THF (15 mL) was added a solution in which LiOH.H 2 O (1 g) was dissolved in water (7 mL) at once.

그 결과물인 혼합물을 실온에서 2시간 교반한 후 물(100mL)에 부었다. 1N HCl로 pH를 약 3으로 조정한 후 그 혼합물을 CH2Cl2(3×100mL)로 추출하였다.The resulting mixture was stirred at room temperature for 2 hours and then poured into water (100 mL). The pH was adjusted to about 3 with 1N HCl and the mixture was extracted with CH 2 Cl 2 (3 × 100 mL).

유기추출물을 건조시키고(MgSO4), 여과한후 농축시켜 백색고체 2.0g을 얻었으며 1H-NMR 및 MS 시험결과 요구되는 산 17과 일치하였다.
The organic extract was dried (MgSO 4 ), filtered and concentrated to yield 2.0 g of white solid, which was consistent with the required acid 17 by 1 H-NMR and MS testing.

< 3-벤질옥시-6-메톡시피콜린산(18) ><3-benzyloxy-6-methoxypicolinic acid (18)>

Figure 112002001377712-pct00019
Figure 112002001377712-pct00019

CN2Cl2(100mL)에 메틸 3-벤질옥시피콜리네이트(4.86g)과 3-클로로퍼옥시벤조산(5.75g, 60% peracid)을 용해시킨 용액을 실온에서 40시간 동안 교반하였다.A solution of methyl 3-benzyloxypicolinate (4.86 g) and 3-chloroperoxybenzoic acid (5.75 g, 60% peracid) in CN 2 Cl 2 (100 mL) was stirred at room temperature for 40 hours.

그 반응 혼합물을 5% 소디움바이술파이트 용액(100mL)으로 추출한후 0.5N NaOH 용액(150mL)으로 추출하였다.The reaction mixture was extracted with 5% sodium bisulfite solution (100 mL) and then with 0.5N NaOH solution (150 mL).

건조(MgSO4)후, 용매를 증발시켜 백색고체로서 메틸 3-벤질옥시 피콜리네이트-1-옥사이드 4.9g을 얻었다. 메틸시클로헥산/톨루엔으로 재결정화하여 m.p 104∼106℃인 결정성고체를 얻었다.
After drying (MgSO 4 ), the solvent was evaporated to afford 4.9 g of methyl 3-benzyloxy picolinate-1-oxide as a white solid. Recrystallization from methylcyclohexane / toluene yielded a crystalline solid with mp 104-106 ° C.

이 화합물(16.1g)을 무수아세트산(80mL)에 용해시킨 용액을 교반하고 오일조에서 120℃에서 3시간동안 가열하였다.The solution of this compound (16.1 g) dissolved in acetic anhydride (80 mL) was stirred and heated in an oil bath at 120 ° C. for 3 hours.

회전증발기 상에서 여분의 무수아세트산을 제거하고 잔류물을 메탄올(200mL)에 수집하였다.Excess acetic anhydride was removed on the rotary evaporator and the residue was collected in methanol (200 mL).

진한 황산(1mL)을 첨가하고 그 결과물인 혼합물을 90분에 걸쳐 환류 가열하였다.Concentrated sulfuric acid (1 mL) was added and the resulting mixture was heated to reflux over 90 minutes.

그후 용매를 증발시키고 잔류물에 소디움 바이카보네이트를 첨가하였다. 그 결과물인 혼합물 CH2Cl2(3×100mL)로 추출하였다. 유기분획을 모으고, 건조(MgSO4 )한 다음 용매증발시켜 황색고체로서 메틸 3-벤질옥시-6-히드록시피콜리네이트 15.5g을 얻었다.The solvent was then evaporated and sodium bicarbonate was added to the residue. The resulting mixture was extracted with CH 2 Cl 2 (3 × 100 mL). The organic fractions were combined, dried (MgSO 4 ) and then solvent evaporated to afford 15.5 g of methyl 3-benzyloxy-6-hydroxypicolinate as a yellow solid.

톨루엔으로 부터 재결정화하여 m.p 91∼92℃인 옅은 황색 고체를 얻었다.Recrystallization from toluene gave a pale yellow solid with m.p 91-92 ° C.

이 화합물(10.25g)을 톨루엔(125mL)에 용해시키고 오일조내에서 60℃로 가온한 교반용액에 탄산은(16.6g)을 첨가한 후 요오드화 메틸(8.52g)을 첨가하였다. 그 결과물인 혼합물을 60℃에서 3시간동안 가열하였다.The compound (10.25 g) was dissolved in toluene (125 mL), and silver carbonate (16.6 g) was added to a stirred solution warmed to 60 ° C. in an oil bath, followed by methyl iodide (8.52 g). The resulting mixture was heated at 60 ° C. for 3 hours.

냉각후, 그 혼합물을 Celite

Figure 112002001377712-pct00020
를 통해 여과하고 용매 증발후 황색오일을 얻었다.After cooling, the mixture was cooled to Celite.
Figure 112002001377712-pct00020
Filtration through and evaporation of the solvent gave a yellow oil.

실리카겔 크로마토그라피(4:1 헥산/아세톤)결과 거의 무색인 오일을 얻었으며, 'H-NMR 및 MS 데이타는 메틸 3-벤질옥시-6-메톡시피콜리네이트와 일치하였다.Silicagel chromatography (4: 1 hexanes / acetone) gave an almost colorless oil, with 'H-NMR and MS data consistent with methyl 3-benzyloxy-6-methoxypicolinate.

이 에스테르의 산18로의 가수분해는 관련 에스테르에 대하여 앞서 기술된바와 같이 LiOH.H2O로 성취되었다.Hydrolysis of this ester to acid 18 was accomplished with LiOH.H 2 O as described previously for the relevant ester.

<4-히드록시피리미딘-5-카복실산(19)><4-hydroxypyrimidine-5-carboxylic acid (19)>

Figure 112002001377712-pct00021
Figure 112002001377712-pct00021

에틸 4-히드록시피리미딘-5-카복실레이트를 M.Pesson et al., Eur.J.Med.Chem.Chim.Ther.1974, 9, 585 에 기술된바에 따라 제조될 수 있다.Ethyl 4-hydroxypyrimidine-5-carboxylate can be prepared as described in M. Pesson et al., Eur. J. Med. Chem. Chem. Ther. 1974, 9, 585.

이 에스테르(500mg, 3mmol)를 THF(10mL)와 MeOH(5mL)에 용해시킨 용액을 LiOH.H2O(373mg, 8.9mmol)로 처리한후 밤새 교반하였다.The solution (500 mg, 3 mmol) dissolved in THF (10 mL) and MeOH (5 mL) was treated with LiOH.H 2 O (373 mg, 8.9 mmol) and stirred overnight.

그 혼합물을 진한 HCl(1mL)과 함께 급냉시키고 EtOAc(2×20mL)로서 추출하였다. 그 결합된 유기 추출물을 건조(MgSO4)시키고, 농축시켜 m.P 220℃(dec.)인 오렌지색 고체로서 화합물 19 260mg을 얻었다.
The mixture was quenched with concentrated HCl (1 mL) and extracted as EtOAc (2 × 20 mL). The combined organic extracts were dried (MgSO 4 ) and concentrated to give 260 mg of compound 19 as an orange solid with mP 220 ° C. (dec.).

< 4-히드록시-2-메틸피리미딘-5-카복시산(20) ><4-hydroxy-2-methylpyrimidine-5-carboxylic acid (20)>

Figure 112002001377712-pct00022
Figure 112002001377712-pct00022

에틸-4-히드록시-2-메틸피리미딘-5-카복실레이트를 Geissman et al., J. Org. Chem., 1946, 11, 741 의 절차에 따라 제조하였다.Ethyl-4-hydroxy-2-methylpyrimidine-5-carboxylate is prepared by Geissman et al., J. Org. Prepared according to the procedure of Chem., 1946, 11, 741.

이 에스테르(750mg, 4.11mmol)을 THF(10mL) 및 MeOH(5mL)에 용해시킨 용액을 LiOH.H2O(431mg, 10.3mmol)로 처리하고 밤새 교반하였다.The solution of this ester (750 mg, 4.11 mmol) dissolved in THF (10 mL) and MeOH (5 mL) was treated with LiOH.H 2 O (431 mg, 10.3 mmol) and stirred overnight.

이 혼합물을 진한 HCl(1mL)과 함께 급냉시키고 EtOAc(2×20mL)로서 추출하였다. 결합된 유기추출물을 건조시키고(MgSO4) 농축시켜 m.p 180℃(dec)인 백색고체화합물 20 150mg을 얻었다.
This mixture was quenched with concentrated HCl (1 mL) and extracted as EtOAc (2 × 20 mL). The combined organic extracts were dried (MgSO 4 ) and concentrated to give 150 mg of a white solid compound 20 which was mp 180 ° C. (dec).

< 5,6-디클로로-3-히드록시피라진-2-카복실산(21) ><5,6-dichloro-3-hydroxypyrazine-2-carboxylic acid (21)>

Figure 112002001377712-pct00023
Figure 112002001377712-pct00023

메틸 3-아미노-5,6-디클로로피라진-2-카복실레이트(5.0g, 23mmol)을 진한 황산(140moL)내에서 교반하고 0℃로 냉각시켰다. 온도를 0℃에 근접되게 유지하면서 아질산나트륨을 천천히 첨가하였다. 0℃에서 첨가 30분후 그 혼합물을 주위온도로 되게한 후 3시간동안 교반하였다. 그 혼합물을 얼음 500g에 붓고 그 결과 거품이 일어났다.Methyl 3-amino-5,6-dichloropyrazine-2-carboxylate (5.0 g, 23 mmol) was stirred in concentrated sulfuric acid (140 moL) and cooled to 0 ° C. Sodium nitrite was added slowly while maintaining the temperature near 0 ° C. After 30 minutes of addition at 0 ° C. the mixture was brought to ambient temperature and stirred for 3 hours. The mixture was poured into 500 g of ice, which resulted in bubbles.

30분후, 그 혼합물을 EtOAc로 3번 추출하였다. 그 결합 유기추출물을 건조(MgSO4), 여과 및 농축시켰다. 잔류한 황색고체를 물로 세척하고 공기 건조하여 m.p 114∼116℃인 황색고체 5.0g을 얻었으며 13C-NMR 스팩트럼 결과 주제 화합물의 메틸에스테르와 일치하였다.
After 30 minutes, the mixture was extracted three times with EtOAc. The combined organic extracts were dried (MgSO 4 ), filtered and concentrated. The remaining yellow solid was washed with water and air dried to give 5.0 g of a yellow solid at mp 114-116 ° C., which was in agreement with the methyl ester of the main compound of the 13 C-NMR spectrum.

이 고체(5.0g)을 1N NaOH(20mL)로 처리하고 그 혼합물을 90℃에서 1.5시간 가열하였다. 냉각되게 한 후, 그 혼합물을 진한 HCl로 산성화시키고 EtOAc로 3번 추출하였다.This solid (5.0 g) was treated with 1N NaOH (20 mL) and the mixture was heated at 90 ° C for 1.5 h. After allowing to cool, the mixture was acidified with concentrated HCl and extracted three times with EtOAc.

건조(MgSO4), 여과 및 농축시켜 진한 황색고체 0.48g을 얻었으며, 1H-NMR 및 MS 스팩트럼 분석결과 산 21과 일치하였다.
Drying (MgSO 4 ), filtration and concentration yielded 0.48 g of a dark yellow solid, which was consistent with acid 21 by 1 H-NMR and MS spectrum analysis.

< 6-클로로-3-히드록시-5-메톡시피라진-2-카복실산(22) ><6-Chloro-3-hydroxy-5-methoxypyrazine-2-carboxylic acid (22)>

Figure 112002001377712-pct00024
Figure 112002001377712-pct00024

순수 MeOH(50mL)에 메틸-3-아미노-5,6-디클로로피라진-2-카복실레이트(5.0g, 23mmol) 및 소디움 메톡사이드(3.6g, 67.5mmol)를 넣은 교반 혼합물을 환류하면서 2시간동안 가열한후 냉각방치하고 진한 HCl로서 산성화 하였다.Pure MeOH (50 mL) was stirred under reflux with a stirring mixture containing methyl-3-amino-5,6-dichloropyrazine-2-carboxylate (5.0 g, 23 mmol) and sodium methoxide (3.6 g, 67.5 mmol) for 2 hours. After heating it was left to cool and acidified with concentrated HCl.

그 침전물을 여과하여 수집하고 수세한 후 공기건조시켜 갈색 고체 3.6g을 얻었다.The precipitate was collected by filtration, washed with water and air dried to yield 3.6 g of a brown solid.

헥산-EtOAc(1:1)로 부터 재결정화하여 담황색고체 2.6g을 얻었으며, 스펙트럼분석 결과 메틸-3-아미노-6-클로로-5-메톡시피라진-2-카복실레이트와 일치하였다. 이 화합물(1g, 4.6mmol)을 진한 황산내에 수집하고 0℃에서 냉각후 아질산나트륨(0.5g, 6.9mmol)으로 천천히 처리하였다. 0℃에서 30분후, 혼합물을 300g 얼음/물에 붓고 거품을 일으켰다. 30분간 교반한 후 고체를 여과하여 수집하고 수세하였다.Recrystallization from hexane-EtOAc (1: 1) yielded 2.6 g of a pale yellow solid, and the spectrum was consistent with methyl-3-amino-6-chloro-5-methoxypyrazine-2-carboxylate. The compound (1 g, 4.6 mmol) was collected in concentrated sulfuric acid and cooled slowly at 0 ° C. and then slowly treated with sodium nitrite (0.5 g, 6.9 mmol). After 30 minutes at 0 ° C., the mixture was poured into 300 g ice / water and bubbled. After stirring for 30 minutes, the solid was collected by filtration and washed with water.

습윤고체를 EtOAc내에서 수집하고, 건조(MgSO4), 여과 및 농축시켰다.The wet solid was collected in EtOAc, dried (MgSO 4 ), filtered and concentrated.

m.p 180∼182℃인 상아색 고체 0.95g을 얻었으며, NMR 스펙트럼 분석결과 메틸 6-클로로-3-히드록시-5-메톡시피라진-2-카복실레이트와 일치하였다.0.95 g of an ivory solid with a m.p of 180-182 ° C. was obtained, which was consistent with methyl 6-chloro-3-hydroxy-5-methoxypyrazine-2-carboxylate by NMR spectrum analysis.

이 고체(0.9g, 4.1mmol)은 1N NaOH(60mL)로 처리하고 그 혼합물을 1시간 교 반한 후 진한 HCl로 산성화하였다. 여과로 침전물을 수집하고 수세한후 EtOAc에 용해시키고 건조(MgSO4), 여과 및 농축시켰다. m.p 170∼173℃인 담황색 고체 0.62g을 얻었으며, 스펙트럼 분석결과 원하는 산 22와 일치하였다.
This solid (0.9 g, 4.1 mmol) was treated with 1N NaOH (60 mL) and the mixture was stirred for 1 hour and acidified with concentrated HCl. The precipitate was collected by filtration, washed with water, dissolved in EtOAc, dried (MgSO 4 ), filtered and concentrated. 0.62 g of a pale yellow solid with mp 170-173 ° C. was obtained, which was consistent with the desired acid 22 by spectral analysis.

<4-히드록시이소티아졸-3-카복실산(23)><4-hydroxyisothiazole-3-carboxylic acid (23)>

이 산은 방법 5에 도시된 순서에 따라 얻어졌다.This acid was obtained in the order shown in Method 5.

Figure 112002001377712-pct00025
Figure 112002001377712-pct00025

이 같이, 질소쓸기된 플라스크내에서 EtOH 75mL에 고체 KOH(88%, 6.98g, 0.11mol)을 용해시킨 교반된 용액에 EtOH 25mL로 세척한 티올아세트산(8.36g, 0.11mol)을 첨가하였다. 그 혼합물을 질소하에 5분간 교반하였다.Thus, thiol acetic acid (8.36 g, 0.11 mol) washed with 25 mL of EtOH was added to a stirred solution in which solid KOH (88%, 6.98 g, 0.11 mol) was dissolved in 75 mL of EtOH in a nitrogen-scraped flask. The mixture was stirred for 5 minutes under nitrogen.

여기에 조질 브롬화합물(M.Hatanaka 및 T. Ishimaru, J. Med. Chem., 1973, 16, 798 에 따라 제조된)을 0.1mol 첨가하였다.0.1 mol of a crude bromine compound (prepared according to M. Hatanaka and T. Ishimaru, J. Med. Chem., 1973, 16, 798) was added thereto.

이 플라스크를 질소쓸기하고 막았다. 그 혼합물을 주위온도에서 수조에 넣고 3시간동안 교반한 후 300mL CH2Cl2 및 1000mL물에 부었다.The flask was nitrogen cleaned and clogged. The mixture was placed in a water bath at ambient temperature, stirred for 3 hours, and poured into 300 mL CH 2 Cl 2 and 1000 mL water.

CH2Cl2 200mL로 수성층을 4번 추출하였다. 합한유기 추출물을 냉수 100mL 및 포화염수로 세척하고 건조시켰다.The aqueous layer was extracted four times with 200 mL of CH 2 Cl 2 . The combined organic extracts were washed with 100 mL of cold water and saturated brine and dried.

그 조질 화합물은 여과 및 농축시켰다. 그 결과물인 오일을 용리액으로 디에틸에테르를 사용하여 실리카겔상에서 크로마토그라피하여 담황색 오일 13g을 얻었으며 이는 방치되면 고화되어 껌상고체로 되었다. 스펙트럼 분석결과 에틸-2-아세틸아미노-4-아세틸티오-3-옥소부타노에미드와 일치하였다.
The crude compound was filtered and concentrated. The resulting oil was chromatographed on silica gel using diethyl ether as eluent to obtain 13 g of a pale yellow oil which solidified when left to become a gum-like solid. Spectral analysis was consistent with ethyl-2-acetylamino-4-acetylthio-3-oxobutanoimide.

450mL 클로로포름내에서 이 화합물(12.95g)을 신속히 교반하고 5℃이하까지 얼음조내에서 냉각시킨 교반용액에 클로로포름 50mL에 브롬(15.8g, 2당량)을 용해시킨 용액을 45분에 걸쳐 적정첨가하였다. 얼음조내에서 45분간 더 교반한 후 주위온도에서 30시간 교반하였다.The compound (12.95 g) was rapidly stirred in 450 mL chloroform and a solution in which bromine (15.8 g, 2 equivalents) was dissolved in 50 mL of chloroform was added to the stirred solution cooled in an ice bath to 5 ° C. or lower, over 45 minutes. The mixture was stirred for 45 minutes in an ice bath and then stirred for 30 hours at ambient temperature.

그후 그 혼합물을 200mL 물로 세척한 다음 다시 물 100mL로 세척하였다.The mixture was then washed with 200 mL water and then again with 100 mL water.

결합된 세척수를 100mL 클로로포름으로 추출하였다. 이 결합된 클로로포름 수용액을 포화염수로 세척한 후 MgSO4를 이용하여 건조시켰다.The combined wash water was extracted with 100 mL chloroform. The combined aqueous chloroform solution was washed with saturated brine and dried using MgSO 4 .

그 용액을 여과 및 농축시켜 조질오일을 얻었다.The solution was filtered and concentrated to give crude oil.

이를 석유 에테르-CH2Cl2 (3:1)에서 CH2Cl2 까지 직렬구배를 이용하여 실리카 겔상에서 크로마토그래피하여 처음에는 에틸 5-브로모-4-히드록시이소티아졸-3-카복실레이트 0.79g 그리고 그후 무색 결정으로서 에틸-4-히드록시이소티아졸-3-카복실레이트 3.4g을 얻었으며, 이들 m.p는 44∼7℃였고 MS 및 1H-NMR과 일치하였다.
This was chromatographed on silica gel using a serial gradient from petroleum ether-CH 2 Cl 2 (3: 1) to CH 2 Cl 2 to initially ethyl 5-bromo-4-hydroxyisothiazole-3-carboxylate. 0.79 g and then 3.4 g of ethyl-4-hydroxyisothiazole-3-carboxylate as colorless crystals were obtained, these mps being 44-7 ° C. and consistent with MS and 1 H-NMR.

THF 30mL에 상기 후자 에스테르 710mg을 넣고 물 10mL에 용해시킨 LiOH.H2O(2.2당량) 370mg을 첨가하였다. 이 혼합물을 주위온도에서 3시간 교반한 후 냉장고내에서 냉각시켰다. 침전된 고체를 여과에 의해 수집하여 카복실산의 디리튬염 710mg을 얻었다. 이 염을 물 7mL내에 넣고 얼음조내에서 냉각시킨다음 2N HCl을 첨가하여 pH1로 조절하였다,710 mg of the latter ester was added to 30 mL of THF, and 370 mg of LiOH.H 2 O (2.2 equivalents) dissolved in 10 mL of water was added thereto. The mixture was stirred at ambient temperature for 3 hours and then cooled in a refrigerator. The precipitated solid was collected by filtration to give 710 mg of the dilithium salt of carboxylic acid. The salt was added to 7 mL of water, cooled in an ice bath and adjusted to pH 1 by addition of 2N HCl.

그 결과물인 용액은 EtOAc 50mL로 3번 추출하였다. 합한 추출물을 염수 5mL로 세척하고 건조(Na2SO4), 여과하고 그 여과물을 냉장고내에 보관하였다. 그 냉각된 용액을 재여과하고 여과물을 농축시켜 m.p 185∼189℃인 무색 고체 230mg을 얻었으며, 1H-NMR 및 13C-NMR 스펙트라는 화합물 23과 일치하였다.
The resulting solution was extracted three times with 50 mL of EtOAc. The combined extracts were washed with 5 mL brine, dried (Na 2 SO 4 ), filtered and the filtrate was stored in the refrigerator. The cooled solution was refiltered and the filtrate was concentrated to give 230 mg of a colorless solid, mp 185-189 ° C., with 1 H-NMR and 13 C-NMR spectra consistent with compound 23.

< 3-벤질옥시-1-메틸피라졸-4-카복실산(24) 및 5-벤질옥시-1-메틸피라졸-4-카복실산(25) ><3-benzyloxy-1-methylpyrazole-4-carboxylic acid (24) and 5-benzyloxy-1-methylpyrazole-4-carboxylic acid (25)>

Figure 112002001377712-pct00026
Figure 112002001377712-pct00026

에틸 3-히드록시-1-메틸피라졸-4-카복실레이트와 에틸 5-히드록시-1-메틸피라졸-4-카복실레이트(Y.Wang, et al., Zhejiang Gongxueyuan Xuebao, 1994, 2, 67의 절차에 따라 얻음)의 혼합물을 S.Yamamoto, et al., 일본특허 JP62148482, 1987에 개시된 바에 따라 벤질화 하였으며, 그 혼합물을 용리액으로서 3:1 헥산:EtOAc 를 사용하여 컬럼 크로마토그래피하여 분리하여 에틸 3-벤질옥시-1-메틸피라졸-4-카본실레이트와 에틸 5-벤질옥시-1-메틸피라졸-4-카복실레이트를 얻었으며 이들은 1H-NMR 결과 순수하였다.
Ethyl 3-hydroxy-1-methylpyrazole-4-carboxylate and ethyl 5-hydroxy-1-methylpyrazole-4-carboxylate (Y. Wang, et al., Zhejiang Gongxueyuan Xuebao, 1994, 2, Obtained according to the procedure of 67) was benzylated as disclosed in S.Yamamoto, et al., Japanese Patent JP62148482, 1987, and the mixture was separated by column chromatography using 3: 1 hexanes: EtOAc as eluent. To ethyl 3-benzyloxy-1-methylpyrazole-4-carbonylate and ethyl 5-benzyloxy-1-methylpyrazole-4-carboxylate, which were pure by 1 H-NMR.

TNF(10mL), MeOH(2mL) 및 물(5mL)에 용해시킨 에틸 3-벤질옥시-1-메틸피라졸-4-카복실레이트(238mg, 1.08mmol)을 LiOH.H2O(91mg, 2.17mmol)로 처리하고 밤새교반 하였다. 그 혼합물을 진한 HCl(1mL)과 함께 냉각시키고 EtOAc(2×20mL)로서 추출하였다.Ethyl 3-benzyloxy-1-methylpyrazole-4-carboxylate (238 mg, 1.08 mmol) dissolved in TNF (10 mL), MeOH (2 mL) and water (5 mL) was dissolved in LiOH.H 2 O (91 mg, 2.17 mmol). ) And stirred overnight. The mixture was cooled with concentrated HCl (1 mL) and extracted as EtOAc (2 × 20 mL).

합한 유기층을 건조(MgSO4) 및 농축시켜 m.p 169∼172℃인 백색고체(227mg)을 얻었으며, 그 스펙트라는 3-벤질옥시-1-메틸피라졸-4-카복실산(24)와 일치하였다. The combined organic layers were dried (MgSO 4 ) and concentrated to give a white solid (227 mg) with mp 169-172 ° C., the spectra consistent with 3-benzyloxy-1-methylpyrazole-4-carboxylic acid (24).

같은방법으로 에틸 5-벤질옥시-1-메틸피라졸-4-카복실레이트(755mg, 2.9mmol)을 THF(20mL), MeOH(4mL), 및 물(10mL)내에서 LiOH.H2O(243mg, 5.8mmol) 을 이용하여 가수분해하여 백색고체로서 m.p 117∼122℃인 5-벤질옥시-1-메틸-4-카복실산(25) 608mg을 얻었다.In the same manner, ethyl 5-benzyloxy-1-methylpyrazole-4-carboxylate (755 mg, 2.9 mmol) was added to LiOH.H 2 O (243 mg) in THF (20 mL), MeOH (4 mL), and water (10 mL). , 5.8 mmol) to give 608 mg of 5-benzyloxy-1-methyl-4-carboxylic acid (25) having a mp 117 to 122 ° C as a white solid.

< 다른 헤테로방향족 카복실산의 제조 ><Production of Other Heteroaromatic Carboxylic Acids>

M. Mittelbach et al., Arch. Pharm(Weinheim, Germany) 1985, 318, 481-486의 절차에 따라 4-히드록시니코틴산을 제조하였다. 2-히드록시-6-메틸니코틴산은 A.Dornow, Chem. Ber. 1940, 73, 153의 방법에 따라 제조할 수 있으며, 4,6-디메틸-2-히드록시니코틴산은 R.Mariella 및 E Belcher, J. Am. Chem. Soc.,1951, 73, 2616의 방법에 따라 제조될 수 있다.
M. Mittelbach et al., Arch. 4-hydroxynicotinic acid was prepared according to the procedure of Pharm (Weinheim, Germany) 1985, 318, 481-486. 2-hydroxy-6-methylnicotinic acid is described in A. Dornow, Chem. Ber. 1940, 73, 153, and 4,6-dimethyl-2-hydroxynicotinic acid can be prepared by R. Mariella and E Belcher, J. Am. Chem. Soc., 1951, 73, 2616.

5-클로로-2-히드록시-6-메틸니코틴산은 A. Cale et.al., J. Med. Chem., 1989, 32, 2178에 의해 제조될수 있으며, 2,5-디히드록시니코틴산은 P.Nantka Namirski와 A Rykowski, Chem. Abstr., 1972, 77, 114205의 방법에 따라 제조될 수 있다.5-Chloro-2-hydroxy-6-methylnicotinic acid is described in A. Cale et.al., J. Med. Chem., 1989, 32, 2178, wherein 2,5-dihydroxynicotinic acid is described by P. Nantka Namirski and A Rykowski, Chem. Abstr., 1972, 77, 114205.

3-히드록시이소니코틴산은 J. D. Crum 및 C. H. Fuchsman, J. Heterocycl. Chem. 1966, 3, 252-256의 방법에 따라 제조되었다.3-hydroxyisonicotinic acid is described in J. D. Crum and C. H. Fuchsman, J. Heterocycl. Chem. It was prepared according to the method of 1966, 3, 252-256.

3-히드록시피라진-2-카복실산은 A.P.Krapcho et al., J.Heterocycl. Chem. 1997, 34, 27의 방법에 따라 제조될 수 있다.3-hydroxypyrazine-2-carboxylic acid is described in A. P. Krapcho et al., J. Heterocycl. Chem. It can be prepared according to the method of 1997, 34, 27.

5,6-디메틸-3-히드록시피라진-2-카복실산은 상응하는 에틸에스테르를 가수분해하여 제조될 수 있으며, 그 합성은 S.I.Zavyalov 및 A.G.Zavozin, Izv. Akad. Nauk SSSR, 1980, (5), 1067-1070 에 기술되어 있다.5,6-dimethyl-3-hydroxypyrazine-2-carboxylic acid can be prepared by hydrolysis of the corresponding ethyl ester, the synthesis of which is described in S.I.Zavyalov and A.G.Zavozin, Izv. Akad. Nauk SSSR, 1980, (5), 1067-1070.

4-히드록시피리다진-3-카복실산은 I.Ichimoto, K.Fujii 및 C.Tatsumi, Agric. Biol. Chem. 1967, 31, 979의 방법에 따라 제조되었으며, 3,5-디히드록시-1,2,4-트리아진-6-카복실산은 E.Falco, E.Pappas, 및 G.Hitchings, J. Am.Chem. Soc., 1956, 78, 1938의 방법에 따라 제조되었다.4-hydroxypyridazine-3-carboxylic acids are described in I. Ichimoto, K. Fujii and C. Tatsumi, Agric. Biol. Chem. 3,5-dihydroxy-1,2,4-triazine-6-carboxylic acid was prepared according to the methods of 1967, 31, 979. E.Falco, E.Pappas, and G.Hitchings, J. Am. Chem. Soc., 1956, 78, 1938.

5-히드록시-3-메틸티오-1,2,4-트리아진-6-카복실산은 R.Barlow 및 A.Welch, J. Am. Chem. Soc., 1956., 78, 1258의 방법에 따라 제조되었으며, 히드록시이소티 아졸-히드록시이소옥사졸-, 및 히드록시피라졸-카복실산은 T.M.Willson et al., Bioorg. Med. Chem. Lett., 1996, 6, 1043의 방법에 의해 제조되었다.5-hydroxy-3-methylthio-1,2,4-triazine-6-carboxylic acid is described by R. Barlow and A. Welch, J. Am. Chem. Soc., 1956., 78, 1258, wherein hydroxyisothiazol-hydroxyisoxazole-, and hydroxypyrazole-carboxylic acids are described in T.M. Willson et al., Bioorg. Med. Chem. Lett., 1996, 6, 1043.

3-히드록시-1,2,5-티아디아졸-4-카복실산은 J.M.Ross et al., J.Am.Chem. Soc., 1964, 86, 2861의 방법에 의해 제조되었으며, 3-히드록시이소옥사졸-4-카복실산은 K. Bowdem et al., J. Chem. Soc.(C), 1968, 172에 기술된 방법에 따라 얻었다.3-hydroxy-1,2,5-thiadiazole-4-carboxylic acid is described in J. M. Ross et al., J. Am. Chem. Soc., 1964, 86, 2861, and 3-hydroxyisoxazole-4-carboxylic acid is described in K. Bowdem et al., J. Chem. Obtained according to the methods described in Soc. (C), 1968, 172.

3-히드록시-1-페닐피라졸-4-카복실레이트는 A.W.Taylor 및 R.T.Cook, Tetrahedron, 1987, 43, 607의 방법에 따라 생성되었으며, 3-벤질옥시키놀린-2-카복실산은 D.L.Boger 및 J.H.Chem, J.Org.Chem.1995, 60, 7369-7371의 방법에 따라 제조되었다.
3-hydroxy-1-phenylpyrazole-4-carboxylate was produced according to the methods of AWTaylor and RTCook, Tetrahedron, 1987, 43, 607, and 3-benzyloxyquinoline-2-carboxylic acid was found in DLBoger and JHChem, J. Org. Chem. 1995, 60, 7369-7371.

< 중간체 아민과 아닐린의 일반적 제법 >General Formulation of Intermediate Amine and Aniline

사이클릭, 아실 및 벤질아민의 합성은 R. O. Hutchins과 M. K. Hutchins in Comprehensive Organic Synthesis; B. M. Trost, Ed.; Pergamon Press: Oxford, 1991; Vol 8, p. 65; 혹은 J. W. Huffman in Comprehensive Organic Synthesis; B. M. Trost, Ed.;Pergamon Press: Oxford, 1991; Vol 8, p. 124에 예시된 바와같이 금속반응물을 용해시키거나 금속하이드리드를 이용하여 상응하는 옥심을 환원시켜 수행되었다.
Synthesis of cyclic, acyl and benzylamines is described by RO Hutchins and MK Hutchins in Comprehensive Organic Synthesis; BM Trost, Ed .; Pergamon Press: Oxford, 1991; Vol 8, p. 65; Or JW Huffman in Comprehensive Organic Synthesis; BM Trost, Ed .; Pergamon Press: Oxford, 1991; Vol 8, p. As illustrated at 124, this was done either by dissolving the metal reactant or by reducing the corresponding oxime using a metal hydride.

선택적으로, 이들 아민들은 R. Carlson, T. Lejon, T. Lunstedt 및 E. LeClouerec, Acta Chem. Scand. 1993, 47, 1046에 예시된 바와같이 Lenckart 반응을 통해 필요한 케톤 및 알데히드로 부터 직접 제조될수도 있다.
Optionally, these amines are described in R. Carlson, T. Lejon, T. Lunstedt and E. LeClouerec, Acta Chem. Scand. It can also be prepared directly from the ketones and aldehydes required via the Lenckart reaction as illustrated in 1993, 47, 1046.

아닐린은 일반적으로 촉매로서 숯에 담지된 Pd나 숯에 담지된 황화백금(sulfided platinum)을 이용하여 상응하는 니트로 방향족 화합물을 촉매 환원시켜 제조된다. 이같은 절차는 예를들어 R.L. Augustine, Catalytic Hydrogenation, Marcel Decker, Inc., New York, 1965 등에 잘 개시되어 있다.
Aniline is generally prepared by catalytic reduction of the corresponding nitro aromatic compound using Pd on charcoal or sulfide on platinum on charcoal. Such procedures are well described, for example, in RL Augustine, Catalytic Hydrogenation, Marcel Decker, Inc., New York, 1965.

9-멤버 디락톤 링 시스템인 아민 19는 M.Simano, N.Kamei, T.Shibata, K.Inoguchi, N.Itoh, T.Ikari 및 H.Senda, Tetrachedron, 1998, 54, 12745의 절차에 따라 혹은 그 절차를 개조하여 제조될 수 있다. 이 같은 개조는 하기 방법 6에 나타나있다.
Amine 19, a 9-membered dilactone ring system, was prepared according to the procedures of M.Simano, N.Kamei, T.Shibata, K.Inoguchi, N.Itoh, T.Ikari and H.Senda, Tetrachedron, 1998, 54, 12745 Or it can be manufactured by modifying the procedure. Such modifications are shown in Method 6 below.

이 같이,(상기 참고자료로부터) 26은 리튬 보로하이드리드로 환원되고 그 결과물인 1차 알콜은 트리이소프로필실란(TIPS)으로 캡핑되어 27을 제공한다.As such, 26 is reduced to lithium borohydride and the resulting primary alcohol is capped with triisopropylsilane (TIPS) to provide 27.

27의 자유 히드록실기는 1-브로모-2-메틸-2-프로펜과 반응후 2중결합을 촉매 환원시켜 28을 제공한다.The free hydroxyl group of 27 catalyzed the double bond after reaction with 1-bromo-2-methyl-2-propene to give 28.

파라-메톡시벤질(PMB) 브로킹 그룹을 선택제거한 후 N-t-BOC-O-벤질-L-세린과 축합하여 29를 제공한다.The para-methoxybenzyl (PMB) breaking group is deselected and then condensed with N-t-BOC-O-benzyl-L-serine to provide 29.

TIPS 기를 제거한 후 그 결과 히드록시기를 산화시켜 30을 얻는다. 이 물질 30은 이어서 상기 참고문헌에 기술된 방법을 이용하여 아민 31로 변환된다.Removal of the TIPS group results in oxidation of the hydroxy group to give 30. This material 30 is then converted to amine 31 using the method described in the above reference.

Figure 112002001377712-pct00027
Figure 112002001377712-pct00027

Figure 112002001377712-pct00028

Figure 112002001377712-pct00028

마찬가지 방법으로 엑소사이클릭 에스테르 가능기가 없는 아미노디락톤 38 및 48의 합성이 하기 방법 7 및 8에 개시되어 있다.Similarly the synthesis of aminodilactones 38 and 48 without exocyclic ester-capable groups is disclosed in methods 7 and 8 below.

Figure 112002001377712-pct00029

Figure 112002001377712-pct00029

Figure 112002001377712-pct00030
Figure 112002001377712-pct00030

< 27의 제조(방법 6참조) > <Preparation of 27 (refer to method 6)>                 

7.5mL 건조 THF내에 리튬 보로하이드리드(THF내에서 2.0M, 7.5mL, 15mmol)을 용해시킨 용액에 0.1mL 트리메틸 보레이트를 첨가하였다. 이 혼합물을 질소기권하에 -30℃까지 냉각시켰다. 이 용액에 10mL THF에 용해시킨 화합물 26(4.58g, 10mmol) 용액을 10분에 걸쳐 적정 첨가하였다. 그 용액을 -30℃에서 1시간동안 교반한 후 0℃에서 5시간동안 교반하였다. 포화된 암모늄 클로라이드 용액 (10mL)를 첨가하고 10분간 교반한 후 상분리하였다.0.1 mL trimethyl borate was added to a solution of lithium borohydride (2.0 M in THF, 7.5 mL, 15 mmol) in 7.5 mL dry THF. The mixture was cooled to −30 ° C. under a nitrogen atmosphere. To this solution was added a solution of Compound 26 (4.58 g, 10 mmol) dissolved in 10 mL THF over 10 minutes. The solution was stirred at −30 ° C. for 1 hour and then at 0 ° C. for 5 hours. Saturated ammonium chloride solution (10 mL) was added and stirred for 10 minutes before phase separation.

수성상을 EtOAc(2×25mL)로 추출하고 그 합한 유기상을 포화염수로 세척한 후 소디움 술페이트로 건조시키고 증발시켜 건조물을 얻었다. 이 조질산물을 크로마토그라피하여 2.1g 백색고체를 얻었다,The aqueous phase was extracted with EtOAc (2 × 25 mL) and the combined organic phases were washed with saturated brine, dried over sodium sulphate and evaporated to dryness. The crude product was chromatographed to give 2.1 g white solid.

헥산-EtOAc로 부터 재결정화된 시료는 백색침상을 보였고 m.p 91∼93℃,Recrystallized from hexane-EtOAc showed a white needle, m.p 91 ~ 93 ℃,

[ ]D 25 = + 31.9° (C =1.04, CHCl3)였다.
[] D 25 = + 31.9 ° (C = 1.04, CHCl 3 ).

이 디올(2.04g, 6.22mmol)을 무수 DMF 4mL에 용해시키고 이미다졸(680mg, 10mmol)을 첨가하였다. 상기 용액을 얼음조내에서 냉각시킨 다음 트리이소프로필클로로실란(1.39mL, 6.5mmol)을 2분에 걸쳐 첨가하였다.This diol (2.04 g, 6.22 mmol) was dissolved in 4 mL of anhydrous DMF and imidazole (680 mg, 10 mmol) was added. The solution was cooled in an ice bath and then triisopropylchlorosilane (1.39 mL, 6.5 mmol) was added over 2 minutes.

그 혼합물을 실온에서 4시간 동안 교반한 다음 얼음-물 내에 붓고 헥산(3×15mL)내에서 20% 에테르도 추출하였다. 결합된 유기상을 염수로 세척하고, 건조한후 실리카겔의 짧은 플럭을 통해 여과하고 통일한 용매 20mL로 세척하였다. 용매를 증발시켜 옅은 교질오일과 같은 화합물 27 2.77g을 얻었으며, 1H-NMR 결과 순수하였다.
The mixture was stirred at rt for 4 h and then poured into ice-water and 20% ether was also extracted in hexane (3 x 15 mL). The combined organic phases were washed with brine, dried and filtered through a short flop of silica gel and washed with 20 mL of uniform solvent. Evaporation of the solvent gave 2.77 g of compound 27 as pale colloidal oil, which was pure by 1 H-NMR.

< 28의 제조 (방법 6참조) >Preparation of 28 (See Method 6)

50mL 플라스크에 소디움하이드리드(60% 오일 분산물, 400mg, 10mmol)을 장입하고 헥산으로 3번 세척하였다.Sodium hydride (60% oil dispersion, 400 mg, 10 mmol) was charged to a 50 mL flask and washed three times with hexane.

DMF(15mL)를 부가하고 5mL 무수 DMF내에 용해시킨 화합물 27(2.53g, 5.19mmol)를 첨가하면서 교반하였다. 상기 반응물을 15분간 교반한 다음 10℃이하로 냉각하고 1-브로모-2-메틸-2-프로펜(1mL, 10mmol)을 5분에 걸쳐 첨가한 다음 실온에서 2시간동안 교반하였다. 그 혼합물을 헥산/얼음냉각 암모늄 크로라이드 용액사이에서 구분시키고 화합물 27의 제조에서와 같이 처리하고 그 조질산물을 크로마토그래피하여 무색오일 2.2g을 얻었으며 1H-NMR 및 원소분석결과 순수하였다. 이 물질(2.38g, 4.4mmol)을 100mL Morton 플라스크내에서 질소하에 EtOAc 50mL에 용해시켰다. 탄소에 담지된 5%Pt 150mg을 첨가하고 그 혼합물을 수소 1기압 대기하에 20분간 교반하였다. 여과하여 촉매를 제거하고 용매를 증발시켜 무색오일인 화합물 28 2.35g을 얻었으며 1H-NMR 에 의한 조사결과 순수하였다.
DMF (15 mL) was added and stirred with addition of Compound 27 (2.53 g, 5.19 mmol) dissolved in 5 mL anhydrous DMF. The reaction was stirred for 15 minutes, then cooled to below 10 ° C. and 1-bromo-2-methyl-2-propene (1 mL, 10 mmol) was added over 5 minutes and then stirred at room temperature for 2 hours. The mixture was partitioned between hexane / ice cooled ammonium chromide solution and treated as in the preparation of compound 27 and the crude product was chromatographed to give 2.2 g of colorless oil which was pure by 1 H-NMR and elemental analysis. This material (2.38 g, 4.4 mmol) was dissolved in 50 mL EtOAc under nitrogen in a 100 mL Morton flask. 150 mg of 5% Pt supported on carbon was added and the mixture was stirred for 20 minutes under a 1 atmosphere of hydrogen. The catalyst was removed by filtration and the solvent was evaporated to yield 2.35 g of compound 28 as a colorless oil, which was purified by 1 H-NMR.

< 29의 제조(방법 6참조) >Preparation of 29 (see Method 6)

자기 교반기가 달린 50mL 플라스크에 40mL CH2Cl2와 2mL물에 용해시킨 에테르(2.0g, 3.68mmol)용액을 장입하였다. In a 50 mL flask equipped with a magnetic stirrer, 40 mL CH 2 Cl 2 and an ether (2.0 g, 3.68 mmol) solution dissolved in 2 mL water were charged.

2,3-디클로로-5,6-디시아노-1,4-벤조퀴논(DDR)(920mg, 4.05mmol)을 한번에 첨가하면서 질소하에 교반하고 얼음조내에서 10℃이하로 냉각시켰다.2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDR) (920 mg, 4.05 mmol) was added under stirring with nitrogen and cooled to 10 ° C. or less in an ice bath.

상기 얼음조를 제거하고 상기 혼합물을 상온에서 1시간 동안 교반 하였다. 금색 서스펜션을 1시간 동안 교반하였으며, 케이크로 2×10mL CH2Cl2로 세척하고, 여과물을 0.2N NaOH(2×25mL)로 추출하였다.The ice bath was removed and the mixture was stirred at room temperature for 1 hour. The gold suspension was stirred for 1 hour, washed with 2 × 10 mL CH 2 Cl 2 with cake and the filtrate was extracted with 0.2N NaOH (2 × 25 mL).

유기층을 건조 및 농축시켜 담 오일을 얻었으며, 크로마토그라피로 정제하여 무색오일 1.53g을 얻었으며, 원소분석결과 순수하였다.The organic layer was dried and concentrated to obtain a pale oil, which was purified by chromatography to give 1.53 g of colorless oil.

이를 25mL CH2Cl2에 용해시키고 DMAP(854mg, 7mmol), EDCI(1.34mg, 7mmol), 및 N-t-BOC-O-벤질-L-세린(2.07g, 7mmol)을 순차적으로 천천히 첨가하면서 질소하에 얼음조내에서 교반하였다.It was dissolved in 25 mL CH 2 Cl 2 and under nitrogen while slowly adding DMAP (854 mg, 7 mmol), EDCI (1.34 mg, 7 mmol), and Nt-BOC-O-benzyl-L-serine (2.07 g, 7 mmol) sequentially. Stir in an ice bath.

냉각조를 제거하고, 혼합물을 실온에서 2시간 동안 교반한 다음 신속히 교반하는 얼음냉각 0.5N HCl 50mL와 CH2Cl2 20mL의 혼합물에 붓고 10분간 냉각하였다. The cooling bath was removed, the mixture was stirred at room temperature for 2 hours, and then poured into a mixture of 50 mL of ice-cooled 0.5N HCl and 20 mL of CH 2 Cl 2 which was stirred rapidly and cooled for 10 minutes.

상을 분리하고 수성상을 1×10mL CH2Cl2로 추출한 후 결합된 유기상을 건조 및 농축시켜 옅은 오일을 얻었다. 이를 크로마토그라피하여 거의 무색인 진한 오일과 같은 화합물 29 2.3g을 얻었다. TLC 및 1H-NMR 결과 아주 순수하였다.
The phases were separated and the aqueous phase was extracted with 1 × 10 mL CH 2 Cl 2 , then the combined organic phases were dried and concentrated to give a pale oil. This was chromatographed to give 2.3 g of a compound 29, like a colorless dark oil. TLC and 1 H-NMR results were very pure.

< 30의 제조(방법 6참조) ><Preparation of 30 (see Method 6)>

시릴 에테르 29를 7mL 무수 피리딘에 용해시키고 얼음조내에서 냉각시켰다. HF-피리딘 복합물(4.5mL)를 1분에 걸쳐 첨가하고 그 용액을 실온에서 17시간 동안 교반 한 다음 4.5시간동안 50℃로 가열하였으며, 그때 변환이 중단되었다.Cyryl ether 29 was dissolved in 7 mL anhydrous pyridine and cooled in an ice bath. HF-pyridine complex (4.5 mL) was added over 1 minute and the solution was stirred at room temperature for 17 hours and then heated to 50 ° C. for 4.5 hours, at which time the conversion was stopped.

그 혼합물을 얼음-물에 넣고 3×50mL 에테르로 추출하였다. 결합된 유기상을 물, 1N HCl로 세척하고나서 건조후 농축시켜 오일을 얻었다.The mixture was poured into ice-water and extracted with 3 x 50 mL ether. The combined organic phases were washed with water, 1N HCl, dried and concentrated to give an oil.

이를 크로마토그라피하여 교질상 오일로서 요구되는 알콜 1.23g 및 회수된 29 365mg을 얻었다.This was chromatographed to give 1.23 g of alcohol required as a colloidal oil and 365 mg recovered 29.

알콜(1.14g, 2.10mmol)을 10mL DMF에 용해시키고 피리디늄 디크로메이트(3.76g, 10 mmol)을 첨가하였다.Alcohol (1.14 g, 2.10 mmol) was dissolved in 10 mL DMF and pyridinium dichromate (3.76 g, 10 mmol) was added.

21시간후, 그 혼합물을 얼음-물에 넣고 1N HCl을 pH가 3이하로 될때까지 첨가한 다음 오렌지색이 탈색될때까지 고체 소디움바이술파이트를 첨가하였다.After 21 hours, the mixture was poured into ice-water and 1N HCl was added until the pH was below 3 and solid sodium bisulfite was added until the orange was decolorized.

수성상을 에테르 (3×50mL)로 추출하였다. 유기상을 합하고, 세척 및 건조(NaSO4)후 농축시켰다. 잔류물을 크로마토그래피하여 순수한 교질오일 811mg을 얻었다. 상기 산을 EtOAc 30mL에 용해시키고 펄맨 촉매(Pearlman's Catalyst) 200mg을 첨가하였다.The aqueous phase was extracted with ether (3 x 50 mL). The organic phases were combined, concentrated after washing and drying (NaSO 4 ). The residue was chromatographed to give 811 mg of pure colloidal oil. The acid was dissolved in 30 mL EtOAc and 200 mg of Pearlman's Catalyst was added.

그 슬러리를 50psi 수소압력하에 4시간동안 흔들고 300mg 새로운 촉매를 첨가하였으며, 2시간 더 흔들었다.The slurry was shaken under 50 psi hydrogen pressure for 4 hours, 300 mg fresh catalyst was added, and shaken for another 2 hours.

그후 여과하였으며 용매 증발시켜 순수한 교질껌 30을 얻었다.
It was then filtered and solvent evaporated to give pure Collagen Gum 30.

< 클레오닌디티안(threoninedithiane) 33 (방법 7참조) ><Threoninedithiane 33 (see Method 7)>

펜틸디티안 32(Hirai, Heterocyles 1990, 30(2, Spec.Issue), 1101)(200mg, 0.97mmol)을 CH2Cl2 10mL에 실온에서 용해시켰다. N-(Z)-O-t-부틸-(L)-트레오닌(900mg, 2.91mmol)을 첨가하고 이어서 DMAP(36mg, 0.29mmol)을 첨가하였다. 이 혼합물에 디시클로헥실 카보디이미드(DCC)(CH2Cl2에 1M, 2.9mL, 209mmol)용액을 적정첨가한 후 실온에서 밤새 교반하였다.Pentyldithiane 32 (Hirai, Heterocyles 1990, 30 (2, Spec. Issue), 1101) (200 mg, 0.97 mmol) was dissolved in 10 mL of CH 2 Cl 2 at room temperature. N- (Z) -Ot-butyl- (L) -threonine (900 mg, 2.91 mmol) was added followed by DMAP (36 mg, 0.29 mmol). A solution of dicyclohexyl carbodiimide (DCC) (1M, 2.9 mL, 209 mmol) in CH 2 Cl 2 was added to the mixture, followed by stirring at room temperature overnight.

그 반응물을 에테르(Et2O)50mL로 희석시키고 여과 및 농축시켰다. 그 결과 잔류물을 작은(4″)실리카 겔 중력 컬럼에 적용하고 4:1 헥삭/EtOAc으로 용출하였다.The reaction was diluted with 50 mL of ether (Et 2 O), filtered and concentrated. As a result, the residue was applied to a small (4 ″) silica gel gravity column and eluted with 4: 1 hex / EtOAc.

상기 실리카 겔 컬럼으로 부터 수집된 용출물을 다시 4:1 헥산/EtOAc를 용리액으로 사용하여 래디얼 크로마토그래피로 정재하였다.The eluate collected from the silica gel column was again purified by radial chromatography using 4: 1 hexanes / EtOAc as eluent.

산물을 증발시키고 일정중량으로 고진공(45℃ ⓐ 0.1 torr)을 유지하여 거의 무색인 진한오일 500mg을 얻었으며 디티안 33(TLC R5=0.32, 1H-NMR)로 식별되었다.
The product was evaporated and maintained at high vacuum (45 ° C. 0.1 torr) at a constant weight to yield 500 mg of a nearly colorless dark oil, identified as Ditian 33 (TLC R 5 = 0.32, 1 H-NMR).

< 트레오닌카복실산 35(방법 7참조) ><Threonine Carboxylic Acid 35 (See Method 7)>

트레오닌티안 33(500mg, 1.01mmol)을 실온에서 9:1 CH3CN/H2O 화합물 10mL에 용해시켰다. [ 비스(트리플루오로아세톡시)요오도 ] 벤젠(650mg, 1.50mmol)을 첨가하고 10분간 교반하였다.Threonintian 33 (500 mg, 1.01 mmol) was dissolved in 10 mL of 9: 1 CH 3 CN / H 2 O compound at room temperature. [Bis (trifluoroacetoxy) iodo] Benzene (650 mg, 1.50 mmol) was added and stirred for 10 minutes.

포화된 NaHCO3(20ml)를 첨가하고 그 용액을 Et2O(3×20mL)로서 추출하였다. Saturated NaHCO 3 (20 ml) was added and the solution was extracted as Et 2 O (3 × 20 mL).

에테르층을 MgSO4로 건조시키고, 여과후 농축시켰다. 알데히드 34는 충분히 순수하며(TLC, GC/MS) 다음반응에 직접 사용가능했다. 조질 알데히드롤 CrO3시약(1g CrO3, 30mL CH3CO2H 및 1mL 피리딘으로 제조됨) 15mL 내에 넣고 실온에서 밤새 교반하였다.The ether layer was dried over MgSO 4 , filtered and concentrated. Aldehyde 34 is pure enough (TLC, GC / MS) and can be used directly for the next reaction. 15 mL crude aldehyde CrO 3 reagent (prepared with 1 g CrO 3 , 30 mL CH 3 CO 2 H and 1 mL pyridine) was added and stirred overnight at room temperature.

그 용액을 30mL 냉수로 희석시키고 Et2O(3×30mL)로 추출하였다. 유기층을 30mL 염수로 세척하고 MgSO4건조후 여과 및 농축하였다. 잔류물을 용리액으로서 2% CH3CO2H 를 함유한 2:1 헵탄/EtOAc를 사용하여 래디얼 크로마토그래피로 정제하였다.The solution was diluted with 30 mL cold water and extracted with Et 2 O (3 × 30 mL). The organic layer was washed with 30 mL brine, dried over MgSO 4 , filtered and concentrated. The residue was purified by radial chromatography using 2: 1 heptanes / EtOAc containing 2% CH 3 CO 2 H as eluent.

카복실산 35(12mg)은 TLC 및 1H-NMR 결과 아주 순수하였다.
Carboxylic acid 35 (12 mg) was very pure by TLC and 1 H-NMR.

< 트레오닌히드록시카복실산 36 (방법 7 참조)><Threonine Hydroxycarboxylic Acid 36 (See Method 7)>

트레오닌카복실산 35(137mg, 0.324mmol)을 트리플루오로아세트산 3mL내에서 10분간 교반하였으며, 그 혼합물을 회전 증발기상에서 농축시켰다.Threoninecarboxylic acid 35 (137 mg, 0.324 mmol) was stirred in 3 mL of trifluoroacetic acid for 10 minutes and the mixture was concentrated on a rotary evaporator.

잔류물을 고압(0.05mm)하에 밤새 건조시켰다. 그 히드록시산 36(119mg)을 다음 단계에 바로 사용하였다.
The residue was dried overnight under high pressure (0.05 mm). The hydroxy acid 36 (119 mg) was used directly in the next step.

< N-Cbz-트레오닌비스락톤 37(방법 7참조) > <N-Cbz-threoninebislactone 37 (see Method 7)>

트레오닌히드록시 카복실산 36(119mg, 0.324mmol)을 1mL벤젠에 용해시키고 Aldrithiol

Figure 112002001377712-pct00031
-2를 첨가(85mg, 0.39mmol)한 후 트리페닐포스핀(0.39mmol, 101mg)을 첨가하고 밤새 교반하였다. 그 조질 티오에스테르를 CH3CN 15mL로 희석하였다. 환류 컨덴서가 달린 별도의 플라스크에 AgClO4 1.0M 1.2mL(1.16mmol)을 톨루엔에 용해시킨 용액을 장입한후, CH3CN 32mL를 장입하였다.Threoninehydroxy carboxylic acid 36 (119 mg, 0.324 mmol) was dissolved in 1 mL benzene and Aldrithiol
Figure 112002001377712-pct00031
-2 was added (85 mg, 0.39 mmol) followed by triphenylphosphine (0.39 mmol, 101 mg) and stirred overnight. The crude thioester was diluted with 15 mL of CH 3 CN. To a separate flask with a reflux condenser was charged with a solution of 1.2 mL (1.16 mmol) of AgClO 4 1.0M in toluene, followed by charging 32 mL of CH 3 CN.

이 용액을 5∼10방울/sec 환류속도로(오일조∼160℃)가열하였다. 그 티오에스테르 용액을 그후 상기 컨덴서의 상단에서 첨가 펀넬을 통해 2시간에 걸쳐 적정 첨가하였다. 그 혼합물을 30분간 더 환류하고, 냉각 및 농축시켰다. 그 잔류물을 10mL 0.5M KCN으로 희석하고 벤젠(3×20mL)으로 추출하였다.The solution was heated at 5 to 10 drops / sec reflux rate (oil bath to 160 ° C.). The thioester solution was then titrated over 2 hours via an addition funnel at the top of the condenser. The mixture was further refluxed for 30 minutes, cooled and concentrated. The residue was diluted with 10 mL 0.5 M KCN and extracted with benzene (3 x 20 mL).

벤젠층을 합하고, 20mL물로 세척하고, MgSO4로 건조하고, 여과 및 농축시켰다. 그 후 잔류물을 2:1 펜탄/Et2O 10mL에 넣고 여과하였다. 고체를 2:1 펜탄/Et2O로 씻고 결합된 유기용액을 농축시켰다. 래디얼 크로마토그라피(2:1 펜탄/Et2O로 용리액으로 사용)결과 비스락톤 37 34mg를 제공하였으며, TLC(R5=0.22)와 1H-NMR 결과 아주 순수하였다.
The benzene layers were combined, washed with 20 mL water, dried over MgSO 4 , filtered and concentrated. The residue was then taken up in 10 mL of 2: 1 pentane / Et 2 O and filtered. The solid was washed with 2: 1 pentane / Et 2 O and the combined organic solutions were concentrated. Radial chromatography (2: 1 pentane / Et 2 O as eluent) gave 34 mg of bislactone 37, which was very pure by TLC (R 5 = 0.22) and 1 H-NMR.

< 3-아미노-4,7,9-트리메틸비스락톤 38 (방법 7참조) ><3-amino-4,7,9-trimethylbislactone 38 (see Method 7)>

N-Cbz-트레오닌비스락톤 37(34mg, 0.097mmole)을 500mL Parr 용기내의 메탄올 10mL에 용해시키고 질소쓸기 하였다. 이 용액에 Pd(블랙) 10mg을 첨가하고 그 혼합물을 45psi 수소압력으로 1시간동안 흔들었다.N-Cbz-threoninebislactone 37 (34 mg, 0.097 mmol) was dissolved in 10 mL of methanol in a 500 mL Parr container and nitrogen-swept. To this solution was added 10 mg of Pd (black) and the mixture was shaken at 45 psi hydrogen pressure for 1 hour.

상기 촉매를 여과하고 용매를 증발시켜 유지 아민 38(20mg, 100%)을 얻었다. 이 아민은 순수하였으며 (1H-NMR) 더이상의 정제없이 그대로 사용되었다.
The catalyst was filtered off and the solvent was evaporated to give oily amine 38 (20 mg, 100%). This amine was pure ( 1 H-NMR) and used as such without further purification.

< 3-벤질-4-히드록시-5-메틸부티로락톤 40 (방법 8참조) ><3-benzyl-4-hydroxy-5-methylbutyrolactone 40 (see method 8)>

펜탄산 39(Shimono et al., Tetrahedron Lett. 1998, 39, 4363)(1.8g, 5.23mmol)을 500mL Parr 용기내의 메탄올 30mL에 용해시키고 질소 쓰기 하였다.Pentanic acid 39 (Shimono et al., Tetrahedron Lett. 1998, 39, 4363) (1.8 g, 5.23 mmol) was dissolved in 30 mL of methanol in a 500 mL Parr vessel and nitrogen was used.

이 용액에 탄소상에 담지된 10% Pd 150mg을 첨가한 후 진한 HCl 6방울을 첨가하였다.To this solution was added 150 mg of 10% Pd supported on carbon followed by the addition of 6 drops of concentrated HCl.

그 혼합물은 50psi 수소압력에서 3시간 흔들었다. 촉매를 규조토를 통해 여과하고 용액을 농축시켰다. 잔류물을 30mL CH2Cl2 내에 취하고 물로 세척(1×10mL)하였다. 이 용액을 MgSO4 상에서 건조시키고, 여과 시킨다음 농축하였다. 1H-NMR 및 GC/MS 결과 부티로락톤 40 및 4-메틸아니솔이 4:1 비율(v/v)로 되어 있었다. 이 물질(GC에 의해 60%순도)은 다음반응에 바로 사용되었다.
The mixture was shaken for 3 hours at 50 psi hydrogen pressure. The catalyst was filtered through diatomaceous earth and the solution was concentrated. The residue was taken up in 30 mL CH 2 Cl 2 and washed with water (1 × 10 mL). This solution was dried over MgSO 4 , filtered and concentrated. 1 H-NMR and GC / MS showed butyrolactone 40 and 4-methylanisole in a 4: 1 ratio (v / v). This material (60% pure by GC) was used directly in the next reaction.

< 3-벤질-5-메틸부테놀이드 41 (방법 8참조) ><3-benzyl-5-methylbutenode 41 (see method 8)>

3-벤질-4-히드록시-5-메틸부티로락톤 40(60%순도, 1.7g, 8.25mmol)을 25mL CH2Cl2 에 용해시키고 0℃로 냉각시켰다. 3-benzyl-4-hydroxy-5-methylbutyrolactone 40 (60% purity, 1.7 g, 8.25 mmol) was dissolved in 25 mL CH 2 Cl 2 and cooled to 0 ° C.

트리에틸아민(2.3mL, 16.5mmol), DMAP(500mg, 4.13mmol) 및 p-톨루엔술포닐 클로라이드(9.0mmol, 1.7g)를 순차적으로 첨가하면서 상기 용액을 교반하였다.The solution was stirred with triethylamine (2.3 mL, 16.5 mmol), DMAP (500 mg, 4.13 mmol) and p-toluenesulfonyl chloride (9.0 mmol, 1.7 g) sequentially.

반응물을 실온으로 한 후 30시간 교반하였다. 반응물을 50mL Et2O로 희석시키고 5% NaHCO3(25mL)로 세척하였다. 그 용액을 MgSO4 상에서 건조하고 여과시킨다음 농축하였다. 잔류물을 용리액으로서 2:1 펜탄/Et2O를 사용하여 래디얼 크로마토그래피를 통해 정제 하였으며 부테놀이드(butenolide)41 677mg 을 얻었다.(95% 이상 순도, GC 및 1H-NMR).
The reaction was brought to room temperature and stirred for 30 hours. The reaction was diluted with 50 mL Et 2 O and washed with 5% NaHCO 3 (25 mL). The solution was dried over MgSO 4 , filtered and concentrated. The residue was purified by radial chromatography using 2: 1 pentane / Et 2 O as eluent to give 677 mg of butenolide 41 (more than 95% purity, GC and 1 H-NMR).

< 시스-3-벤질-5-메틸부티로락톤 42 (방법 8참조) ><Cis-3-benzyl-5-methylbutyrolactone 42 (see Method 8)>

3-벤질-5-메틸부테놀이드 41(677mg, 3.60mmol)을 500mL Parr 용기내에서 EtOAc 30mL에 용해시키고 질소 쓸기 하였다. 이 용액에 10% Pd/c 300mg을 첨가하고 그 혼합물을 45psi 수소압력에서 밤새 흔들었다.3-benzyl-5-methylbutenode 41 (677 mg, 3.60 mmol) was dissolved in 30 mL of EtOAc in a 500 mL Parr vessel and purged with nitrogen. 300 mg of 10% Pd / c was added to the solution and the mixture was shaken at 45 psi hydrogen pressure overnight.

상기 촉매를 여과하고 용매를 증발시켰다. 용리액으로 2:1 펜탄/Et2O를 사용하여 래디얼 크로마토그래피하여 잔류물을 정제하여 무색오일 484mg을 얻었다(CDCl3 내에서의 1H-NMR 및 GC로 순수물질 71%수율).
The catalyst was filtered off and the solvent was evaporated. The residue was purified by radial chromatography using 2: 1 pentane / Et 2 O as the eluent to give 484 mg of colorless oil (71% yield of pure material by 1 H-NMR and GC in CDCl 3 ).

< 2-벤질펜틸티안 43(방법 8참조) ><2-benzylpentylthiane 43 (see Method 8)>

시스-3-벤질-5-메틸부티로락톤 42(550mg, 2.89mmole)을 Et2O 15mL에 용해시키고 -78℃까지 냉각시켰다. Cis-3-benzyl-5-methylbutyrolactone 42 (550 mg, 2.89 mmole) was dissolved in 15 mL of Et 2 O and cooled to -78 ° C.

디이소부틸 알루미늄 하이드리드(헥산내 1.0M, 3.47mmole, 3.5mL)를 직접첨가하고 -78℃에서 2시간동안 교반하였다. 15분에 걸쳐 메탄올(3.3mL)를 첨가하고 -78℃에서 30분간 더 반응물을 교반하였다. 소디움 포타슐 타르트레이트(물 5mL내의 1.65g)를 첨가하고 반응물을 실온으로 승온시키고 밤새 교반하였다.Diisobutyl aluminum hydride (1.0 M in hexane, 3.47 mmol, 3.5 mL) was added directly and stirred at −78 ° C. for 2 hours. Methanol (3.3 mL) was added over 15 minutes and the reaction stirred for 30 minutes at -78 ° C. Sodium potassile tartrate (1.65 g in 5 mL of water) was added and the reaction was allowed to warm to room temperature and stirred overnight.

층분리하고 수성층은 Et2O(2×10mL)로 추출하였다. 결합된 에테르층을 포화 NaHCO3 및 염수(1×10mL)로 세척하였다. 그 용액을 MgSO4 상에서 건조하고 여과 및 농축시켰다. 조질 락톨(555mg)을 CH2Cl2 5mL에 용해시키고 0℃로 냉각하였다.The layers were separated and the aqueous layer was extracted with Et 2 O (2 × 10 mL). The combined ether layer was washed with saturated NaHCO 3 and brine (1 × 10 mL). The solution was dried over MgSO 4 , filtered and concentrated. Crude lactol (555 mg) was dissolved in 5 mL of CH 2 Cl 2 and cooled to 0 ° C.

1,3-프로판디티올(3.46mmol, 0.35mL)를 첨가한후 보론 트리플루오라이드 에테레이트 0.37mL(2.89mmol)을 첨가하였다. 반응물을 실온으로 승온시킨다음 밤새 교반하였다. 포화 NaHCO3 를 첨가하고(20mL) 그 혼합물을 1시간 교반하였다. 층분리하고 수성층을 CH2Cl2 (2×10mL)로 추출하였다.1,3-propanedithiol (3.46 mmol, 0.35 mL) was added followed by 0.37 mL (2.89 mmol) boron trifluoride etherate. The reaction was allowed to warm up to room temperature and then stirred overnight. Saturated NaHCO 3 was added (20 mL) and the mixture was stirred for 1 h. The layers were separated and the aqueous layer was extracted with CH 2 Cl 2 (2 × 10 mL).

결합된 유기층은 염수(1×20mL)로 씻고 MgSO4 상에서 건조한후 여과 및 농축시켰다. 잔류물을 용리액으로서 3:1 헥산/EtOAc을 이용한 래디얼 크로마토그라피 정제하여 황색오일 560mg을 얻었다(1H-NMR 및 GC 에 의한 순수 물질은 수율 69%).
The combined organic layer was washed with brine (1 × 20 mL), dried over MgSO 4 , filtered and concentrated. The residue was purified by radial chromatography using 3: 1 hexanes / EtOAc as eluent to give 560 mg of yellow oil (69% yield for pure material by 1 H-NMR and GC).

< 세리디티안 44 (방법 8참조) ><Seridian 44 (See Method 8)>

2-벤질페닐디티안 43(560mg, 1.99mmol)을 DMF 5mL에 용해시키고 0℃로 냉각시켰다. DMAP(0.29mmol, 36mg)을 첨가한 후 EDCI(0.57g, 2.98mmol)을 첨가하였다. N-t-BOC-O-벤질-(L)-세린(760mg, 2.58mmol)을 그후 첨가한 다음 실온으로 승온시키고 밤새 교반하였다.2-benzylphenyldithiane 43 (560 mg, 1.99 mmol) was dissolved in 5 mL of DMF and cooled to 0 ° C. DMAP (0.29 mmol, 36 mg) was added followed by EDCI (0.57 g, 2.98 mmol). N-t-BOC-O-benzyl- (L) -serine (760 mg, 2.58 mmol) was then added and then warmed to room temperature and stirred overnight.

반응물을 급속시 교반하는 얼음냉각 0.5N HCl 10mL와 20% 에테르/헥산 20mL의 혼합물에 붓고 10분간 교반하였다. 층분리하고 수성층을 20% 에트르/헥산(1×10mL)으로 추출하였다. 결합유기층을 0.5N HCl(20mL)과 염수(2×20mL)로 세척하였다. 그 용액을 MgSO4 상에서 건조시키고 여과 및 농축시켰다. 그 결과물인 잔류물을 고진공(45℃ⓐ 0.1 torr)하여 일정중량으로 방치하여 거의 무색인 헤비오일 1.06g을 얻었으며 디티안 44로 식별되었다(TLC R5=0.3, 3:1 헥산/EtOAc).
The reaction was poured into a mixture of 10 mL of ice cold 0.5N HCl and 20 mL of 20% ether / hexane, which was stirred rapidly and stirred for 10 minutes. The layers were separated and the aqueous layer was extracted with 20% ether / hexanes (1 × 10 mL). The combined organic layer was washed with 0.5N HCl (20 mL) and brine (2 × 20 mL). The solution was dried over MgSO 4, filtered and concentrated. The resulting residue was subjected to high vacuum (45 ° C ⓐ 0.1 torr) and left to constant weight to give 1.06 g of a substantially colorless heavy oil, identified as Ditian 44 (TLC R 5 = 0.3, 3: 1 hexanes / EtOAc). .

< N-t-BOC-O-벤질세린카복실산 45(방법 8참조) ><N-t-BOC-O-benzylserinecarboxylic acid 45 (see Method 8)>

세린디티안 44(1.06g, 1.90mmol)을 실온에서 9:1 CH3CN/H2O 혼합물 20mL에 용해시켰다.Serindian 44 (1.06 g, 1.90 mmol) was dissolved in 20 mL of a 9: 1 CH 3 CN / H 2 O mixture at room temperature.

[비스(트리플루오로아세톡시)요오도] 벤젠(1.2g, 2.82mmol)을 첨가하고 10분간 교반하였다. 포화 NaHCO3를 첨가하고(40mL) Et2O (3×40mL) 로 용액추출하였다. [Bis (trifluoroacetoxy) iodo] Benzene (1.2 g, 2.82 mmol) was added and stirred for 10 minutes. Saturated NaHCO 3 was added (40 mL) and the solution extracted with Et 2 O (3 × 40 mL).

에테르층을 MgSO4 상에서 건조시키고, 여과 및 농축시켰다. 이 알데히드는 충분히 순수하여(TLC, GS/Ms, 1H-NMR) 다음반응에 직접 사용할 수 있었다.The ether layer was dried over MgSO 4 , filtered and concentrated. This aldehyde was sufficiently pure (TLC, GS / Ms, 1 H-NMR) and could be used directly for the next reaction.

조질 알데히드를 CrO3 시약(CrO3 1g, CH3CO2H 30mL 및 피리딘 1mL로 제조된) 30mL(9.70mmol)에 처리하고 실온에서 밤새 교반하였다.Crude aldehyde was treated with 30 mL (9.70 mmol) of CrO 3 reagent (prepared with 1 g CrO 3 , 30 mL CH 3 CO 2 H and 1 mL pyridine) and stirred overnight at room temperature.

그 용액을 냉수 6mL로 희석하고 Et2O(3×60mL)로 추출하였다. 유기층을 2×60mL 염수로 세척하고, MgSO4 상에서 건조시키고, 여과 및 농축하였다. 그 잔류물을 2:1 헵탄/EtOAc 내에 넣고 증발하였다. 용리액으로 2% CH3CO2H를 함유한 1.5:1 헵탄/EtOAc를 사용하여 래디얼 크로마토그래피하여 정제하였다. 그 카본실산(536mg)은 TLC 및 1H-NMR에 의해 아주 순수한것으로 보였으며 CDCl3에서는 2개의 t-BOC 로테이머(rotamers)가 명확하였으나 아세톤-d6에서는 그렇지 않았다.
The solution was diluted with 6 mL of cold water and extracted with Et 2 O (3 × 60 mL). The organic layer was washed with 2 x 60 mL brine, dried over MgSO 4 , filtered and concentrated. The residue was taken up in 2: 1 heptane / EtOAc and evaporated. Purification by radial chromatography using 1.5: 1 heptane / EtOAc containing 2% CH 3 CO 2 H as eluent. The carbonic acid (536 mg) appeared to be very pure by TLC and 1 H-NMR and two t-BOC rotamers were apparent in CDCl 3 but not in acetone-d 6 .

< N-t-BOC-세린비스락톤 47 (방법 8참조) ><N-t-BOC-serinebislactone 47 (see Method 8)>

N-t-BOC-O-벤질세린카복실산 45(536mg, 1.11mmol)을 500mL Parr 용기내에서 EtOAc 15mL내에 용해시켰으며 질소쓸기 하였다. 이 용액에 10% Pd/c 390mg을 첨가하고 그 혼합물을 50psi 수소압에서 17시간동안 흔들었다.N-t-BOC-O-benzylserinecarboxylic acid 45 (536 mg, 1.11 mmol) was dissolved in 15 mL of EtOAc in a 500 mL Parr vessel and purged with nitrogen. 390 mg of 10% Pd / c was added to this solution and the mixture was shaken at 50 psi hydrogen pressure for 17 hours.

규조토를 통해 상기 촉매를 여과하고 용매를 증발시켜 히드록시산 46(440mg)을 얻었다. 조질 히드록시산 46을 벤젠 23L에 용해시키고 트리페닐포스핀(0.34g, 1.28mmol)을 실온에서 첨가하였다. 디이소프로필아조디카복실레이트 (DIAD, 0.25mL, 1.28mmol)을 적정첨가하고 반응물을 실온에서 밤새 교반하였다.The catalyst was filtered through diatomaceous earth and the solvent was evaporated to give hydroxy acid 46 (440 mg). Crude hydroxy acid 46 was dissolved in 23 L of benzene and triphenylphosphine (0.34 g, 1.28 mmol) was added at room temperature. Diisopropylazodicarboxylate (DIAD, 0.25 mL, 1.28 mmol) was titrated and the reaction stirred overnight at room temperature.

용액을 농축시키고 그 결과물인 잔류물은 작은(4″)중력컬럼에 적용하고 2:1 헥산/EtOAc로 용출하였다. 실리카겔 컬럼으로부터 나온 용출물은 용리액으로서 2:1 펜탄/에테르를 사용하여 래디얼 크로마토그래피로 정제시켰다. 산물을 증발시켜 N-t-BOC-세린비스락톤로 식별된 황색오일 132mg을 얻었다(TLC Rf=0.32, 1H-NMR에 의해 순수).
The solution was concentrated and the resulting residue was applied to a small (4 ″) gravity column and eluted with 2: 1 hexanes / EtOAc. The eluate from the silica gel column was purified by radial chromatography using 2: 1 pentane / ether as eluent. The product was evaporated to give 132 mg of yellow oil, identified as Nt-BOC-serinebislactone (TLC R f = 0.32, pure by 1 H-NMR).

< 3-아미노-7-벤질-9-메틸비스락톤 48 (방법 8참조) ><3-amino-7-benzyl-9-methylbislactone 48 (see Method 8)>

N-t-BOC-세린비스락톤 47(132mg, 0.35mmole)을 트리플루오로아세트산 3mL에서 30분간 교반하고, 그 반응물을 회전증발기에서 농축시켰다. 잔류물을 고진공(0.05mm)하에서 밤새 건조시켰다. 아민 48(0.35mmol)의 트리플루오로아세트산염은 1H-NMR에 의해 아주 순수했으며 더이상의 정제없이 사용되었다.
Nt-BOC-serinebislactone 47 (132 mg, 0.35 mmol) was stirred in 3 mL of trifluoroacetic acid for 30 minutes and the reaction was concentrated on a rotary evaporator. The residue was dried under high vacuum (0.05 mm) overnight. Trifluoroacetic acid salt of amine 48 (0.35 mmol) was very pure by 1 H-NMR and used without further purification.

< 3-(3-클로로펜옥시) 아닐린 ><3- (3-chlorophenoxy) aniline>

Figure 112002001377712-pct00032
Figure 112002001377712-pct00032

DMSO(100mL)내에 포타슘 t-부톨사이드(12.3g)을 용해시킨 교반용액에 3-클로로페놀(12.86g)을 단번에 첨가하였다. 그 결과물인 용액을 실온에서 5분간 교반한 후 3-플루오로니트로벤젠(12.70g)을 단번에 첨가하였다.3-chlorophenol (12.86 g) was added all at once to a stirring solution in which potassium t-butoxide (12.3 g) was dissolved in DMSO (100 mL). The resulting solution was stirred for 5 minutes at room temperature and then 3-fluoronitrobenzene (12.70 g) was added in one portion.

그 결과적인 짙은 혼합물을 12시간동안 120℃로 가열하고 실온으로 냉각시킨다음 물에 부었다(700mL). 그 결과 혼합물을 에테르(2×200mL)로 추출하였다.The resulting dark mixture was heated to 120 ° C. for 12 hours, cooled to room temperature and poured into water (700 mL). As a result, the mixture was extracted with ether (2 × 200 mL).

유기분을 2N NaOH(100mL)으로 세척한 후 물(100mL)로 세척하였다. 건조(MgSO4)후, 용매를 증발시키고 그 결과물인 짙은 오일을 증류시켜 황색오일로서 3-(3-클로로페녹시)니트로벤젠을 얻었으며, 0.05mm에서 b.p 135∼140℃ 였다.The organics were washed with 2N NaOH (100 mL) and then with water (100 mL). After drying (MgSO 4 ), the solvent was evaporated and the resulting dark oil was distilled to give 3- (3-chlorophenoxy) nitrobenzene as a yellow oil, bp 135-140 ° C. at 0.05 mm.

3-(3-클로로펜옥시) 니트로벤젠(14g)과 황화탄소에 담지시킨 5%Pt를 EtOAc(150mL)에 혼합한 혼합물을 Parr 세이커 상에서 수소대기(초기 압력=50psi)에 처하였다.A mixture of 3- (3-chlorophenoxy) nitrobenzene (14 g) and 5% Pt supported on carbon sulfide in EtOAc (150 mL) was subjected to hydrogen atmosphere (initial pressure = 50 psi) on a Parr shaker.

4시간후, 그 혼합물을 철저히 탈기(수소를 질소로 대체), 건조(MgSO4) 및 여과(#50 Whatman paper)하였다. 용매를 증발시켜 담황색으로(12g)을 얻었으며 GC에 의해 순도60% 이상이었다. 1H-NMR(CDCl3)와 GC/MS(m/e=219, 221)는 3-(3-클로로펜옥시)아닐린과 일치하였다.
After 4 hours, the mixture was thoroughly degassed (replace hydrogen with nitrogen), dried (MgSO 4 ) and filtered (# 50 Whatman paper). The solvent was evaporated to give a pale yellow (12 g), which was more than 60% pure by GC. 1 H-NMR (CDCl 3 ) and GC / MS (m / e = 219, 221) were consistent with 3- (3-chlorophenoxy) aniline.

< 3-(4-트리플루오로메틸펜옥시)아닐린 ><3- (4-trifluoromethylphenoxy) aniline>

Figure 112002001377712-pct00033
Figure 112002001377712-pct00033

DMSO(50mL)내에 3-히드록시아닐린(6.55g)과 4-플루오로 벤조트리 플루오라이드(9.85g)을 용해시킨 교반용액에 포타슘 tert-부톡사이드(7.86g)을 단번에 첨가하 였다. 그 결과물인 짙은 용액을 95℃에서 4시간동안 가열하고 실온으로 냉각시킨다음 물(600mL)에 부었다. 그 혼합물을 에테르(3×125mL)로 추출하였다. 유기상을 2N 수산화나트륨(2×75mL) 및 물(100mL)로 세척하고, 건조(MgSO4)하였으며, 용매를 증발시켜 짙은 오일을 얻었다. 이 오일을 증류하여 무색오일인 원하는 아닐린을 얻었으며(8.7g), 0.15mm에서 b.p 110∼112℃였다.
Potassium tert-butoxide (7.86 g) was added at once to a stirring solution in which 3-hydroxyaniline (6.55 g) and 4-fluoro benzotrifluoride (9.85 g) were dissolved in DMSO (50 mL). The resulting dark solution was heated at 95 ° C. for 4 hours, cooled to room temperature and poured into water (600 mL). The mixture was extracted with ether (3 x 125 mL). The organic phase was washed with 2N sodium hydroxide (2 × 75 mL) and water (100 mL), dried (MgSO 4 ) and the solvent was evaporated to give a dark oil. This oil was distilled off to obtain the desired aniline as a colorless oil (8.7 g), at bp 110-112 ° C. at 0.15 mm.

< 4-(4-트리플루오로메틸페닐티오) 어닐린 ><4- (4-trifluoromethylphenylthio) anneal>

Figure 112002001377712-pct00034
Figure 112002001377712-pct00034

4-플루오로벤조트리 플루오라이드(9.85g) 및 4-아미노티오페놀(7.51g)을 DMSO(60mL)에 용해시키고 얼음조내에서 냉각시킨 교반용액에 포타슘 t-부톡사이드(6.73g)을 단번에 첨가하였다.4-fluorobenzotrifluoride (9.85 g) and 4-aminothiophenol (7.51 g) were dissolved in DMSO (60 mL) and potassium t-butoxide (6.73 g) was added all at once to a stirred solution cooled in an ice bath. It was.

그 결과 혼합물을 0℃에서 10분간 교반한 다음 60℃에서 밤새교반하였다. 냉각후, 그 혼합물을 물(600mL)에 붓고 그 결과물인 혼합물을 에테르(2×200mL)로 추출하였다. 유기상은 2N 수산화나트륨(50mL)로 세척한 후 물(50mL)로 세척하였다. 건조후(MgSO4), 용매를 증발시켜 갈색고체를 얻었다. 헥산으로 부터 재결정화하여 황색고체로서 m.p 97∼99℃인 바라는 어닐린을 얻었다.
The resulting mixture was stirred at 0 ° C. for 10 minutes and then stirred at 60 ° C. overnight. After cooling, the mixture was poured into water (600 mL) and the resulting mixture was extracted with ether (2 x 200 mL). The organic phase was washed with 2N sodium hydroxide (50 mL) and then with water (50 mL). After drying (MgSO 4 ), the solvent was evaporated to give a brown solid. Recrystallization from hexane gave the desired anneal, which was mp 97-99 ° C. as a yellow solid.

< 4-(3-트리플루오로메틸벤질) 어닐린 ><4- (3-trifluoromethylbenzyl) anneal>

Figure 112002001377712-pct00035
Figure 112002001377712-pct00035

마그네슘터닝(1.09g)을 무수 THF(10mL)에 혼합한 교반 혼합물에 4-브로모-N, N-비스-(트리메틸실릴)어닐린(9.48g)을 무수THF(75mL)에 용해시킨 용액을 첨가하여 그리냐드(Grinard)시약을 제조하였다.To a stirred mixture of magnesium turning (1.09 g) in anhydrous THF (10 mL) was dissolved a solution of 4-bromo-N, N-bis- (trimethylsilyl) aniline (9.48 g) in anhydrous THF (75 mL). Grinard reagent was prepared by addition.

무수 THF(25mL)에 CuCl2(0.20g) 및 LiCl(0.13g)을 첨가하고 균질용액이 얻어질때 까지 교반하여 촉매 Li2CuCl4(0.33g)의 제 2용액을 제조하였다.CuCl 2 (0.20 g) and LiCl (0.13 g) were added to anhydrous THF (25 mL) and stirred until a homogeneous solution was obtained to prepare a second solution of catalyst Li 2 CuCl 4 (0.33 g).

이 촉매용액은 그후 무수 THF(75mL)에 3-트리플루오로메틸벤질 브로마이드(7.17g)을 용해시킨 용액에 첨가되었다. 그 오렌지-레드 색상 용액을 얼음조 내에서 냉각시키고(N2 대기)(앞서 얼음조내에서 냉각된) 상기 그리냐드 시약을 배관을 통해 급송하였다.This catalyst solution was then added to a solution of 3-trifluoromethylbenzyl bromide (7.17 g) dissolved in anhydrous THF (75 mL). The orange-red color solution was cooled in an ice bath (N 2 atmosphere) (previously cooled in an ice bath) and the Grignard reagent was fed through a tube.

0℃에서 15분간 교반한 후 그 혼합물을 실온에서 밤새 교반하였다. 그 반응 혼합물을 포하 NH4Cl 용액(25mL)을 첨가하여 급냉시켰다.After 15 min stirring at 0 ° C. the mixture was stirred overnight at room temperature. The reaction mixture was quenched by addition of NH 4 Cl solution (25 mL).

오렌지 상을 분리하고, 건조(MgSO4)하였으며, 용매를 증발시켜 짙은 오일(11g)을 얻었다. The orange phase was separated, dried (MgSO 4 ) and the solvent was evaporated to give a dark oil (11 g).

이 오일에 4N HCl(50mL)을 첨가 하였으며, 그 혼합물을 실온에서 3시간 교반하였다. 이 혼합물은 고체 소디움 카보네이트를 주의깊게 첨가한 후 에테르(3×100mL)로 추출하였다. 4N HCl (50 mL) was added to the oil, and the mixture was stirred at room temperature for 3 hours. This mixture was extracted with ether (3 × 100 mL) after careful addition of solid sodium carbonate.                 

유기상을 건조시키고(MgSO4) 용매를 증발시켰다. EtOAc(100mL)를 첨가하고 용액을 불용성물질로부터 따뤄내었다.The organic phase was dried (MgSO 4 ) and the solvent was evaporated. EtOAc (100 mL) was added and the solution was withdrawn from insoluble material.

다시 용매를 증발시키고 잔류물을 크로마토그래피(실리카겔, 3:1 헥산/EtOAc)하였다. 2번째 용출액을 수집하여 오렌지 오일을 얻었으며, 이는 급속히 짙은 색으로 변화되었다. NMR(CDCl3) 및 GC/MS(m/e-251)결과 바라는 화합물과 일치하였다. 이 물질은 HCl염으로 변환되어 갈색고체를 얻었다.
The solvent was evaporated again and the residue was chromatographed (silica gel, 3: 1 hexanes / EtOAc). The second eluate was collected to give an orange oil which quickly turned dark. NMR (CDCl 3 ) and GC / MS (m / e-251) matched the desired compound. This material was converted to HCl salt to give a brown solid.

< 4-(3-트리플루오로메틸벤조일)어닐린 ><4- (3-trifluoromethylbenzoyl) aniline>

Figure 112002001377712-pct00036
Figure 112002001377712-pct00036

4-브로모-N, N-비스-(트리메틸실릴)어닐린(9.24g)을 무수 THF(100mL)에 용해시킨 교반용액을 아르곤 대기하에서 -78℃까지 냉각하였다.The stirred solution in which 4-bromo-N and N-bis- (trimethylsilyl) aniline (9.24 g) was dissolved in anhydrous THF (100 mL) was cooled to -78 ° C under an argon atmosphere.

여기에 헥산(12mL)내에 용해된 n-부틸리튬 2.5M 용액을 천천히 첨가하였다. 첨가완료후 반응 혼합물을 -78℃에서 10분간 교반한 후 무수 THF(25mL)내에 N-메틸-N-메톡시-3-트리플루오로메틸벤자미드(6.8g)을 용해시킨 용액을 직접첨가하였다.To this slowly added n-butyllithium 2.5M solution dissolved in hexane (12 mL). After the addition was completed, the reaction mixture was stirred at −78 ° C. for 10 minutes, and a solution in which N-methyl-N-methoxy-3-trifluoromethylbenzamide (6.8 g) was dissolved in anhydrous THF (25 mL) was added directly. .

첨가완료후, 그 혼합물을 -78℃에서 1시간 교반한 다음 냉각조를 제거하고 반응온도를 10℃까지 승온시켰다. 포화 NH4Cl 용액(50mL) 및 그 후 물(10mL)을 첨 가하여 반응물을 급냉시켰다. 유기상을 분리하고, 건조하였으며(MgSO4), 용매를 증발시켜 황색액체(12g)을 얻었다.After the addition was completed, the mixture was stirred at -78 ° C for 1 hour, then the cooling bath was removed and the reaction temperature was raised to 10 ° C. The reaction was quenched by addition of saturated NH 4 Cl solution (50 mL) and then water (10 mL). The organic phase was separated, dried (MgSO 4 ) and the solvent was evaporated to give a yellow liquid (12 g).

이를 에테르(100mL)에 넣고 4N HCl(100mL)을 첨가하였다.It was taken up in ether (100 mL) and 4N HCl (100 mL) was added.

그 결과 혼합물을 실온에서 30분간 교반하였으며, 그 동안 고체를 분리하였다. 이 고체를 여과하고, 에테르도 여러번 세척한 다음, 교반된, 포화 NaHCO3 용액(100mL)에 주의깊게 첨가하였다. 그 결과물인 혼합물을 에테르(2×100mL)로 추출하였으며, 유기상을 건조 시키고(MgSO4), 용매를 증발시켜 황백색 고체(5.7g)을 얻었다.As a result, the mixture was stirred at room temperature for 30 minutes, during which the solids were separated. This solid was filtered off, washed with ether several times and then carefully added to a stirred, saturated NaHCO 3 solution (100 mL). The resulting mixture was extracted with ether (2 × 100 mL), the organic phase was dried (MgSO 4 ) and the solvent was evaporated to yield an off white solid (5.7 g).

메탄올/물로부터 재결정화하여 m.p 130∼131℃인 백색 고체를 얻었다. 스펙트럼 데이타는 바라는 화합물과 일치하였다.
Recrystallization from methanol / water gave a white solid with mp 130-131 ° C. Spectral data were consistent with the desired compound.

< 에틸 2-아미노-5-(4-트리플루오로메틸페녹시) 벤조에이트 ><Ethyl 2-amino-5- (4-trifluoromethylphenoxy) benzoate>

Figure 112002001377712-pct00037
Figure 112002001377712-pct00037

DMSO(75mL)내에 포타슘 t- 부톡사이드(15.71g)을 용해시켜 기계적으로 교반한 용액에 5-히드록시안트라닐산(10.2g)을 첨가하였다. 그 혼합물을 아르곤 기권하에서 실온에서 10분간 교반한 후 4-플루오로벤조트리플루오라이드(11.16g)을 첨가하고, 그 결과 혼합물을 교반하고 75∼80℃에서 밤새 가열하였다.To the mechanically stirred solution of potassium t-butoxide (15.71 g) in DMSO (75 mL) was added 5-hydroxyanthranilic acid (10.2 g). The mixture was stirred at room temperature under argon for 10 minutes, after which 4-fluorobenzotrifluoride (11.16 g) was added, as a result of stirring the mixture and heating at 75-80 ° C. overnight.

냉각후, 혼합물을 물(600mL)에 붙고 pH를 약 2.5로 조절하였다. 그 결과물 인 고체를 여과하고, 물로 여러번 세척한 다음 메탄올/물(숯)으로 재결정화하여 황갈색 고체(13.5g), m.p 165∼167℃를 얻었다.After cooling, the mixture was attached to water (600 mL) and the pH adjusted to about 2.5. The resulting solid was filtered, washed several times with water and recrystallized with methanol / water (charcoal) to give a tan solid (13.5 g), m.p 165-167 ° C.

이 고체를 무수에탄올(250mL)에 넣고 진한 황산(15mL)를 주의깊게 첨가하였다.This solid was taken up in anhydrous ethanol (250 mL) and concentrated sulfuric acid (15 mL) was carefully added.

그 결과 혼합물을 환류로 24시간동안 가열한 후 대부분의 에탄올을 증발시켰다. 그 잔류분을 얼음물(600mL)에 주의깊게 첨가하고, 그 결과물인 혼합물에 50% NaOH 용액을 천천히 첨가하여 염기성으로 한 다음 에테르(2×150mL)로 추출하였다. 유기상을 물(100mL)로 세척한후 포화 NaCl 용액(50mL)으로 세척하였다.As a result, the mixture was heated to reflux for 24 hours and then most of the ethanol was evaporated. The residue was carefully added to ice water (600 mL), and the resulting mixture was made basic by slowly adding 50% NaOH solution and extracted with ether (2 × 150 mL). The organic phase was washed with water (100 mL) and then with saturated NaCl solution (50 mL).

건조후(MgSO4), 용매를 증발시켜 98% GC순도인 황색오일을 얻었다. GC/MS는 바라는 화합물과 일치한 이온 m/e=325를 나타내었다.
After drying (MgSO 4 ), the solvent was evaporated to give a yellow oil with 98% GC purity. GC / MS showed ionic m / e = 325 consistent with the desired compound.

< 2-아미노벤조노보난 ><2-aminobenzonobonan>

Figure 112002001377712-pct00038
Figure 112002001377712-pct00038

아르곤 대기하에 0℃로 냉각된, 무수 THF(8mL)에 벤조노보넨(2.84g)을 용해시킨 교반용액에 THF(6.7mL)에 용해시킨 보난 1M 용액을 신속히 첨가하였다.To an agitated solution in which benzonorbornene (2.84 g) was dissolved in anhydrous THF (8 mL), cooled to 0 ° C. under argon atmosphere, a Bonan 1 M solution dissolved in THF (6.7 mL) was added quickly.

그 용액을 0 ℃에서 10분간 교반한 다음 실온에서 90분간 교반하였다. 그 반응 혼합물을 다시 0℃로 냉각시키고 히드록시아민-0-술폰산(1.58g)을 단번에 첨가하였다. 얼음조를 제거하고 그 반응 혼합물을 실온에서 2시간 교반하였다. 1N HCl(25mL)와 에테르 (20mL)를 첨가하고, 10분간 더 교반하였다. 상분리하고 유기상을 버렸다. 수상은 50% NaOH 용액을 조심스럽게 첨가하여 염기성으로 되게 한다음 에테르(3×30mL)로 추출하였다.The solution was stirred at 0 ° C. for 10 minutes and then at room temperature for 90 minutes. The reaction mixture was cooled back to 0 ° C. and hydroxyamine-0-sulfonic acid (1.58 g) was added in one portion. The ice bath was removed and the reaction mixture was stirred for 2 hours at room temperature. 1N HCl (25 mL) and ether (20 mL) were added and further stirred for 10 minutes. Phase separated and the organic phase was discarded. The aqueous phase was made basic by carefully adding 50% NaOH solution and then extracted with ether (3 × 30 mL).

유기상을 건조시키고(MgSO4) 용매를 증발시켜 GC로 측정시 순도 98%인 황색액체(1.35g)을 얻었다. NMR(CDCl3)와 GC/MS(m/e=159) 결과 바라는 화합물과 일치하였다.The organic phase was dried (MgSO 4 ) and the solvent was evaporated to give a yellow liquid (1.35 g) having a purity of 98% as measured by GC. NMR (CDCl 3 ) and GC / MS (m / e = 159) results were consistent with the desired compound.

Figure 112002001377712-pct00039

Figure 112002001377712-pct00039

< (3-트리플루오로메틸벤질옥시메틸)노르보닐아민 53의 혼합물 제조 ><Preparation of a mixture of (3-trifluoromethylbenzyloxymethyl) norbornylamine 53>

이 혼합물의 제법이 상기 방법 9에 도시되어 있다. 엑소(exo)- 및 엔도(endo)-노르보넨카복실산 49(∼1:4비)(0.7g), 2-요오드프로판(12.8g) 및 포타슘 카보네이트(10.4g)을, DMSO(40mL)에 혼합한 혼합물을 교반하고 55℃에서 밤새 가열하였다. 냉각후 그 혼합물을 물(125mL)로 희석시킨후 펜탄으로 추출하였다.The preparation of this mixture is shown in Method 9 above. Exo- and endo-norbornenecarboxylic acids 49 (-1: 4 ratio) (0.7 g), 2-iodine propane (12.8 g) and potassium carbonate (10.4 g) were mixed in DMSO (40 mL). One mixture was stirred and heated at 55 ° C. overnight. After cooling the mixture was diluted with water (125 mL) and extracted with pentane.

유기상을 건조(MgSO4)하고 용매를 증발시켜 무색오일(8.2g)을 얻었다. The organic phase was dried (MgSO 4 ) and the solvent was evaporated to give a colorless oil (8.2 g).

이 오일은 2-프로판(100mL)에 용해시킨 소디움 2-포로폭사이드(3.9g) 용액에 첨가한 후, 그 결과 혼합물을 환류로 16시간 가열하였다. 2-프로판을 제거하고 물(200mL)로 희석한 후 펜탄을 추출하여 엑소 : 엔토의 비율이 52:48인 노르보넨 이소프로필 에스테르 50을 얻었다.This oil was added to a solution of sodium 2-pooxide (3.9 g) dissolved in 2-propane (100 mL), and the resulting mixture was heated to reflux for 16 hours. 2-propane was removed, diluted with water (200 mL), and pentane was extracted to obtain norbornene isopropyl ester 50 having an exo: ento ratio of 52:48.

이는 크로마토그래피(실리카겔, 95:5 헥산/EtOAc)를 통해 순수이성체로 분리되었다. 엑소(exo) 이성질체 50(4.0g)을 에테르(50mL)에 용해시키고, 0℃로 냉각시킨후 에테르(14mL)에 용해시킨 리튬 알루미늄 하이드리드 1M 용액을 천천히 첨가하였다. 첨가완료후, 그 혼합물을 1시간동안 환류로 가열하였다.It was isolated as pure isomer via chromatography (silica gel, 95: 5 hexanes / EtOAc). The exo isomer 50 (4.0 g) was dissolved in ether (50 mL), cooled to 0 ° C. and then slowly added lithium aluminum hydride 1M solution dissolved in ether (14 mL). After complete addition, the mixture was heated to reflux for 1 hour.

냉각후, 반응물을 물(0.53mL), 15% NaOH 용액(0.53mL) 및 물(1.59mL)을 순차적으로 부가하여 급냉시켰다. 그 결과 혼합물을 건조(MgSO4), 여과 및 용매증발시켜 무색액체인 엑소-알콜 51(2.7g)을 얻었다.After cooling, the reaction was quenched by sequentially adding water (0.53 mL), 15% NaOH solution (0.53 mL) and water (1.59 mL). As a result, the mixture was dried (MgSO 4 ), filtered and evaporated to give exo-alcohol 51 (2.7 g) as a colorless liquid.

GC/MS(m/e=124)결과 할당된 구조와 일치하였다.
GC / MS (m / e = 124) results matched the assigned structure.

무수 THF(25mL)에 포타슘 하이드리드(1.0g)을 혼합한 교반 혼합물에 THF(10mL)에 화합물 51(2.7g)을 용해시킨 용액을 조심스럽게 첨가하였다.To a stirred mixture of potassium hydride (1.0 g) in anhydrous THF (25 mL), a solution of Compound 51 (2.7 g) in THF (10 mL) was carefully added.

첨가 완료후, 그 혼합물을 실온에서 30분간 교반하고 트리플루오로메틸 벤질브로마이드(5.98g)을 단번에 첨가하였다(발열반응).
After the addition was completed, the mixture was stirred for 30 minutes at room temperature and trifluoromethyl benzylbromide (5.98 g) was added at once (exothermic reaction).

그 반응물을 환류로 2시간동안 가열하고, 냉각한 다음 물(150mL)에 부었다. The reaction was heated to reflux for 2 hours, cooled and poured into water (150 mL).                 

에테르 추출(2×75mL), 건조(MgSO4) 및 용매 증발시켜 황색오일을 얻었으며, 이를 크로마토그라피(실리카겔, 97:3 헥산/아세톤)을 통해 정제하여 무색오일로서 순수물질 52(5.2g)을 얻었다.Ether extraction (2 × 75 mL), drying (MgSO 4 ) and solvent evaporation yielded a yellow oil which was purified by chromatography (silica gel, 97: 3 hexanes / acetone) to give a colorless oil as a pure substance 52 (5.2 g). Got.

NMR(CDCl3) 및 GC/MS(m/e=282) 결과 52의 구조와 일치하였다. 화합물 52를 아민 53의 부분입체 혼합물로의 전환을 앞서 기술된 보란/히드록실아민-0-술포산 순서를 통해 이루었다(20%수율).
NMR (CDCl 3 ) and GC / MS (m / e = 282) results were consistent with the structure of 52. The conversion of compound 52 to the diastereomeric mixture of amine 53 was through the borane / hydroxylamine-0-sulfoic acid sequence described above (20% yield).

< 3-(3-피리딜)-1-프로판 아민 ><3- (3-pyridyl) -1-propane amine>

Figure 112002001377712-pct00040
Figure 112002001377712-pct00040

이 아민 B. Jursic et al., Synthesis, 1988, (Ⅱ), 868의 순서에 따라 먼저 3-(3-피리딜)-1-프로판올을 상응하는 염화물로 변환시키고, 그후 이 염화물을 D.J.Dumas et al., J. Org. Chem. 1988, 53, 4650 의 순서에 따라 아민으로 변환시켜 얻었다.
The amines B. Jursic et al., Synthesis, 1988, (II), 868, first convert 3- (3-pyridyl) -1-propanol to the corresponding chlorides, which are then converted into DJDumas et al. , J. Org. Chem. It was obtained by converting into an amine in the order of 1988, 53, 4650.

< 3-[[5-(트리플루오로메틸)-2-피리딜]옥시]-1-프로판아민 ><3-[[5- (trifluoromethyl) -2-pyridyl] oxy] -1-propanamine>

Figure 112002001377712-pct00041
Figure 112002001377712-pct00041

2-플루오로-5-트리플루오로메틸피리딘(1.831g, 11mmol)을 질소분위기하에 교반하면서 무수 THF(15mL)내에 용해시키고, 얼음조내에서 0℃ 까지 냉각시켰다. 여 기에 무소 THF(15mL)에 3-아미노-1-프로판올(0.76mL, 10mmol)을 용해시킨 용액과 THF(10mL, 10mmol) 내의 1M 포타슘 tert-부톨사이드 용액을 30분에 걸쳐 직접 첨가하였다. 황색 용액을 교반하고 밤새 실온으로 승온 시켰다.2-Fluoro-5-trifluoromethylpyridine (1.831 g, 11 mmol) was dissolved in dry THF (15 mL) with stirring under nitrogen atmosphere and cooled to 0 ° C in an ice bath. Here, a solution of 3-amino-1-propanol (0.76 mL, 10 mmol) in arsenic THF (15 mL) and 1 M potassium tert-butoxide solution in THF (10 mL, 10 mmol) were added directly over 30 minutes. The yellow solution was stirred and warmed to room temperature overnight.

그 반응 혼합물을 물(75mL)에 붓고 에테르(2×50mL)로 추출하였다. 유기상을 염수(50mL)로 씻어내고 건조(Na2SO4), 및 여과하고 진공하에 증발시켜 MS 및 NMR 결과 거의 순수한 황색 액체를 얻었으며, 더이상의 정제과정을 거치지 않고 사용하였다.
The reaction mixture was poured into water (75 mL) and extracted with ether (2 × 50 mL). The organic phase was washed with brine (50 mL), dried (Na 2 SO 4 ), filtered and evaporated in vacuo to give almost pure yellow liquid as a result of MS and NMR, which was used without further purification.

< (+)-트란스-1-히드록시-2-아미노시클로펜탄 하이드로브로마이드 ><(+)-Trans-1-hydroxy-2-aminocyclopentane hydrobromide>

Figure 112002001377712-pct00042
Figure 112002001377712-pct00042

(+)-트란스-1-벤질옥시-2-아미노 시클로펜탄 하이드로브로마이드(8.2g, 42.8mmol)을 40% HBr(60mL)로 처리하였다. 3일간 교반후, 그 용액을 진공내 농축시켜 7.09g(91%) 1H-NMR(DMSO-d6)결과 순수한 오렌지색 고체 하이드로 브로마이드 염을 얻었다.
(+)-Trans-1-benzyloxy-2-amino cyclopentane hydrobromide (8.2 g, 42.8 mmol) was treated with 40% HBr (60 mL). After stirring for 3 days, the solution was concentrated in vacuo to afford 7.09 g (91%) 1 H-NMR (DMSO-d 6 ) pure orange solid hydrobromide salt.

< 2,3-디하이드로-2,2-디메틸-1H-인덴-1-아민 ><2,3-dihydro-2,2-dimethyl-1H-inden-1-amine>

Figure 112002001377712-pct00043
Figure 112002001377712-pct00043

이 아민은 WO9927783에 기재된 절차에 따라 제조되었다. This amine was prepared according to the procedure described in WO9927783.

Figure 112002001377712-pct00044
Figure 112002001377712-pct00044

<10-아미노-엔도(endo)-2,5-메타노 바이시클로 [4,4,0]데크(DEC)-3-엔(ENE)(56)><10-Amino-endo-2,5-methanobicyclo [4,4,0] deck (DEC) -3-ene (ENE) (56)>

이 혼합물은 상기 방법 10의 순서에 따라 제조되었다. 알루미늄 클로라이드(700mg, 5.2mmol)을 2-시클로헥센-1-온(2.0g, 20.8mmol)을 톨루엔(200mL)에 용해시킨 용액에 첨가하였다.This mixture was prepared according to the procedure of Method 10 above. Aluminum chloride (700 mg, 5.2 mmol) was added to a solution of 2-cyclohexen-1-one (2.0 g, 20.8 mmol) dissolved in toluene (200 mL).

40분후, 새롭게 증류된 시클로펜타디엔(13.7g, 208mmol)을 첨가하고 2시간동안 100℃까지 가열하였다. 냉각후, 그 혼합물을 Et2O(300mL)로 희석시키고 포화 NaHCO3(2×150mL) 및 염수(100mL)로 씻었다.After 40 minutes, freshly distilled cyclopentadiene (13.7 g, 208 mmol) was added and heated to 100 ° C. for 2 hours. After cooling, the mixture was diluted with Et 2 O (300 mL) and washed with saturated NaHCO 3 (2 × 150 mL) and brine (100 mL).

결합된 유기층을 건조(MgSO4), 여과 및 농축시켰다. 그 잔류물을 용리액으로서 50:1 헥산:Et2O를 사용하여 플래쉬 크로마토그래피하에 정제하여, 2.5-메타노바이시클로[4,4,0]데크-3-엔-10-온(54)의 엔도-(1.74g) 및 엑소-(943mg) 이성체를 얻었으며, 이는 1H-NMR 및 GC/MS 결과 순수하였다.
The combined organic layer was dried (MgSO 4 ), filtered and concentrated. The residue was purified by flash chromatography using 50: 1 hexanes: Et 2 O as eluent to afford 2.5-methanobicyclo [4,4,0] dec-3-en-10-one (54). Endo- (1.74 g) and exo- (943 mg) isomers were obtained, which were pure by 1 H-NMR and GC / MS.

소디움 아세테이트(1.79g, 21.8mmol)을 엔도-2,5-메타노바이시클로[4,4,1]데 크(dec)-3-dps(en)-10-온(one) 54(1.61g, 9.9mmol) 및 히드록실아민 하이드로클로라이드(758mg, 10.9mmol)을 메탄올(33mL)에 용해시킨 용액에 나누어 첨가하고 실온에서 밤새 교반하였다.Sodium acetate (1.79 g, 21.8 mmol) was added to endo-2,5-methanobicyclo [4,4,1] dec (dec) -3-dps (en) -10-one 54 (1.61 g) , 9.9 mmol) and hydroxylamine hydrochloride (758 mg, 10.9 mmol) were added in portions to a solution dissolved in methanol (33 mL) and stirred overnight at room temperature.

반응물을 H2O로 급냉시키고 에테르(2×50mL)로 추출하였다. 결합된 유기층을 건조(MgSO4), 여과 및 농축하여 엔도(endo)-2,5-메타노바이시클로[4,4,0]데크-3-엔-10-온 옥심(55)를 얻었으며, 1H-NMR 및 GC/MS 결과 순수하였다.
The reaction was quenched with H 2 O and extracted with ether (2 × 50 mL). The combined organic layers were dried (MgSO 4 ), filtered and concentrated to give endo-2,5-methanobicyclo [4,4,0] dec-3-en-10-one oxime (55). , 1 H-NMR and GC / MS results were pure.

엔도-2,5-메타노바이시클로[4.4.1]데크-3-엔-10온 옥심(55)(500mg, 2.79mmol)을 EtOAc(25ml)에 용해시키고 10% Pd/c(50mg)을 첨가 하였다.
Endo-2,5-methanobicyclo [4.4.1] dec-3-en-10one oxime (55) (500 mg, 2.79 mmol) was dissolved in EtOAc (25 ml) and 10% Pd / c (50 mg) Was added.

H2(40psi)하에 3시간 경과후, 그 서스펜션을 Celite

Figure 112002001377712-pct00045
를 통해 여과하고 농축하였다.After 3 hours under H 2 (40 psi), the suspension was
Figure 112002001377712-pct00045
Filtered through and concentrated.

그 결과 잔류물을 EtOH(25ml)에 용해시키고 Raney

Figure 112002001377712-pct00046
-Ni(1.0g)으로 장입하였다.As a result, the residue was dissolved in EtOH (25 ml) and Raney
Figure 112002001377712-pct00046
Charged with -Ni (1.0 g).

그 서스펜션을 NH3로 포화시키고 H2(45psi)로 가압하였다.The suspension was saturated with NH 3 and pressurized with H 2 (45 psi).

6시간 후, 그 서스펜션을 Celite

Figure 112002001377712-pct00047
를 통해 여과하고, EtOAc(100ml)로 희석시키고, 포화 NaHCO3(100ml)로 세척하였다. 결합한 유기층을 MgSO4상에서 건조시키고, 여과 및 농축하였다.After 6 hours, the suspension was
Figure 112002001377712-pct00047
Filtered through, diluted with EtOAc (100 ml) and washed with saturated NaHCO 3 (100 ml). The combined organic layer was dried over MgSO 4 , filtered and concentrated.

1H-NMR및 GC/MS결과 부분입체이성질체의 2:1혼합물로서 원하는 아민 56인 것으로 나 타났다.(418mg) 1 H-NMR and GC / MS results showed the desired amine 56 as a 2: 1 mixture of diastereomers (418 mg).

Figure 112002001377712-pct00048
Figure 112002001377712-pct00048

<10-아미노-4-(4'-메틸펜트-3'-에닐)-바이시클로[4.4.0]데크-3-엔(59)>
<10-Amino-4- (4'-methylpent-3'-enyl) -bicyclo [4.4.0] dec-3-ene (59)>

이 화합물은 상기 방법 11에 나타난 바에 따라 제조되었다.This compound was prepared as shown in Method 11.

알루미늄 클로라이드(700mg, 5.2mmol)을 톨루엔(100ml)에 2-시클로헥센-1-온(2.0g, 20.8mmol)을 용해시킨 용액에 첨가하였다.Aluminum chloride (700 mg, 5.2 mmol) was added to a solution of 2-cyclohexen-1-one (2.0 g, 20.8 mmol) dissolved in toluene (100 ml).

40분후, 미르센(myrcene)(17g, 125mmol)을 첨가하고 25시간동안 100℃로 가열하였다.After 40 minutes, myrcene (17 g, 125 mmol) was added and heated to 100 ° C. for 25 hours.

냉각후 그 혼합물을 Et2O(300ml)로 희석시키고 포화 NaHCO3(2X150ml)와 염수(100ml)로 세척하였다. 그 결합된 유기층을 MgSO4상에서 건조하고 여과 및 농축시켰다. 잔류물을 용리액으로서 50:1 헥산:Et2O를 사용하여 플래쉬 크로마토그래피를 통해 정제하여 4-(4'-메틸펜트-3'-에닐)-바이시클로[4.4.0]데크-3-엔-10-온(57)(2.55g)을 제공했으며, 이는 1H-NMR 및 GC/MS에 의해 순수하였다.
After cooling the mixture was diluted with Et 2 O (300 ml) and washed with saturated NaHCO 3 (2 × 150 ml) and brine (100 ml). The combined organic layer was dried over MgSO 4 , filtered and concentrated. The residue was purified via flash chromatography using 50: 1 hexanes: Et 2 O as eluent to afford 4- (4'-methylpent-3'-enyl) -bicyclo [4.4.0] dec-3-ene. -10-one (57) (2.55 g) was provided, which was pure by 1 H-NMR and GC / MS.

4-(4'-메틸-펜트-3'-에닐)-바이시클로 [4.4.0]데크-3-엔-10-온(57)(2.23g,9.6mmol) 과 히드록실아민 하이드로클로라이드(733mg, 10.5mmol)을 메탄올(32ml)에 용해시킨 용액에 소디움 아세테이트(1.73g, 21mmol)를 나누어 첨가하고 실온에서 밤새 교반하였다. 4- (4'-Methyl-pent-3'-enyl) -bicyclo [4.4.0] dec-3-en-10-one (57) (2.23 g, 9.6 mmol) and hydroxylamine hydrochloride (733 mg) , 10.5 mmol) was added sodium acetate (1.73 g, 21 mmol) in portions to a solution dissolved in methanol (32 ml) and stirred overnight at room temperature.

그 반응물을 H2O로 급냉시키고 에테르(2x 50ml)로 추출하였다.The reaction was quenched with H 2 O and extracted with ether (2 × 50 ml).

결합된 유기층을 MgSO4상에서 건조하고, 여과 및 농축하였다.The combined organic layer was dried over MgSO 4 , filtered and concentrated.

반죽같은 잔류물로서 4-(4'-메틸-펜트-3'-에닐)-바이시클로[4.4.0]데크-3-엔-10-온 옥심(58)을 얻었으며 1H-NMR및 GC/MS결과 순수하였다.As a doughy residue, 4- (4'-methyl-pent-3'-enyl) -bicyclo [4.4.0] dec-3-en-10-one oxime (58) was obtained with 1 H-NMR and GC / MS results were pure.

4-(4'-메틸펜트-3'-에닐)-바이시클로[4.4.0]데크-3-엔-10-온 옥심(600mg, 2.42mmol)을 EtOH(25ml)에 용해시키고 Raney

Figure 112002001377712-pct00049
-Ni(1.0g)을 장입하였다. 그 서스펜션을 NH3로 포화시키고 H2(45psi)로 가압하였다.4- (4'-Methylpent-3'-enyl) -bicyclo [4.4.0] dec-3-en-10-one oxime (600 mg, 2.42 mmol) was dissolved in EtOH (25 ml) and Raney
Figure 112002001377712-pct00049
-Ni (1.0 g) was charged. The suspension was saturated with NH 3 and pressurized with H 2 (45 psi).

6시간후, 그 서스펜션을 Celite

Figure 112002001377712-pct00050
를 통해 여과하고, EtOAc(100ml)로 희석시켰으며 포화 NaHCO3(100ml)로 세척하였다. 합한 유기층을 MgSO4상에서 건조하고, 여과및 농축하였다. 1H-NMR및 GC/MS결과 순수한 바라는 아민(550mg)이었다.After 6 hours, the suspension was Celite
Figure 112002001377712-pct00050
Filtered through, diluted with EtOAc (100 ml) and washed with saturated NaHCO 3 (100 ml). The combined organic layers were dried over MgSO 4 , filtered and concentrated. Pure desired amine (550 mg) by 1 H-NMR and GC / MS.

Figure 112002001377712-pct00051
Figure 112002001377712-pct00051

<2-아미노-7-퓨릴-3-메틸-4-크로마논하이드로클로라이드(63)> <2-Amino-7-furyl-3-methyl-4-chromanone hydrochloride (63)>                 

이 아민 하이드로클로라이드염은 상기 방법 12에 따라 제조되었다. 7-트리플루오로메탄술포네이트-3-메틸-4-크로마논(3.0g, 9.7mmol)(K.Koch, 및 M.S.Biggers, J.Org.Chem. 1994,59,1216의 절차에 따라 제조됨)을 2-(트리부틸스탠닐)퓨란 (3.79g, 10.6mmol), Pd(PPh3)4(223mg, 0.19mmol), LiCl(1.23g, 29.0mmol)및 2 크리스탈의 2,6-디-t-부틸-4-메틸페놀을 1,4-디옥산(50ml)에 용해시킨 용액에 첨가하고 12시간동안 환류를 위해 가열하였다. This amine hydrochloride salt was prepared according to Method 12 above. 7-trifluoromethanesulfonate-3-methyl-4-chromanone (3.0 g, 9.7 mmol) (prepared according to the procedures of K. Koch, and MS Biggers, J. Org. Chem. 1994, 59, 1216) 2- (tributylstannyl) furan (3.79 g, 10.6 mmol), Pd (PPh 3 ) 4 (223 mg, 0.19 mmol), LiCl (1.23 g, 29.0 mmol) and 2,6-di-t of 2 crystals -Butyl-4-methylphenol was added to the solution dissolved in 1,4-dioxane (50 ml) and heated for reflux for 12 hours.

냉각후, 혼합물을 포화 NH4Cl(40ml)로 급냉시킨후 Et2O(2x50ml)로 추출하였다.After cooling, the mixture was quenched with saturated NH 4 Cl (40 ml) and extracted with Et 2 O (2 × 50 ml).

결합된 유기층을 MgSO4상에서 건조하고, 여과및 농축시켰다.The combined organic layer was dried over MgSO 4 , filtered and concentrated.

잔류물을 용리액으로서 20:1 헥산:EtOAc를 사용하여 플래쉬 크로마토그라피를 통해 정제하여 황색고체이며, m.p 94∼95℃인 7-퓨릴-3-메틸-4-크로마논(60)(1.78g)을 얻었다.The residue was purified by flash chromatography using 20: 1 hexanes: EtOAc as eluent to give a yellow solid, mp 94-95 ° C., 7-puryl-3-methyl-4-chromanone (60) (1.78 g). Got.

7-퓨릴-3-메틸-4-크로마논(60)(500mg, 2.19mmol)및 히드록실아민 하이드로클로라이드(167mg, 2.41mmol)을 메탄올(5ml)에 용해시킨 용액에 소디움 아세테이트(395mg, 4.82mmol)을 나누어 첨가하였으며, 실온에서 밤새 교반하였다.Sodium acetate (395 mg, 4.82 mmol) in a solution of 7-puryl-3-methyl-4-chromenone (60) (500 mg, 2.19 mmol) and hydroxylamine hydrochloride (167 mg, 2.41 mmol) dissolved in methanol (5 ml). ) Was added in portions and stirred overnight at room temperature.

그 반응물을 H2O로 급냉시키고 에테르(2x25ml)로 추출하였다.The reaction was quenched with H 2 O and extracted with ether (2 × 25 ml).

합한 유기층을 MgSO4상에서 건조시키고, 여과 및 농축시켜 백색고체로서 m.p.175-177℃인 7-퓨릴-3-메틸-4-크로마논옥심(61)을 얻었다.
The combined organic layers were dried over MgSO 4 , filtered and concentrated to afford 7-puryl-3-methyl-4-chromanone oxime (61) as mp175-177 ° C. as a white solid.

톨루엔술포닐클로라이드(397mg, 2.08mmol)을 7-퓨릴-3-메틸-4-크로마논옥심(61)(461mg, 1.89mmol)및 피리딘(0.5ml)을 Toluenesulfonylchloride (397 mg, 2.08 mmol) was added 7-furyl-3-methyl-4-chromanone oxime (61) (461 mg, 1.89 mmol) and pyridine (0.5 ml).

CH2Cl2(10ml)에 용해시킨 0℃용액에 첨가하였다.It was added to a 0 ° C. solution dissolved in CH 2 Cl 2 (10 ml).

6시간후, 그 혼합물을 CH2Cl2(30ml)로 희석시키고 5% HCl(20ml)로 세척하였다. 유기층을 MgSO4 상에서 건조하였고, 여과후 농축시켰다. After 6 h the mixture was diluted with CH 2 Cl 2 (30 ml) and washed with 5% HCl (20 ml). The organic layer was dried over MgSO 4 , filtered and concentrated.

용리액으로서 5:1 헥산:EtOAc를 사용하여 잔류물을 플래쉬크로마토그래피로 정제시켜 핑크색 고체인 m.p 163∼164℃(dec)인 7-퓨릴-3-메틸-4-크로마논 0-(톨루엔술포닐)-옥심(62)(429mg)을 얻었다.The residue was purified by flash chromatography using 5: 1 hexanes: EtOAc as eluent to afford 7-puryl-3-methyl-4-chromanone 0- (toluenesulfonyl, mp 163-164 ° C. (dec) as a pink solid. ) -Oxime (62) (429 mg) was obtained.

7-퓨릴-3-메틸-4-크로마논-0-(톨루엔술포닐)-옥심(62)(410mg,1.0mmol)을 벤젠(4ml)에 용해시킨 교반용액에 소디움 에톡사이드의 에탄올용액(0.35ml, 2.87M, 1.0mmol)을 첨가하였다.Ethanol solution of sodium ethoxide (0.35) in a stirred solution of 7-puryl-3-methyl-4-chromanone-0- (toluenesulfonyl) -oxime (62) (410 mg, 1.0 mmol) dissolved in benzene (4 ml). ml, 2.87M, 1.0 mmol) was added.

18시간후, 3N HCl(6ml)를 첨가하고 층을 분리하였다.After 18 h, 3N HCl (6 ml) was added and the layers separated.

유기상을 3N HCl(2x10ml)로 추출하였으며, 결합한 수성추출물을 농축시켜 오렌지색 고체(388mg)로서 조질 화합물 63을 얻었으며, 이들을 더이상의 정제없이 그대로 사용하였다.The organic phase was extracted with 3N HCl (2 × 10 ml) and the combined aqueous extracts were concentrated to yield crude Compound 63 as an orange solid (388 mg), which was used as such without further purification.

Figure 112002001377712-pct00052
Figure 112002001377712-pct00052

<2-아미노-7-(3'메톡시프로피닐)-3-메틸-4-크로마논하이드로클로라이드(65)>
<2-amino-7- (3'methoxypropynyl) -3-methyl-4-chromenonehydrochloride (65)>

이 아민 하이드로 클로라이드는 방법13에 도시된 바와같이 제조하였다.This amine hydrochloride was prepared as shown in Method 13.

7-트리플루오로메탄술포네이트-3-메틸-4-크로마논(3.10g, 10mmol)(K.Koch, 및 M.S.Biggers, J.Org.Chem. 1994,59,1216의 절차에 따라 제조됨)을 메틸 프로파길 에테르(1.05g, 15mmol), (Ph3P)4Pd(210mg, 0.30mmol)및 Et3N(6ml)을 DMF(30ml)에 용해시킨 용액에 첨가하고 70℃에서 1시간동안 가열하였다.7-trifluoromethanesulfonate-3-methyl-4-chromenone (3.10 g, 10 mmol) (prepared according to the procedures of K. Koch, and MS Biggers, J. Org. Chem. 1994, 59, 1216) Methyl propargyl ether (1.05 g, 15 mmol), (Ph 3 P) 4 Pd (210 mg, 0.30 mmol) and Et 3 N (6 ml) were added to a solution dissolved in DMF (30 ml) and heated at 70 ° C. for 1 hour. It was.

냉각후, 그 혼합물을 포화 NH4Cl(40ml)로 급냉시키고 Et2O(2x50ml)로 추출하였다. After cooling, the mixture was quenched with saturated NH 4 Cl (40 ml) and extracted with Et 2 O (2 × 50 ml).

결합된 유기층을 MgSO4상에서 건조하였으며, 여과 및 농축하였다. 용리액으로서 9:1헥산-EtOAc를 사용하여 잔류물을 플래쉬 크로마토그래피로 정제하여 백색고체로서 m.p. 60-63℃인 7-(3'-메톡시프로피닐)-3-메틸-4-크로마논(64)(1.40g)을 얻었다.The combined organic layer was dried over MgSO 4 , filtered and concentrated. The residue was purified by flash chromatography using 9: 1 hexane-EtOAc as eluent to afford 7- (3'-methoxypropynyl) -3-methyl-4-chromanone (mp 60-63 ° C. as a white solid). 64) (1.40 g).

2-아미노-7-퓨릴-3-메틸-4-크로마논 하이드로클로라이드에 대하여 상술한 바와같은 방법으로 화합물 64를 화합물 65로 변환시켰다.Compound 64 was converted to compound 65 in the same manner as described for 2-amino-7-furyl-3-methyl-4-chromanone hydrochloride.

Figure 112002001377712-pct00053
Figure 112002001377712-pct00053

<2-아미노-α-테트라론 하이드로클로라이드><2-amino-α-tetraron hydrochloride>

이 화합물은 2-아미노-7-퓨릴-3-메틸-4-크로마논하이드로클로라이드에 대하여 상기한 바와같은 방법으로, 방법 14에 도시된 바와같이 α-테트라론으로부터 제조되었 다.This compound was prepared from α-tetraron as shown in Method 14, in the same manner as described above for 2-amino-7-furyl-3-methyl-4-chromenonehydrochloride.

Figure 112002001377712-pct00054
Figure 112002001377712-pct00054

<2-아미노-엔도-6,9-에타노바이시클로[4.4.0]데크-7-에논 하이드로클로라이드(70)><2-Amino-endo-6,9-ethanocyclocyclo [4.4.0] deck-7-enone hydrochloride (70)>

이 아민 하이드로클로라이드는 방법 15에 도시된 바와같이 제조되었다.This amine hydrochloride was prepared as shown in Method 15.

톨루엔(100ml)에 2-시클로헥센-1-온(2.0g, 20.8mmol)을 용해시킨 용액에 알루미늄 클로라이드(700mg, 5.2mmol)을 첨가하였다. 40분후 시클로헥사디엔(8.3g, 104mmol)을 첨가하고 2시간동안 100℃로 가열하였다.Aluminum chloride (700 mg, 5.2 mmol) was added to a solution of 2-cyclohexen-1-one (2.0 g, 20.8 mmol) in toluene (100 ml). After 40 minutes cyclohexadiene (8.3 g, 104 mmol) was added and heated to 100 ° C. for 2 hours.

냉각시, 상기 혼합물을 Et2O(300ml)로 희석시키고 포화 NaHCO3(2x150ml)및 염수(100ml)로 세척하였다.Upon cooling, the mixture was diluted with Et 2 O (300 ml) and washed with saturated NaHCO 3 (2 × 150 ml) and brine (100 ml).

결합한 유기층을 MgSO4상에서 건조하고, 여과후 농축하였다.The combined organic layer was dried over MgSO 4 , filtered and concentrated.

용리액으로서 50:1 헥산-Et2O를 사용하여 잔류물을 플래쉬크로마토그래피로 정제하여 엔도-2,5-에타노바이시클로[4.4.0]데크-7-엔-10-온(67)(2.77g)을 제공하였으며, 이는 1H-NMR과 GC/MS에 의해 순수하였다.The residue was purified by flash chromatography using 50: 1 hexanes-Et 2 O as eluent to give endo-2,5-ethanocyclo [4.4.0] dec-7-en-10-one (67) ( 2.77 g), which was pure by 1 H-NMR and GC / MS.

THF(20ml)에 엔도-2,5-에타노바이시클로[4.4.0]데크-7-엔-10-온(67)(2.17g, 12.3mmol)을 용해시킨 용액을 THF(30ml)에 LDA(6.7ml, THF내에서 2.0M, 13.5mmol)을 용해시킨 -78℃용액에 첨가하였다.
A solution of endo-2,5-ethanocyclo [4.4.0] dec-7-en-10-one (67) (2.17 g, 12.3 mmol) in THF (20 ml) was dissolved in THF (30 ml). (6.7 ml, 2.0 M in THF, 13.5 mmol) was added to the dissolved -78 ° C solution.

45분후, 트리메틸실릴 크로라이드(2.0g, 18.5mmol)을 첨가하였으며, 그 혼합물을 0℃로 천천히 승온하였다. 그 혼합물을 포화 NaHCO3용액(30ml)로 희석하고 Et2O(2x30ml)로 추출하였으며, 건조(MgSO4)및 농축하였다. 잔류물을 THF(60ml)에 용해시켰으며 N-브로모숙신이미드(2.6g, 14.7mmol)을 첨가하였다.After 45 minutes, trimethylsilyl chromide (2.0 g, 18.5 mmol) was added and the mixture was slowly warmed to 0 ° C. The mixture was diluted with saturated NaHCO 3 solution (30 ml) and extracted with Et 2 O (2 × 30 ml), dried (MgSO 4 ) and concentrated. The residue was dissolved in THF (60 ml) and N-bromosuccinimide (2.6 g, 14.7 mmol) was added.

30분후, 그 혼합물을 포화 NH4Cl용액(30ml)으로 희석시키고 Et2O(2x40ml)로 추출하였다. 그 결합된 유기층을 건조하고 (MgSO4) 농축시켰다. 용리액으로서 33:1 헥산-Et2O를 사용하여 플래쉬 크로마토그래피로 잔류물을 정제하여 담황색오일인 2-브로모-엔도-6,9-에타노바이시클로[4.4.0]데크-7-에논(68)(1.44g)을 얻었으며 1H-NMR 및 GC/MS결과 순수하였다.After 30 minutes, the mixture was diluted with saturated NH 4 Cl solution (30 ml) and extracted with Et 2 O ( 2 × 40 ml). The combined organic layer was dried (MgSO 4 ) and concentrated. Purify the residue by flash chromatography using 33: 1 hexanes-Et 2 O as eluent to give the pale yellow oil, 2-bromo-endo-6,9-ethanocyclo [4.4.0] dec-7-enone. (68) (1.44 g) was obtained and purified by 1 H-NMR and GC / MS.

2-브로모-엔도-6,9-에타노바이시클로[4.4.0]데크-7-에논(68)(850g,3.9mmol)을 DMF(20ml)에 용해시킨 용액에 소디움아지드(280mg, 4.3mmol)을 첨가하였다. Sodium azide (280 mg, in a solution of 2-bromo-endo-6,9-ethanocyclocyclo [4.4.0] deck-7-enone (68) (850 g, 3.9 mmol) dissolved in DMF (20 ml) 4.3 mmol) was added.

2시간후, 그 혼합물을 물 (30ml)로 희석하고 Et2O(2x40ml)로 추출하였다. After 2 h the mixture was diluted with water (30 ml) and extracted with Et 2 O ( 2 × 40 ml).

결합한 유기층을 건조하고 (MgSO4)농축시켰다. 용리액으로서 20:1 헥산:Et2O를 사용하여 플래쉬 크로마토그래피로 잔류물을 정제하여 오일상의 2-아지도-엔도-6,9-에타노바이시클로[4.4.0]데크-7-에논(69)(469mg)을 얻었으며 1H-NMR결과 순수하였다. The combined organic layer was dried (MgSO 4 ) and concentrated. Purify the residue by flash chromatography using 20: 1 hexanes: Et 2 O as eluent to afford 2-azido-endo-6,9-ethanocyclo [4.4.0] dec-7-enone (oil phase). 69) (469 mg) was obtained by 1 H-NMR.

THF(10ml)에 2-아지도-엔도-6,9-에타노바이시클로[4.4.0]데크-7-에논(69)(310mg, 1.42mmol)을 용해시킨 용액에 트리페닐포스핀(486mg, 1.85mmol)을 첨가하였다. 12시간 교반한 후, 그 혼합물을 6N HCl(10ml)로 희석시키고 층분리하였다. 유기상을 6N HCl(2x5ml)로 추출하고 결합된 수성층은 농축시켜 진한 오렌지오일(500mg)로서 요구되는 화합물 70을 얻었으며 그 1H-NMR(DMSO-d6)는 주어진 구조와 일치하였다. Triphenylphosphine (486 mg) in a solution of 2-azido-endo-6,9-ethanocyclo [4.4.0] dec-7-enone (69) (310 mg, 1.42 mmol) dissolved in THF (10 ml). , 1.85 mmol) was added. After stirring for 12 hours, the mixture was diluted with 6N HCl (10 ml) and layered. The organic phase was extracted with 6N HCl (2 × 5 ml) and the combined aqueous layers were concentrated to give compound 70, which is required as a dark orange oil (500 mg) and its 1 H-NMR (DMSO-d 6 ) is consistent with the given structure.

<이소프로필 엔도-2-아미노노르보난-5-카복실레이트(71) 및<Isopropyl endo-2-aminonorbornan-5-carboxylate (71) and

이소프로필 엔도-2-아미노노르보난-6-카복실레이트(72)> Isopropyl endo-2-aminonorbornane-6-carboxylate (72)>

Figure 112002001377712-pct00055
Figure 112002001377712-pct00055

이들 아민은 앞서 기술한 것과 같은 방법으로 (방법 9참조)These amines are prepared in the same manner as described above (see Method 9).

이소프로필 노르본-2-엔-5-카복실레이트로부터 제조되었다.
Prepared from isopropyl norborn-2-ene-5-carboxylate.

<케톤의 아민으로의 환원성 아민화를 위한 일반적 절차>
General procedure for reductive amination of ketones to amines

케톤(1mmol), 암모늄 아세테이트(20mmol)및 3A 분자체(2.8당량, 중량)를 질소분위기 하에서 건조플라스크내에서 무수 메탄올에 혼합하였다. 소디움 시아노보로하이드리드(4mmol)을 첨가하고 그 결과 혼합물을 TLC분석에 의해 가르키는 바에 따라 출발 케톤이 사라질때까지 실온에서 교반하였다. 메탄올을 진공하에 반응 혼합물로부터 분리하고 잔류물을 6N HCl에 용해시켰다. 15분간 교반후, 디에틸에테르로 비 염기성 물질을 추출제거하였다. 수성상의 pH는 50% NaOH수용액을 이용하여 8까지 상승시켰으며, 아민을 EtOAc로 추출하였다.(3번) EtOAc추출물을 합하고, 염수세척하고, 건조하였으며(Na2SO4), 여과 및 농축하여 상응하는 아민을 얻었다.Ketone (1 mmol), ammonium acetate (20 mmol) and 3A molecular sieves (2.8 equiv., Weight) were mixed with dry methanol in a dry flask under nitrogen atmosphere. Sodium cyanoborohydride (4 mmol) was added and the resulting mixture was stirred at room temperature until the starting ketone disappeared as indicated by TLC analysis. Methanol was separated from the reaction mixture under vacuum and the residue was dissolved in 6N HCl. After stirring for 15 minutes, the non-basic substance was extracted and removed with diethyl ether. The pH of the aqueous phase was raised to 8 using 50% aqueous NaOH solution, and the amine was extracted with EtOAc (3 times). The EtOAc extracts were combined, brine, dried (Na 2 SO 4 ), filtered and concentrated to The corresponding amine was obtained.

조질아민은 전체적으로 순수하여 더이상의 정제없이 사용되었다.Crude amine was pure in its entirety and used without further purification.

<아민의 BOC-보호해제(deprotection)을 위한 일반절차.>
<General procedure for BOC-protection of amines.>

BOC-보호된 아민(1 mmol)을 무수(dry) CH2Cl2(1ml)에 용해시킨 얼음-냉각 용액에 트리에틸실란(0.5ml)과 트리플루오로아세트산 (1ml)를 첨가하였다.Triethylsilane (0.5 ml) and trifluoroacetic acid (1 ml) were added to an ice-cooled solution in which BOC-protected amine (1 mmol) was dissolved in dry CH 2 Cl 2 (1 ml).

반응진행을 출발물질의 감소로 모니터하였다. (5분에서 1.5시간) 반응혼합물을 톨루엔으로 희석시킨후 농축하였다.Reaction progress was monitored with a decrease in starting material. (5 min to 1.5 h) The reaction mixture was diluted with toluene and concentrated.

잔류물을 물 (10ml)및 EtOAc(20ml)에 용해시키고, pH를 8까지 조절하고 유기상을 분리하였다.The residue was dissolved in water (10 ml) and EtOAc (20 ml), the pH adjusted to 8 and the organic phase separated.

수성상을 EtOAc(2x15ml)로 추출하였다.The aqueous phase was extracted with EtOAc (2x15 ml).

유기상을 합하고 염수로 세척한후 건조(Na2SO4), 여과 및 농축하여 아민을 얻었다. The organic phases were combined, washed with brine, dried (Na 2 SO 4 ), filtered and concentrated to give an amine.

<아민 73 및 74의 제조>Preparation of Amine 73 and 74

Figure 112002001377712-pct00056
Figure 112002001377712-pct00056

이들 아민은 상기한 표준 환원성 아민화조건을 통해 상응하는 공지의 케토디락톤(J.Org. Chem. 1998, 63, 9889-94)으로부터 제조되었다.These amines were prepared from the corresponding known ketodilactones (J. Org. Chem. 1998, 63, 9889-94) through the standard reductive amination conditions described above.

1H, 13C NMR및 IR 스팩트럼 분석결과 주어진 구조와 일치하였다. 1 H, 13 C NMR and IR spectrum analysis were consistent with the given structure.

Figure 112002001377712-pct00057
Figure 112002001377712-pct00057

<아민 77 및 78의 제조>
Preparation of Amine 77 and 78

이들 아민의 제조단계가 상기 방법 16에 나타나있다.The preparation of these amines is shown in Method 16 above.

마크로디락톤 75는 J. Org. Chem. 1998, 63, 9889-94의 절차에 따라 제조하였다.Macrodilactone 75 is J. Org. Chem. Prepared according to the procedure of 1998, 63, 9889-94.

N-t-BOC-아스파르트산 (2.33g)을 상기 자료에 개시된 표준 매크로락톤화조건하에 DMF(100ml)내에서 2-클로로메틸-3-클로로프로판(1.25g)및 Cs2CO3(7.0g)과 반응시켜 유리질고체인 상기 화합물 75 1.12g(40%수율)을 얻었다.Nt-BOC-aspartic acid (2.33 g) was mixed with 2-chloromethyl-3-chloropropane (1.25 g) and Cs 2 CO 3 (7.0 g) in DMF (100 ml) under the standard macrolactoneization conditions described above. Reaction gave 1.12 g (40% yield) of the said compound 75 which is a glassy solid.

매스 스펙트럼(EI-)결과(m/e)284에서[M-1]+를 나타내었으며 1H, 13CNMR및 IR 스펙트라 결과는 75의 구조와 일치하였다.
Mass spectrum (EI-) results (m / e) showed [M-1] + at 284 and the 1 H, 13 CNMR and IR spectra results were consistent with the structure of 75.

무수 EtOAc(6ml)내에 상기 알켄 75(288mg, 1.01mmol)을 용해시킨 용액에 10% Pd/탄소(60mg)을 첨가하였다.To a solution of the alkene 75 (288 mg, 1.01 mmol) in anhydrous EtOAc (6 ml) was added 10% Pd / carbon (60 mg).

그 결과물인 혼합물을 질소퍼즈하고 Parr 수소화기내에서 45psi 수소압하에 2.5시간동안 교반하였다.The resulting mixture was nitrogen purged and stirred for 2.5 h under 45 psi hydrogen pressure in a Parr hydrogenator.

반응혼합물을 질소퍼즈하고 여과 및 농축하였다.The reaction mixture was purged with nitrogen, filtered and concentrated.

플래쉬 컬럼 크로마토그래피(실라카겔, 7:3 헥산-EtOAc혼합물)로 정제시 잔류물은 환원산물 76 91mg(32% 수율)을 제공하였다.Purification by flash column chromatography (silica gel, 7: 3 hexanes-EtOAc mixtures) gave 91 mg (32% yield) of the reduced product 76.

1H, 13C-NMR및 IR 스펙트럼 분석결과 구조 76과 일치하였다.
1 H, 13 C-NMR and IR spectrum analysis were consistent with the structure 76.

앞서기술된 일반적인 BOC-보호해제 절차에 따라 화합물 75 및 76으로부터 BOC보호기를 제거하여 각각 아민 77및 78을 얻었다. Amine 77 and 78 were obtained by removing BOC protecting groups from compounds 75 and 76 according to the general BOC-deprotection procedure described above.                 

1H, 13C-NMR 및 IR 스펙트럼 분석결과 주어진 구조와 일치하였다. 1 H, 13 C-NMR and IR spectrum analysis were consistent with the given structure.

Figure 112002001377712-pct00058
Figure 112002001377712-pct00058

<페닐디락톤 81의 합성>
<Synthesis of Phenyldilactone 81>

이 화합물의 제조단계가 상기 방법 17에 나타나있다.
The preparation of this compound is shown in Method 17 above.

무수 CH2Cl2(55ml)에 페닐숙신산(0.922g, 5.2mmol)및 DMAP(0.064g, 0.52mmol)을 용해시킨 0℃의 잘교반된 용액에 질소분위기하에서 BOC-세리놀(Synthesis 1998, 1113-1118)(1.0g, 5.2mmol)용액을 30분에 걸쳐 적정첨가 하였다. 그 결과물인 혼합물을 실온으로 천천히 승온시킨후 12시간 더 교반하고 CH2Cl2(40ml)로 희석시킨다음 포화 소디움 바이카보네이트 수용액(3x10ml)으로 추출하였다.
BOC-serinol (Synthesis 1998, 1113) under nitrogen atmosphere in a well stirred solution at 0 ° C. in which phenylsuccinic acid (0.922 g, 5.2 mmol) and DMAP (0.064 g, 0.52 mmol) were dissolved in anhydrous CH 2 Cl 2 (55 ml). -1118) (1.0 g, 5.2 mmol) was added to the solution over 30 minutes. The resulting mixture was slowly warmed to room temperature, stirred for another 12 hours, diluted with CH 2 Cl 2 (40 ml) and extracted with saturated aqueous sodium bicarbonate solution (3 × 10 ml).

염기성 추출물을 합하고 주의깊게 2N HCl로 산성화시킨 다음 EtOAc(3x20ml)로 추출 하였다.The basic extracts were combined, carefully acidified with 2N HCl and extracted with EtOAc (3 × 20 ml).

합한 EtOAc추출물을 염수로 세척하고, 건조시킨 다음(Na2SO4), 여과 및 농축하여 흰색거품(1.7g)을 얻었다.
The combined EtOAc extracts were washed with brine, dried (Na 2 SO 4 ), filtered and concentrated to give a white foam (1.7 g).

1H-NMR결과 산 79의 1:1 부분입체 혼합물을 나타내었다.
1 H-NMR showed a 1: 1 diasteremic mixture of acid 79.

산 79(1.00g, 2.72mmol)과 트리페닐포스핀(786mg, 3.0mmol)을 무수 THF(122ml)에 첨가한 잘 교반된 얼음 냉각 서스펜션에 THF(55ml)에 디에틸 아조디카복실레이트(0.52g, 3.0mmol)을 용해시킨 용액을 3시간에 걸쳐 적정 첨가하였다.Diethyl azodicarboxylate (0.52 g) in THF (55 ml) in a well stirred ice cold suspension in which acid 79 (1.00 g, 2.72 mmol) and triphenylphosphine (786 mg, 3.0 mmol) were added to anhydrous THF (122 ml). , 3.0 mmol) was dissolved in a solution added over 3 hours.

그 결과 혼합물을 실온으로 천천히 승온시키고 다시 5시간 교반하고 나서 5ml로 농축시켰다. 그 잔류 혼합물을 EtOAc(50ml)및 물 (20ml)로 희석하였다. 유기상을 분리하고, NaHCO3수용액(10ml)및 염수(10ml)로 세척, 건조(Na2SO4), 여과및 농축시켜 오일상 잔류물을 얻었다.As a result, the mixture was slowly warmed to room temperature, stirred for another 5 hours, and then concentrated to 5 ml. The residual mixture was diluted with EtOAc (50 ml) and water (20 ml). The organic phase was separated, washed with aqueous NaHCO 3 (10 ml) and brine (10 ml), dried (Na 2 SO 4 ), filtered and concentrated to give an oily residue.

플래쉬 크로마토그래피로 (실리카겔, 헥산)정제하여 m.p=161∼162℃인 디락톤 80의 1:1 혼합물 228mg(22%수율)을 얻었다.
Flash chromatography gave (silica gel, hexane) to give 228 mg (22% yield) of a 1: 1 mixture of dilactone 80 with mp = 161-162 ° C.

매스 스펙트럼(EI)조사결과 m/c 349에서 M+를 나타내었다. Mass spectrum (EI) results showed M + at m / c 349.                 

앞서 기술된 표준 BOC 보호해제 조건하에 BOC보호기를 제거하여 아민 81을 얻었다.The amine 81 was obtained by removing the BOC protecting group under the standard BOC deprotection conditions described above.

Figure 112002001377712-pct00059

Figure 112002001377712-pct00059

<디락톤 아민 84및 85의 합성>
<Synthesis of dilactone amines 84 and 85>

이들 화합물의 제법이 방법 18에 나타나있다.The preparation of these compounds is shown in Method 18.

세리놀(3.0g, 15.7mmol), 피리딘(1.24g, 0.98mol)및 DMAP(0.19g, 1.57mmol)을 무수 CH2Cl2(140ml)에 용해시킨 교반용액에 N-CBz 아스파르트산 무수물 (3.52g, 14.13mmol)을 무수 THF(20ml)에 용해시킨 용액에 적정 첨가하였다.
N-CBz aspartic anhydride (3.52) in a stirring solution in which cerinol (3.0 g, 15.7 mmol), pyridine (1.24 g, 0.98 mol) and DMAP (0.19 g, 1.57 mmol) were dissolved in anhydrous CH 2 Cl 2 (140 ml). g, 14.13 mmol) was added to the solution dissolved in anhydrous THF (20 ml).

실온에서 2시간 교반한 후, 그 반응 혼합물을 약 10ml체적으로 농축하고 EtOAc(100ml)및 물 (30ml)로 희석시켰다.After stirring for 2 hours at room temperature, the reaction mixture was concentrated to about 10 ml volume and diluted with EtOAc (100 ml) and water (30 ml).

pH를 8.5로 조절하고 (NaHCO3수용액) 수상을 분리한후 2N HCl로 pH3으로 산성화 하 였으며 EtOAc(3x20ml)로 추출하였다. 결합한 유기 추출물을 염수로 세척하고 건조(Na2SO4), 여과 및 농축시켜 거품상의 백색물질로서 화합물 82 5.8g을 얻었다. The pH was adjusted to 8.5 (NaHCO 3 aqueous solution) and the aqueous phase was separated, acidified to pH 3 with 2N HCl and extracted with EtOAc (3 × 20 ml). The combined organic extracts were washed with brine, dried (Na 2 SO 4 ), filtered and concentrated to give 5.8 g of compound 82 as a foamy white substance.

1H-NMR결과 아주 순수하였으며 부분입체 이성질체 혼합물을 함유하였다.
1 H-NMR showed very pure and contained diastereomeric mixtures.

트리페닐 포스핀(3.6g, 13.75mmol)과, 1,3-디이소프로필카보디이미드(2.8g, 13.75mmol)을 무수THF(1.15L)에 용해시킨 용액에 상기 산 82(5.5g, 12.5mmol)을 무수 THF(100ml)에 용해시킨 용액에 3시간에 걸쳐 적정 첨가하였다.
The acid 82 (5.5 g, 12.5) in a solution in which triphenyl phosphine (3.6 g, 13.75 mmol) and 1,3-diisopropylcarbodiimide (2.8 g, 13.75 mmol) were dissolved in anhydrous THF (1.15 L). mmol) was added to the solution dissolved in anhydrous THF (100 ml) over 3 hours.

그 결과 혼합물을 6시간 더 교반하고, 약 20ml로 진공내에서 농축하고 에테르(200ml)및 물(100ml)로서 희석하였다.
The resulting mixture was stirred for another 6 h, concentrated in vacuo to about 20 ml and diluted as ether (200 ml) and water (100 ml).

유기상을 분리하고, 5% NaHCO3수용액 및 염수로서 세척하고, 건조(Na2SO4), 여과 및 진공내 농축하였다.The organic phase was separated, washed with 5% aqueous NaHCO 3 and brine, dried (Na 2 SO 4 ), filtered and concentrated in vacuo.

오일상의 잔류물을 플래쉬 컬럼 크로마토그래피하여 요구되는 디락톤 83 1.3g(23%수율)을 얻었다.Flash column chromatography of the residue on the oil gave 1.3 g (23% yield) of the required dilactone 83.

매스 스펙트럼(ES-)은 m/e 421(M-1)+를 나타내었다.The mass spectrum (ES−) showed m / e 421 (M-1) +.

1H, 13C-NMR및 IR스펙트라는 구조 83과 일치하였다. 1 H, 13 C-NMR and IR spectra were consistent with structure 83.

디락톤 83을 표준 BOC보호해제(deprotection)조건하에 보호해제하여 아민 84를 얻 었다.
Dilactone 83 was deprotected under standard BOC deprotection conditions to afford amine 84.

EtOAc(10ml)에 N-CBz-보호된 디락톤 83(200mg, 0.47mmol)을 용해시킨 용액에 10% Pd/C(40mg)을 첨가하고, 그 결과 혼합물을 수소가스압하에 12시간 교반하였다. 그 반응 혼합물을 N2퍼즈하고 소성 유리 판넬을 통해 여과한 다음 농축시켜 아민 85(126mg)을 얻었다. 그 조질아민은 더이상의 정제없이 사용하였다.10% Pd / C (40 mg) was added to a solution of N-CBz-protected dilactone 83 (200 mg, 0.47 mmol) in EtOAc (10 ml), and the resulting mixture was stirred under hydrogen gas pressure for 12 hours. The reaction mixture was purged with N 2, filtered through a calcined glass panel and concentrated to give amine 85 (126 mg). The crude amine was used without further purification.

Figure 112002001377712-pct00060

Figure 112002001377712-pct00060

<아민 86과 88의 제조>
Preparation of Amine 86 and 88

아민 88에 대한 전구체인, 2,6,6,-트리메틸-2,4-시클로헵타디에닐아민(86)과 2,3,6,6-테트라메틸-3-시클로헵테논(87)의 합성이 상기 방법 19에 나타나있다.Synthesis of 2,6,6, -trimethyl-2,4-cycloheptadienylamine (86) and 2,3,6,6-tetramethyl-3-cycloheptenone (87), precursors to amine 88 This is shown in Method 19 above.

유카르본(eucarvone)(Can. J. Chem. 1974, 52, 1352)를 Synlett 1999, 1781에 기술된 티타늄 이소프로폭사이드/ NaBH4/Et3N-중계 환원성 아민화 절차를 이용하여 쉽게 상응하는 아민 86으로 변환시켰다.Eucarvone (Can. J. Chem. 1974, 52, 1352) can be readily matched using the titanium isopropoxide / NaBH 4 / Et 3 N-mediated reductive amination procedure described in Synlett 1999, 1781. Was converted to amine 86.

Tetrahedron 1995, 51, 743-754에 기술된 절차를 이용하여 트리메틸 알루미늄을 유 카르본에 Cu(I)-촉매반응 마이클부가한결과 2,3,5,5-테트라메틸-3-시클로헵테논(87)을 얻었다.Using the procedure described in Tetrahedron 1995, 51, 743-754, Cu (I) -catalyzed Michael addition of trimethyl aluminum to milk carbon resulted in 2,3,5,5-tetramethyl-3-cycloheptenone ( 87).

이는 다시 WO 9927783에 기재된 절차에 따라 2,3,5,5-테트라메틸-2-시클로헵테닐아민(88)로 변환되었다.
This was again converted to 2,3,5,5-tetramethyl-2-cycloheptenylamine 88 according to the procedure described in WO 9927783.

<N-메틸-N-(2-(페닐에틸)-(1,5,5-트리메틸-3-아미노시클로헥실)카바마이드(89)><N-methyl-N- (2- (phenylethyl)-(1,5,5-trimethyl-3-aminocyclohexyl) carbamide (89)>

Figure 112002001377712-pct00061
Figure 112002001377712-pct00061

1,5,5-트리메틸-3-옥소-1-시클로헥실카복실산(M.S.Ziegler 및 R.M. Herbst, J. Org. Chem. 1951, 16, 920)을 표준 HOAt, EDCI 및 DMAP-매개 결합조건을 사용하여 N-메틸-2-페닐에틸아민에 결합시켜 담황색오일로서 [N-메틸-N-(2-페닐에틸)]-1,5,5-트리메틸-3-옥소-1-시클로헥실카보옥사미드를 얻었다.
1,5,5-trimethyl-3-oxo-1-cyclohexylcarboxylic acid (MSZiegler and RM Herbst, J. Org. Chem. 1951, 16, 920) was subjected to N using standard HOAt, EDCI and DMAP-mediated binding conditions. -Methyl-2-phenylethylamine was bonded to give [N-methyl-N- (2-phenylethyl)]-1,5,5-trimethyl-3-oxo-1-cyclohexylcaroxamide as light yellow oil. .

매스 스펙트럼은 m/e 301에서 모이온을 나타내었다.The mass spectrum showed moieties at m / e 301.

1H 및 13C-NMR스펙트라는 이 구조와 일치하였다.
1 H and 13 C-NMR spectra were consistent with this structure.

WO9927783의 일반적인 절차에 따라 상응하는 N-히드록시옥심으로 변환시키고 Raney

Figure 112002001377712-pct00062
Ni의 존재하에 수소화시켜 이 케톤으로부터 아민 89를 제조하였다. 아민의 1H-NMR은 1:1 부분입체 이성질체 혼합물을 나타내었다.
Conversion to the corresponding N-hydroxyoxime according to the general procedure of WO9927783 and Raney
Figure 112002001377712-pct00062
Amine 89 was prepared from this ketone by hydrogenation in the presence of Ni. 1 H-NMR of the amine showed a 1: 1 diastereomeric mixture.

<3-(3,3-디메틸부톡시카보닐)-3,5,5,-트리메틸시클로헥실아민(90)><3- (3,3-dimethylbutoxycarbonyl) -3,5,5, -trimethylcyclohexylamine (90)>

Figure 112002001377712-pct00063
Figure 112002001377712-pct00063

1,5,5-트리메틸-3-옥소-1-시클로헥실카복실산(3.0g)(M.S. Ziegler 및 R.M. Herbst, J. Org. Chem. 1951, 16, 920)을 표준 결합 조건하에서 CH2Cl2(80ml)내에서 3,3-디메틸펜탄올(1.84g), DMAP(2.21g)및 1,3-디이소프로필 카보디이미드(2.17g)으로 처리하여 3-(3,3-디메틸부톡시카보닐)-3,5,5-트리메틸시클로헥사논 2.41g(55%수율)을 얻었다. 매스 스펙트럼(EI)는 m/e 268에서 모이온(Parention)을 나타내었다.
1,5,5-trimethyl-3-oxo-1-cyclohexylcarboxylic acid (3.0 g) (MS Ziegler and RM Herbst, J. Org. Chem. 1951, 16, 920) was added to CH 2 Cl 2 ( 3- (3,3-dimethylbutoxycarbo) treated with 3,3-dimethylpentanol (1.84 g), DMAP (2.21 g) and 1,3-diisopropyl carbodiimide (2.17 g) in 80 ml) 2.41 g (55% yield) of 3,5,5-trimethylcyclohexanone was obtained. The mass spectrum (EI) showed a parention at m / e 268.

이 캐톤을 WO9927783의 일반적 절차에 따라 상응하는 옥심으로 변환시킨후 Raney

Figure 112002001377712-pct00064
Ni의 존재하에 수소화하여 아민 90으로 변환시켰다.After converting this canton into the corresponding oxime according to the general procedure of WO9927783, Raney
Figure 112002001377712-pct00064
Hydrogenation in the presence of Ni was converted to amine 90.

Figure 112002001377712-pct00065

Figure 112002001377712-pct00065

<4-(4,6-비스)트리플루오로메틸-2-피리딜)옥시-3,3,5,5,-테트라메틸시클로헥실아민(93)>
<4- (4,6-bis) trifluoromethyl-2-pyridyl) oxy-3,3,5,5, -tetramethylcyclohexylamine (93)>

이 아민의 합성이 상기 방법 20에 나타나있다.The synthesis of this amine is shown in Method 20 above.

4-히드록시-3,3,5,5-테트라메틸시클로헥실-1,1-에틸렌글리콜 아세탈(900mg, 4.2mmol)을 무수 DMF(8.4ml)에 용해시키고, 그 혼합물을 0℃로 냉각하고 KH의 35%(wt)오일 서스펜션(591mg, 5.04mmol)을 첨가하였다.4-hydroxy-3,3,5,5-tetramethylcyclohexyl-1,1-ethyleneglycol acetal (900 mg, 4.2 mmol) was dissolved in anhydrous DMF (8.4 ml) and the mixture was cooled to 0 ° C 35% (wt) oil suspension of KH (591 mg, 5.04 mmol) was added.

1시간 동안 그 혼합물을 교반한 후, 2-클로로-4,6-비스-트리플루오로메틸-2-피리딘(1.48g, 6.3mmol)을 DMF(2ml)에 용해시킨 용액을 적정첨가 하였다. 이 혼합물을 0℃에서 1시간 교반한 다음 실온에서 12시간 교반하고 염화암모늄으로 조심스럽게 급냉시켰다. 디에틸에테르(100ml)를 첨가하였으며 상을 분리하고 염수세척후, 건조(MgSO4)및 농축하여 암갈색 고체를 얻었다.After stirring the mixture for 1 hour, a solution of 2-chloro-4,6-bis-trifluoromethyl-2-pyridine (1.48 g, 6.3 mmol) dissolved in DMF (2 ml) was titrated. The mixture was stirred at 0 ° C. for 1 hour and then at room temperature for 12 hours and carefully quenched with ammonium chloride. Diethyl ether (100 ml) was added and the phases were separated, washed with brine, dried (MgSO 4 ) and concentrated to give a dark brown solid.

고온의 헥산으로 재결정화하여 4-(4,6-비스-트리플루오로메틸-2-피리딜)옥시 -3,3,5,5,-테트라메틸시클로헥실-1,1-에틸렌글리콜아세탈(91)(m.p=105∼106℃)를 얻었다.
Recrystallized from hot hexane to give 4- (4,6-bis-trifluoromethyl-2-pyridyl) oxy-3,3,5,5, -tetramethylcyclohexyl-1,1-ethylene glycol acetal ( 91) (mp = 105-106 degreeC) were obtained.

상기 아세탈 91(900mg)을 THF, 디옥산 및 2N HCl의 1:1:1 혼합물(30ml)에 용해시키고, 그 결과 용액을 실온에서 12시간 교반했을때, GC가 출발물질이 완전히 사라졌음을 나타내었다. 이 혼합물을 물 및 디에틸에테르 (각각 50ml)로 희석하고, 유기 상을 분리하였으며, 염수로 세척하고, 건조(Na2SO4)및 농축하여 오일상의 잔류물을 얻었다.The acetal 91 (900 mg) was dissolved in a 1: 1: 1 mixture (30 ml) of THF, dioxane and 2N HCl, and as a result, GC showed complete disappearance of starting material when the solution was stirred at room temperature for 12 hours. It was. The mixture was diluted with water and diethyl ether (50 ml each), the organic phase was separated, washed with brine, dried (Na 2 SO 4 ) and concentrated to give an oily residue.

이 잔류물을 실리카겔(헥산-EtOAc, 5:1)에서 크로마토그래피하여 무색오일의 케톤 92 712mg(96% 수율)을 얻었다. 매스 스펙트럼(EI)는 383의모이온 m/e를 나타내었다.This residue was chromatographed on silica gel (hexane-EtOAc, 5: 1) to give 712 mg (96% yield) of colorless oil ketone 92. The mass spectrum (EI) showed a moion m / e of 383.

WO 9927783의 일반절차에 따라 92를 환원성 아민화하여 아민 93으로 제조하였다.92 was prepared as amine 93 by reductive amination according to the general procedure of WO 9927783.

Figure 112002001377712-pct00066
Figure 112002001377712-pct00066

<3-(2,3-디클로로프로필옥시)메틸-3,5,5,-트리메틸시클로헥실아민(97)><3- (2,3-Dichloropropyloxy) methyl-3,5,5, -trimethylcyclohexylamine (97)>

아민 97의 합성방법이 상기 방법 21에 나타나있다.The synthesis of amine 97 is shown in Method 21 above.

Tetrahedron Lett. 1991, 32, 1831∼4의 절차에 따라 알켄 94를 디클로로화하여 아세탈 95를 얻었다.Tetrahedron Lett. The acetal 95 was obtained by dichloroating the alkene 94 following the procedure of 1991, 32, 1831-4.

그 아세탈(500 mg)을 THF와 2N HCl의 1:1 혼합물에 용해시키고, 그 결과 용액을 실온에서 1시간 교반하였으며, 그때 TLC는 출발물질이 사라진것을 나타내었다.The acetal (500 mg) was dissolved in a 1: 1 mixture of THF and 2N HCl, and the result was stirred for 1 hour at room temperature, at which time TLC showed no starting material.

상기 혼합물을 EtOAc와 물(각 30ml)로 희석하고 오렌지상을 분리한 다음 염수세척 하고, 건조(Na2SO4)및 여과후 농축하여 오일상의 케톤96 383mg을 얻었다.The mixture was diluted with EtOAc and water (30 ml each), the orange phase was separated, washed with brine, dried (Na 2 SO 4 ), filtered and concentrated to give 383 mg of ketone 96 as an oil.

1H-NMR은 이성체의 부분입체 이성질체 혼합물과 일치하였다. 1 H-NMR was consistent with the diastereomeric mixture of isomers.

앞서 기술한 표준 절차에 따른 환원 아민화에 의해 아민 97을 얻었다.Amine 97 was obtained by reductive amination according to the standard procedure described above.

Figure 112002001377712-pct00067

Figure 112002001377712-pct00067

<3-벤조일-3,5,5-트리메틸시클로헥실아민(100)>
<3-benzoyl-3,5,5-trimethylcyclohexylamine (100)>

이 아민의 제법이 상기 방법 22에 나타나있다.The preparation of this amine is shown in Method 22 above.

3-시아노-3,5,5,-테트라메틸시클로헥실-1,1-에틸렌글리콜아세탈(98)(WO9927783)을 페닐리튬과 반응후 산가수분해하여 케톤99를 얻었으며, 이는 상기 문헌의 방법에 따라 아미노케톤(100)으로 변환되었다.After reacting 3-cyano-3,5,5, -tetramethylcyclohexyl-1,1-ethylene glycol acetal (98) (WO9927783) with phenyllithium, the acid was hydrolyzed to obtain ketone 99. According to the method was converted into amino ketone (100).

Figure 112002001377712-pct00068

Figure 112002001377712-pct00068

<5β-(2-페닐에틸)-3β-메톡시-4β-메틸-4-니트로-시클로헥실아민(105)>
<5β- (2-phenylethyl) -3β-methoxy-4β-methyl-4-nitro-cyclohexylamine (105)>

상기 아민 105의 제법이 상기 방법 23에 나타나있다.The preparation of amine 105 is shown in Method 23 above.

Bull.Chem.Soc.Jap.1968, 41, 1441의 절차에 따라 니트로에탄을 디하이드로 신남알데히드와 축합시켜 상응하는 니트로알콜 101을 얻었다.
Nitroethane was condensed with dihydrocinnamaldehyde according to the procedures of Bull.Chem.Soc.Jap.1968, 41, 1441 to afford the corresponding nitroalcohol 101.

Synthesis, 1982, 1017의 절차에 따라 화합물 101을 탈수시킨후 중합체지지된 트리페닐포스핀-매개 이성체화(Tetrahedron Lett. 1998, 39, 811-812)하여 알켄103을 얻었다.Compound 101 was dehydrated following the procedure of Synthesis, 1982, 1017 and then polymer-supported triphenylphosphine-mediated isomerization (Tetrahedron Lett. 1998, 39, 811-812) to obtain alkene 103.

Tetrahedron Lett. 2000, 41, 1717의 절차에 따라 화합물 103은 Danishefsky의 디엔으로 Diels-Alder 시클로첨가하여 케톤104를 얻었다. Tetrahedron Lett. Compound 103 was subjected to Diels-Alder cycloaddition with a diene of Danishefsky following the procedure of 2000, 41, 1717 to obtain ketone 104.                 

상기 케톤 104는 WO 9927783의 표준 절차에 따라 아민 105로 변환되었다.The ketone 104 was converted to amine 105 according to the standard procedure of WO 9927783.

Figure 112002001377712-pct00069

Figure 112002001377712-pct00069

<3-시아노-3,5,5-트리메틸시클로헥실아민(106)><3-cyano-3,5,5-trimethylcyclohexylamine (106)>

상기한 표준 환원 아민화 절차에 따라 3-시아노-3,5,5-트리메틸시클로헥사논을 환원 아민화하여 이 화합물을 제조하였다.(방법24).This compound was prepared by reductive amination of 3-cyano-3,5,5-trimethylcyclohexanone according to the standard reductive amination procedure described above (Method 24).

매스스펙트럼(EI)는 167의 모 이온 m/e를 나타내었다.The mass spectrum (EI) showed a parent ion of m / e of 167.

Figure 112002001377712-pct00070

Figure 112002001377712-pct00070

<3-아미노-5-페닐티오피란(107)><3-amino-5-phenylthiopyran (107)>

이 화합물은 상기 방법 25에 도시된 바와같이 제조되었다.This compound was prepared as shown in Method 25, above.

무수메탄올 50ml에 용해시킨 5-페닐-3-티오피라논(P.T.Lansbury, et al., J. Am. Chem. Soc. 1970, 92, 5649) 0.96g(5 mmol)에 암모늄아세테이트 7.7g(100mmol)및 3A 분자체 6.5g을 첨가하였다.7.7 g (100 mmol) of ammonium acetate in 0.96 g (5 mmol) of 5-phenyl-3-thiopyranone (PTLansbury, et al., J. Am. Chem. Soc. 1970, 92, 5649) dissolved in 50 ml of anhydrous methanol. And 6.5 g of 3A molecular sieve.

실온에서 30분간 교반후 소디움 시아노보로하이드라이드 1.25g(20mmol)을 나누어 첨가하였다.After stirring for 30 minutes at room temperature, sodium cyanoborohydride 1.25 g (20 mmol) was added in portions.

16시간 교반한 후, 그 혼합물을 중력여과하고 진공하에 메탄올을 증발시켰다. 잔류물을 얼음/HCl과 에테르로 분배하였다.After stirring for 16 hours, the mixture was gravity filtered and the methanol was evaporated under vacuum. The residue was partitioned between ice / HCl and ether.

산성 수상을 에테르로 2번더 추출한후 얼음 및 50%NaOH 수용액으로 염기성으로 만들었다.The acidic aqueous phase was extracted twice with ether and then basified with ice and 50% aqueous NaOH solution.

이 혼합물을 CH2Cl2로 추출하고, 건조시킨후(MgSO4) 증발하여 원하는 화합물 0.19g(20%)를 얻었다.The mixture was extracted with CH 2 Cl 2 , dried (MgSO 4 ) and evaporated to afford 0.19 g (20%) of the desired compound.

GC/MS결과 193의 분자이온을 갖는 100%순도를 나타내었다.GC / MS showed 100% purity with a molecular ion of 193.

Figure 112002001377712-pct00071

Figure 112002001377712-pct00071

<4-(4-트리플루오로메틸)페녹시 시클로헥실아민(109)><4- (4-Trifluoromethyl) phenoxy cyclohexylamine (109)>

방법 26에 따라 이 화합물을 제조하였다.This compound was prepared according to Method 26.

DMF 50ml에 소디움 하이드리드(1.2g, 0.05mol)을 용해시킨 교반용액에 1,4-디옥사스피로[4,5]데칸-8-올(7.5g, 0.047mol)을 DMF 15ml에 용해시킨 용액을 10분에 걸쳐 적정 첨가하였다.A solution of 1,4-dioxaspiro [4,5] decane-8-ol (7.5 g, 0.047 mol) dissolved in 15 ml of DMF in a stirring solution in which sodium hydride (1.2 g, 0.05 mol) was dissolved in 50 ml of DMF. Titration was added over 10 minutes.

그 혼합물을 주위온도에서 30분간 교반하였으며, 4-플루오로벤조트리플루오라이드 (7.71g, 0.047mol)을 단번에 첨가하였으며 그 반응물을 실온에서 2시간동안 교반하 고 밤새 70℃에서 교반하였다. 그 반응혼합물을 냉수(700ml)에 붓고 1N HCl을 첨가하여 용액을 약 산성으로 하였다. 혼합물을 여과하고 헥산(2x150ml)으로 수용성 여과물을 추출하였다.The mixture was stirred at ambient temperature for 30 minutes, 4-fluorobenzotrifluoride (7.71 g, 0.047 mol) was added in one portion and the reaction was stirred at room temperature for 2 hours and at 70 ° C. overnight. The reaction mixture was poured into cold water (700 ml) and 1N HCl was added to make the solution slightly acidic. The mixture was filtered and the aqueous filtrate was extracted with hexane (2x150 ml).

여과된 고체를 헥산추출물에 용해시키고 물(50ml)로서 세척하였다. The filtered solid was dissolved in hexane extract and washed with water (50 ml).

그 용액을 MgSO4에서 건조시키고, 여과및 농축하여 백색고체를 얻었다. 이 고체를 메탄올/물로부터 재결정화시켜 순수케탈(ketal)(8.6g, 61%)를 얻었다.
The solution was dried over MgSO 4 , filtered and concentrated to give a white solid. This solid was recrystallized from methanol / water to give pure ketal (8.6 g, 61%).

실리카 겔(30g)을 CH2Cl2 150ml에 부유시켰다.Silica gel (30 g) was suspended in 150 ml of CH 2 Cl 2 .

이 서스펜션에 물에 용해시킨 12%HCl 용액 7ml를 5분에 걸쳐 적정첨가 시켰다. 이 혼합물이 군집되는 것을 막기위해 격렬히 교반하였다. CH2Cl2 75ml에 상기 케탈(8.0g, 26.49mmol)을 용해시킨 용액을 첨가하고 반응물을 3시간동안 교반하였다. 그후 혼합물을 여과하고 500ml CH2Cl2로서 실라카겔 패드를 세척하였다.
To this suspension was added 7 ml of a 12% HCl solution dissolved in water over 5 minutes. The mixture was stirred vigorously to prevent crowding. To 75 ml of CH 2 Cl 2 was added a solution of the ketal (8.0 g, 26.49 mmol) and the reaction was stirred for 3 hours. The mixture was then filtered and the silica gel pad washed with 500 ml CH 2 Cl 2 .

용매를 증발시켜 4-(4-트리플루오로페녹시)시클로헥사논(108) 5.8g(86%)를 얻었다.The solvent was evaporated to give 5.8 g (86%) of 4- (4-trifluorophenoxy) cyclohexanone (108).

상기한 표준 환원 아민화법에 따라 케톤108을 환원 아민화하여 화합물 109를 얻었 다.According to the standard reduction amination method described above, ketone 108 was reduced amination to obtain compound 109.

Figure 112002001377712-pct00072

Figure 112002001377712-pct00072

<4-벤조일옥시-3,3,5,5-테트라메틸시클로헥실아민(111)><4-benzoyloxy-3,3,5,5-tetramethylcyclohexylamine (111)>

이 화합물은 방법 27의 절차에 따라 제조되었다.This compound was prepared according to the procedure of Method 27.

0℃로 냉각된 THF 6ml 에 7,7,9,9 - 테트라메틸-1,4-디옥사스피로[4,5]데칸-8-올(0.37g, 1.73mmol)을 용해시킨 교반된 용액에 n-BuLi(헥산내에 2.5M, 1.73mmol, 0.7ml)을 적정 첨가하였다.To a stirred solution of 7,7,9,9-tetramethyl-1,4-dioxaspiro [4,5] decane-8-ol (0.37 g, 1.73 mmol) dissolved in 6 ml of THF cooled to 0 ° C. n-BuLi (2.5M in hexanes, 1.73mmol, 0.7ml) was titrated.

이 반응물을 10분간 교반하였다. 그후 벤조일 클로라이드(1.73mmol, 0.2ml)을 첨가한후, 그 반응물을 실온으로 승온하여 밤새 교반하였다. 그 반응혼합물을 0.5N NaOH 50ml에 붙고 에테르(3x 20ml)로 추출하였다.The reaction was stirred for 10 minutes. After adding benzoyl chloride (1.73 mmol, 0.2 ml), the reaction was allowed to warm to room temperature and stirred overnight. The reaction mixture was attached to 50 ml of 0.5 N NaOH and extracted with ether (3 × 20 ml).

에테르층을 MgSO4상에서 건조하고, 여과 및 농축시켰다.The ether layer was dried over MgSO 4 , filtered and concentrated.

용리액으로 4:1 헥산-EtOAc 를 사용하여 래디얼 크로마토그래피로 잔류물을 정제하였다. 그렇게 얻은것은 벤조일옥시케탈 0.55g(100%까지)였다.The residue was purified by radial chromatography using 4: 1 hexane-EtOAc as eluent. The result was 0.55 g (up to 100%) of benzoyloxyketal.

실리카 겔(2.2g)을 CH2Cl2 10ml에 부유시켰다.Silica gel (2.2 g) was suspended in 10 ml of CH 2 Cl 2 .

이 서스펜션에 12% HCl 수용액 0.5ml를 5분에 걸쳐 적정첨가하였다. 군집을 막기위해 이 혼합물을 격렬히 교반하였다.
To this suspension was added 0.5 ml of a 12% aqueous HCl solution over 5 minutes. The mixture was stirred vigorously to prevent crowding.

상기 벤조일옥시 케탈을 5ml CH2Cl2에 용해시킨 용액을 첨가하고 그 반응물을 3시간 교반하였다. 그후 혼합물을 여과하고 실리카겔 패드를 100ml CH2Cl2로 세척하였다. A solution of the benzoyloxy ketal dissolved in 5 ml CH 2 Cl 2 was added and the reaction stirred for 3 hours. The mixture was then filtered and the silica gel pad was washed with 100 ml CH 2 Cl 2 .

용매를 증발시켜 투명오일인 벤조일옥시시클로헥사논 110 0.46g(90%)를 얻었다.The solvent was evaporated to obtain 0.46 g (90%) of benzoyloxycyclohexanone 110 as a transparent oil.

메탄올 4ml에 벤조일 옥시시클로헥사논110(0.46g, 1.68mmol)을 용해시킨 교반용액에 물 4ml에 히드록실아민 하이드로클로라이드(0.23g, 3.25mmol)및 포타슘 아세테이트(0.32g, 3.25mmol)을 용해시킨 용액을 단번에 첨가하였다. 반응물을 밤새 실온에서 교반하였다. 물 (20ml)를 첨가하고 그 결과물인 혼합물을 에테르(3x10ml)로 추출하였다. 에테르 추출물을 합하고, 포화 NaHCO3(1x20ml) 및 염수(1x15ml)로 세척하였다. 에테르층을 MgSO4상에서 건조시키고, 여과 및 농축하여 E 및 Z 이성체의 혼합물로서 원하는 옥심(0.39g, 80%)을 얻었다.
Hydroxylamine hydrochloride (0.23 g, 3.25 mmol) and potassium acetate (0.32 g, 3.25 mmol) were dissolved in 4 ml of water in a stirred solution in which benzoyl oxycyclohexanone 110 (0.46 g, 1.68 mmol) was dissolved in 4 ml of methanol. The solution was added at once. The reaction was stirred overnight at room temperature. Water (20 ml) was added and the resulting mixture was extracted with ether (3 × 10 ml). The ether extracts were combined and washed with saturated NaHCO 3 (1 × 20 ml) and brine (1 × 15 ml). The ether layer was dried over MgSO 4 , filtered and concentrated to afford the desired oxime (0.39 g, 80%) as a mixture of E and Z isomers.

500ml Parr 압력병내의 Raney

Figure 112002001377712-pct00073
니켈(0.8g 습윤중량, Aldrich Chemical Co.)을 물 (3x20ml)로 세척한 후 에탄올(3x20ml)로 세척하였으며, 그 세척용매는 매번 따뤘다.Raney in 500ml Parr Pressure Bottle
Figure 112002001377712-pct00073
Nickel (0.8 g wet weight, Aldrich Chemical Co.) was washed with water (3x20ml) followed by ethanol (3x20ml), the washing solvent followed every time.

이 세척된 촉매에 무수에탄올(30ml)에 옥심(0.39g, 1.35mmol)을 용해시킨 용액을 첨가하였다.To this washed catalyst was added a solution of oxime (0.39 g, 1.35 mmol) dissolved in anhydrous ethanol (30 ml).

이용액의 가열이 용해를 위해 요구되었다.Heating of the solution was required for dissolution.

그 결과 혼합물을 그 용액을 통해 암모니아가스를 기포시킴으로서 암모니아 포화시 켰다. 이 용액을 Parr 세이커상에서 수소대기(초기 수소압=50psi)아래 놓고 7시간동안 진탕하였다.As a result, the mixture was saturated with ammonia by bubbling ammonia gas through the solution. This solution was placed on a Parr shaker under hydrogen atmosphere (initial hydrogen pressure = 50 psi) and shaken for 7 hours.

그 반응 혼합물을 Celite

Figure 112002001377712-pct00074
패드를 통해 여과하였으며 용매를 증발시켜 거의 무색인액체(0.37g, 정량수율)를 얻었다.The reaction mixture was Celite
Figure 112002001377712-pct00074
Filtration through the pad and evaporation of the solvent gave a nearly colorless liquid (0.37 g, quantitative yield).

양자 NMR 및 GC/MS는 아민 111의 부분입체 이성질체(4:1비) 혼합물인 이 물질과 일치하였다. 이 물질은 더이상의 정제없이 그대로 사용되었다. Quantum NMR and GC / MS were consistent with this material, which was a diastereomeric (4: 1 ratio) mixture of amines 111. This material was used as is without further purification.

Figure 112002001377712-pct00075

Figure 112002001377712-pct00075

<4-아미노-2,2,6,6-테트라메틸시클로헥실-6-클로로-2-피리딘카복실레이트(113)><4-Amino-2,2,6,6-tetramethylcyclohexyl-6-chloro-2-pyridinecarboxylate (113)>

이 화합물은 방법 28에 도시된 바에따라 합성되었다.This compound was synthesized as shown in Method 28.

0℃로 냉각된 THF 5ml에 7,7,9,9-테트라메틸-1,4-디옥사스피로[4,5]데칸-8-올(0.32g, 1.50mmol)을 용해시킨 교반용액에 n-BuLi(헥센내에서 2.5M, 1.50mmol, 0.6ml)을 적정첨가하였다. N in a stirred solution of 7,7,9,9-tetramethyl-1,4-dioxaspiro [4,5] decane-8-ol (0.32 g, 1.50 mmol) dissolved in 5 ml of THF cooled to 0 ° C. -BuLi (2.5 M, 1.50 mmol, 0.6 ml in hexene) was titrated.

그 혼합물을 10분간 교반하였다.The mixture was stirred for 10 minutes.

그후 6-클로로피콜리노일 클로라이드(1.50mmol, 0.26g)을 1ml THF내의 용액으로서 첨가한후 그 반응물을 실온으로 승온시켰다. 그 용액을 고화시키고, THF 5ml를 첨가하고 반응물을 밤새 교반하였다. 반응 혼합물을 0.5N NaOH에 붓고 에테르(3x20ml)로 추출하였다.6-chloropicolinoyl chloride (1.50 mmol, 0.26 g) was then added as a solution in 1 ml THF and the reaction was allowed to warm to room temperature. The solution was solidified, 5 ml of THF was added and the reaction stirred overnight. The reaction mixture was poured into 0.5N NaOH and extracted with ether (3x20ml).

에테르층을 MgSO4상에서 건조시키고, 여과하고 농축하였다. 양자 NMR은 출발물질과 함께 산물이 1.6:1비율인것으로 나타났다.The ether layer was dried over MgSO 4 , filtered and concentrated. Quantum NMR showed a 1.6: 1 ratio of product with starting material.

이들 화합물은 실리카 겔 크로마토그래피로 분리할수 없었으며, 그래서 혼합물을 다음단계에 계속 사용하고 거기서 정제하였다.
These compounds could not be separated by silica gel chromatography, so the mixture was continued to the next step and purified there.

실리카 겔(1.4g)을 CH2Cl2 10ml 에 부유시켰다.Silica gel (1.4 g) was suspended in 10 ml of CH 2 Cl 2 .

이 서스펜션에 12% HCl수용액 0.3ml를 5분에 걸쳐 적정첨가하였다. 그 혼합물을 군집을 막기위해 격렬히 교반하였다. 상기 혼합물을 5ml CH2Cl2에 용해시킨 용액을 첨가하였으며, 그 혼합물을 3시간 교반하였다.0.3 ml of 12% aqueous HCl solution was added to the suspension over 5 minutes. The mixture was stirred vigorously to prevent crowding. A solution of the mixture dissolved in 5 ml CH 2 Cl 2 was added and the mixture was stirred for 3 hours.

그후 그 혼합물을 여과하고 실리카겔 패드를 100ml CH2Cl2로 세척하였다.The mixture was then filtered and the silica gel pad was washed with 100 ml CH 2 Cl 2 .

용매를 증발시켜 오일을 얻었다.The solvent was evaporated to give an oil.

4:1 헥산-EtOAc용액을 10ml 첨가하여 필요한 피콜린 에스테르 112의 침전을 행하였다.
10 ml of a 4: 1 hexane-EtOAc solution was added to precipitate the required picoline ester 112.

그 결과물인 고체를 여과하고 4:1 헥산-EtOAc 10ml로 세척하였다. 헥산-EtOAc 세척물을 합하고 증발시켜 오일을 얻었다. The resulting solid was filtered and washed with 10 ml 4: 1 hexane-EtOAc. The hexane-EtOAc washes were combined and evaporated to give an oil.

상기 절차를 3번 반복하여 백색고체로서 피콜린에스테르 112를 얻었다.(214mg, 2단계에 대하여 46%). This procedure was repeated three times to give picolin ester 112 as a white solid (214 mg, 46% for step 2).                 

양자 NMR및 GC/MS 결과 순도 95%이상인 필요한 순도를 나타내었다.Quantum NMR and GC / MS results showed the required purity of 95% or more.

이 에스테르(200mg, 0.65mmol), 티타늄(IV)이소프로폭사이드(1.30mmol, 0.38ml), 암모늄 클로라이드(1.30mmol, 70mg)및 트리에틸아민(1.30mmol, 0.18ml)를 순수 에탄올(10ml)에 혼합한 혼합물을 주위온도에서 12시간동안 질소분위기하에 교반하였다. This ester (200 mg, 0.65 mmol), titanium (IV) isopropoxide (1.30 mmol, 0.38 ml), ammonium chloride (1.30 mmol, 70 mg) and triethylamine (1.30 mmol, 0.18 ml) were pure ethanol (10 ml). The mixture was then stirred under nitrogen atmosphere for 12 hours at ambient temperature.

그후 소디움 보로하이드리드(0.97mmol, 40mg)을 첨가하였으며 그 결과 혼합물을 주위온도에서 8시간 더 교반하였다.Sodium borohydride (0.97 mmol, 40 mg) was then added and the resultant mixture was stirred for an additional 8 hours at ambient temperature.

그후 반응물을 암모니아수(20ml, 2.0M)내에 부어 급냉시키고, 그 결과 용액을 에테르(3x20ml)로 추출하였다.The reaction was then poured into ammonia water (20 ml, 2.0 M) and quenched, resulting in extraction of the solution with ether (3 × 20 ml).

합한 에테르 추출물을 2N HCl(2x20ml)로 추출하여 비-염기성 물질을 분리하였다. 그 산성용액을 에테르(20ml)로 한번 세척하였으며 그후 NaOH(2N)로 처리하여 pH를 10-12로 조절하고, EtOAc(3x20ml)로 추출하였다.The combined ether extracts were extracted with 2N HCl (2 × 20 ml) to separate non-basic materials. The acidic solution was washed once with ether (20 ml) and then treated with NaOH (2N) to adjust the pH to 10-12 and extracted with EtOAc (3 × 20 ml).

합한 EtOAc 세척물을 MgSO4상에서 건조하였으며, 여과 및 농축시켜 오일을 얻었다.The combined EtOAc washes were dried over MgSO 4 , filtered and concentrated to an oil.

이 물질은 바라는 시클로헥실아민의 6:1 부분입체 이성질체 혼합물과 일치하였다.This material was consistent with the 6: 1 diastereomeric mixture of the desired cyclohexylamine.

양자 NMR과 GC/MS결과 75% 순도의 바라는 산물을 나타내었다.Quantum NMR and GC / MS showed the desired product with 75% purity.

이 아민 혼합물을 더이상의 정제없이 사용하였다.This amine mixture was used without further purification.

<트랜스-2-티오메틸시클로헥실아민><Trans-2-thiomethylcyclohexylamine>

Figure 112002001377712-pct00076
Figure 112002001377712-pct00076

이 아민은 B.M. Trost와 T. Shibata, J. Am. Chem. Soc. 1982, 104, 3225의 아자술페닐화 기술을 이용하여 시클로 헥산으로 부터 제조되었다.This amine is B.M. Trost and T. Shibata, J. Am. Chem. Soc. Prepared from cyclohexane using the azasulphenylation technique of 1982, 104, 3225.

Figure 112002001377712-pct00077

Figure 112002001377712-pct00077

<4-페닐티오시클로헥실아민(115)><4-phenylthiocyclohexylamine (115)>

이 화합물은 상기 방법 29에 도시된 절차에 따라 제조되었다.This compound was prepared according to the procedure shown in Method 29 above.

메탄올 20ml에 용해시킨 4-페닐티오시클로헥사논(V.K.Yadav및 D.A. Jeyaraj, J.Org. Chem. 1998,63,3474)(1.20g, 5.83mmol)의 교반용액에 물 20ml에 용해시킨 벤질옥시아민 하이드로클로라이드(1.80g, 11.22mmol)과 포타슘 아세테이트(1.10g, 11.22mmol)용액을 한번에 첨가하였다. 이 반응물을 실온에서 밤새 교반하였다. 물(60ml)을 첨가하고 그 결과 혼합물을 에테르(3x40ml)로 추출하였다. 그 에테르 추출물을 합하고, 포화 NaHCO3(1x50ml)및 염수(1x40ml)로 세척하였다. Benzyloxyamine hydro dissolved in 20 ml of water in a stirring solution of 4-phenylthiocyclohexanone (VKYadav and DA Jeyaraj, J. Org. Chem. 1998, 63, 3474) (1.20 g, 5.83 mmol) dissolved in 20 ml of methanol. Chloride (1.80 g, 11.22 mmol) and potassium acetate (1.10 g, 11.22 mmol) solutions were added in one portion. The reaction was stirred overnight at room temperature. Water (60 ml) was added and the resulting mixture was extracted with ether (3 × 40 ml). The ether extracts were combined and washed with saturated NaHCO 3 (1 × 50 ml) and brine (1 × 40 ml).

그 에테르층을 MgSO4상에서 건조시키고, 여과한후 농축하여 오일을 얻었다.
The ether layer was dried over MgSO 4 , filtered and concentrated to an oil.

이 물질을 래디얼 크로마토그라피(9:1 헥산- EtOAc)로 정제하여 E 및 Z이성체의 혼합물로서 상응하는 0-벤질옥심 114(1.72g, 95%)를 얻었다.
This material was purified by radial chromatography (9: 1 hexanes- EtOAc) to give the corresponding 0-benzyloxime 114 (1.72 g, 95%) as a mixture of E and Z isomers.

리튬 알루미늄 하이드리드(5.08mmol, 0.19g)을 무수에테르 10ml에 부유시키고 0℃로 냉각시켰다.Lithium aluminum hydride (5.08 mmol, 0.19 g) was suspended in 10 ml of anhydrous ether and cooled to 0 ° C.

에테르 5ml에 용해시킨 0-벤질옥심 114를 적정첨가하고 그 반응물을 실온으로 되게한후 4시간동안 교반하였다. 0-benzyloxime 114 dissolved in 5 ml of ether was titrated and the reaction was allowed to come to room temperature and stirred for 4 hours.

과량의 리튬 알루미늄 하이드리드를 물 (0.2ml)및 1N NaOH(0.2ml)를 주의깊게 동시 첨가하여 무력화하였다.Excess lithium aluminum hydride was neutralized by careful simultaneous addition of water (0.2 ml) and 1N NaOH (0.2 ml).

그 혼합물을 여과하고 염을 에테르 50ml로 세척하였다.The mixture was filtered and the salt washed with 50 ml of ether.

용매를 증발시켜 오일상인 아민 115 0.62g(93%)를 얻었다.
The solvent was evaporated to yield 0.62 g (93%) of amine 115 as an oily phase.

양자 NMR및 GC/MS결과 그 산물은 순도 95%이상인 부분입체이성질체 아민이 1.3:1혼합물인 것으로 밝혀졌다.Quantum NMR and GC / MS results indicate that the product is a 1.3: 1 mixture of diastereomeric amines with a purity of at least 95%.

Figure 112002001377712-pct00078

Figure 112002001377712-pct00078

<3-{[3-(트리플루오로메틸)-2-피리디닐]술파닐}-시클로헥실아민(117)><3-{[3- (trifluoromethyl) -2-pyridinyl] sulfanyl} -cyclohexylamine (117)>

이 아민은 상기 방법 30에 도시된 방법에 따라 제조되었다.This amine was prepared according to the method shown in Method 30 above.

2-시클로헥센-1-온(0.44ml, 4.58mmol)과 2-메르카토-5-트리플루오로메틸피리딘(0.82g, 4.58mmol)을 20ml CH2Cl2에 용해시킨 교반용액에 비 스무스 트리클로라이드(60mg, 0.18mmol)을 첨가하였다.Bismuth tree in a stirring solution in which 2-cyclohexen-1-one (0.44 ml, 4.58 mmol) and 2-merkato-5-trifluoromethylpyridine (0.82 g, 4.58 mmol) were dissolved in 20 ml CH 2 Cl 2 . Chloride (60 mg, 0.18 mmol) was added.

그 반응물을 실온에서 밤새 교반하고 농축하였다. 잔류물을 용리액으로서 4:1 헥센-EtOAc를 사용하여 래디얼 크로마토그라피로 정제하여 콘슈게이트 부가산물 2-(3-옥소-시클로헥실티오)-5-트리플루오로메틸피리딘(116) 1.12g(89%)를 얻었다.
The reaction was stirred at rt overnight and concentrated. The residue was purified by radial chromatography using 4: 1 hexene-EtOAc as eluent to yield 1.12 g (89) of the conjugate adduct 2- (3-oxo-cyclohexylthio) -5-trifluoromethylpyridine (116) %) Was obtained.

상기 화합물 116(0.26g, 0.95mmol)을 메탄올 3ml에 용해시킨 교반용액에 벤질옥시아민 하이드로클로라이드(0.29g, 1.83mmol)과 포타슘 아세테이트(0.18g, 1.83mmol)를 물 3ml에 용해시킨 용액을 단번에 첨가하였다.A solution of benzyloxyamine hydrochloride (0.29 g, 1.83 mmol) and potassium acetate (0.18 g, 1.83 mmol) in 3 ml of water was added to a stirred solution in which Compound 116 (0.26 g, 0.95 mmol) was dissolved in 3 ml of methanol. Added.

그 반응물을 실온에서 밤새 교반하였다.The reaction was stirred at rt overnight.

물(10ml)를 첨가하고 그 결과 혼합물을 에테르(3x10ml)로 추출하였다. 이 에테르추출물을 합하고, 포화 NaHCO3(1x15ml)및 염수(1x15ml)로 세척하였다.Water (10 ml) was added and the resulting mixture was extracted with ether (3 × 10 ml). The ether extracts were combined and washed with saturated NaHCO 3 (1 × 15 ml) and brine (1 × 15 ml).

에테르층을 MgSO4상에서 건조하고, 여과 및 농축하여 오일을 얻었다.The ether layer was dried over MgSO 4 , filtered and concentrated to an oil.

이 물질을 래디얼 크로마토그래피하여(9:1 헥산-EtOAc)분리된 옥심(0.32g, 89%)을 얻었다.This material was radial chromatographed (9: 1 hexane-EtOAc) to give isolated oxime (0.32 g, 89%).

E-이성체 (Rf=0.33)과 Z-이성체(Rf=0.25)는 일치하는 양자 NMR 및 GC/MS스펙트럼 특성을 나타내었다.
E-isomers (Rf = 0.33) and Z-isomers (Rf = 0.25) showed consistent quantum NMR and GC / MS spectrum characteristics.

리튬 알루미늄 하이드라이드(1.33mmol, 50mg)을 무수에테르 3ml에 부유시키고 0℃로 냉각시켰다. 결합한 옥심을 에테르 1ml에 용해시키고 적정첨가하였으며, Lithium aluminum hydride (1.33 mmol, 50 mg) was suspended in 3 ml of anhydrous ether and cooled to 0 ° C. The combined oximes were dissolved in 1 ml of ether and titrated.                 

그 반응물을 실온으로 되게한후 4시간 교반하였다.The reaction was allowed to come to room temperature and stirred for 4 hours.

과량의 리튬 알루미늄 하이드리드는 물(50ml)과 1N NaOH(50ml)를 동시첨가하여 무력화하였다.Excess lithium aluminum hydride was neutralized by the simultaneous addition of water (50 ml) and 1N NaOH (50 ml).

그 혼합물을 여과하고 그 염을 에테르로 100ml 체적까지 세척하였다.The mixture was filtered and the salt washed with ether to 100 ml volume.

2N HCl(2x50ml)로 에테르 용액을 추출하여 비-염기성물질을 분리하였다. 산성수용액은 에테르(50ml)로 한번 세척한후 NaOH(2M)수용액으로 처리하여 pH를 10-12로 하였으며 에테르(3x50ml)로 추출하였다.
The non-basics were separated by extracting the ether solution with 2N HCl (2 × 50 ml). The acidic aqueous solution was washed once with ether (50 ml) and treated with aqueous NaOH (2M) solution to obtain a pH of 10-12 and extracted with ether (3 × 50 ml).

에테르층을 MgSO4상에서 건조하고, 여과 및 농축시켜 오일상의 원하는 아민 117 121mg(52%)을 얻었다.The ether layer was dried over MgSO 4 , filtered and concentrated to give 121 mg (52%) of the desired amine 117 in oil.

양자 NMR 및 GC/MS 결과 그 산물은 순도 95%이상인 부분입체 아민 1.3:1 비율인 것으로 밝혀졌다.Quantum NMR and GC / MS results showed that the product had a 1.3: 1 ratio of diasteric amine with a purity of at least 95%.

Figure 112002001377712-pct00079

Figure 112002001377712-pct00079

<1-(5-아미노-1,2,3-트리메틸시클로헥실)-4-페닐-1-부타논(120)><1- (5-Amino-1,2,3-trimethylcyclohexyl) -4-phenyl-1-butanone (120)>

이 아민의 합성은 상기 방법 31의 방법으로 수행되었다.Synthesis of this amine was carried out by the method of Method 31 above.

THF 10ml에 나프탈렌(1.23g, 9.57mmol)및 리튬과립(67 mg, 9.57mmol)을 부유시킨 서스펜션을 주위온도에서 밤새 교반하였다. A suspension suspended in 10 ml THF with naphthalene (1.23 g, 9.57 mmol) and lithium granules (67 mg, 9.57 mmol) was stirred overnight at ambient temperature.

이 리튬 나프탈라이드 용액을 -60℃로 냉각시키고 페닐 3-페닐프로필 술파이드(1.1g, 4.78mmol)를 첨가하였다.This lithium naphthalide solution was cooled to -60 ° C and phenyl 3-phenylpropyl sulfide (1.1 g, 4.78 mmol) was added.

반응물을 -20℃까지 승온하여 반응완료를 도모하였으며 -60℃로 재냉각시켰다.The reaction was heated to -20 ° C to complete the reaction and recooled to -60 ° C.

7-시아노-7,9,9-트리메틸-1,4-디옥사스피로[4.5]데칸(0.5g, 2.39mmol)을 5ml THF에 용해시킨 용액을 첨가하고 그 용액을 0℃까지 승온시킨다음 그 온도에서 2시간 교반하였다.A solution of 7-cyano-7,9,9-trimethyl-1,4-dioxaspiro [4.5] decane (0.5 g, 2.39 mmol) dissolved in 5 ml THF is added and the solution is warmed to 0 ° C. It stirred at that temperature for 2 hours.

포화 암모늄 클로라이드 용액 10ml를 첨가한 다음 2N HCl로 처리하여 pH를 4까지 조정하였으며 실온에서 밤새 교반하였다.10 ml of saturated ammonium chloride solution was added and then treated with 2N HCl to adjust the pH to 4 and stirred overnight at room temperature.

그 혼합물을 에테르 (3x30ml)로 추출하였으며, MgSO4상에서 건조하고 여과 및 증발하였다. 잔류물을 용리액으로 6:1 헥산-EtOAc를 사용하여 래디얼 크로마토그래피로 정제하였다. 이같이하여 얻어진 것은 3-(2-옥소-4-페닐부틸)-3,5,5-트리메틸시클로헥사논 118(136mg, Rf=0.18)과 불완전한 가수분해 산물인 그 케탈(509mg, Rf=0.33)의 1:3 혼합물이었으며 1-리티오-3-페닐프로판을 그 니트릴에 첨가하기 위한 전체 산물은 85%인것으로 계산되었다.
The mixture was extracted with ether (3 × 30 ml), dried over MgSO 4 , filtered and evaporated. The residue was purified by radial chromatography using 6: 1 hexanes-EtOAc as eluent. This was obtained with 3- (2-oxo-4-phenylbutyl) -3,5,5-trimethylcyclohexanone 118 (136 mg, Rf = 0.18) and its ketal as an incomplete hydrolysis product (509 mg, Rf = 0.33). It was a 1: 3 mixture of and the total product to add 1-rithio-3-phenylpropane to the nitrile was calculated to be 85%.

실라카 겔(1.82g)을 CH2Cl2 10 ml에 부유시켰다.Silica gel (1.82 g) was suspended in 10 ml of CH 2 Cl 2 .

이 서스펜션에 12% HCl수용액 0.41ml를 5분에 걸쳐 적정부가하였다. 그 혼합물을 군집방지를 위해 격렬히 교반하였다. 2ml CH2Cl2 에 용해된 상기 케탈용액을 첨가하 고 50ml CH2Cl2로서 실리카겔 패드를 세척하였다.0.41 ml of an aqueous 12% HCl solution was added to the suspension over 5 minutes. The mixture was stirred vigorously to prevent crowding. The ketal solution dissolved in 2 ml CH 2 Cl 2 was added and the silica gel pad was washed with 50 ml CH 2 Cl 2 .

용매를 증발하여 투명오일로서 그 NMR 및 GC/MS성질과 일치하는 3-(1-옥소-4-페닐부틸)-3,5,5,-트리메틸시클로헥사논(118) 0.48g(100%)을 얻었다.
0.48 g (100%) of 3- (1-oxo-4-phenylbutyl) -3,5,5, -trimethylcyclohexanone (118) as evaporated solvent, consistent with its NMR and GC / MS properties as transparent oil. Got.

이 비스-케톤(0.62g, 2.17mmol)을 메탄올 7ml에 용해시킨 교반된 용액에 히드록실아민 하이드로클로라이드(0.16g, 2.28mmol)및 소디움 아세테이트(0.25g, 3.03mmol)을 물 7ml에 용해시킨 용액을 단숨에 첨가하였다. 반응물을 실온에서 1시간 교반하고, 물 (20ml)를 첨가하고 결과물인 혼합물을 에테르(3x20ml)로 추출하였다. 이 에테르 추출물을 합하고 포화 NaHCO3(1x20ml)및 염수(1x20ml)로 세척하였다. 에테르층을 MgSO4상에서 건조, 여과 및 농축하여 E 및 Z 이성체의 혼합물로서 바라는 모노-옥심 119(0.57g, 87%)를 얻었다.
This bis-ketone (0.62 g, 2.17 mmol) dissolved in 7 ml of methanol was dissolved in hydroxylamine hydrochloride (0.16 g, 2.28 mmol) and sodium acetate (0.25 g, 3.03 mmol) in 7 ml of water. Was added at once. The reaction was stirred at rt for 1 h, water (20 ml) was added and the resulting mixture was extracted with ether (3 × 20 ml). The ether extracts were combined and washed with saturated NaHCO 3 (1 × 20 ml) and brine (1 × 20 ml). The ether layer was dried over MgSO 4 , filtered and concentrated to afford the desired mono-oxime 119 (0.57 g, 87%) as a mixture of E and Z isomers.

500ml Parr 압력용기내에 있는 Raney

Figure 112002001377712-pct00080
니켈(0.8g, 습윤중량, Aldrich Chemical Co.)을 물 (3x20ml)로 세척한 후, 에탄올(3x 20ml)로 세척하고, 세척용매는 매번 따뤄 내었다.Raney in 500ml Parr pressure vessel
Figure 112002001377712-pct00080
Nickel (0.8 g, wet weight, Aldrich Chemical Co.) was washed with water (3x20ml), followed by ethanol (3x20ml) and the washing solvent was decanted each time.

이 세척된 촉매에 옥심 119(0.57g, 1.89mmol)을 무수에탄올(40ml)에 용해시킨 용액을 첨가하였다.To this washed catalyst was added a solution of oxime 119 (0.57 g, 1.89 mmol) dissolved in anhydrous ethanol (40 ml).

그 결과 혼합물을 용액을 통해 암모니아 가스를 1분간 기포시킴으로써 암모니아 포화시켰다. As a result, the mixture was saturated with ammonia by bubbling ammonia gas through the solution for 1 minute.                 

그 용액을 Parr 세이커상에서 수소대기(초기 수소압=50psi)하에 놓고 7시간동안 진탕(흔들기)하였다.The solution was placed on a Parr shaker under hydrogen atmosphere (initial hydrogen pressure = 50 psi) and shaken (shaking) for 7 hours.

그후 그 반응혼합물을 Celite

Figure 112002001377712-pct00081
패드로 여과하고 용매증발시켜 오일(0.43g, 80%)을 얻었다.The reaction mixture is then Celite
Figure 112002001377712-pct00081
Filtration with a pad and solvent evaporation gave an oil (0.43 g, 80%).

GC/MS분석결과 소량의 미확인 부산물과 함께 아민 120의 1:1 부분입체 이성질체 혼합물을 나타내었다. GC / MS analysis showed a 1: 1 diastereomeric mixture of amine 120 with a small amount of unidentified by-products.

이 아민 혼합물을 더이상의 정제없이 그대로 사용하였다.This amine mixture was used as is without further purification.

Figure 112002001377712-pct00082

Figure 112002001377712-pct00082

<2-벤질-6-메틸-4-피라닐아민(122)><2-benzyl-6-methyl-4-pyranylamine (122)>

이 아민은 상기 방법 32에 따라 제조되었다.This amine was prepared according to Method 32 above.

2-벤질-6-메틸-4-피라논(G.Piancatilli, et al., Synthesis, 1982, 248) 0.37g에 메탄올 10ml 내에서 히드록실아민 하이드로클로라이드 0.22g(3.1mmol)과 소디움 아세테이트 0.16g(2 mmol)을 첨가하였다.0.22 g (3.1 mmol) of hydroxylamine hydrochloride and 0.16 g of sodium acetate in 10 ml of methanol in 0.37 g of 2-benzyl-6-methyl-4-pyranone (G.Piancatilli, et al., Synthesis, 1982, 248) (2 mmol) was added.

밤새 교반한 후, 그 혼합물을 CH2Cl2와 물로 분리하였다.After stirring overnight, the mixture was separated with CH 2 Cl 2 and water.

유기상을 건조 및 증발시켰다. 오일상 잔류물을 실온에서 방치하여 고화시켜 219의 분자이온을 갖는 GC/MS에 의해 Z/E 이성질체 1:1혼합물로 확인된 원하는 옥심 121 ㅡ 0.4g(99%)을 얻었다.
The organic phase was dried and evaporated. The oily residue was left at room temperature to solidify to give the desired oxime 121-0.4 g (99%) identified as Z / E isomer 1: 1 mixture by GC / MS with a molecular ion of 219.

95% 에탄올 50ml에 용해시킨 2-벤질-6-메틸-4-피라논 옥심(121)(1.8mmol) 0.4g에 물로 3번 그리고 에탄올로 3번 세척한 Raney

Figure 112002001377712-pct00083
니켈 0.8g(습윤중량)을 첨가하였다. 이 혼합물을 Parr 세이커내에서 41 psig 수소대기하에 32시간동안 방치하였다.Raney washed three times with water and three times with ethanol in 0.4 g of 2-benzyl-6-methyl-4-pyranone oxime (121) (1.8 mmol) dissolved in 50 ml of 95% ethanol.
Figure 112002001377712-pct00083
0.8 g nickel (wet weight) was added. This mixture was left in a Parr shaker for 32 hours under 41 psig hydrogen atmosphere.

환기후, 그 혼합물을 중력여과하고 진공하에 증발시켰다. 잔류물을 CH2Cl2와 탄산나트륨(Sodium carbonate)수용액으로 분리하였다.
After ventilation, the mixture was gravity filtered and evaporated in vacuo. The residue was separated by CH 2 Cl 2 and sodium carbonate aqueous solution.

유기상을 건조 및 진공증발시켜 원하는 아민 122와 옥심 121이 2:1로 혼합된 (GC/MS분석)혼합물 0.19g을 얻었다.The organic phase was dried and evaporated in vacuo to give 0.19 g of a mixture of the desired amine 122 and oxime 121 in a 2: 1 (GC / MS analysis) mixture.

이 혼합물은 더이상의 분리없이 그대로 사용되었다.
This mixture was used as is without further separation.

<1-벤조일-4-아미노피페리딘><1-benzoyl-4-aminopiperidine>

Figure 112002001377712-pct00084
Figure 112002001377712-pct00084

Bhattacharyya, et al., SynLett, 1999, 11, 1781의 방법에 따라 이 화합물을 제조 하였다.This compound was prepared according to the method of Bhattacharyya, et al., SynLett, 1999, 11, 1781.

Figure 112002001377712-pct00085

Figure 112002001377712-pct00085

<1-(4-메틸벤질)-4-피페리디닐아민(125)><1- (4-Methylbenzyl) -4-piperidinylamine (125)>

상기 방법 33에 따라 이 화합물을 합성하였다.This compound was synthesized according to Method 33 above.

tert-부탄올에 4-히드록시피페리딘 5.05g(50mmol)및 P-메틸벤질클로라이드 7.08g(50mmol)을 용해시킨 것에 과량의 고체 포타슘카보네이트를 첨가하였으며, 그 혼합물을 수증기조상에서 3시간 가열하였다.
To dissolve 5.05 g (50 mmol) of 4-hydroxypiperidine and 7.08 g (50 mmol) of P-methylbenzylchloride in tert-butanol was added an excess of solid potassium carbonate, and the mixture was heated in a steam bath for 3 hours. .

그 혼합물을 실온으로 냉각시키고 에테르와 물로 분리하였다. The mixture was cooled to rt and separated into ether and water.

유기상은 냉각된 희석 HCl로 추출하였으며, 산성수상은 에테르로 2번 추출하였다.The organic phase was extracted with cooled dilute HCl and the acidic aqueous phase was extracted twice with ether.

얼음 및 50%, NaOH 수용액으로 상기 수상을 염기성으로 한 후 에테르로 추출하였다. The aqueous phase was basified with ice and 50% aqueous NaOH solution and then extracted with ether.

상기 에테르상을 희석 소디움바이카보네이트 용액, 염수로 세척한후, 건조시키고 진공하에 증발시켜 오일상의 1-(4-메틸벤질)-4-히드록시 피페리딘 5.3g(52%)(123)을 얻었다. GC/MS결과 분자이온 205인 100% 순도를 나타내었다.
The ether phase was washed with dilute sodium bicarbonate solution, brine, dried and evaporated in vacuo to give 5.3 g (52%) (123) of 1- (4-methylbenzyl) -4-hydroxy piperidine in oil phase. Got it. GC / MS showed 100% purity with molecular ion 205.

CH2Cl2 75ml에 옥살릴 클로라이드 2.8ml(32 mmol)을 용해시킨 용액에 78℃에서 DMSO 4.6ml(64mmol)을 첨가하였다.To a solution of 2.8 ml (32 mmol) of oxalyl chloride in 75 ml of CH 2 Cl 2 was added 4.6 ml (64 mmol) of DMSO at 78 ° C.

이 혼합물에 CH2Cl2 10ml에 1-(4-메틸벤질)-4-피피리디놀 123 5.3g(26mmol)을 용해시킨 용액을 첨가하였으며, 그 혼합물을 저온에서 5시간 교반하였다.To this mixture was added a solution of 5.3 g (26 mmol) of 1- (4-methylbenzyl) -4-pipyridinol 123 dissolved in 10 ml of CH 2 Cl 2 , and the mixture was stirred at low temperature for 5 hours.

그 혼합물을 트리에틸아민 18ml(129mmol)로 급냉한후 실온으로 되게 하였으며 포화된 암모늄 클로라이드 수용액을 첨가하였다. 유기상을 물 및 염수로 세척하고, 건조시킨후 증발시켜 1-(4-메틸벤질)-4-피페리디논(124) 4.27g(81%)를 얻었으며, 더이상의 정제없이 그대로 사용하였다.The mixture was quenched with 18 ml (129 mmol) of triethylamine and brought to room temperature and saturated aqueous ammonium chloride solution was added. The organic phase was washed with water and brine, dried and evaporated to afford 4.27 g (81%) of 1- (4-methylbenzyl) -4-piperidinone (124), which was used as such without further purification.

GC/MS결과 분자이온이 203인 100%순도를 나타내었다.
GC / MS showed 100% purity with a molecular ion of 203.

무수메탄올 200ml에 1-(4-메틸벤질)-4-피페리디논 124 4.25g(21mmol)을 용해시킨 용액에 암모늄아세테이트 32.2g(420mmol)및 3A 분자체 25g을 첨가하였다.To the solution of 4.25 g (21 mmol) of 1- (4-methylbenzyl) -4-piperidinone 124 in 200 ml of anhydrous methanol, 32.2 g (420 mmol) of ammonium acetate and 25 g of 3A molecular sieve were added.

30분간 교반한 후, 소디움 시아노보로하이드라이드 5.25g(84mmol)을 나누어 첨가하였다.After stirring for 30 minutes, 5.25 g (84 mmol) of sodium cyanoborohydride were added in portions.

16시간 교반후, 그 혼합물을 중력 여과하고 진공하에 메탄올을 증발시켰다. 잔류물을 에테르 및 얼음/HCl로 분리하였다.After stirring for 16 hours, the mixture was gravity filtered and the methanol was evaporated under vacuum. The residue was separated by ether and ice / HCl.

그 산성 수성층을 에테르로 2번 추출하고 50% NaOH수용액및 얼음으로 염기성화하였으며 CH2Cl2로 추출하여 진한 오일상 아민 125 2.1g(48%)를 얻었다. The acidic aqueous layer was extracted twice with ether, basified with 50% aqueous NaOH solution and ice, and extracted with CH 2 Cl 2 to give 2.1 g (48%) of a thick oily amine 125.

GC/MS결과 분자이온 204이었다. 그 산물을 더이상의 정제없이 그대로 사용하였다.GC / MS showed molecular ion 204. The product was used as is without further purification.

Figure 112002001377712-pct00086

Figure 112002001377712-pct00086

<1-(3-트리플루오로메틸벤질)-4-피페리디닐아민(127)><1- (3-Trifluoromethylbenzyl) -4-piperidinylamine (127)>

방법 34에 따라 제조하였다.Prepared according to Method 34.

피리딘 7ml에[1-(4-메틸벤질)-4-피페리디논)123에서와 같은 방법으로 제조된] 1-(3-트리플루오로메틸벤질)-4-피페리돈 0.8g(3.1mmol)을 용해시킨 것에 히드록실아민 하이드로클로라이드 0.22g(3.1mmol)을 첨가하고 그 혼합물을 밤새 교반하였다.0.8 g (3.1 mmol) of 1- (3-trifluoromethylbenzyl) -4-piperidone [prepared in the same manner as in 1- (4-methylbenzyl) -4-piperidinone) 123 in 7 ml of pyridine To this was dissolved 0.22 g (3.1 mmol) of hydroxylamine hydrochloride and the mixture was stirred overnight.

그 혼합물을 진공하에 증발하고 잔류물을 에테르와 희석 소디움바이카보네이트 수용액사이에서 분배하였다.The mixture was evaporated in vacuo and the residue partitioned between ether and dilute sodium bicarbonate aqueous solution.

유기상을 건조시키고 진공하에 증발시켜 오일상의 옥심 0.52g(62%)를 얻었으며, 이는 하기 수소화단계에서 그대로 사용하였다. GC/MS결과 분자이온 272였다.
The organic phase was dried and evaporated in vacuo to yield 0.52 g (62%) of oxime in oil phase, which was used as such in the following hydrogenation step. GC / MS showed a molecular ion of 272.

이옥심 0.5g(2mmol)을 에탄올 75ml에 용해시킨 용액에 물과 에탄올로 각각 3번씩 세척한 Raney

Figure 112002001377712-pct00087
니켈 0.5g(습윤중량)을 첨가하였다.
Raney washed three times with water and ethanol in a solution of 0.5 g (2 mmol) of dioxime in 75 ml of ethanol
Figure 112002001377712-pct00087
0.5 g (wet weight) of nickel was added.

암모니아가스를 수분간 그 혼합물내로 기포시켰으며 모두 Parr 세이커내에서 45 psig의 수소하에 7시간동안 재치하였다. 용기를 환기하고 혼합물을 증력여과하였다.Ammonia gas was bubbled into the mixture for several minutes and all were placed in a Parr shaker under 45 psig of hydrogen for 7 hours. The vessel was vented and the mixture was filtered filtered.

잔류물을 에테르에 용해시키고, 여과, 및 증발하여 아민 127 0.43g(81%)를 얻었으며, 이는 더이상의 정제없이 그대로 사용되었다. GC/MS결과 분자이온 258인 단일 피이크를 나타내었다.The residue was dissolved in ether, filtered and evaporated to afford 0.43 g (81%) of amine 127, which was used as such without further purification. GC / MS showed a single peak with a molecular ion of 258.

Figure 112002001377712-pct00088

Figure 112002001377712-pct00088

<시스/트랜스-2-메틸-3-테트라하이드로퓨릴아민(128)><Cis / trans-2-methyl-3-tetrahydrofurylamine (128)>

이 아민을 방법 35의 방법에 따라 얻었다.This amine was obtained following the method in Method 35.

메탄올 50ml내에 용해시킨 2-메틸테트라 하이드로 퓨란-3-온 옥심(상업적으로 구입가능한 2-메틸테트라하이드로퓨란-3-온으로부터 표준 공정으로 제조됨)1.15g(10mmol)에 물 및 에탄올로 각각 3회 세척한 Raney

Figure 112002001377712-pct00089
니켈 1g(습윤 중량)을 첨가하고 수소 44psig하에 Parr 세이커내에 놓았다.2-methyltetrahydrofuran-3-one oxime dissolved in 50 ml of methanol (prepared from a commercially available 2-methyltetrahydrofuran-3-one as a standard process) in 1.15 g (10 mmol) of water and ethanol, respectively, 3 Raney Washed Times
Figure 112002001377712-pct00089
1 g nickel (wet weight) was added and placed in a Parr shaker under 44 psig hydrogen.

18시간후, 그 혼합물을 탈기하고 중력여과 하였다.After 18 hours, the mixture was degassed and gravity filtered.

진공하에 메탄올을 증발시키고 잔류물을 에테르내에 수집하여 건조시켰다. 에테르 산을 진공하에 증발시켜 시스/트랜스 혼합물로서 아민 128 0.6g(59%)을 얻었다.Methanol was evaporated under vacuum and the residue was collected in ether and dried. The ether acid was evaporated in vacuo to yield 0.6 g (59%) of amine 128 as a cis / trans mixture.

GC/MS결과 분자이온 101인 41%, 분자이온 101인 59%로 구성되었다. 이 아민 혼합물은 더이상의 정제없이 그대로 사용되었다.GC / MS showed 41% of molecular ion 101 and 59% of molecular ion 101. This amine mixture was used as is without further purification.

Figure 112002001377712-pct00090

Figure 112002001377712-pct00090

<2-벤질-2,6-디메틸-4-피라닐아민(133)><2-benzyl-2,6-dimethyl-4-pyranylamine (133)>

이 아민은 상기 방법 36에 도시된 절차에 따라 얻어졌다.This amine was obtained following the procedure shown in Method 36 above.

CH2Cl2 40ml에 융해시킨 3-트리메틸실릴옥시부티르산 트리메틸실릴 에스테르 4.88g(19.7mmol)에 -78℃에서 페닐아세톤 2.4g(18mmol)과 트리메틸실릴 트리플레이트 1방울을 첨가하였다. 이 혼합물을 저온에서 2일간 방치한후 0.5ml 피리딘으로 급냉시키고 실온으로 되게하였다.To 4.88 g (19.7 mmol) of 3-trimethylsilyloxybutyric acid trimethylsilyl ester dissolved in 40 ml of CH 2 Cl 2 , 2.4 g (18 mmol) of phenylacetone and 1 drop of trimethylsilyl triflate were added at -78 ° C. The mixture was left at low temperature for 2 days, then quenched with 0.5 ml pyridine and brought to room temperature.

그 유기상을 희석.소디움 바이카보네이트 수용액으로 세척하고, 건조시킨후 진공하에 증발하였다.The organic phase was diluted. Washed with aqueous sodium bicarbonate solution, dried and evaporated in vacuo.

잔류물을 진공하에 증류하여 2-벤질-2,6-디메틸-4-메틸렌-1,3-디옥산-4-온(129)(b.p 125-32@0.6mm) 2.89g(67%)를 얻었다. GC/MC 결과 각강이 베이스피크 134(페닐아세톤)인 2개의 이성체를 나타내었다.
The residue was distilled under vacuum to afford 2.89 g (67%) of 2-benzyl-2,6-dimethyl-4-methylene-1,3-dioxan-4-one (129) (bp 125-32@0.6 mm). Got it. GC / MC results showed two isomers of each steel with base peak 134 (phenylacetone).

2-벤질-2,6-디메틸-4-메틸렌-1,3-디옥산-4-온(129) 1.5gr에 질소하에 20ml 무수 THF 에 용해시킨 비스-(시클로펜틸)-비스-메틸 티타노센 2.9g(13.9mmol)을 첨가하였다. 그 혼합물을 16시간동안 환류로 가열하였다.Bis- (cyclopentyl) -bis-methyl titanocene dissolved in 1.5 ml of 2-benzyl-2,6-dimethyl-4-methylene-1,3-dioxan-4-one (129) in 20 ml anhydrous THF under nitrogen. 2.9 g (13.9 mmol) were added. The mixture was heated to reflux for 16 h.

그 반응 혼합물을 실온으로 냉각시키고 과잉 에테르로 급냉시켰다. 전체 혼합물을 실리카겔 베드를 통해 용리액으로 에테르를 사용하여 여과시켰다. The reaction mixture was cooled to room temperature and quenched with excess ether. The entire mixture was filtered using ether as eluent through a silica gel bed.

여과물을 증발시키고 0.2% 트리에틸아민을 함유한 EtOAc와 헥산(1:4)으로 크로마토그라피 하였다.The filtrate was evaporated and chromatographed with EtOAc with 0.2% triethylamine and hexane (1: 4).

산물을 함유한 분획을 증발시키고 석유에테르내에서 슬러리화 시킨다음 진공하에 여과하여 고체 1.2g 을 얻었다.Fractions containing the product were evaporated, slurried in petroleum ether and filtered under vacuum to give 1.2 g of solid.

GC/MS 결과 분자이온 218 인 2-벤질-2,6-디메틸-4-메틸렌-1,3-디옥산(130)과 출발물질 129의 3:1 혼합물을 나타내었다. 이 혼합물은 아래 재배열에서 그대로 사용되었다.GC / MS results showed a 3: 1 mixture of 2-benzyl-2,6-dimethyl-4-methylene-1,3-dioxane (130) with molecular ion 218 and starting material 129. This mixture was used as is in the rearrangement below.

이 혼합물 1.2g(5.5 mmol)을 톨루엔 5ml에 용해시킨 용액에 질소하에 -78℃에서 트리-이소부틸 알루미늄 하이드리드 10.99ml(11mmol)을 첨가하였다.To a solution of 1.2 g (5.5 mmol) of this mixture in 5 ml of toluene was added 10.99 ml (11 mmol) of tri-isobutyl aluminum hydride at −78 ° C. under nitrogen.

이 반응물을 16시간 방치하여 식히고 물 몇방울로 급냉시켰다. 그 혼합물을 실온으로 되게한 후 과잉의 포화 암모늄 클로라이드 수용액을 첨가하였다.The reaction was left for 16 hours to cool and quenched with a few drops of water. The mixture was brought to room temperature and excess saturated aqueous ammonium chloride solution was added.

그 혼합물을 여분의 CH2Cl2 10ml로 추출하고, 알루미늄 염으로부터 어렵게 분리하였다. 유기층을 건조 및 증발시켜 75:25 이성체 혼합물(GC/MS에 의해)로서 2-벤질-2,6-디메틸-4-히드록시피라놀 1.1g(90%)를 얻었다. The mixture was extracted with 10 ml of excess CH 2 Cl 2 and difficult to separate from aluminum salts. The organic layer was dried and evaporated to give 1.1 g (90%) of 2-benzyl-2,6-dimethyl-4-hydroxypyranol as a 75:25 isomer mixture (by GC / MS).

CH2Cl2 10ml내에 용해시킨 화합물 131 1.1g(5mmol)에 자기 교반하면서 피리디늄 클로로크로메이트 1.6g(7.5mmol)을 나누어 첨가하였다. 실온에서 1시간후 에테르를 첨가하고 그 혼합물을 실리카겔 베드를 통해 여과한후, 에테르로 세척하였다.To 1.1 g (5 mmol) of Compound 131 dissolved in 10 ml of CH 2 Cl 2, 1.6 g (7.5 mmol) of pyridinium chlorochromate was added in portions with magnetic stirring. After 1 hour at room temperature ether was added and the mixture was filtered through a silica gel bed and washed with ether.

여과물을 증발하여 2-벤질-2,6-디메틸-4-피라논(132) 0.88g(80%)를 얻었다.The filtrate was evaporated to yield 0.88 g (80%) of 2-benzyl-2,6-dimethyl-4-pyranone (132).

GC/MS결과 베이스피크가 127(M-벤질)인 99% 순도를 나타내었다.GC / MS showed 99% purity with a base peak of 127 (M-benzyl).

이 이성체 혼합물을 하기 환원성 아민화에 그대로 사용되었다.This isomer mixture was used as such for the following reductive amination.

무수메탄올 40ml에 장입한 상기 화합물 132 0.88g(4mmol)에 암모늄 아세테이트 6.16g과 3A 분자체 5g을 첨가하였다. 실온에서 45분간 교반후,To 0.88 g (4 mmol) of Compound 132 charged in 40 ml of anhydrous methanol, 6.16 g of ammonium acetate and 5 g of 3A molecular sieve were added. After stirring for 45 minutes at room temperature,

소디움 시아노 보로하이드리드 1.02g(16mmol)을 자기교반하면서 나누어 첨가하였다. 그 혼합물을 중력여과하고 메탄올을 진공하에 증발하였다.Sodium cyano borohydride 1.02 g (16 mmol) was added in portions while magnetically stirring. The mixture was gravity filtered and methanol was evaporated in vacuo.

잔류물을 에테르와 희석 냉 HCl사이로 분배하였다.The residue was partitioned between ether and dilute cold HCl.

수상을 에테르로 2번 추출한 후, 얼음 및 50% NaOH 수용액으로 염기성화 하였다.The aqueous phase was extracted twice with ether and then basified with ice and 50% aqueous NaOH solution.

그 산물을 CH2Cl2 로 추출하고, 건조시킨후 증발하여 아민 133의 2가지성분 이성체 혼합물 0.43g(49%)를 얻었다.The product was extracted with CH 2 Cl 2 , dried and evaporated to afford 0.43 g (49%) of a two-component isomer mixture of amine 133.

GC/MS결과 분자이온 128이 58% 였고, 분자이온 128이 42% 였다.GC / MS showed 128% molecular ion and 42% molecular ion.

Figure 112002001377712-pct00091

Figure 112002001377712-pct00091

<1-(3-페닐프로피오닐)-4-아미노피페리딘(136)><1- (3-phenylpropionyl) -4-aminopiperidine (136)>

상기 방법 37의 방법에 따라 이 아민을 합성하였다.This amine was synthesized according to the method of Method 37 above.

톨루엔 20ml 에 4-히드록시피페리딘 4g(40mmol)을 용해시킨 용액에 (과잉의 티오닐 클로라이드내에 페닐프로피온산 6g(40mmol)을 용해시켜 유도된)페닐 프로피오닐 클로라이드를 첨가하였다.To a solution of 4 g (40 mmol) of 4-hydroxypiperidine in 20 ml of toluene was added phenyl propionyl chloride (derived by dissolving 6 g (40 mmol) of phenylpropionic acid in excess thionyl chloride).

이 혼합물에 과잉 2N NaOH 수용액을 첨가하였다.To this mixture was added excess 2N NaOH aqueous solution.

24시간 교반후, 톨루엔층을 버리고 수성상을 CH2Cl2로 추출하고, 건조 및 진공증발시켜 1-(3-페닐프로피오닐)-4-히드록시피페리딘(134) 3.63g(39%)를 얻었다.After stirring for 24 hours, the toluene layer was discarded and the aqueous phase was extracted with CH 2 Cl 2 , dried and evaporated in vacuo to give 3.63 g (39%) of 1- (3-phenylpropionyl) -4-hydroxypiperidine (134). )

GC/MS결과 분자이온 233인 순도 100%를 나타내었다.
GC / MS showed a purity of 100% with a molecular ion of 233.

CH2Cl2 35ml에 옥사릴 클로라이드 1.68ml (19.2mmol)을 용해시키고 -78℃에서 무수 DMSO 2.73ml(38.5mmol)를 CH2Cl2 5ml 에 용해시킨 용액을 첨가하였다. 첨가후 1-(3-페닐프로피오닐)-4-히드록시피페리딘 134 3.6g(15.4mmol)을 CH2Cl2 5ml에 용해시킨 것을 첨가하고, 그 혼합물을 5분간 찬 공기에서 교반하였다.Dissolving the oxalyl chloride, 1.68ml (19.2mmol) in CH 2 Cl 2 35ml and was added to a solution obtained by dissolving the anhydrous DMSO 2.73ml (38.5mmol) in CH 2 Cl 2 5ml at -78 ℃. After addition, 3.6 g (15.4 mmol) of 1- (3-phenylpropionyl) -4-hydroxypiperidine 134 dissolved in 5 ml of CH 2 Cl 2 was added, and the mixture was stirred in cold air for 5 minutes.

CH2Cl2 5ml에 용해시킨 트리에틸아민 10.73ml(77mmol)을 첨가하고 그 혼합물을 실온으로 되게 하였다.10.73 ml (77 mmol) of triethylamine dissolved in 5 ml of CH 2 Cl 2 were added and the mixture was allowed to come to room temperature.

그 혼합물을 포화 암모늄 클로라이드 수용액으로 급냉시켰다. The mixture was quenched with saturated aqueous ammonium chloride solution.                 

유기산을 물로 2번 세척후 포화 염수로 세척하고, 건조 및 진공증발시켜 1-(3-페닐프로피오닐)-4-케토피페리딘(135) 3.2g(89%)을 얻었다. GC/MS결과 분자이온 231이고 순도 100%를 나타내었다.
The organic acid was washed twice with water and then with saturated brine, dried and evaporated to give 3.2 g (89%) of 1- (3-phenylpropionyl) -4-ketopiperidine (135). GC / MS showed molecular ion 231 and showed 100% purity.

상기 화합물 135 3.2g(13.8mmol)을 무수메탄올 125ml에 용해시킨 것에 암모늄 아세테이트 21.3g 및 3A 분자체 20g을 첨가하였다.To 3.2 g (13.8 mmol) of Compound 135 was dissolved in 125 ml of anhydrous methanol, 21.3 g of ammonium acetate and 20 g of 3A molecular sieve were added.

30분간 교반후, 소디움 시아노보로하이드리드 3.47g(55.2mmol)을 교반하면서 나누어 첨가하였다. 3시간후 그 혼합물을 중력여과하고 진공하에 메탄올 증발시켰다. 잔류물을 얼음/HCl과 에테르 사이에서 분배(partition)하였다.After stirring for 30 minutes, 3.47 g (55.2 mmol) of sodium cyanoborohydride were added in portions with stirring. After 3 hours the mixture was gravity filtered and methanol evaporated in vacuo. The residue was partitioned between ice / HCl and ether.

산성 수성상을 에테르로 2번더 추출하였다. 수성상을 얼음 및 50% NaOH 수용액으로 처리하여 염기성화 하였다.The acidic aqueous phase was extracted twice more with ether. The aqueous phase was basified by treatment with ice and 50% aqueous NaOH solution.

그 혼합물을 CH2Cl2로 추출하고, 건조하였으며 진공하에 증발하여 아민 136 1.5g(47%)를 얻었다. The mixture was extracted with CH 2 Cl 2 , dried and evaporated in vacuo to give 1.5 g (47%) of amine 136.

GC/MS결과 분자이온 232이며 순도 100%를 나타내었다.GC / MS showed molecular ion of 232 and showed purity of 100%.

Figure 112002001377712-pct00092

Figure 112002001377712-pct00092

<아민 139의 제조>Preparation of Amine 139

이 아민은 상기 방법 38에 따라 합성되었다.This amine was synthesized according to Method 38 above.

스크류 캡 테프론 튜브에 화합물 137(M.Shimano et al., Tetrahedron, 1998, 54, 12745)(0.80g, 1.21mmol) 및 피리딘 6ml를 장입하였다. 상기 용액을 0℃로 냉각시키고 HF-피리딘 복합물 1.1ml 로 처리하고 그 용액을 실온으로 승온한 다음 17시간 교반하였다.Into a screw cap Teflon tube was loaded Compound 137 (M. Shimano et al., Tetrahedron, 1998, 54, 12745) (0.80 g, 1.21 mmol) and 6 ml of pyridine. The solution was cooled to 0 ° C. and treated with 1.1 ml HF-pyridine complex and the solution was allowed to warm to room temperature and stirred for 17 hours.

그후 HF-피리딘 1.1ml 를 더 첨가하고 반응물을 30시간 더 교반하였다. 이 혼합물을 40ml 1N HCl및 20ml 1:1 헥산-디에틸에테르로된 교반된 얼음 냉각 용액에 부었다. 층을 분리하였으며 수성층을 1:1-헥산-디에틸에테르(2x20ml)로 추출하였다.Then 1.1 ml of HF-pyridine was added and the reaction stirred for another 30 hours. This mixture was poured into a stirred ice cold solution of 40 ml 1N HCl and 20 ml 1: 1 hexane-diethyl ether. The layers were separated and the aqueous layer was extracted with 1: 1-hexane-diethyl ether (2 × 20 ml).

합한 유기층을 얼음-냉각 1N HCl(1x20ml)및 염수 (1x20ml)로 세척하였다. The combined organic layers were washed with ice-cold 1N HCl (1 × 20 ml) and brine (1 × 20 ml).                 

용액을 MgSO4상에서 건조하고, 여과 및 농축하였다.The solution was dried over MgSO 4 , filtered and concentrated.

조질산물을 래디얼 크로마토그래피(3:1 헥산-EtOAc)하여 히드록시 에스테르 282mg(+소량의 불순물)을 얻었으며, 이는 다음 단계에 바로 사용되었다.
The crude product was subjected to radial chromatography (3: 1 hexanes-EtOAc) to give 282 mg (+ small amount of impurities) of hydroxy ester, which was used directly in the next step.

피리딘에 조질 히드록시에스테르(282mg, 0.48mmol)을 용해시킨 0℃로 냉각된 교반용액에 이소부티릴 클로라이드(0.2ml, 1.92mmol)를 적정 첨가하였다. 냉각조를 제거하고 혼합물을 5시간 교반하였다. 물 (2ml)를 첨가하고 그 혼합물을 30분간 더 교반하였다.Isobutyryl chloride (0.2 ml, 1.92 mmol) was added to the stirring solution cooled to 0 ° C. in which crude hydroxyester (282 mg, 0.48 mmol) was dissolved in pyridine. The cooling bath was removed and the mixture was stirred for 5 hours. Water (2 ml) was added and the mixture was stirred for 30 more minutes.

용액을 에테르(3x10ml)를 추출하였다.The solution was extracted ether (3 × 10 ml).

에테르층을 얼음냉각 1N HCl(2x10ml), 포화 NaHCO3(1x10ml)및 염수(1x10ml)로 계속적으로 세척하였다. 용액을 MgSO4상에서 건조하고, 여과 및 농축하였다.The ether layer was washed continuously with ice cold 1N HCl ( 2 × 10 ml), saturated NaHCO 3 (1 × 10 ml) and brine (1 × 10 ml). The solution was dried over MgSO 4 , filtered and concentrated.

그 조질산물을 래디얼 크로마토그래피(4:1 헥산-EtOAc)로 정제하여 이소부티릴 에스테르 138 171mg(2단계에서 전체 23%)를 얻었다.The crude product was purified by radial chromatography (4: 1 hexane-EtOAc) to give 171 mg of isobutyryl ester 138 (23% total in 2 steps).

이 에스테르의 BOC기를 앞서 기술한 표준 BOC-보호해제 조건에 따라 제거하여 원하 는 139를 얻었다.The BOC group of this ester was removed according to the previously described standard BOC-unprotection conditions to afford the desired 139.

Figure 112002001377712-pct00093

Figure 112002001377712-pct00093

<아민 145의 제조>Preparation of Amine 145

이 아민은 상기 방법 39에 따라 제조되었다.This amine was prepared according to Method 39 above.

히드록시에스테르 140(M. Shimano et.al., Tetrahedron, 1998, 54, 12745)(6.27mmol)을 15ml DMF에 용해시키고 0℃로 냉각하였다. 이 용액에 DMAP(1.53g, 12.53mmol), EDCI(1.8g, 9.40mmol)및 N-BOC-O-Bn-(L)-트레오닌(2.52g, 8.15mmol)을 계속적으로 첨가하였다.Hydroxyester 140 (M. Shimano et. Al., Tetrahedron, 1998, 54, 12745) (6.27 mmol) was dissolved in 15 ml DMF and cooled to 0 ° C. DMAP (1.53 g, 12.53 mmol), EDCI (1.8 g, 9.40 mmol) and N-BOC-O-Bn- (L) -threonine (2.52 g, 8.15 mmol) were continuously added to this solution.

반응물을 실온으로 승온하고 밤새 교반하였다.The reaction was warmed to room temperature and stirred overnight.

용액을 급속교반된 30ml 얼음냉각 0.5N HCl과 5ml 4:1 헥산-에테르의 혼합물에 부었다. The solution was poured into a mixture of rapidly stirred 30 ml ice cold 0.5N HCl and 5 ml 4: 1 hexane-ether.

층을 분리하였으며 수성층을 4:1 헥산-에테르(1x30ml)로 추출하였다. 합한 유기층을 0.5N HCl(1x20ml)및 염수 (2x20ml)로 세척하였다. 이 용액을 MgSO4상에서 건조하 고, 여과하였으며 농축시켰다.The layers were separated and the aqueous layer was extracted with 4: 1 hexane-ether (1 × 30 ml). The combined organic layers were washed with 0.5N HCl (1 × 20 ml) and brine (2 × 20 ml). This solution was dried over MgSO 4 , filtered and concentrated.

아니스알데히드를 용리하기 위하여 3:1 CH2Cl2-헥산 1.25L를 사용하여 실리카겔 (150g)상에서 크로마토그래피하고 결합산물 141(3.95g, 88%)를 용리하기 위해 65:10:25 CH2Cl2-에테르 -헥산을 사용하였다.Chromatography on silica gel (150 g) using 1.25 L of 3: 1 CH 2 Cl 2 -hexane to elute anisealdehyde and 65:10:25 CH 2 Cl to elute binding product 141 (3.95 g, 88%) 2 -ether-hexane was used.

EtOAc 25ml 에 용해시킨 벤질 에테르 141(1.32g, 1.84mmol)과 200mg 10% Pd/C를 Parr용기내에서 50Psi의 수소압하에 5시간동안 흔들었다.Benzyl ether 141 (1.32 g, 1.84 mmol) dissolved in 25 ml of EtOAc and 200 mg 10% Pd / C were shaken in a Parr container for 5 hours under hydrogen pressure of 50 Psi.

그 혼합물을 Celite

Figure 112002001377712-pct00094
패드로 여과하고 농축시켜 NMR 분석결과 아주 순수한 히드록시 산 142(680mg, 70%)를 얻었다.The mixture is Celite
Figure 112002001377712-pct00094
Filtration with pad and concentration gave NMR analysis, which gave very pure hydroxy acid 142 (680 mg, 70%).

히드록시산 142(1.54g, 2.86mmol)및 벤질브로마이드(1.5ml, 12.29mmol)을 7ml DMF에 용해시킨 교반용액에 고체 소디움 바이카보네이트(1.2g, 14.27mmol)을 첨가하였다. 그 혼합물을 실온에서 24시간동안 교반한 후 25ml물과 10ml 4:1 헥산-에테르 사이에서 분배하였다. 층분리하고 수성층을 4:1 헥산-에테르(2x10ml)로 추출하였다. 합한 유기층을 0.1N NaOH(1x10ml)및 물 (1x10ml)로 세척하였다.Solid sodium bicarbonate (1.2 g, 14.27 mmol) was added to a stirring solution in which hydroxy acid 142 (1.54 g, 2.86 mmol) and benzyl bromide (1.5 ml, 12.29 mmol) were dissolved in 7 ml DMF. The mixture was stirred at rt for 24 h and then partitioned between 25 ml water and 10 ml 4: 1 hexane-ether. The layers were separated and the aqueous layer was extracted with 4: 1 hexane-ether (2 × 10 ml). The combined organic layers were washed with 0.1N NaOH (1 × 10 ml) and water (1 × 10 ml).

용액을 MgSO4상에서 건조시키고, 여과 및 농축시켰다.The solution was dried over MgSO 4 , filtered and concentrated.

조질산물을 래디얼 크로마토그래피(4:1 헥산-EtOAc)로 정제하여 히드록시벤질 에스테르 143 1.04g(60%)를 얻었다.
The crude product was purified by radial chromatography (4: 1 hexane-EtOAc) to give 1.04 g (60%) of hydroxybenzyl ester 143.

에스테르 143(840mg, 1.34 mmol) 및 무수아세트산(1.0ml, 10.68mmol)을 7ml 피리딘에 용해시킨 교반용액에 DMAP(40mg, 0.67mmol)을 첨가하였다. DMAP (40 mg, 0.67 mmol) was added to a stirred solution of ester 143 (840 mg, 1.34 mmol) and acetic anhydride (1.0 ml, 10.68 mmol) in 7 ml pyridine.                 

그 반응물을 실온에서 4시간 교반하고 80ml EtOAc로서 희석하였다. 이 용액을 포화 CaSO4(3x30ml), 1N HCl(1x30ml), 포화 NaHCO3(1x 30ml)및 염수(1x30ml)로 연속적으로 세척하였다.The reaction was stirred at rt for 4 h and diluted as 80 ml EtOAc. This solution was washed successively with saturated CaSO 4 ( 3 × 30 ml), 1N HCl (1 × 30 ml), saturated NaHCO 3 (1 × 30 ml) and brine (1 × 30 ml).

그 용액을 MgSO4상에서 건조하고, 여과 및 농축시켜 스펙트럼 분석결과 아주 순수한 아세테이트 114 0.9g (100%)를 얻었다. 이 아세테이트 144를 앞서 기술된 것과 같은 방법으로 아민 145로 변환시켰다.The solution was dried over MgSO 4 , filtered and concentrated to give 0.9 g (100%) of very pure acetate 114 by spectral analysis. This acetate 144 was converted to amine 145 in the same manner as previously described.

Figure 112002001377712-pct00095

Figure 112002001377712-pct00095

<2,3,4-트리-0-알킬-베타-D-자이로피라노실아민 147c,d,e><2,3,4-tri-0-alkyl-beta-D-gyropyranosylamine 147c, d, e>

이들 아민의 합성이 상기 방법 40에 나타나있다.The synthesis of these amines is shown in Method 40 above.

트리아세톡시-2-아지독실로피라노실아지드(triacetoxy-2-azidoxylopyranosyl azide> 146(Acros Chemicals Co.)를 CH3OH에 용해시킨 교반용액에 실온에서 메탄올에 용해시킨 소디움 메톡사이드 1M용액을 1.1ml(1.06ml)첨가하였다.Sodium methoxide 1M solution dissolved in methanol at room temperature in a stirred solution of triacetoxy-2-azidoxylopyranosyl azide> 146 (Acros Chemicals Co.) dissolved in CH 3 OH 1.1 ml (1.06 ml) was added.

그 반응물을 밤새 교반하고, 5x8-100 산성수지(∼0.6g)로 중화시켰다. 그 용액을 여과 및 농축하였다. The reaction was stirred overnight and neutralized with 5 × 8-100 acidic resin (˜0.6 g). The solution was filtered and concentrated.                 

얻은 아지도트리올 147a는 다음단계에서 바로 사용되었다.
The obtained azidotriol 147a was immediately used in the next step.

조질 트리올 147a 를 15ml DMF에 용해시키고, NaH(60% 분산, 0.53g, 13.28mmol)를 15분간 4번에 걸쳐 첨가하였다. 반응물을 실온에서 30분간 교반하고 알릴브로마이드(2.7ml, 33.20mmol)를 첨가하고 그 혼합물을 밤새 교반하였다.Crude triol 147a was dissolved in 15 ml DMF and NaH (60% dispersion, 0.53 g, 13.28 mmol) was added four times over 15 minutes. The reaction was stirred at rt for 30 min and allyl bromide (2.7 ml, 33.20 mmol) was added and the mixture was stirred overnight.

포화 암모늄클로라이드(10ml)를 주의깊게 첨가한후 물 50ml를 첨가하였다.Saturated ammonium chloride (10 ml) was added carefully followed by 50 ml of water.

수용액을 EtOAc(3x30ml)로 추출하였다.The aqueous solution was extracted with EtOAc (3x30ml).

유기층을 물(4x30ml)및 염수(2x30ml)로 연속하여 세척하였다.The organic layer was washed successively with water (4x30ml) and brine (2x30ml).

그 용액을 MgSO4상에서 건조시켰으며, 여과 및 농축하였다.The solution was dried over MgSO 4 , filtered and concentrated.

조질물질을 래디얼 크로마토그라피(6:1 헥산-EtOAc)를 통해 정제하여 트리-O-n-알릴-2-아지독시로파라노즈 147b 753mg(77%)를 얻었다.The crude material was purified by radial chromatography (6: 1 hexane-EtOAc) to give 753 mg (77%) of tri-O-n-allyl-2-azidodoxyparanose 147b.

그 결과물인 아지드와 알릴분획을 40ml EtOAc내에 10% Pd/C 150mg 을 첨가하여 수소 1기압하에서 4시간동안 교반하여 환원시켰다. 그 결과물인 용액을 Celite

Figure 112002001377712-pct00096
패드를 통해 여과하고 증발시켜 아민 147c를 얻었다.The resulting azide and allyl fractions were reduced by adding 150 mg of 10% Pd / C in 40 ml EtOAc and stirring for 4 hours under 1 atmosphere of hydrogen. The resulting solution was transferred to Celite
Figure 112002001377712-pct00096
Filtration through the pad and evaporation gave amine 147c.

아민 147d의 제조는 147c과 비슷하였으나 알킬화 단계에서 벤질브로마이드를 사용한후 상기한 바와같이 아지드를 아민으로 환원하였다. 수소 1기압하에서 EtOAc내의 10% Pd/C과 비슷하게 아지드 146을 수소화하여 아민 147e를 얻었다. Preparation of amine 147d was similar to 147c but the use of benzylbromide in the alkylation step reduced the azide to amine as described above. Azide 146 was hydrogenated at 1 atmosphere of hydrogen, similar to 10% Pd / C in EtOAc to afford amine 147e.                 

<2,3,4-트리-0-아세틸-베타-L-푸코피라노실 아민(148)의 제조><Preparation of 2,3,4-tri-0-acetyl-beta-L-fucopyranosyl amine 148>

Figure 112002001377712-pct00097
Figure 112002001377712-pct00097

2,3,4-트리-0-아세틸-베타-L-푸코피라노실아지드(Acros)(750mg, 2.38mmol)을 EtOAc 40ml내에 용해시킨 용액을 10% Pd/c 120mg 을 첨가하였다.120 mg of 10% Pd / c was added to a solution of 2,3,4-tri-0-acetyl-beta-L-fucopyranosylazide (Acros) (750 mg, 2.38 mmol) dissolved in 40 ml of EtOAc.

이 용액을 수소가스 1기압하에 3시간 교반하였다.The solution was stirred for 3 hours under 1 atmosphere of hydrogen gas.

그 혼합물을 Celite

Figure 112002001377712-pct00098
패드를 통해 여과하고 그 패드를 EtOAc(25ml)로 세척하였다. 그 용액을 증발하여 원하는 아민 148(688mg, 100%)을 얻었다.
The mixture is Celite
Figure 112002001377712-pct00098
Filter through a pad and wash the pad with EtOAc (25 ml). The solution was evaporated to afford the desired amine 148 (688 mg, 100%).

<1,3,4,6-테트라-0-아세틸-2-아미노-2-드옥시-알파-D-글루코피라노즈(149)의 제조><Preparation of 1,3,4,6-tetra-0-acetyl-2-amino-2-deoxy-alpha-D-glucopyranose 149>

Figure 112002001377712-pct00099
Figure 112002001377712-pct00099

1,3,4,6-테트라-0-아세틸-2-아지도-2-드옥시(deoxy)-알파-D-글루코피라노즈(TCI-US)(300mg, 0.80mmol)을 EtOAc 25ml에 용해시킨 용액에 10% Pd/C 180 mg을 첨가하였다. 이용액을 수소가스 1기압하에 3시간동안 교반하였다. 그 혼합물을 Celite

Figure 112002001377712-pct00100
패드를 통해 여과하였으며, 그 패드를 EtOAc(20ml)로 세척하였다. Dissolve 1,3,4,6-tetra-0-acetyl-2-azido-2-deoxy-alpha-D-glucopyranose (TCI-US) (300 mg, 0.80 mmol) in 25 ml of EtOAc. 180 mg of 10% Pd / C was added to the resulting solution. The solution was stirred for 3 hours under 1 atmosphere of hydrogen gas. The mixture is Celite
Figure 112002001377712-pct00100
Filter through a pad and wash the pad with EtOAc (20 ml).

그 용액을 증발하여 원하는 아민 149(282mg, 100%)를 얻었다. The solution was evaporated to afford the desired amine 149 (282 mg, 100%).                 

<벤질 및 메틸 3-아미노-트리드옥시-L-아라비노헥소피라노시드 150a 및 150b의 제조><Preparation of benzyl and methyl 3-amino-tridoxy-L-arabinohexopyranoside 150a and 150b>

Figure 112002001377712-pct00101
Figure 112002001377712-pct00101

이들 아민들은 L. Daley, et al., Synth. Commun. 1998, 28,61의 방법을 통해 합성되었다.These amines are described in L. Daley, et al., Synth. Commun. It was synthesized by the method of 1998, 28,61.

Figure 112002001377712-pct00102

Figure 112002001377712-pct00102

<아민 153의 제조>Preparation of Amine 153

상기 방법 41에 도시된 바에 따라 이 아민을 제조하였다.This amine was prepared as shown in Method 41, above.

[(3S, 7R, 8R, 9S)-7-벤질-8-히드록시-9-메틸-2,6-디옥소-[1,5]디옥소난-3-일]-카 르밤산 tert-부틸 에스테르(151)을 M.Shimano et Al., Tetrahedron, 1998, 54, 12745에 기술된 바에 따라 제조하였다.[(3S, 7R, 8R, 9S) -7-benzyl-8-hydroxy-9-methyl-2,6-dioxo- [1,5] dioxonan-3-yl] -carbamic acid tert- Butyl ester 151 was prepared as described in M. Shimano et Al., Tetrahedron, 1998, 54, 12745.

피리딘(5ml)에 이 에스테르(120mg, 0.3mmol)를 용해시킨 교반용액에 메타크릴로일 클로라이드(0.10ml, 1.0mmol)을 5분에 걸쳐 첨가하였다. 그 결과 혼합물을 N2대기하에 실온에서 밤새 교반하였다.Methacryloyl chloride (0.10 ml, 1.0 mmol) was added over 5 minutes to a stirring solution in which this ester (120 mg, 0.3 mmol) was dissolved in pyridine (5 ml). The resulting mixture was stirred overnight at room temperature under N 2 atmosphere.

그 반응 혼합물을 EtOAc(75ml)와 1N HCl(50ml)사이에서 구분하였다.The reaction mixture was partitioned between EtOAc (75 ml) and 1N HCl (50 ml).

유기층을 물로 세척한후 포화 NaCl로 세척한후 MgSO4상에서 건조하고 농축하여 투명오일을 얻었다.The organic layer was washed with water, washed with saturated NaCl, dried over MgSO 4 and concentrated to give a transparent oil.

이 조질오일을 용리액으로서 헥산내에 30% EtOAc 에 용해시킨것을 이용하여 실리카겔상에서 크로마토그래피하여 투명유리질인 아크릴레이트화된 중간체 152(138mg)을 얻었다.This crude oil was chromatographed on silica gel using a solution of 30% EtOAc in hexane as eluent to obtain acrylated intermediate 152 (138 mg) as a clear glassy substance.

이 중간체로부터 상기 기술된 바와같이 BOC 기를 제거하여 원하는 아민 153을 얻었다.From this intermediate the BOC groups were removed as described above to afford the desired amine 153.

<안티마이신 A3의 아닐린 (154)의 제조><Preparation of Aniline (154) of Antimycin A 3 >

Figure 112002001377712-pct00103

Figure 112002001377712-pct00103

안티마이신 A3(25mg, 0.048mmol)을 CH2Cl2 2.5ml에 용해시키고 0℃로 냉각된 교반용 액에 피리딘(11ml)및 PCl5(27mg, 0.13mmol)을 첨가하였다. 이 혼합물을 1.5시간동안 환류시킨후 -30℃로 냉각하고 메탄올(2.5ml)을 첨가 하였으며, 그 혼합물을 실온으로 되게한후 밤새 교반하였다.Antimycin A 3 (25 mg, 0.048 mmol) was dissolved in 2.5 ml CH 2 Cl 2 and pyridine (11 ml) and PCl 5 (27 mg, 0.13 mmol) were added to the stirred solution cooled to 0 ° C. The mixture was refluxed for 1.5 hours, then cooled to -30 ° C and methanol (2.5 ml) was added, and the mixture was allowed to come to room temperature and stirred overnight.

그 용액을 13ml CH2Cl2와 13ml 포화된 소디움 바이카보네이트의 0℃혼합물에 부었다. 그 혼합물을 분할 판넬에서 진탕하고 층분리를 하였다. 수성층을 CH2Cl2(2x5ml)로 추출하였으며 합한 유기층을 건조시키고 (MgSO4), 여과한후 농축하여 안티마이신 A3 의 아닐린을 얻었다. The solution was poured into a 0 ° C. mixture of 13 ml CH 2 Cl 2 and 13 ml saturated sodium bicarbonate. The mixture was shaken on a split panel and layered. The aqueous layer was extracted with CH 2 Cl 2 ( 2 × 5 ml) and the combined organic layers were dried (MgSO 4 ), filtered and concentrated to give aniline of antimycin A 3 .

<아민을 오르소-히드록시 헤테로방향족 카복실산으로 커플링하여 헤테로사이클릭 방향족 아미드 2를 생성시키는 일반적 방법>
General method of coupling an amine to an ortho-hydroxy heteroaromatic carboxylic acid to produce heterocyclic aromatic amide 2

커플링 절차A : N-(2-(4-클로로페닐)에틸)-3-히드록시피리딘-2-카복스아미드(233)의 제조. Coupling Procedure A : Preparation of N- (2- (4-chlorophenyl) ethyl) -3-hydroxypyridine-2-carboxamide (233).

Figure 112002001377712-pct00104
Figure 112002001377712-pct00104

3-히드록시피리딘-2-카복실산(1.39g, 0.01mol)을 무수THF(60ml)에 용해시킨 교반혼합물을 아르곤하에서 -20℃로 냉각시켰다. 이에 톨루엔(5.1g, 0.01mol)내에 용해시킨 포스겐 20% 용액을 단숨에 부가하고 그 결과물인 혼합물을 온도를 천천히 0℃로 상승시키면서 90분간 교반하였다.The stirred mixture in which 3-hydroxypyridine-2-carboxylic acid (1.39 g, 0.01 mol) was dissolved in anhydrous THF (60 ml) was cooled to -20 ° C under argon. The 20% solution of phosgene dissolved in toluene (5.1 g, 0.01 mol) was added at once, and the resulting mixture was stirred for 90 minutes while slowly raising the temperature to 0 ° C.

그후 반응 혼합물을 -20℃로 재냉각시켰으며The reaction mixture was then recooled to -20 ° C

디이소프로필에틸아민(2.58g, 0.02mol)을 THF(20ml)에 용해시킨 용액을 30분에 걸쳐 적정첨가하였다.A solution in which diisopropylethylamine (2.58 g, 0.02 mol) was dissolved in THF (20 ml) was titrated over 30 minutes.

첨가완료후, 그 혼합물을 온도를 천천히 0℃로 상승시키면서 다시 2시간동안 교반하였다. 교반은 0℃에서 밤새 계속되었다.After the addition was completed, the mixture was stirred for another 2 hours while slowly raising the temperature to 0 ° C. Stirring continued at 0 ° C. overnight.

이 교반된 혼합물에 2-(4-클로로페닐)에틸아민(1.56g, 0.01mol)을 단숨에 첨가하였으며, 그 결과 혼합물을 실온에서 6시간동안 교반하였다.2- (4-chlorophenyl) ethylamine (1.56 g, 0.01 mol) was added to this stirred mixture at once, and the mixture was stirred at room temperature for 6 hours.

그 혼합물을 에테르(100ml)로 희석하고 1N HCl(100ml)로 세척하고, 건조하였으며(MgSO4) 농축하여 회백색고체인 요구되는 화합물을 얻었다.(1.95g) 매스스팩트럼(MS)결과 m/e 276 및 278에서 3:1 모이온비를 나타내었다.
The mixture was diluted with ether (100 ml), washed with 1N HCl (100 ml), dried (MgSO 4 ) and concentrated to afford the desired compound as an off-white solid. (1.95 g) Mass spectrum (MS) Result in m / e 276 And 3: 1 molar ratio at 278.

커플링 절차B : 3-히드록시-4-메톡시-N-(4-(4-트리플루오로 메틸페녹시)페닐)-피리딘-2-카복스아미드(425)의 제조 Coupling Procedure B: Preparation of 3-hydroxy-4-methoxy-N- (4- (4-trifluoro methylphenoxy) phenyl) -pyridine-2-carboxamide 425

Figure 112002001377712-pct00105
Figure 112002001377712-pct00105

4-(4-트리플루오로메틸페녹시)아닐린 (0.20g, 0.8mmol)과 DMAP(0.10g, 0.085mmol)을 CH2Cl2(10ml)에 용해시킨 교반용액에 3-벤질옥시-6-브로모-4-메톡시피리딘-2-카보닐클로라이드(3)(0.29g, 0.8mmol)을 CH2Cl2(5ml)에 용해시킨 용액을 단숨에 첨가하였다.3-benzyloxy-6- in a stirred solution of 4- (4-trifluoromethylphenoxy) aniline (0.20 g, 0.8 mmol) and DMAP (0.10 g, 0.085 mmol) dissolved in CH 2 Cl 2 (10 ml). A solution of bromo-4-methoxypyridine-2-carbonylchloride (3) (0.29 g, 0.8 mmol) dissolved in CH 2 Cl 2 (5 ml) was added at once.

그 결과 혼합물을 실온에서 밤새 교반한 후 2N HCl(10ml)에 부었다. 유기층을 분리하고 수성층은 CH2Cl2(2x10ml)로 추출하였다. 유기층을 합하여, 건조시키고 (MgSO4 ) 농축하여 껌상 고체를 얻었다.The resulting mixture was stirred at rt overnight and then poured into 2N HCl (10 ml). The organic layer was separated and the aqueous layer was extracted with CH 2 Cl 2 ( 2 × 10 ml). The organic layers were combined, dried (MgSO 4 ) and concentrated to give a gum solid.

이 고체를 EtOAc(20ml)에 모으고, 트리에틸아민(0.80g, 0.8mmol)및 5% Pt/C(0.10g)을 첨가하였다. 그 결과 혼합물을 Parr 세이커상에서 수소대기(초기압력=50psi)에 30분간 처리하였다. This solid was collected in EtOAc (20 ml) and triethylamine (0.80 g, 0.8 mmol) and 5% Pt / C (0.10 g) were added. As a result, the mixture was treated with hydrogen atmosphere (initial pressure = 50 psi) for 30 minutes on a Parr shaker.                 

그 혼합물을 여과하고, 0.1N HCl(20ml)로 세척하고, 건조(MgSO4)및 농축하여 회백색 고체인 원하는 화합물(0.14g)을 얻었다(m.p=122∼129℃)
The mixture was filtered, washed with 0.1 N HCl (20 ml), dried (MgSO 4 ) and concentrated to afford the desired compound (0.14 g) as an off-white solid (mp = 122-129 ° C.).

커플링 절차C : N-(4-시클로헥실페닐)-3-히드록시피리딘-2-카복스아미드의 제조 Coupling Procedure C : Preparation of N- (4-cyclohexylphenyl) -3-hydroxypyridine-2-carboxamide

Figure 112002001377712-pct00106
Figure 112002001377712-pct00106

(앞서 기술한 바와같이 Pd/C의 존재하에 촉매수소화 반응시켜 화합물 16으로 부터 얻은) 3-히드록시피리딘-2-카복실산(0.42g, 3mmol)과 4-시클로헥실아닐린(0.35g, 2mmol)을 무수 DMF(5ml)에 용해시킨 교반 용액에 1-히드록시벤조트리아졸 (0.48g), EDCI(0.65g)및 N-메틸모포린(1.41g)을 연속 첨가하였다.3-hydroxypyridine-2-carboxylic acid (0.42 g, 3 mmol) and 4-cyclohexyl aniline (0.35 g, 2 mmol) obtained from compound 16 by catalytic hydrogenation in the presence of Pd / C as described above To the stirred solution dissolved in anhydrous DMF (5 ml) was continuously added 1-hydroxybenzotriazole (0.48 g), EDCI (0.65 g) and N-methylmorpholine (1.41 g).

DMF(5ml)를 더 첨가하고 그 반응 혼합물을 실온에서 밤새 교반하였다. 그 혼합물을 물 (200ml)에 부은다음 EtOAc(2x75ml)로 추출하였다.More DMF (5 ml) was added and the reaction mixture was stirred at rt overnight. The mixture was poured into water (200 ml) and extracted with EtOAc (2 × 75 ml).

유기 추출물을 합하고, 물 (100ml)및 포화 NaCl용액(50ml)로 세척하고, 건조(MgSO4)및 농축시켰다.The organic extracts were combined, washed with water (100 ml) and saturated NaCl solution (50 ml), dried (MgSO 4 ) and concentrated.

방치시 고화된 조질오일을 실리카 겔 상에서 크로마토그래피 (4:1 석유에테르-EtOAc)하여 담황색 고체인 원하는 화합물(0.42g)을 얻었다.(m.p. 91∼93℃).
The crude oil solidified on standing was chromatographed (4: 1 petroleum ether-EtOAc) on silica gel to give the desired compound (0.42 g) as a pale yellow solid (mp 91-93 ° C.).

<헤테로 사이클릭 방향족 아미드를 다른 헤테로사이클릭방향족 아미드로 개질>
Modification of heterocyclic aromatic amides to other heterocyclic aromatic amides

4-히드록시티오펜-N-(3,3,5,5,-테트라메틸시클로헥실)-3-카복스아미드(554)의 제조Preparation of 4-hydroxythiophene-N- (3,3,5,5, -tetramethylcyclohexyl) -3-carboxamide 554

Figure 112002001377712-pct00107
Figure 112002001377712-pct00107

4-메톡시티오펜카복실산과 3,3,5,5-테트라메틸시클로헥실아민을 앞서 기술된 일반적인 커플링절차 C에 따라 커플링하여 4-메톡시티오펜 N-(3,3,5,5-테트라메틸시클로헥실)-3-카복스아미드를 얻었다.
4-methoxythiophenecarboxylic acid and 3,3,5,5-tetramethylcyclohexylamine were coupled according to the general coupling procedure C described above to produce 4-methoxythiophene N- (3,3,5,5- Tetramethylcyclohexyl) -3-carboxamide was obtained.

이 메톡시티오펜아미드 500mg을 건조튜브하에서 15ml 클로로포름내에 용해시킨 용액을 드라이아이스-아세톤조내에서 5분간 교반하였다. 이 용액에 보론 트리브로마이드(2당량) 940mg을 클로로포름 10ml 에 용해시킨 용액을 15분에 걸쳐 적정 첨가하였다.A solution of 500 mg of this methoxythiophenamide in 15 ml chloroform under a dry tube was stirred for 5 minutes in a dry ice-acetone bath. To this solution, a solution in which 940 mg of boron tribromide (2 equivalents) was dissolved in 10 ml of chloroform was appropriately added over 15 minutes.

반응 혼합물이 실온으로 될때까지 교반은 계속되었으며 그후 밤새교반하였다.Stirring was continued until the reaction mixture was brought to room temperature and then stirred overnight.

그후 그 반응 혼합물을 냉수조내에 넣고 물 15ml을 적정첨가하였다. 15분간 교반후, 그 혼합물을 CH2Cl2 50ml로 희석하고 유기층을 분리하였다. 물 층을 CH2 Cl2 The reaction mixture was then placed in a cold water bath and 15 ml of water was titrated. After stirring for 15 minutes, the mixture was diluted with 50 ml of CH 2 Cl 2 and the organic layer was separated. Water Layers CH 2 Cl 2

50ml로 세척하였다.Wash with 50 ml.

합한 유기 추출물을 물 25ml 및 포화염용액으로 씻고 건조시켰다. 그 추출물을 여과하고 농축시켰다. 용리액으로서 CH2Cl2-5% EtOAc를 이용하여 실리카겔상에서 크로 마토그래피하여 담황색결정으로서 m.p 170∼174℃인 원하는 화합물 310mg을 얻었다.The combined organic extracts were washed with 25 ml of water and saturated salt solution and dried. The extract was filtered and concentrated. Chromatography on silica gel using CH 2 Cl 2 -5% EtOAc as eluent gave 310 mg of the desired compound as light yellow crystals, mp 170-174 ° C.

시료를 석유 에테르-EtOAc로 부터 재결정하여 담황색 침상을 얻었다.(m.p 171∼173℃)The sample was recrystallized from petroleum ether-EtOAc to give a pale yellow needle. (M.p 171-173 ° C.)

Figure 112002001377712-pct00108
Figure 112002001377712-pct00108

<결합된 중간체 156a-d의 제조>Preparation of Bound Intermediates 156a-d

이들 중간체는 상기 방법42에 도시된 바에 따라 제조되었다. These intermediates were prepared as shown in Method 42 above.

(±)-세린 하이드로클로라이드의 이소프로필 에스테르(2.75g)과 트리에틸아민(3.55g)을 CH2Cl2(75ml)에 용해시킨 교반용액에 3-벤조일옥시-6-브로모-4-메톡시피리딘-2-카보닐클로라이드(3)(5.32g)을 CH2Cl2(15ml)에 용해시킨 용액을 5분에 걸쳐 첨가하였다.Isopropyl ester of (±) -serine hydrochloride (2.75 g) and triethylamine (3.55 g) were dissolved in CH 2 Cl 2 (75 ml) in 3-benzoyloxy-6-bromo-4-meth A solution of oxypyridine-2-carbonylchloride (3) (5.32 g) in CH 2 Cl 2 (15 ml) was added over 5 minutes.

그 혼합물을 실온에서 30분에 걸쳐 교반하고The mixture was stirred over 30 minutes at room temperature

1N HCl(75ml)에 부었다.Pour into 1N HCl (75 ml).

유기층을 분리하였으며, 물로 세척하고(25ml), 건조(Na2SO4)및 용매증발시켜 황색 껌(6.7g)을 얻었다.The organic layer was separated, washed with water (25 ml), dried (Na 2 SO 4 ) and solvent evaporated to give a yellow gum (6.7 g).

이 물질은 에테르/헥산으로 부터 재결정화하여 m.p 100∼103℃인 백색고체 155a를 얻었다.This material was recrystallized from ether / hexane to give a white solid 155a with a m.p of 100 to 103 ° C.

(±)-세린 하이드로클로라이드의 메틸에스테르를 사용하여 마찬가지 공정으로 메틸에스테르 중간체 155b를 얻었다.
The methyl ester intermediate 155b was obtained by the same process using the methyl ester of (±) -serine hydrochloride.

화합물 155a(1.17g), 트리에틸아민(0.31g)및 DMAP(0.06g)을 CH2Cl2(25ml)에 용해시킨 교반용액에 α-메틸 하이드로신남모일 클로라이드(0.46g)을 한번에 첨가하였다.Α-methyl hydrocinnamoyl chloride (0.46 g) was added to the stirred solution in which Compound 155a (1.17 g), triethylamine (0.31 g) and DMAP (0.06 g) were dissolved in CH 2 Cl 2 (25 ml).

그결과 혼합물을 실온에서 4시간 교반한 다음 2N HCl(15ml)에 부었다.As a result, the mixture was stirred at room temperature for 4 hours and then poured into 2N HCl (15 ml).

유기층을 분리하고, 1N NaOH(15ml)로 세척하고, 건조(MgSO4) 및 용매증발하여 황색오일 156a(1.45g)을 얻었다. The organic layer was separated, washed with 1N NaOH (15 ml), dried (MgSO 4 ) and evaporated to yield yellow oil 156a (1.45 g).

NMR(CDCl3) 결과 이 오일은 부분입체이성체 1:1 혼합물이었다.NMR (CDCl 3 ) showed this oil was a diastereomer 1: 1 mixture.

(A. Wissner 와 C.V. Grudzinskas, J. Org. Chem., 1978, 43, 3972의 방법에 의해 상응하는 t-부틸디메틸실릴에스테르로부터 제조된) 3-(t-부틸디메틸실릴옥시)부티릴 클로라이드(3.55g)을 CH2Cl2(10ml)에 용해시킨 용액을 화합물 155b(6.6g)과 DMAP(0.18g)을 무수 피리딘(25 ml)에 용해시킨 찬(0℃) 교반용액에 신속히 첨가하였다.3- (t-butyldimethylsilyloxy) butyryl chloride (prepared from the corresponding t-butyldimethylsilylester by the method of A. Wissner and CV Grudzinskas, J. Org. Chem., 1978, 43, 3972) 3.55 g) was dissolved in CH 2 Cl 2 (10 ml) and quickly added to a cold (0 ° C.) stirred solution in which compound 155b (6.6 g) and DMAP (0.18 g) were dissolved in anhydrous pyridine (25 ml).

그 반응 혼합물을 0℃에서 15분간 교반한 다음 실온에서 3시간동안 교반하였다. The reaction mixture was stirred at 0 ° C. for 15 minutes and then at room temperature for 3 hours.                 

에테르(200ml)로 희석시킨다음 그 혼합물을 물 (2x100ml)로 추출하고, 건조(MgSO4)하였으며, 용매 증발시켰다.Dilution with ether (200 ml) then the mixture was extracted with water (2 × 100 ml), dried (MgSO 4 ) and solvent evaporated.

그 잔류물에 톨루엔(25ml)을 첨가하고 다시 용매증발시켰다.Toluene (25 ml) was added to the residue and the solvent was evaporated again.

크로마토그라피(실리카겔, 7:3 헥산/아세톤)을 통해 그 황색 오일상 잔류물을 정제하여 부분입체이성체의 혼합물로서 화합물 156b를 얻었다.The yellow oily residue was purified by chromatography (silica gel, 7: 3 hexanes / acetone) to give compound 156b as a mixture of diastereomers.

2-벤질-3-(t-부틸디메틸실릴옥시)프로피온산(7.36g)(N.P.Peet, N.L. Lentz, M.W. Dudley, A.M.L. Ogden, D.E. McCarty 및 M.M.Racke, J. Med. Chem., 1993, 36, 4015)를 DMF(20ml)에 용해시킨 교반용액에 t-부틸디메틸시릴 클로라이드(4.52g)을 단번에 첨가하고 그후 이미다졸(4.1g)을 첨가한 다음 그 결과 혼합물을 실온에서 24시간동안 교반하였다.2-benzyl-3- (t-butyldimethylsilyloxy) propionic acid (7.36 g) (NPPeet, NL Lentz, MW Dudley, AML Ogden, DE McCarty and MMRacke, J. Med. Chem., 1993, 36, 4015 T-butyldimethylsilyl chloride (4.52 g) was added in one portion to a stirring solution dissolved in DMF (20 ml), and then imidazole (4.1 g) was added, and the resulting mixture was stirred at room temperature for 24 hours.

그 혼합물을 물 (300ml)로 희석한후 펜탄(3x100ml)로 추출하였다. 그 펜탄상을 물로 세척하고, 건조하였으며(Na2SO4) 용매증발시켜 무색오일(9.5g)을 얻었다. NMR(CDCl3)는 부분입체이성체 혼합물인것과 일치하였다. 이 에스테르(4.1g)을 N.P. Peete, et al., J. Org. Chem., 1978, 43, 3972의 방법에 따라 상응하는 산 클로라이드로 변환되었다.The mixture was diluted with water (300 ml) and extracted with pentane (3 × 100 ml). The pentane phase was washed with water, dried (Na 2 SO 4 ) and solvent evaporated to give a colorless oil (9.5 g). NMR (CDCl 3 ) was consistent with the diastereomeric mixture. This ester (4.1 g) was obtained from NP Peete, et al., J. Org. Converted to the corresponding acid chloride according to the method of Chem., 1978, 43, 3972.

이 산 클로라이드는 상기한 바와같이 화합물 155b(4.4g)과 축합되어 실리카겔 크로마토 그라피후(4:1 헥산/아세톤) 부분입체 이성체 혼합물로서 원하는 156c를 얻었다.
This acid chloride was condensed with compound 155b (4.4 g) as described above to afford the desired 156c as a silica gel chromatography (4: 1 hexanes / acetone) diastereomeric mixture.

상기 화합물 156c(4.5g)을 메탄올(35ml)에 용해시킨 교반용액에 진한 HCl(1.5ml)을 첨가하였다.To the stirred solution in which Compound 156c (4.5 g) was dissolved in methanol (35 ml), concentrated HCl (1.5 ml) was added.

그 결과 혼합물을 실온에서 30분간 교반하였으며, 물 (200ml)로 희석한 다음 The resulting mixture was stirred at room temperature for 30 minutes, diluted with water (200 ml) and then

CH2Cl2(2x100ml)로 추출하였다. 유기상을 건조하고(MgSO4), 용매추출하였다. 잔류물을 실리카겔 크로마토그래피(7:3 헥산/아세톤)하여 엷은 황색껌상의 화합물 156d(2.8g)을 얻었다.Extracted with CH 2 Cl 2 ( 2 × 100 ml). The organic phase was dried (MgSO 4 ) and the solvent extracted. The residue was purified by silica gel chromatography (7: 3 hexane / acetone) to give 156 d (2.8 g) as a pale yellow gum.

NMR(CDCl3)결과 부분입체이성체 혼합물인것으로 나타났다.NMR (CDCl 3 ) results showed a diastereomeric mixture.

상기 156a∼d는 기술된 바와같이 Pd/C의 존재하에 수소화반응시켜 상응하는 보호해제된 헤테로사이클릴 방향족 아미드로 변환되었다.The 156a-d were converted to the corresponding unprotected heterocyclyl aromatic amide by hydrogenation in the presence of Pd / C as described.

Figure 112002001377712-pct00109
Figure 112002001377712-pct00109

<중간체 158의 제조><Production of Intermediate 158>

이 중간체의 합성이 상기 방법 43에 나타나 있다.The synthesis of this intermediate is shown in Method 43 above.

아미드 157은(+)-트랜스-1-히드록시-2-아미노시클로펜탄하이드로브로마이드 (7.09g, 38.9mmol)및 3-벤질옥시-6-브로모-4-메톡시피리딘-2-카보닐클로라이드(3)(13.8g, 38.9mmol)을 CH2Cl2(150ml)에 용해시킨 용액으로부터 일반적인 커플링 절차 B를 따라 제조되고 용리액으로서 1:1 헥산-EtOAc를 이용한 플래쉬 크로마토그래피로 정제하였다. Amide 157 is (+)-trans-1-hydroxy-2-aminocyclopentanehydrobromide (7.09 g, 38.9 mmol) and 3-benzyloxy-6-bromo-4-methoxypyridine-2-carbonylchloride (3) (13.8 g, 38.9 mmol) was prepared following the general coupling procedure B from a solution dissolved in CH 2 Cl 2 (150 ml) and purified by flash chromatography using 1: 1 hexane-EtOAc as eluent.

이에따라 백색고체로서 화합물 157(13.4g)을 얻었다. m.p. 56∼57℃.
This resulted in compound 157 (13.4 g) as a white solid. mp 56-57 ° C.

디메틸술폭사이드(7.4ml, 104.1mmol)을 옥살릴 클로라이드(4.54ml, 52.08mmol)을 CH2Cl2(100ml)에 용해시킨 78℃용액에 천천히 첨가한후 아미드 157(10.46g, 24.8mmol)을 CH2Cl2(25ml)에 용해시킨 용액에 첨가하였다.Dimethyl sulfoxide (7.4 ml, 104.1 mmol) was slowly added to oxalyl chloride (4.54 ml, 52.08 mmol) in 78 ° C. solution dissolved in CH 2 Cl 2 (100 ml), followed by amide 157 (10.46 g, 24.8 mmol). To the solution dissolved in CH 2 Cl 2 (25 ml).

30분후, Et3N을 첨가하고 그 용액을 천천히 실온으로 승온시켰다. 그 혼합물을 포화 NH4Cl(100ml)에 붓고 CH2Cl2(2x100ml)로 추출하였다.After 30 minutes, Et 3 N was added and the solution was slowly warmed to room temperature. The mixture was poured into saturated NH 4 Cl (100 ml) and extracted with CH 2 Cl 2 ( 2 × 100 ml).

합한 유기층을 염수로 세척하고, 건조 및 용매 증발하였다.The combined organic layers were washed with brine, dried and solvent evaporated.

그 잔류물을 용리액으로서 1:1 EtOAc-헥산을 이용하여 컬럼 크로마토그라피를 거쳐 정제되어 케톤158(9.64g, 94%)을 얻었으며, GC/MS및 1H-NMR 결과 순수하였다.The residue was purified by column chromatography using 1: 1 EtOAc-hexane as eluent to afford ketone 158 (9.64 g, 94%), which was pure by GC / MS and 1 H-NMR.

화합물 157 및 158 모두는 앞서 기술한 바와같이 Pd/C의 존재하에 수소화하여 상응 하는 보호해제된 헤테로사이클릭 방향족 아미드로 변환되었다.Both compounds 157 and 158 were hydrogenated in the presence of Pd / C as described above to convert to the corresponding unprotected heterocyclic aromatic amides.

Figure 112002001377712-pct00110
Figure 112002001377712-pct00110

<중간체 160a-d의 제조><Production of Intermediate 160a-d>

상기 방법 44에 따라 이들 중간체를 제조하였다.These intermediates were prepared according to Method 44 above.

일반 커플링 절차 C를 따라 세리놀을 3-벤질옥시-6-브로모-4-메톡시피콜린산(16)과 커플링하여 무색오일로서 1,3-디올 159를 얻었으며 1H, 13C-NMR 및 IR 스펙트라 결과 순수하였다.Serinol was coupled with 3-benzyloxy-6-bromo-4-methoxypicolinic acid (16) following the general coupling procedure C to give 1,3-diol 159 as colorless oil and 1 H, 13 C. -NMR and IR spectra results were pure.

1,3-디올 159(1mmol)을 Dean-Stark 셋업내에서 촉매량의 p-톨루엔술폰산(0.1mmol)의 존재하에 벤젠(20ml/mmol)내에서 환류시켜 적절한 카보닐 화합물(2 mmol) 혹은 상응하는 디메틸 아세탈(2 mmol)과 축합하였다.
1,3-diol 159 (1 mmol) was refluxed in benzene (20 ml / mmol) in the presence of a catalytic amount of p-toluenesulfonic acid (0.1 mmol) in a Dean-Stark setup to obtain the appropriate carbonyl compound (2 mmol) or the corresponding Condensation with dimethyl acetal (2 mmol).

화합물 159와, 1,3,3,-트리메톡시프로판의 축합은 Syn 및 anti 부분입체 이성체의 2:1 혼합물로서 아세탄 160a 를 제공하였다.Condensation of compound 159 with 1,3,3, -trimethoxypropane provided Acetan 160a as a 2: 1 mixture of Syn and anti diastereoisomers.

매스 스펙트럼(ES)는 (m/e)495 및 497에서 [M+]를 나타내었다. 1H-13C-NMR 및 IR 스 펙트라는 구조 160a 와 일치하였다.The mass spectrum (ES) shows [M +] at (m / e) 495 and 497. 1 H- 13 C-NMR and IR spectra were consistent with structure 160a.

화합물 159와 2-메틸-3-(4-tert-부틸)페닐프로파논의 축합결과 Syn-과 anti 부분입체이성체의 3:1 혼합물로서 아세탈 160b를 부여하였다. 매스 스펙트럼(ES)는 (m/e)597에서 [M+]를 나타내었다.Condensation of compound 159 with 2-methyl-3- (4-tert-butyl) phenylpropanone gave acetal 160b as a 3: 1 mixture of Syn- and anti diastereomers. Mass spectrum (ES) shows [M +] at (m / e) 597.

1H, 13C-NMR 및 IR 스펙트라는 구조 160b 와 일치하였다.
1 H, 13 C-NMR and IR spectra were consistent with structure 160b.

화합물 159와 디하이드로-β-이오논(ionone)의 축합결과 Syn과 anti 부분입체이성체의 2:1 혼합물로서 아세탈 160c를 부여하였다. 매스 스펙트럼(EI)는 (m/e)587에서 [M+]를 나타내었다.Condensation of Compound 159 with dihydro-β-ionone gave acetal 160c as a 2: 1 mixture of Syn and anti diastereomers. Mass spectrum (EI) showed [M +] at (m / e) 587.

1H, 13C-NMR 및 IR 스펙트라는 구조 160c 와 일치하였다.
1 H, 13 C-NMR and IR spectra were consistent with structure 160c.

화합물 159와 3,3,5,5-테트라메틸시클로헥사논의 축합결과 아세탈 160d를 제공했으며, 1H, 13C-NMR 및 IR 스펙트라 결과 일치하였다.
Condensation of compound 159 with 3,3,5,5-tetramethylcyclohexanone provided acetal 160d and was consistent with 1 H, 13 C-NMR and IR spectra results.

상기 중간체 160a∼d는 앞서 기술된 바와같이 Pd/C의 존재하에 수소화반응에의해 상응하는 보호해제된 헤테로사이클릭 방향족아미드로 변환되었다.The intermediates 160a-d were converted to the corresponding unprotected heterocyclic aromaticamides by hydrogenation in the presence of Pd / C as described above.

Figure 112002001377712-pct00111
Figure 112002001377712-pct00111

<화합물 280과 281의 제조>Preparation of Compounds 280 and 281

방법 45는 이들 화합물의 제조를 기술하고 있다.Method 45 describes the preparation of these compounds.

먼저 2,3,6,6-테트라메틸-2-시클로헵테닐아민을 표준 커플링 절차C를 이용하여 2-히드록시-3-메톡시-2-피콜린산에 커플링시켜 중간체 161을 얻었다.First, Intermediate 161 was obtained by coupling 2,3,6,6-tetramethyl-2-cycloheptenylamine to 2-hydroxy-3-methoxy-2-picolinic acid using standard coupling procedure C. .

Tetrahedron Lett. 1991, 32, 1831∼1834의 절차에 따라 화합물 161을 디클로로화하여 디클로로 유도체 281을 얻었다.Tetrahedron Lett. Compound 161 was dichlorolated according to the procedures of 1991, 32, 1831-1834 to give dichloro derivative 281.

CH2Cl2내에서 상기 화합물 161을 표준 m-CPBA 산화하여 N-옥사이드-함유 에폭시 아나로그 162를 제조한후, 표준 촉매 수소화 조건하에 H2(45psi)및 10% Pd/c처리하여 화합물 280을 형성하였다.Compound 161 was prepared by oxidation of the compound 161 in CH 2 Cl 2 with standard m-CPBA to prepare an N-oxide-containing epoxy analog 162, followed by treatment with H 2 (45 psi) and 10% Pd / c under standard catalytic hydrogenation conditions. Formed.

Figure 112002001377712-pct00112
Figure 112002001377712-pct00112

<트랜스-4-히드록시-3,3,5,5-테트라메틸피콜린아미드(264)의 제조><Production of trans-4-hydroxy-3,3,5,5-tetramethylpicolinamide (264)>

상기 방법 46에 따라 이 화합물을 제조하였다.This compound was prepared according to Method 46 above.

케토-피콜린아미드 266(56mg,0.18mmol)을 메탄올 2ml에 용해시킨 교반용액에 소디움 보로하이드리드(20mg, 0.53mmol)을 첨가하였다. 그 반응물을 5시간동안 교반하고 메탄올을 증발시켰다. 그 조질물질을 5ml 물로 희석시키고 EtOAc(3x5ml)로 추출하였다.Sodium borohydride (20 mg, 0.53 mmol) was added to the stirred solution in which keto-picolinamide 266 (56 mg, 0.18 mmol) was dissolved in 2 ml of methanol. The reaction was stirred for 5 hours and methanol was evaporated. The crude was diluted with 5 ml water and extracted with EtOAc (3 × 5 ml).

유기층을 물(1x5ml) 및 염수(1x5ml)로 세척하였다.
The organic layer was washed with water (1 × 5 ml) and brine (1 × 5 ml).

그 용액을 MgSO4상에서 건조하고, 여과한후 농축시켰다. The solution was dried over MgSO 4 , filtered and concentrated.

NMR및 GC분석결과 순도 95%로 트랜스 입체화학을 갖는 화합물 264와 일치하였다.NMR and GC analyzes were consistent with compound 264 having a trans stereochemistry with a purity of 95%.

Figure 112002001377712-pct00113
Figure 112002001377712-pct00113

<화합물 341의 제조>Preparation of Compound 341

이 화합물의 제법이 상기 방법 47에 나타나있다.The preparation of this compound is shown in Method 47 above.

벤질 에스테르 전구체 139(방법 39)(33mg, 0.046mmol)을 EtOAc 10ml에 용해시키고 Pearlman 촉매 110mg을 첨가하였다.Benzyl ester precursor 139 (method 39) (33 mg, 0.046 mmol) was dissolved in 10 ml EtOAc and 110 mg of Pearlman catalyst was added.

그 혼합물을 수소압 50psi 하에 Parr 용기내에서 12시간동안 진탕하였다. 그 용액을 그후 여과하고 농축하였다.The mixture was shaken for 12 h in a Parr vessel under hydrogen pressure 50 psi. The solution was then filtered and concentrated.

그후 잔류물을 최소량의 에테르에 용해시켰으며 침전물이 형성될때까지 석유에테르를 첨가하였다. 여과에의해 고체를 수집하고 건조하여 화합물 341을 얻었다.The residue was then dissolved in a minimum amount of ether and petroleum ether was added until a precipitate formed. The solid was collected by filtration and dried to give compound 341.

<N-(3-히드록시-4-메톡시-2-피리딜카보닐)-2-아미노-2-드옥시-알파-D-글루코피라노 즈(334)의 제조><Preparation of N- (3-hydroxy-4-methoxy-2-pyridylcarbonyl) -2-amino-2-deoxy-alpha-D-glucopyranose 334>

Figure 112002001377712-pct00114
Figure 112002001377712-pct00114

표준 커플링 절차 C를 이용하여 1,3,4,6-테트라-0-아세틸-2-아미노-2-드옥시-알파-D-글루코피라노즈(151)과 3-히드록시-4-메톡시 피콜린산을 함께 결합시켰다.
1,3,4,6-tetra-0-acetyl-2-amino-2-deoxy-alpha-D-glucopyranose (151) and 3-hydroxy-4-methine using standard coupling procedure C Toxy picolinic acid was bound together.

그 결과물인 피콜린아미드(0.19g, 0.39mmol)을 메탄올 6ml에 용해시킨 용액에 리튬 하이드록사이드 모노 하이드레이트(0.92mmol, 40mg)을 첨가 하였다.
Lithium hydroxide monohydrate (0.92 mmol, 40 mg) was added to a solution of the resulting picolinamide (0.19 g, 0.39 mmol) in 6 ml of methanol.

그 반응 혼합물을 실온에서 밤새 교반하였다.The reaction mixture was stirred at rt overnight.

그 용액을 DOWEX

Figure 112002001377712-pct00115
5x8-100 산성수지(0.5g)을 첨가하여 중성화시켰다. 그 혼합물을 여과하고 농축시켜 원하는 화합물(110mg, 88%)을 얻었다.DOWEX the solution
Figure 112002001377712-pct00115
5x8-100 acidic resin (0.5 g) was added to neutralize. The mixture was filtered and concentrated to afford the desired compound (110 mg, 88%).

Figure 112002001377712-pct00116
Figure 112002001377712-pct00116

<엑소사이클릭 에스테르 166a, 카바메이트 166b 및 카보네이트 166c 의 일반제법>
<General preparation method of exocyclic ester 166a, carbamate 166b, and carbonate 166c>

이들 화합물들은 M.Shimono, et al., Tetrahedron, 1998,54,12745의 제법에 따라 제조된 아민 164를 출발물질로하여 상기 방법 48에 도시된 바와같이 제조되었다.
These compounds were prepared as shown in Method 48 above using amine 164 prepared according to the method of M. Shimono, et al., Tetrahedron, 1998,54,12745.

이 아민은 전술된 표준 커플링절차 C에 따라 3-벤질옥시-6-브로모-4-메톡시피콜린산 16과 결합되었으며, 그후 그 결과물인 중간체 165를 염기존재하에 적절한 카복실산 클로라이드, 알킬이소시아네이트, 혹은 알킬클로로포르메이트와 반응시켜 원하는 보호된 에스테르 166a, 카바메이트 166b, 혹은 카보메이트 166c를 각각 얻었다.This amine was combined with 3-benzyloxy-6-bromo-4-methoxypicolinic acid 16 according to the standard coupling procedure C described above, and then the resulting intermediate 165 was added in the presence of a suitable carboxylic acid chloride, alkylisocyanate, Or reacted with alkylchloroformate to give the desired protected ester 166a, carbamate 166b, or carbomate 166c, respectively.

Pd/c의 존재하에 H2를 이용하여 앞서 기술된 절차에 따라 이들 화합물을 탈양자하여 요구되는 에스테르, 카바메이트 혹은 카보메이트를 얻었다.
These compounds were deprotonated using H 2 in the presence of Pd / c according to the procedure described above to obtain the required ester, carbamate or carbomate.

다른 동족에스테르, 카바메이트 및 카보메이트를 제조하기 위해 상기 단계들을 이용하였다.
The above steps were used to prepare other cognate esters, carbamate and carbomate.

166a 의 제조Preparation of 166a

화합물 165(180mg, 0.29mmol)을 피리딘(10ml)에 용해시킨 교반용액에 시클로프로판 카보닐 클로라이드(0.45ml, 5mmol)을 5분에 걸쳐 천천히 첨가하였다.Cyclopropane carbonyl chloride (0.45 ml, 5 mmol) was slowly added to the stirred solution in which Compound 165 (180 mg, 0.29 mmol) was dissolved in pyridine (10 ml) over 5 minutes.

그 혼합물을 실온에서 N2대기하에 밤새 교반하였다.The mixture was stirred overnight at room temperature under N 2 atmosphere.

그 결과 혼합물을 1N HCl(30ml)내에 붓고 EtOAc(2x75ml)로 추출하였다.The resulting mixture was poured into 1N HCl (30 ml) and extracted with EtOAc (2 × 75 ml).

유기층을 모으고 물(25ml)로 세척한 다음 포화 NaCl(25ml)로 세척하였으며 MgSO4상에서 건조시키고 농축하여 오렌지색 오일을 얻었다.The organic layers were combined, washed with water (25 ml) then washed with saturated NaCl (25 ml), dried over MgSO 4 and concentrated to give an orange oil.

그 조질오일을 용리액으로 헥산 그래디엔트내에서 30-50% EtOAc를 이용하여 실리카 겔상에서 크로마토 그래프하여 투명오일로서 화합물 166a(100mg)을 얻었다.
The crude oil was chromatographed on silica gel using 30-50% EtOAc in hexane gradient as eluent to afford compound 166a (100 mg) as a clear oil.

166b의 제조Preparation of 166b

화합물 165(200mp, 0.33mmol)을 CH2Cl2(5ml)에 용해시킨 교반용액에 트리에틸아민(2방울), DMAP(1mg),및 이소프로필 이소시아네이트(0.2ml, 2mmol)을 첨가하였다.Triethylamine (2 drops), DMAP (1 mg), and isopropyl isocyanate (0.2 ml, 2 mmol) were added to a stirred solution of compound 165 (200 mp, 0.33 mmol) dissolved in CH 2 Cl 2 (5 ml).

그 결과 혼합물을 질소분위기하에 실온에서 밤새 교반하였다.The resulting mixture was stirred overnight at room temperature under a nitrogen atmosphere.

반응혼합물을 1N HCl(25ml)에 붓고 EtOAc(2x50ml)로 추출하였다. 유기층을 모으고 물 및 포화 NaCl로 순차적으로 세척하고나서 MgSO4상에서 건조하고 농축시켜 핑크색 거품을 얻었다. 이중 용리액으로서 헥산그레디언트에서 30%∼50% EtOAc를 이용하여 실리카겔상에서 크로마토그래피하여 백색고체로서 화합물 166b(90mg)을 얻었다.
The reaction mixture was poured into 1N HCl (25 ml) and extracted with EtOAc (2 × 50 ml). The organic layers were combined, washed sequentially with water and saturated NaCl, dried over MgSO 4 and concentrated to give a pink foam. Chromatography on silica gel using 30% to 50% EtOAc in hexane gradients as a double eluent gave compound 166b (90 mg) as a white solid.

화합물 166c 의 제조Preparation of Compound 166c

화합물 165(180mg, 0.29mmol)을 피리딘(5ml)및 CH2Cl2(5ml)에 용해시킨 교반용액을 질소분위기하에 얼음조내에서 0℃로 냉각시켰다.Compound 165 (180 mg, 0.29 mmol) dissolved in pyridine (5 ml) and CH 2 Cl 2 (5 ml) was cooled to 0 ° C. in an ice bath under a nitrogen atmosphere.

이소프로필 클로로 포르메이트(톨루엔에서 1M, 5ml)을 그 냉각된 혼합물에 1분에 걸쳐 천천히 첨가하였다.Isopropyl chloro formate (1M in toluene, 5 ml) was added slowly to the cooled mixture over 1 minute.

얼음조를 제거하고 그 혼합물을 실온에서 밤새 교반하였다.The ice bath was removed and the mixture was stirred at rt overnight.

반응 혼합물을 1N HCl(25ml)와 EtOAc(75ml)로 구분하였다. 유기층을 물 및 포화 NaCl로 순차적으로 세척하고 MgSO4상에서 건조시킨 다음 농축하여 투명오일을 얻었다. 그 조질오일을 용리액으로 헥산 그래디엔트에서의 30%∼50% EtOAc를 이용하여 실리카 겔상에서 크로마토그래피하여 투명오일로서 화합물 166c(80mg)을 얻었다.The reaction mixture was partitioned between 1N HCl (25 ml) and EtOAc (75 ml). The organic layer was washed sequentially with water and saturated NaCl, dried over MgSO 4, and concentrated to give a transparent oil. The crude oil was chromatographed on silica gel using 30% -50% EtOAc in hexane gradient as eluent to afford compound 166c (80 mg) as a clear oil.

Figure 112002001377712-pct00117
Figure 112002001377712-pct00117

<중간체 167과 168의 제조><Production of Intermediates 167 and 168>

상기한 바와같이 얻은 아민 53의 부분입체이성체 혼합물(방법9참조)을 앞서 기술된 일반 커플링절차 A를 통해 산클로라이드 3으로 결합시켜 부분입체 이성체 167과 168혼합물을 얻었다. 이들을 실리카겔 크로마토그래피(85:15 헥산/아세톤)하여 35% 수율로 순수 화합물 167및 168을 얻었다.The diastereomeric mixture of amine 53 (see method 9) obtained as described above was combined with acid chloride 3 via the general coupling procedure A described above to give a diastereomer 167 and 168 mixture. These were subjected to silica gel chromatography (85:15 hexanes / acetone) to give pure compounds 167 and 168 in 35% yield.

이들을 앞서 기술된 바와같이 Pd/c의 존재하에 H2로 보호 해제(deprotect)되었다.They were deprotected with H 2 in the presence of Pd / c as described above.

<헤테로 사이클릭 방향족아미드(2)를 0-아실 헤테로사이클릭 방향족 아미드(2Y:M=아실), 0-아실 헤테로사이클릭 방향족 아미드(2Y:M=시릴) 및 0-술포닐 헤테로사이클릭 방향족 아미드(2Y:M=술포닐)로 변환시키는 일반제법>Heterocyclic aromaticamides (2) include 0-acyl heterocyclic aromatic amides (2Y: M = acyl), 0-acyl heterocyclic aromatic amides (2Y: M = silyl) and 0-sulfonyl heterocyclic aromatics. General formula to convert to amide (2Y: M = sulfonyl)>

Figure 112002001377712-pct00118

Figure 112002001377712-pct00118

0-(3,3-디메틸)부타노일 화합물 610의 제조Preparation of 0- (3,3-dimethyl) butanoyl Compound 610

(M. Shimano et al., Tetrahedron 1998, 54, 12745의 방법에 따라 제조된)화합물 169를 출발물질로한 이 화합물의 제법이 상기 방법 50에 도시되어 있다.
The preparation of this compound starting with Compound 169 (prepared according to the method of M. Shimano et al., Tetrahedron 1998, 54, 12745) is shown in Method 50 above.

화합물 169(100mg, 0.19mmol)및 DMAP(5mg, 0.04mmol)을 무수 피리딘(5ml)에 용해시킨 교반용액을 3,3-디메틸부타노일 클로라이드로 처리하고, 그 혼합물을 주위온도에서 5.5시간동안 교반하였다.A stirred solution of Compound 169 (100 mg, 0.19 mmol) and DMAP (5 mg, 0.04 mmol) dissolved in anhydrous pyridine (5 ml) was treated with 3,3-dimethylbutanoyl chloride and the mixture was stirred at ambient temperature for 5.5 hours. It was.

그후 물(15ml)로 처리하고 EtOAc(20ml)로 추출하였다.Then treated with water (15 ml) and extracted with EtOAc (20 ml).

그 유기추출물을 물 및 포화 NaHCO3 수용액으로 계속하여 세척하고, 건조시킨후(Na2SO4), 여과 및 농축하였다.The organic extract was washed successively with water and saturated aqueous NaHCO 3 solution, dried (Na 2 SO 4 ), filtered and concentrated.

용리액으로서 에테르를 사용하여 실리카겔 상에서 크로마토그래피하여 회백색 고체로서 m.p 151∼152℃인 화합물을 얻었다.Chromatography on silica gel using ether as eluent gave the compound m.p 151-152 ° C. as an off-white solid.

1H-NMR및 MS 데이타는 할당된 구조와 일치하였다. 1 H-NMR and MS data were consistent with the assigned structure.

다른 0-아실 헤테로사이클릭 방향족 아미드를 상기 제법을 기초로 변형하여 제조하였다. 그 변형은 예를들어 컬럼크로마토그래피 또는 재결정화같이, 이분야에서 통상의 지식을 가진자에게 잘 알려진 다른 기술에의한 정제등을 포함하였다.
Other 0-acyl heterocyclic aromatic amides were prepared by modifications based on the above recipe. Such modifications include purification by other techniques well known to those of ordinary skill in the art, such as, for example, column chromatography or recrystallization.

0-tert-부틸디메틸시릴 화합물 720의 제조Preparation of 0-tert-butyldimethylsilyl Compound 720

이 화합물의 제법이 방법 50에 도시되어 있다.The preparation of this compound is shown in Method 50.

화합물 169(100mg, 0.19mmol)및 N-메틸모포린(0.13ml, 1.18mmol)을 무수 DMF(2ml)에 용해시킨 교반용액을 tert-부틸디메틸시릴 클로라이드(57mg, 0.38mmol)로 처리하였으며, 그 혼합물을 주위온도에서 1일간 교반하였다. Compound 169 (100 mg, 0.19 mmol) and N-methylmorpholine (0.13 ml, 1.18 mmol) dissolved in anhydrous DMF (2 ml) were treated with tert-butyldimethylsilyl chloride (57 mg, 0.38 mmol). The mixture was stirred at ambient temperature for 1 day.                 

그 결과 혼합물을 물(10 ml)및 EtOAc(15ml)로 구분하였으며, 그 유기상을 포화 NaHCO3수용액 및 염수로 순차적으로 세척하고, 여과 및 농축하였다.The resulting mixture was partitioned between water (10 ml) and EtOAc (15 ml) and the organic phase was washed sequentially with saturated aqueous NaHCO 3 and brine, filtered and concentrated.

에테르를 용리액으로 사용하여 그 잔류물을 플래쉬-그래이드 실리카 겔 컬럼상에서 크로마토그래피하여 투명그리이스로서 화합물 74mg을 얻었다. 1H-NMR스펙트럼은 할당된 구조와 일치하였다.
The residue was chromatographed on a flash-graded silica gel column using ether as eluent to afford 74 mg of compound as a clear grease. The 1 H-NMR spectrum was consistent with the assigned structure.

0-p-톨루엔술포닐 화합물 722의 제조Preparation of 0-p-toluenesulfonyl Compound 722

이 화합물의 제법이 방법 50에 도시되어 있다.The preparation of this compound is shown in Method 50.

p-톨루엔술포닐 클로라이드(90mg, 0.466mmol)을 무수아세톤(3ml)내에 화합물 169(200mg, 0.388mmol) 및 포타슘 카보네이트(65mg, 0.466mmol)을 부유시킨 교반된 서스펜션에 첨가하였다.p-toluenesulfonyl chloride (90 mg, 0.466 mmol) was added to a stirred suspension in which compound 169 (200 mg, 0.388 mmol) and potassium carbonate (65 mg, 0.466 mmol) were suspended in anhydrous acetone (3 ml).

주위온도에서 12시간 교반한 후, 그 혼합물을 EtOAc(25ml)로 희석시키고 H2O(2x10ml)로 세척하였다.After stirring for 12 h at ambient temperature, the mixture was diluted with EtOAc (25 ml) and washed with H 2 O ( 2 × 10 ml).

유기상은 건조하였으며(MgSO4), 여과 및 진공내 농축하였다. 헥산-EtOAc(1:1)로 용리하면서 잔류물을 플래쉬 크로마토그래피로 정제하여 m.p 153∼155℃인 백색고체 197mg을 얻었으며, 그 1H-NMR스펙트럼은 원하는 화합물과 일치하였다.
The organic phase was dried (MgSO 4 ), filtered and concentrated in vacuo. The residue was purified by flash chromatography, eluting with hexane-EtOAc (1: 1) to give 197 mg of a white solid with mp 153-155 ° C., the 1 H-NMR spectrum was consistent with the desired compound.

방법 Ⅰ은 상기한 제법으로 적절한 출발물질로 부터 제조된 식Ⅰ의 다른 화합물을 예시한 것이다.Method I illustrates another compound of formula I prepared from a suitable starting material by the above preparation.

이들 화합물 모두에 대한 1H-NMR스펙트럼 데이타는 할당된 구조와 일치하였다.
1 H-NMR spectrum data for all of these compounds was consistent with the assigned structure.

살균제 유용성Fungicide Usability

본 발명의 화합물은 진균(fungi)특히 식물 병원체와 목재부식 균류를 제어하는 것이 발견되었다.The compounds of the present invention have been found to control fungi, particularly plant pathogens and wood eroding fungi.

식물 균류질병을 처리하는데 사용시, 이 화합물은 질병억제 및 식물학적으로 수용가능한 량으로 식물에 적용된다. When used to treat plant fungal diseases, these compounds are applied to plants in disease inhibiting and botanically acceptable amounts.

적용은 식물에 진균류가 감염되기전 및/또는 후에 수행될수 있다. Application can be carried out before and / or after the fungus is infected with the plant.

적용은 식물의 씨앗, 식물이 자라는 토양, 파종하는 전답, 혹은 살포액등을 통해 이루어질수도 있다. 다른 적용은 목제 및 /또는 목제품의 파괴를 제어하기위해 목제 처리제를 통해 수행될수 있다.
Application can also be through the seed of the plant, the soil in which the plant grows, the sowing field or the spreading solution. Other applications can be carried out through wood treatments to control the destruction of wood and / or wood products.

여기서 사용되는 용어 "질병억제 및 식물학적으로 수용가능한 량"이란 식물 병원체를 죽이거나 억제하거나 그리고 제어가 요구되는 식물 질병을 예방하고, 박멸하거나 억제시키기는 하나 식물에는 크게 독성적이지 않는 본 발명의 화합물의 량을 가르킨다.As used herein, the term "disease suppression and botanically acceptable amount" refers to the invention of the present invention which kills or inhibits plant pathogens and prevents, eradicates or inhibits plant diseases requiring control, but which is not highly toxic to plants. Point to the amount of compound.

이 량은 일반적으로 1∼1000ppm 범위 일수 있으며, 바람직하게는 10∼500ppm이 좋 다.This amount may generally be in the range of 1 to 1000 ppm, preferably 10 to 500 ppm.

요구되는 정확한 농도는 제어될 균류 질병에 사용될 제제의 종류, 적용방법, 특정식물중, 기후조건 및 기타 요소에 따라 달라진다. 적절한 적용율은 전형적으로 50∼1000gr/헥타르(g/Ha)이다.The exact concentration required will depend on the type of preparation to be used for the fungal disease to be controlled, the method of application, the specific plant, climatic conditions and other factors. Suitable application rates are typically 50-1000 gr / ha (g / Ha).

본 발명의 화합물은 또한 저장된 곡식 및 기타 장소를 균감염으로 부터 보호하기 위해 사용될수도 있다.
The compounds of the present invention may also be used to protect stored grain and other places from fungal infections.

하기 실험은 본 발명의 화합물의 살균류적 효능을 조사하기위해 실험실에서 수행되었다.
The following experiments were conducted in the laboratory to investigate the bactericidal efficacy of the compounds of the present invention.

시험관내(In vitro ( in vitroin vitro ) 균류 성장 억제의 생물학적 평가.) Biological assessment of fungal growth inhibition.

배양 조건: 균류의 분생자 또는 균사체 절편의 현탁액을 멸균 포테이토 덱스트로즈 브로스(Difco)에 마그타프로테 그리세아(Magnaporthe grisea)(피리쿨라리아 오리자에(Pyricularia oryzae) - PYRIOR), 리족토니아 솔라니(Rhizoctonia solani)(RHIZSO), 미코스페렐라 그라미니콜라(Mycosphaerella graminicola)(셉토리아 트리티시(Septoria tritici) - SEPTTR), 스타고노스포라 노도룸(Stagonospora nodorum)(렙토스페리아 노도룸(Leptosphaeria nodorum) - LEPTNO), 우스틸라고 매이디스(Ustilago maydis)(USTIMA) 그리고 호밀 시드 브로스에 피토프토라 인페스탄스(Phytophthora infestans)(PHYTIN)로 제조하였다. 상기 현탁액을 디메틸술폭시드에 용해된 실험 살균류제들의 시료를 함유하고 있는 멸균 96웰 마이크로타이터 플 래이트에 파이펫팅하였다. 살균류제의 농도는 최종 용매 농도가 배지의 1%를 초과하지않은채로 0.001-100ppm으로 달리하였다. 상기 균류들은 단지 용매만 함유하는 대조군의 웰에서 웰이 균류의 성장으로 불투명해질때까지 24-30℃에서 여러시간 간격동안 배양되었다. 이 시점에서 성장 억제는 용매 처리된 대조군이 측정되는 것과 비교하여 각 웰의 시각적 검사 및 퍼센트 억제로 측정하였다.Cultivation conditions: Suspensions of fungi conidia or mycelium sections were transferred to sterile potato dextrose broth (Difco) Magnaporthe grisea ( Pyricularia oryzae -PYRIOR), li footonia solar you (Rhizoctonia solani) (RHIZSO), Miko Legaspi Relais gras mini-cola (Mycosphaerella graminicola) (counts Astoria tree Tea City (Septoria tritici) - SEPTTR), star and North Fora surf Room (Stagonospora nodorum) (rep toss Feria surf Room ( Leptosphaeria nodorum )-LEPTNO), Ustilago maydis (USTIMA) and rye seed broth with Phytophthora infestans (PHYTIN). The suspension was pipetted into a sterile 96 well microtiter plate containing a sample of experimental fungicides dissolved in dimethyl sulfoxide. The concentration of the fungicide was varied from 0.001-100 ppm with the final solvent concentration not exceeding 1% of the medium. The fungi were incubated for several hours at 24-30 ° C. until wells were opaque to the growth of fungi in wells of controls containing only solvent. At this point, growth inhibition was determined by visual inspection and percent inhibition of each well compared to the solvent treated control.

표 2에서, "+"는 상기 병원을 성장 배지에 25ppm의 농도로 편입시킨 경우 시험 물질이 최소 80% 성장 억제를 제공하였음을 나타내며, "-"는 80%미만의 성장 억제를 제공하였음을 나타낸다. 빈칸은 시험되지않은 것이다.
In Table 2, "+" indicates that the test substance provided at least 80% growth inhibition when the hospital was incorporated into the growth medium at a concentration of 25 ppm, and "-" indicates less than 80% growth inhibition. . Blanks have not been tested.

생체내에서 전체 식물 균류 감염 제어의 생물학적 평가.Biological Evaluation of Control of Whole Plant Fungus Infection in Vivo.

화합물 배합은 연속 희석으로 아세톤에 물질들을 기술적으로 용해시키고 원하는 농도로 아세톤에 제조함으로써 수행되었다. 최종 처리 체적은 0.05% 수성 Tween-20 또는 0.01% Triton X-100을 9 볼륨 첨가(병원에 따라 달라짐)함으로써 얻어진다.Compound compounding was performed by technical dissolution of the material in acetone in serial dilutions and preparation in acetone at the desired concentration. The final treatment volume is obtained by adding 9 volumes of 0.05% aqueous Tween-20 or 0.01% Triton X-100 (depending on the hospital).

포도의 도우니 백분병(Downy Mildew)(플라스모파라 비티콜라( Plasmopara viticola ) - PLASVI)(24시간 예방보호제): 포도나무(품종 카리그네인(Carignane))를 토양이 없는 토탄-기초 포팅 혼합물("메트로믹스(Metromix)")에서 씨앗으로부터 그 씨앗이 10-20cm 크기가 될때가지 성장시켰다. 그 다음 이들 식물에 상기 시험 화합물을 100ppm의 비율로 분무하였다. 24시간후, 시험 식물들은 플라스모파라 비티콜라((Plasmopara viticola)의 수성 포자낭 현탁액으로 분무 접종되고, 습도포화 챔버(dew chamber)에 밤새 유지되었다. 그 다음 그 식물들은 처리되지않은 대조군 식물에서 질병이 발생될때가지 온실로 옮겨졌다. Doy Mildew ( Plasmopara viticola -PLASVI) (24-hour preventive) of grapes: A soil-based peat-based potting mixture of vines (variety Carignane) ("Metromix") grew from seed until the seed was 10-20 cm in size. These plants were then sprayed with the test compound at a rate of 100 ppm. After 24 hours, the test plants were spray inoculated with an aqueous spore sac suspension of Plasmopara viticola and kept in a dew chamber overnight.The plants were then diseased in untreated control plants. It was transferred to the greenhouse until it occurred.

토마토의 감자역병(Late Blight)(피토프토라 인페스탄스( Phytophthora infestans ) - PhYTIN)(24시간 예방보호제): 토마토(품종 러트거스(Rutgers))를 토양이 없는 토탄-기토 포팅 혼합물("메트로믹스")에서 씨앗으로부터 그 씨앗이 10-20cm 크기가 될때가지 성장시켰다. 그 다음 이들 식물에 상기 시험 화합물을 100ppm의 비율로 분무하였다. 24시간후, 시험 식물들은 피토프토라 인페스탄스(Phytophthora infestans)의 수성 포자낭 현탁액으로 분무 접종되고, 습도포화 챔버에 밤새 유지되었다. 그 다음 그 식물들은 처리되지않은 대조군 식물에서 질병이 발생될때가지 온실로 옮겨졌다. Late Blight of Tomato ( Phytophthora infestans -PhYTIN) (24-hour preventive) : A soil-free peat-earth potting mixture ("Metro") In the mix ") until the seeds are 10-20 cm in size. These plants were then sprayed with the test compound at a rate of 100 ppm. After 24 hours, the test plants were spray inoculated with an aqueous spore sac suspension of Phytophthora infestans and kept overnight in a humidity saturation chamber. The plants were then transferred to the greenhouse until the disease developed in untreated control plants.

밀의 갈색 녹병(Brown Rust)(푸씨니아 레콘디타( Puccinia recondita ) - PUCCRT)(24시간 예방보호제): 밀(품종 유마(Yuma))을 토양이 없는 토탄-기토 포팅 혼합물("메트로믹스")에서 씨앗으로부터 그 씨앗이 10-20cm 크기가 될때가지 성장시켰다. 그 다음 이들 식물에 상기 시험 화합물을 100ppm의 비율로 분무하였다. 24시간후, 시험 식물들은 푸씨니아 레콘디타(Puccinia recondita)의 수성 포자낭 현탁액으로 분무 접종되고, 습도포화 챔버에 밤새 유지되었다. 그 다음 그 식물들은 처리되지않은 대조군 식물에서 질병이 발생될때가지 온실로 옮겨졌다. Brown Rust of wheat ( Puccinia recondita -PUCCRT) (24 hour preventive) : Wheat (breed Yuma) in soil-free peat-earth potting mixture ("Metromix") From the seeds were grown until the seeds were 10-20 cm in size. These plants were then sprayed with the test compound at a rate of 100 ppm. After 24 hours, the test plants were spray inoculated with an aqueous spore sac suspension of Puccinia recondita and kept overnight in a humidity saturation chamber. The plants were then transferred to the greenhouse until the disease developed in untreated control plants.

밀의 분말성 백분병(Powdery Mildew)(에리시페 그라미니스( Erysiphe graminis ) - ERYSGT)(24시간 예방보호제): 밀(품종 모논(Monon))을 토양이 없는 토탄-기토 포팅 혼합물("메트로믹스")에서 씨앗으로부터 그 씨앗이 10-20cm 크기가 될때가지 성장시켰다. 그 다음 이들 식물에 상기 시험 화합물을 100ppm의 비율로 분무하였다. 24시간후, 시험 식물들은 분말성 백분병 감염된 밀 식물의 분생자로 더스팅함으로써 접종되었다. 그 다음 그 식물들은 처리되지않은 대조군 식물에서 질병이 발생될때가지 온실로 옮겨졌다. Powder Mildew ( Erysiphe graminis -ERYSGT) (24 hour preventive) : Wheat (variety Monon) is a soil-free peat-earth potting mixture ("Metro In the mix ") until the seeds are 10-20 cm in size. These plants were then sprayed with the test compound at a rate of 100 ppm. After 24 hours, the test plants were inoculated by dusting with conidia of powdery powdery mildew infected wheat plants. The plants were then transferred to the greenhouse until the disease developed in untreated control plants.

밀의 점무늬병(Leaf Blotch)(셉토리아 트리티시( Septoria tritici ) - SEPTTR)(24시간 예방보호제): 밀(품종 유마(Yuma))을 토양이 없는 토탄-기토 포팅 혼합물("메트로믹스")에서 씨앗으로부터 그 씨앗이 10-20cm 크기가 될때가지 성장시켰다. 그 다음 이들 식물에 상기 시험 화합물을 100ppm의 비율로 분무하였다. 24시간후, 시험 식물들은 셉토리아 트리티시(Septoria tritici)의 수성 포자 현탁액으로 분무 접종되고, 습도포화 챔버에 밤새 유지되었다. 그 다음 그 식물들은 처리되지않은 대조군 식물에서 질병이 발생될때가지 온실로 옮겨졌다. Wheat jeommunuibyeong (Leaf Blotch) (Counts Astoria Tree Tea City (Septoria tritici) - SEPTTR) ( 24 hours preventive protectant): Wheat (cultivar Yuma (Yuma)) with no soil peat - gito in potting mixture ( "Metro Mix") From the seeds were grown until the seeds were 10-20 cm in size. These plants were then sprayed with the test compound at a rate of 100 ppm. After 24 hours, the test plants were spray inoculated with an aqueous spore suspension of Septoria tritici and kept in a humidified chamber overnight. The plants were then transferred to the greenhouse until the disease developed in untreated control plants.

밀 껍질마름병(Glume Blotch)(렙토스페리아 노도룸(Leptosphaeria nodorum) - LEPTNO)(24시간 예방보호제): 밀(품종 유마(Yuma))을 토양이 없는 토탄-기토 포팅 혼합물("메트로믹스")에서 씨앗으로부터 그 씨앗이 10-20cm 크기가 될때가지 성장시켰다. 그 다음 이들 식물에 상기 시험 화합물을 100ppm의 비율로 분무하였다. 24시간후, 시험 식물들은 (렙토스페리아 노도룸(Leptosphaeria nodorum))의 수성 포자 현탁액으로 분무 접종되고, 습도포화 챔버에 밤새 유지되었다. 그 다음 그 식물들은 처리되지않은 대조군 식물에서 질병이 발생될때가지 온실로 옮겨졌다. Wheat Blotch ( Leptosphaeria nodorum -LEPTNO) (24-hour preventive) : Wheat (breed Yuma) soil-free peat-earth potting mixture ("Metromix") The seeds were grown from seeds until they were 10-20 cm in size. These plants were then sprayed with the test compound at a rate of 100 ppm. After 24 hours, the test plants were spray inoculated with an aqueous spore suspension of ( Leptosphaeria nodorum ) and kept overnight in a humidity saturation chamber. The plants were then transferred to the greenhouse until the disease developed in untreated control plants.

방법 2에서, "++"는 상기 병원을 성장 배지에 100ppm의 농도로 편입시킨 경우 시험 물질이 처리되지않은 식물에 대하여 질병 발생 비교시 균류 감염의 최소 75-100% 제어도을 제공하였음을 나타내며, "+"는 균류 감염의 25-74% 제어도를 제공하였음을 나타내며, 그리고 "-"는 균류 감염의 <25% 제어도를 제공하였음을 나타낸다. 빈칸은 시험되지않은 것이다.In method 2, "++" indicates that the incorporation of the hospital into the growth medium at a concentration of 100 ppm provided at least 75-100% control of fungal infection when compared to disease occurrence for plants that were not treated with the test substance, "+" Indicates 25-74% control of fungal infection, and "-" indicates <25% control of fungal infection. Blanks have not been tested.

[표 1]TABLE 1

Figure 112002001377712-pct00119
Figure 112002001377712-pct00119

[표 1]TABLE 1

Figure 112002001377712-pct00120
Figure 112002001377712-pct00120

[표 1]TABLE 1

Figure 112002001377712-pct00121
Figure 112002001377712-pct00121

[표 1]TABLE 1

Figure 112002001377712-pct00122
Figure 112002001377712-pct00122

[표 1]TABLE 1

Figure 112002001377712-pct00123
Figure 112002001377712-pct00123

[표 1]TABLE 1

Figure 112002001377712-pct00124
Figure 112002001377712-pct00124

[표 1]TABLE 1

Figure 112002001377712-pct00125
Figure 112002001377712-pct00125

[표 1]TABLE 1

Figure 112002001377712-pct00126
Figure 112002001377712-pct00126

[표 1]TABLE 1

Figure 112002001377712-pct00127
Figure 112002001377712-pct00127

[표 1]TABLE 1

Figure 112002001377712-pct00128
Figure 112002001377712-pct00128

[표 1]TABLE 1

Figure 112002001377712-pct00129
Figure 112002001377712-pct00129

[표 1]TABLE 1

Figure 112002001377712-pct00130
Figure 112002001377712-pct00130

[표 1]TABLE 1

Figure 112002001377712-pct00131
Figure 112002001377712-pct00131

[표 1]TABLE 1

Figure 112002001377712-pct00132
Figure 112002001377712-pct00132

[표 1]TABLE 1

Figure 112002001377712-pct00133
Figure 112002001377712-pct00133

[표 1]TABLE 1

Figure 112002001377712-pct00134
Figure 112002001377712-pct00134

[표 1]TABLE 1

Figure 112002001377712-pct00135
Figure 112002001377712-pct00135

[표 1]TABLE 1

Figure 112002001377712-pct00136
Figure 112002001377712-pct00136

[표 1]TABLE 1

Figure 112002001377712-pct00137
Figure 112002001377712-pct00137

[표 1]TABLE 1

Figure 112002001377712-pct00138
Figure 112002001377712-pct00138

[표 1]TABLE 1

Figure 112002001377712-pct00139
Figure 112002001377712-pct00139

[표 1]TABLE 1

Figure 112002001377712-pct00140
Figure 112002001377712-pct00140

[표 1]TABLE 1

Figure 112002001377712-pct00141
Figure 112002001377712-pct00141

[표 1]TABLE 1

Figure 112002001377712-pct00142
Figure 112002001377712-pct00142

[표 1]TABLE 1

Figure 112002001377712-pct00143
Figure 112002001377712-pct00143

[표 1]TABLE 1

Figure 112002001377712-pct00144
Figure 112002001377712-pct00144

[표 1]TABLE 1

Figure 112002001377712-pct00145
Figure 112002001377712-pct00145

[표 1]TABLE 1

Figure 112002001377712-pct00146
Figure 112002001377712-pct00146

[표 1]TABLE 1

Figure 112002001377712-pct00147
Figure 112002001377712-pct00147

[표 1]TABLE 1

Figure 112002001377712-pct00148
Figure 112002001377712-pct00148

[표 1]TABLE 1

Figure 112002001377712-pct00149
Figure 112002001377712-pct00149

[표 1]TABLE 1

Figure 112002001377712-pct00150
Figure 112002001377712-pct00150

[표 1]TABLE 1

Figure 112002001377712-pct00151
Figure 112002001377712-pct00151

[표 1]TABLE 1

Figure 112002001377712-pct00152
Figure 112002001377712-pct00152

[표 1]TABLE 1

Figure 112002001377712-pct00153
Figure 112002001377712-pct00153

[표 1]TABLE 1

Figure 112002001377712-pct00154
Figure 112002001377712-pct00154

[표 1]TABLE 1

Figure 112002001377712-pct00155
Figure 112002001377712-pct00155

[표 1]TABLE 1

Figure 112002001377712-pct00156
Figure 112002001377712-pct00156

[표 1]TABLE 1

Figure 112002001377712-pct00157
Figure 112002001377712-pct00157

[표 1]TABLE 1

Figure 112002001377712-pct00158
Figure 112002001377712-pct00158

[표 1]TABLE 1

Figure 112002001377712-pct00159
Figure 112002001377712-pct00159

[표 1]TABLE 1

Figure 112002001377712-pct00160
Figure 112002001377712-pct00160

[표 1]TABLE 1

Figure 112002001377712-pct00161
Figure 112002001377712-pct00161

[표 1]TABLE 1

Figure 112002001377712-pct00162
Figure 112002001377712-pct00162

[표 1]TABLE 1

Figure 112002001377712-pct00163
Figure 112002001377712-pct00163

[표 1]TABLE 1

Figure 112002001377712-pct00164
Figure 112002001377712-pct00164

[표 1]TABLE 1

Figure 112002001377712-pct00165
Figure 112002001377712-pct00165

[표 1]TABLE 1

Figure 112002001377712-pct00166
Figure 112002001377712-pct00166

[표 1]TABLE 1

Figure 112002001377712-pct00167
Figure 112002001377712-pct00167

[표 1]TABLE 1

Figure 112002001377712-pct00168
Figure 112002001377712-pct00168

[표 1]TABLE 1

Figure 112002001377712-pct00169
Figure 112002001377712-pct00169

[표 1]TABLE 1

Figure 112002001377712-pct00170
Figure 112002001377712-pct00170

[표 1]TABLE 1

Figure 112002001377712-pct00171
Figure 112002001377712-pct00171

[표 1]TABLE 1

Figure 112002001377712-pct00172
Figure 112002001377712-pct00172

[표 1]TABLE 1

Figure 112002001377712-pct00173
Figure 112002001377712-pct00173

[표 1]TABLE 1

Figure 112002001377712-pct00174
Figure 112002001377712-pct00174

[표 1]TABLE 1

Figure 112002001377712-pct00175
Figure 112002001377712-pct00175

[표 1]TABLE 1

Figure 112002001377712-pct00176
Figure 112002001377712-pct00176

[표 1]TABLE 1

Figure 112002001377712-pct00177
Figure 112002001377712-pct00177

[표 1]TABLE 1

Figure 112002001377712-pct00178
Figure 112002001377712-pct00178

[표 1]TABLE 1

Figure 112002001377712-pct00179
Figure 112002001377712-pct00179

[표 2]TABLE 2

Figure 112002001377712-pct00180
Figure 112002001377712-pct00180

[표 2]TABLE 2

Figure 112002001377712-pct00181
Figure 112002001377712-pct00181

[표 2]TABLE 2

Figure 112002001377712-pct00182
Figure 112002001377712-pct00182

[표 2]TABLE 2

Figure 112002001377712-pct00183
Figure 112002001377712-pct00183

[표 2]TABLE 2

Figure 112002001377712-pct00184
Figure 112002001377712-pct00184

[표 2]TABLE 2

Figure 112002001377712-pct00185
Figure 112002001377712-pct00185

[표 2]TABLE 2

Figure 112002001377712-pct00186
Figure 112002001377712-pct00186

[표 2]TABLE 2

Figure 112002001377712-pct00187
Figure 112002001377712-pct00187

[표 2]TABLE 2

Figure 112002001377712-pct00188
Figure 112002001377712-pct00188

[표 2]TABLE 2

Figure 112002001377712-pct00189
Figure 112002001377712-pct00189

[표 2]TABLE 2

Figure 112002001377712-pct00190
Figure 112002001377712-pct00190

[표 2]TABLE 2

Figure 112002001377712-pct00191
Figure 112002001377712-pct00191

[표 2]TABLE 2

Figure 112002001377712-pct00192
Figure 112002001377712-pct00192

[표 2]TABLE 2

Figure 112002001377712-pct00193
Figure 112002001377712-pct00193

[표 2]TABLE 2

Figure 112002001377712-pct00194
Figure 112002001377712-pct00194

[표 2]TABLE 2

Figure 112002001377712-pct00195
Figure 112002001377712-pct00195

본 발명의 화합물은 하나 또는 그 이상의 화학식 1의 화합물과 식물학적으로- 수용가능한 캐리어를 포함하는 조성물 형태로 적용하는 것이 바람직하다. 상기 조성물은 적용시 물 또는 다른 액체에 분산된 농축 배합물이거나 혹은 후속 처리없이 적용되는 분말(dust) 혹은 과립상(granular) 배합물일 수 있다. 상기 조성물은 농업분야에 일반적으로 알려져 있는 방법으로 제조되나, 본 발명의 화합물이 존재함으로 새롭고 중요한 것이다. 농화학자가 원하는 조성물을 용이하게 제조할 수 있도록 조성물의 몇몇 배합에 대하여 제시하였다. The compounds of the present invention are preferably applied in the form of a composition comprising one or more compounds of formula 1 and a botanically-acceptable carrier. The composition can be a concentrated formulation dispersed in water or other liquids upon application or a powder or granular formulation applied without subsequent treatment. The compositions are prepared by methods generally known in the agricultural arts, but are new and important because of the presence of the compounds of the present invention. Several formulations of the compositions have been presented so that agrochemists can easily prepare the desired compositions.

화합물이 적용되는 분산은 대개 화합물의 농축된 배합물로 부터 제조되는 수성 서스펜션 혹은 에멀션이다. 이와 같은 수용성, 수-분산성 혹은 에멀션화가능한 배합물은 고형물, 일반적으로 습윤분말로 알려진 고형물 혹은 수성 액체, 일반적으로 에멀션화가능한 농축물 또는 수성 서스펜션으로 알려진 액체이다. 본 발명은 본 발명의 화합물을 살균제로 사용하기 위해 운반하도록 배합될 수 있는 모든 매개물(vehicles)를 포함하는 것으로 의도된다. 본 발명의 화합물이 첨가될 수 있는 어떠한 물질이, 살균제로서 본 발명에 의한 화합물의 활성을 현저하게 저해하지 않는한 사용될 수 있는 것으로 이해된다. The dispersions to which the compounds are applied are usually aqueous suspensions or emulsions prepared from concentrated formulations of the compounds. Such water-soluble, water-dispersible or emulsifiable blends are solids, solids generally known as wet powders or aqueous liquids, generally emulsifiable concentrates or liquids known as aqueous suspensions. The present invention is intended to include all vehicles that can be formulated to deliver the compounds of the invention for use as fungicides. It is understood that any substance to which a compound of the present invention may be added may be used as long as it does not significantly inhibit the activity of the compound according to the present invention as a fungicide.

압축하여 수분산가능한 과립으로 형성할 수 있는 습윤 분말은 활성 화합물, 불활성 캐리어(carrier) 및 계면활성을 포함한다. 활성 화합물의 농도는 일반적으로 약 10 w/w% ∼ 90w/w%, 보다 바람직하게는 약 25 w/w% ∼ 75w/w% 이다. 습윤 분말 조성물의 제조시, 독성 생성물은 변질안산암(prophyllite), 활석(talc), 쵸크(chalk), 석고, Fuller의 토(earth), 벤토나이트, 애터펄자이트, 전분, 카세인, 글루텐, 몬모릴로나이트, 점토, 규조토, 정제된 실리케이트등과 같은 어떠한 미분된 고형분과 혼합될 수 있다. 이 때. 미분된 캐리어는 휘발성 유기 용매에서 분쇄되거나 혹은 독성물질과 혼합될 수 있다. 습윤 분말을 약 0.5-10% 포함하는 유 효 계면활성제로는 술폰화된 리그닌, 나프탈렌술포네이트, 알킬벤젠술포네이트, 알킬 술페이트 및 알킬 페놀의 에틸렌 옥사이드 부가물과 같은 비-이온성 계면활성제를 포함한다. Wet powders that can be compressed into water dispersible granules include the active compound, an inert carrier and surfactant. The concentration of the active compound is generally about 10 w / w% to 90 w / w%, more preferably about 25 w / w% to 75 w / w%. In the preparation of the wet powder compositions, the toxic products are altered andesite, talc, chalk, gypsum, Fuller's earth, bentonite, attapulgite, starch, casein, gluten, montmorillonite, It can be mixed with any finely divided solids such as clays, diatomaceous earth, purified silicates and the like. At this time. The finely divided carrier may be ground in a volatile organic solvent or mixed with toxic substances. Effective surfactants comprising about 0.5-10% of wet powders include non-ionic surfactants such as ethylene oxide adducts of sulfonated lignin, naphthalenesulfonates, alkylbenzenesulfonates, alkyl sulfates and alkyl phenols. Include.

본 발명에 의한 화합물의 에멀션화가능한 농축물은 적합한 액체에서 약 10-50w/w%와 같은 농도로 포함된다. 화합물은 물과 혼화가능한 용매 혹은 물과-혼화되지 않는 유기 용매와 에멀션화제의 혼합물인 불활성 캐리어에 용해된다. 상기 농축물은 물과 오일로 희석하여 오일-물 에멀션 형태의 분무 혼합물을 형성할 수 있다. 유용한 유기 용매로는 방향족, 특히, 중(heavy) 방향족 나프타와 같은 석유의 끓는점이 높은 나프탈렌 혹은 올레핀 부분을 포함한다. 예를들어, 로진 유도체를 포함하는 테르펜 용매, 시클로헥사논과 같은 지방족 케톤 및 2-에톡시에탄올과 같은 복합 알코올과 같은 다른 유기 용매가 또한 사용될 수 있다. Emulsifiable concentrates of the compounds according to the invention are included at a concentration such as about 10-50 w / w% in a suitable liquid. The compound is dissolved in an inert carrier which is a solvent miscible with water or a mixture of an emulsifier and an organic solvent that is not miscible with water. The concentrate may be diluted with water and oil to form a spray mixture in the form of an oil-water emulsion. Useful organic solvents include high boiling naphthalene or olefin moieties of petroleum, such as aromatic, in particular heavy aromatic naphtha. For example, other organic solvents may also be used, such as terpene solvents containing rosin derivatives, aliphatic ketones such as cyclohexanone and complex alcohols such as 2-ethoxyethanol.

본 발명에 이롭게 사용될 수 있는 에멀션화제는 이 기술분야의 기술자에 의해 쉽게 결정될 수 있으며 여러가지 비이온성, 음이온성, 양이온성 및 양쪽성 계면활성제 혹은 둘 또는 그 이상의 계면활성제의 혼합물을 포함한다. 에멀션화 가능한 농축물의 제조에 유용한 비이온성 에멀션화제의 예로는 폴리알킬렌 글리콜 에테르 및 알킬 및 아릴 페놀, 지방족 알코올, 지방족 아민, 혹은 지방산의 에틸렌 옥사이드, 에톡시화된 알킬 페놀과 같은 프로필렌 옥사이드 및 폴리올 혹은 폴리옥시알킬렌으로 가용화된 카르복시산 에스테르로의 축합 산물을 포함한다. 양이온 계면활성제로는 4차 암모늄 화합물 및 지방산 아민염을 포함한다. 음이온성 계면활성제로는 알킬아릴 술폰산의 오일-가용성 염(예를들어, 칼슘), 술페이트화 폴리글리콜 에테 르의 오일-가용성염 및 포스페이트화 폴리글리콜 에테르의 적절한 염을 포함한다. Emulsifying agents that can be advantageously used in the present invention can be readily determined by one skilled in the art and include various nonionic, anionic, cationic and amphoteric surfactants or mixtures of two or more surfactants. Examples of nonionic emulsifiers useful in the preparation of emulsifiable concentrates are polyalkylene glycol ethers and propylene oxides and polyols such as alkyl and aryl phenols, aliphatic alcohols, aliphatic amines, or ethylene oxides of fatty acids, ethoxylated alkyl phenols or Condensation products to carboxylic acid esters solubilized with polyoxyalkylenes. Cationic surfactants include quaternary ammonium compounds and fatty acid amine salts. Anionic surfactants include oil-soluble salts of alkylaryl sulfonic acids (eg calcium), oil-soluble salts of sulfated polyglycol ethers and suitable salts of phosphated polyglycol ethers.

본 발명에 의한 에멀션화가능한 농축물의 제조에 사용될 수 있는 유기 액체의 예는 크실렌과 같은 방향족 액체, 프로필 벤젠 분획 혹은 혼합된 나프탈렌 분획, 광유, 디옥틸 프탈레이트, 케로센 및 여러가지 지방산의 디알킬 아미드와 같은 치환된 방향족 유기 액체; 특히 디에틸렌 글리콜의 n-부틸 에테르, 에틸 에테르 혹은 메틸에테르 및 트리에틸렌 글리콜의 메틸 에테르와 같은 지방산 글리콜 및 글리콜 유도체의 디메틸 아미드이다. 바람직한 유기액체는 크실렌과 프로필 벤젠 분획이며, 크실렌이 가장 바람직한 것이다. Examples of organic liquids that can be used in the preparation of emulsifiable concentrates according to the invention include aromatic liquids such as xylenes, propyl benzene fractions or mixed naphthalene fractions, mineral oils, dioctyl phthalates, kerosene and dialkyl amides of various fatty acids. Substituted aromatic organic liquids such as; Especially dimethyl amides of fatty acid glycols and glycol derivatives such as n-butyl ether, diethyl glycol or methyl ether of diethylene glycol and methyl ether of triethylene glycol. Preferred organic liquids are the xylene and propyl benzene fractions, with xylene being the most preferred.

계면 활성 분산제는 분산제와 활성 화합물의 총중량의 0.1-20중량%의 양으로 액체 조성물에 일반적으로 사용된다. 활성 조성물은 또한 다른 혼화가능한 첨가제, 예를들어, 식물 성장 조절제 및 농경에 사용되는 다른 생물학적 활성 화합물을 함유할 수 있다. Surfactant dispersants are generally used in liquid compositions in amounts of 0.1-20% by weight of the total weight of the dispersant and active compound. The active composition may also contain other miscible additives such as plant growth regulators and other biologically active compounds used in agriculture.

수성 서스펜션은 수성 부형제에 약 5-50w/w%의 농도로 분산된 본 발명의 물-불용성 화합물의 분산물을 포함한다. 서스펜션은 미세하게 분쇄된 화합물로 부터 이를 물과 상기한 동일한 타입으로 부터 선택된 계면활성제를 포함하는 부형제에 결렬하게 혼합하여 제조된다. 무기염 및 합성 혹은 천연 고무(gums)과 같은 불활성 성분을 또한 첨가하여 수성 부형제의 밀도 및 점도를 증가시킬 수 있다. 화합물을 수성 혼합물을 분리하고 이를 샌드밀, 볼밀 혹은 피스톤-타입의 균질화기에서 균질화함과 동시에 분쇄 및 혼합하는 것이 대개 가장 효과적이다.Aqueous suspensions include dispersions of water-insoluble compounds of the invention dispersed in aqueous excipients at concentrations of about 5-50 w / w%. Suspensions are prepared by intimately mixing the finely ground compound into water and an excipient comprising a surfactant selected from the same type described above. Inorganic salts and inert ingredients such as synthetic or natural gums may also be added to increase the density and viscosity of the aqueous excipient. It is usually most effective to separate the aqueous mixture and to grind and mix it simultaneously while homogenizing it in a sand mill, ball mill or piston-type homogenizer.

화합물은 토양에 적용하기에 특히 유용한 과립 조성물로서 또한 적용될 수 있다. 과립 조성물은 일반적으로 전부 혹은 대부분이 거칠게 분쇄된 애터펄자이트, 벤토나이트, 규조암, 점토 혹은 유사한 저렴한 물질로 구성되는 불활성 캐리어에 분산된 약 0.5-10w/w %의 화합물을 함유한다.The compounds can also be applied as granule compositions which are particularly useful for application to soil. The granular composition generally contains about 0.5-10 w / w% of the compound dispersed in an inert carrier composed of all or most roughly milled attapulgite, bentonite, diatomite, clay or similar inexpensive material.

이와 같은 조성물은 화합물을 적합한 용매에 용해시키고 약 0.5∼3㎜ 범위의 적합한 입자크키로 예비형성된 과립 캐리어에 적용하여 일반적으로 제조한다. 이와 같은 조성물은 또한 캐리어와 화합물의 반죽 혹은 페이스트를 제조하고 원하는 과립 입자를 얻도록 건조하여 배합할 수 있다. Such compositions are generally prepared by dissolving the compound in a suitable solvent and applying the granular carrier preformed with a suitable particle size in the range of about 0.5 to 3 mm. Such compositions can also be blended by preparing a dough or paste of carrier and compound and drying to obtain the desired granulated particles.

화합물을 함유하는 분말(dust)은 분말 형태의 화합물을 예를들어, 카올린, 점도, 분쇄된 화산암등과 같은 적합한 분말상 농경 캐리어와 단순히 혼합하여 제조된다. 분말은 화합물을 약 1-10w/w%로 적절하게 함유할 수 있다. The powder containing the compound is prepared by simply mixing the compound in powder form with a suitable powdered agricultural carrier such as, for example, kaolin, viscosity, pulverized volcanic rock and the like. The powder may suitably contain about 1-10 w / w% of the compound.

활성조성물은 보조 계면활성제를 함유하여 목적하는 곡물 및 유기체상에대한 조성물의 침적(deposition), 젖음(wetting) 침투(penetration)를 증대시킬 수 있다. 이들 보조 계면활성제는 임의로 배합물의 성분 혹은 용기 혼합물로 사용될 수 있다. 보조 계면활성제의 양은 물의 분무-체적으로 기준으로 0.01-1.0 v/v %, 바람직하게는 0.05-0.5 v/v %일 수 있다. 적합한 보조 계면활성제로는 에톡시화된 노릴 페놀, 에톡시화된 합성 혹은 천연 알코올, 술포숙신산 에스테르의 염, 에톡시화된 유기실리콘, 에톡시화된 지방산 아민 및 계면활성제와 광유 혹은 식물성유의 혼합물일 수 있다. The active composition may contain auxiliary surfactants to increase deposition, wetting penetration of the composition onto the desired grains and organisms. These co-surfactants may optionally be used as components or container mixtures of the formulation. The amount of co-surfactant may be 0.01-1.0 v / v%, preferably 0.05-0.5 v / v%, based on the spray-volume of water. Suitable cosurfactants may be ethoxylated noryl phenols, ethoxylated synthetic or natural alcohols, salts of sulfosuccinic acid esters, ethoxylated organosilicones, ethoxylated fatty acid amines, and mixtures of surfactants with mineral or vegetable oils.

상기 조성물은 본 발명의 하나 또는 그 이상의 화합물 최소 1%와 다른 살충 화합물을 포함하는 살균 배합물을 임으로 포함할 수 있다. 이와 같은 부가적인 살 충 화합물은 적용하기 위해 선택한 매질에서 본 발명의 화합물과 혼화가능하고 본 발명의 활성에 길항작용을 하지 않는 살균제, 살충제, 살자포제(nematocides), 살비제(miticides), 절지류 살생제(arthropodicides), 살박테리아제 혹은 이들의 결합일 수 있다. The composition may optionally comprise a sterile combination comprising at least 1% of one or more compounds of the invention and other pesticidal compounds. Such additional insecticidal compounds are fungicides, insecticides, nematocides, miticides, arthropod killings that are compatible with the compounds of the present invention and do not antagonize the activity of the present invention in the medium chosen for application. Arthropodicides, bactericides or combinations thereof.

따라서, 이와 같은 구현에 있어서, 다른 살충 화합물이 동일한 또는 다른 살충제의 사용에 보조적인 독성제로 사용된다. 배합에서 상기 화합물은 일반적으로 1:100∼100:1의 비율로 존재할 수 있다. Thus, in such an embodiment, different pesticidal compounds are used as toxicants which assist in the use of the same or different pesticides. The compound in the combination may generally be present in a ratio of 1: 100 to 100: 1.

본 발명 범주에 균류의 공격을 제어 혹은 방지하는 방법이 포함된다. 이들 방법은 균류가 있는 장소 혹은 감염이 방지되어야 하는 장소에 본 발명에 의한 하나 또는 그 이상의 화합물 혹은 조성물을 살균양 적용(예를들어, 곡류 혹은 포도식물에 적용)하는 것을 포함한다. 상기 화합물은 여러가지 식물을 낮은 식물학적 독성을 나타내는 살균수준으로 처리하는데 적합하다. 화합물은 예방보호제(protectant) 혹은 박멸(eradicant)로 유용하다. 본 발명의 화합물은 화합물로서 혹은 화합물을 포함하는 조성물로서 알려져 있는 여러가지 기술중 어떠한 방법으로 적용될 수 있다. 예를들어, 화합물은 식물을 상업적 가치를 손상하지 않고 여러가지 균류를 제어하고자 하는 식물의 뿌리, 종자 혹은 잎에 적용될 수 있다. 물질은 어떠한 일반적으로 사용되는 배합물 형태, 예를들어, 용액, 분말, 습윤 분말, 유동성 농축물 혹은 에멀션화가능한 농축물로 적용될 수 있다. 이들 물질은 여러가지 알려져 있는 방식으로 일반적으로 적용될 수 있다.The present invention includes methods for controlling or preventing fungal attack. These methods include the application of one or more compounds or compositions according to the invention in a sterile amount (eg, in cereals or grape plants) in places where fungi are present or where infection is to be prevented. The compounds are suitable for treating various plants at bactericidal levels that exhibit low botanical toxicity. The compound is useful as a protectant or eradicant. The compounds of the present invention can be applied by any of a variety of techniques known as compounds or as compositions comprising the compounds. For example, the compounds can be applied to the roots, seeds or leaves of plants that want to control the various fungi without compromising the commercial value of the plants. The material may be applied in any commonly used combination form, for example as a solution, powder, wet powder, flow concentrate or emulsifiable concentrate. These materials can be generally applied in various known ways.

본 발명의 화합물은 현저한 살균 효과, 특히 농경에 대하여 현저한 살균효과 를 갖는다. 많은 화합물이 농경학적 곡류 및 원예작물 혹은 목재, 페인트, 가죽 혹은 카페트 배킹(backing)에 특히 효과적이다. The compounds of the present invention have a significant bactericidal effect, in particular against agricultural. Many compounds are particularly effective in agronomic grain and horticultural crops or wood, paint, leather or carpet backing.

특히, 화합물은 유용한 식물 농작물을 감염시키는 여러가지 바람직하지 않은 균류를 효과적으로 제어한다. 예를들어, 다음에 예시되는 균류 종(species)을 포함하는 여러가지 균류에 대한 활성이 실증되었다: 포도 노균병(Downy Mildew)(플라스모파라 비티콜라(Plasmopara viticola) - PLASVI), 토마토 잎마름병(피토프토라 인레스탄스(Phytophthora infestans)-PHYTIN), 사과 붉은 곰팡이 병(벤투리아 이내퀄리스(Venturia inaequalis)-VENTIN), 밀 Brown Rust(푸치니아 레콘디타(Puccinia recondita)-PUCCRT), 밀 황녹병(Stripe Rust)(푸치니아 스트리포미스(Puccinia striiformis)-PUCCST), 도열병(Rice Blast)(피리쿨라리아 오리자이(Pyricularia oryzae)-PYRIOR), 비트(Beet) 가지갈색원성병(Cerospora Leaf Spot)(세르코스포라 베티콜라(Cercospora Beticola)-CERCBE), 밀 백분병(Powdery Mildew)(에리스페 그라미니스(Erysiphe graminis)-ERYGST), 밀 얼룩점병(Leaf Blotch)(세프토리아 트리티시(Septoria tritici)-SEPTTR), 밀 잎집무늬마름병(Sheath Blight)(리조토니아 솔라니(Rhizoctonia solani)-RHIZSO), 밀 안정병(Eyespot)(프세우도세르코스포렐라(Pseudocercosporella herpotrichoides)-PSDCHE), 복숭아 염수병(Brown Rot)(모닐리아 프루티콜라(Monilinia fructicola)-MONIFC) 및 밀 껍질마름병(Glume Blotch of Wheat)(레프토르라에리아 노도륨(Leptosphaeria nodorum)-LEPTNO). 본 발명에 의한 화합물의 상기한 균류에 대한 효율은 화합물을 살균제로 이용하는 일반적인 용도에 해당하는 것으로 이 기 술분양의 기술자에게 이해될 수 있다. In particular, the compounds effectively control various undesirable fungi that infect useful plant crops. For example, activity against various fungi has been demonstrated including the following fungal species: Downy Mildew ( Plasmopara viticola -PLASVI), tomato leaf blight (Pi) Phytophthora infestans- PHYTIN, apple red mold disease ( Venturia inaequalis- VENTIN), wheat Brown Rust ( Puccinia recondita- PUCCRT), wheat rust (Stripe Rust) ( Puccinia striiformis- PUCCST), Rice Blast ( Pyricularia oryzae- PYRIOR), Beet (Cerospora Leaf Spot) ( Cercospora Beticola- CERCBE), Wheat Mildew ( Erysiphe graminis- ERYGST), Wheat Blotch ( Septoria Tritici tritici) -SEPTTR), wheat sheath blight (sheath blight) (Rhizopus California solani (Rhizoctonia solani) -RHIZSO), wheat anjeongbyeong (Eyespot) (peuse likelihood SERE course included mozzarella (Pseudocercosporella herpotrichoides) -PSDCHE), peach saline bottles (Brown Rot) (monilriah fruity Cola (Monilinia fructicola) -MONIFC) and Glume Blotch of Wheat ( Leptosphaeria nodorum- LEPTNO). The efficiency of the above fungi of the compounds according to the invention corresponds to the general use of the compounds as fungicides and can be understood by those skilled in the art.

본 발명의 화합물은 광범위한 살균 효율을 갖는다. 적용되는 활성물질의 정확한 양은 적용되는 특정한 활성물질 뿐만 아니라 원하는 특정한 작용, 제어하려는 균류종 및 이들의 성장단계뿐만 아니라 톡성 활성성분과 접촉되는 식물 또는 다른 산물의 부분(part)에 따라 달라진다. 따라서, 본 발명에 의한 화합물의 모든 활성성분 및 이를 함유하는 조성물은 비슷한 농도 혹은 같은 균류종에 대하여 그 효과가 동일하지 않을 수 있다. 본 발명의 화합물 및 조성물은 식물의 질병 제어에 식물학적으로 수용가능한 양으로 효과적으로 사용된다. The compounds of the present invention have a wide range of sterilization efficiencies. The exact amount of active substance to be applied depends not only on the specific active substance applied but also on the specific action desired, the fungal species to be controlled and their growth stages, as well as the part of the plant or other product which is in contact with the toxin active ingredient. Thus, all active ingredients and compositions containing them of the compounds according to the invention may not have the same effect on similar concentrations or on the same fungal species. The compounds and compositions of the present invention are effectively used in a botanically acceptable amount for disease control of plants.

Claims (45)

하기 식 Ⅰ의 화합물Compound of Formula I (식Ⅰ)(Formula I)
Figure 112006089133699-pct00199
Figure 112006089133699-pct00199
단, 상기 식에서In the above formula (a) X1은 N, X2 및 X3는 CH이며, X4는 CH, COMe, CMe, CCl, COEt 혹은 CSMe이며,(a) X 1 is N, X 2 and X 3 are CH, X 4 is CH, COMe, CMe, CCl, COEt or CSMe, (b) Z는 O,S 또는 N0Rz 이며, Rz는 H 또는 C1-C3알킬이며;(b) Z is O, S or NORz and Rz is H or C 1 -C 3 alkyl; (c) A는 다음을 나타내며,(c) A represents (ⅰ) 치환되지 않았거나, 할로겐, 히드록시, C1-C6알킬, C1-C6할로알킬, 시아노, 니트로, C6 혹은 C10 아로일, C6 혹은 C10 아릴옥시, 헤테로아릴옥시, C1-C6알킬티오, C6 혹은 C10 아릴티오, 헤테로아릴티오, C1-C6알콕시, C1-C6할로알콕시, C1-C8아실옥시, C6 혹은 C10 아릴, 헤테로아릴, C1-C6아실, 카보 C6 혹은 C10아릴옥시, 카보헤테로아릴옥시, C1-C6카보알콕시 또한 치환되지 않았거나 1 또는 2의 C1-C6알킬기로 치환된 아미도로 치환될 수 있는, 0∼3 헤테로원자와 0∼2 불포화를 함유한 C3-C14시클로알킬, 다만, 상기 치환기중 헤테로아릴부는 하나 또는 그 이상의 헤테로 원자를 갖는 5 혹은 6원자 방향족 고리이며; (Iii) unsubstituted, halogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, nitro, C 6 or C 10 aroyl, C 6 or C 10 aryloxy, hetero Aryloxy, C 1 -C 6 alkylthio, C 6 or C 10 arylthio, heteroarylthio, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 8 acyloxy, C 6 or C 10 aryl, heteroaryl, C 1 -C 6 acyl, carbo C 6 or C 10 aryloxy, carboheteroaryloxy, C 1 -C 6 carboalkoxy and also unsubstituted or 1 or 2 C 1 -C 6 alkyl groups C 3 -C 14 cycloalkyl containing 0 to 3 heteroatoms and 0 to 2 unsaturations, which may be substituted by substituted amido, provided that the heteroaryl moiety in the substituent has 5 or 6 atoms with one or more heteroatoms An aromatic ring; (ⅱ) 치환되지 않았거나, 할로겐, 히드록시, C1-C6알킬, C1-C6할로알킬, 시아노, 니트로, C6 혹은 C10 아로일, C6 혹은 C10 아릴옥시, 헤테로아릴옥시, C1-C6알킬티오, C6 혹은 C10 아릴티오, 헤테로아릴티오, C1-C6알콕시, C1-C6할로알콕시, C1-C8아실옥시, C6 혹은 C10 아릴, 헤테로아릴, C1-C6아실, 카보 C6 혹은 C10아릴옥시, 카보헤테로아릴옥시, C1-C6카보알콕시 혹은 치환되지 않았거나 1 또는2의 C1-C6알킬기로 치환된 아미도로 치환될 수 있는, 0∼3 헤테로원자 및 0∼2 불포화를 함유한, C6-C14 2(bi)또는 3(tri)-사이클릭고리시스템, 다만, 상기 치환기중 헤테로아릴부는 하나 또는 그 이상의 헤테로 원자를 갖는 5 혹은 6원자 방향족 고리이며; (Ii) unsubstituted, halogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, nitro, C 6 or C 10 aroyl, C 6 or C 10 aryloxy, hetero Aryloxy, C 1 -C 6 alkylthio, C 6 or C 10 arylthio, heteroarylthio, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 8 acyloxy, C 6 or C 10 aryl, heteroaryl, C 1 -C 6 acyl, carbo C 6 or C 10 aryloxy, carboheteroaryloxy, C 1 -C 6 carboalkoxy or unsubstituted or 1 or 2 C 1 -C 6 alkyl group C 6 -C 14 2 (bi) or 3 (tri) -cyclic ring systems containing 0 to 3 heteroatoms and 0 to 2 unsaturations, which may be substituted with substituted amido, provided heteroaryl in the substituent A part is a 5 or 6 membered aromatic ring having one or more hetero atoms; (ⅲ)
Figure 112006089133699-pct00198
(Ⅲ)
Figure 112006089133699-pct00198
단, 상기 식에서 x는 부착점이며,Where x is the attachment point, Q1, Q2는 O 또는 S 이며;Q 1 , Q 2 is O or S; W는 O, CH2, CHR6, 또는 본드이며;W is O, CH 2 , CHR 6 , or a bond; R1은 C1-C8알킬, C2-C8알케닐, C2-C8알키닐, C3-C8시클로알킬, C6 혹은 C10 아릴 또는 하나 또는 그 이상의 헤테로 원자를 갖는 5 혹은 6원자 방향족 고리인 헤테로아릴이며; R 1 is C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 or C 10 aryl or 5 with one or more hetero atoms Or heteroaryl which is a 6 membered aromatic ring; R2는 H, C1-C3알킬, C2-C5알케닐 또는 C2-C5알키닐이며;R 2 is H, C 1 -C 3 alkyl, C 2 -C 5 alkenyl or C 2 -C 5 alkynyl; R3는 H, R1, OR1, OC(O)R1, OC(O)OR1 또는 CO(O)NR1R6 이며;R 3 is H, R 1 , OR 1 , OC (O) R 1 , OC (O) OR 1 or CO (O) NR 1 R 6 ; R4와 R5는 독립적으로 H, C1-C6알킬, 또는 C2-C6알케닐이나, R4와 R5의 전체 R 4 and R 5 are independently H, C 1 -C 6 alkyl, or C 2 -C 6 alkenyl, but the total of R 4 and R 5 탄수소는 6이하이며, R4와 R5는 합하여 C3-C6고리를 형성할 수 있으며; Carbohydrates are 6 or less, and R 4 and R 5 may combine to form a C 3 -C 6 ring; R6와 R7은 독립적으로 H, C1-C6알킬, C3-C6시클로알킬, C2-C5알케닐 혹은 R 6 and R 7 are independently H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 5 alkenyl or C2-C5알키닐이나 R6와 R7중 최소 하나는 H 이며;C 2 -C 5 alkynyl or at least one of R 6 and R 7 is H; (d) M은 C(O)CH2CH2OCH3이다. (d) M is C (O) CH 2 CH 2 OCH 3 .
삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 삭제delete 제1항에 있어서, 상기 A는 0∼3 헤테로원자와 0∼2 불포화를 함유한 C3-C14시클로알킬이며, 이는 치환되지 않았거나 할로겐, 히드록시, C1-C6 알킬, C1-C6 할로알킬, 시아노, 니트로, C6 혹은 C10 아로일, C6 혹은 C10 아릴옥시, 헤테로아릴옥시, C1-C6알킬티오, C6 혹은 C10 아릴티오, 헤테로아릴티오, C1-C6알콕시, C1-C6 할로알콕시, C1-C8 아실옥시, C6 혹은 C10 아릴, 헤테로아릴, C1-C6아실, 카보 C6 혹은 C10 아릴옥시, 카보헤테로아릴옥시, C1-C6 카보알콕시 혹은 치환되지 않았거나 1 또는 2의 C1-C6알킬기로 치환된 아미도로 치환될 수 있으며, 상기 치환기중 헤테로아릴부는 하나 또는 그 이상의 헤테로 원자를 갖는 5 혹은 6원자 방향족 고리임을 특징으로 하는 화합물.The compound of claim 1, wherein A is C 3 -C 14 cycloalkyl containing 0-3 heteroatoms and 0-2 unsaturation, which is unsubstituted or halogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, nitro, C 6 or C 10 aroyl, C 6 or C 10 aryloxy, heteroaryloxy, C 1 -C 6 alkylthio, C 6 or C 10 arylthio, heteroarylthio , C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 8 acyloxy, C 6 or C 10 aryl, heteroaryl, C 1 -C 6 acyl, carbo C 6 or C 10 aryloxy, Carboheteroaryloxy, C 1 -C 6 carboalkoxy or amido unsubstituted or substituted with 1 or 2 C 1 -C 6 alkyl groups, wherein the heteroaryl moiety is substituted with one or more heteroatoms. Compound having a 5 or 6 membered aromatic ring having. 제 1항에 있어서, 상기 A는 0∼3 헤테로원자와 0∼2 불포화를 함유한 C6-C14바이(bi)- 혹은 트리(tri) 사이클릭 고리 시스템이며, 이는 치환되지 않았거나 할로겐, 히드록시, C1-C6알킬, C1-C6 할로알킬, 시아노, 니트로, C6 혹은 C10 아로일, C6 혹은 C10 아릴옥시, 헤테로아릴옥시, C1-C6알킬티오, C6 혹은 C10 아릴티오, 헤테로아릴티오, C1-C6알콕시, C1-C6 할로알콕시, C1-C8 아실옥시, C6 혹은 C10 아릴, 헤테로아릴, C1-C6아실, 카보 C6 혹은 C10 아릴옥시, 카보헤테로아릴옥시, C1-C6 카보알콕시 혹은 치환되지 않았거나 1 또는 2의 C1-C6 알킬기로 치환된 아미도로 치환될 수 있으며, 상기 치환기중 헤테로아릴부는 하나 또는 그 이상의 헤테로 원자를 갖는 5 혹은 6원자 방향족 고리임을 특징으로 하는 화합물.The compound of claim 1, wherein A is a C 6 -C 14 bi- or tricyclic ring system containing 0-3 heteroatoms and 0-2 unsaturation, which is unsubstituted or halogen, Hydroxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, nitro, C 6 or C 10 aroyl, C 6 or C 10 aryloxy, heteroaryloxy, C 1 -C 6 alkylthio , C 6 or C 10 arylthio, heteroarylthio, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 8 acyloxy, C 6 or C 10 aryl, heteroaryl, C 1 -C 6 acyl, carbo C 6 or C 10 aryloxy, carboheteroaryloxy, C 1 -C 6 carboalkoxy or amido unsubstituted or substituted with 1 or 2 C 1 -C 6 alkyl groups, wherein A heteroaryl moiety in a substituent is a compound characterized in that it is a 5 or 6 membered aromatic ring having one or more hetero atoms. 제 1항에 있어서, The method of claim 1, 상기 A는
Figure 112006089133699-pct00200
이며,
A is
Figure 112006089133699-pct00200
Is,
상기 식에서 *는 부착점이며Where * is the attachment point Q1, Q2는 0 또는 S이며; Q 1 , Q 2 is 0 or S; W 는 0, CH2, CHR6, 또는 본드이며;W is 0, CH 2 , CHR 6 , or a bond; R1은 C1-C8알킬, C2-C8알케닐, C2-C8알키닐, C3-C8시클로알킬, C6 혹은 C10 아릴 또는 하나 또는 그 이상의 헤테로 원자를 갖는 5 혹은 6원자 방향족 고리인 헤테로아릴이며;R 1 is C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 or C 10 aryl or 5 with one or more hetero atoms Or heteroaryl which is a 6 membered aromatic ring; R2는 H, C1-C3알킬, C2-C5알케닐 또는 C2-C5알키닐이며;R 2 is H, C 1 -C 3 alkyl, C 2 -C 5 alkenyl or C 2 -C 5 alkynyl; R3는 H, R1, OR1, OC(O)R1, OC(O)OR1 또는 CO(O)NR1R6이며;R 3 is H, R 1 , OR 1 , OC (O) R 1 , OC (O) OR 1 or CO (O) NR 1 R 6 ; R4와 R5는 독립적으로 H, C1-C6알킬, 또는 C2-C5알케닐이나, R4와 R5의 전체 R 4 and R 5 are independently H, C 1 -C 6 alkyl, or C 2 -C 5 alkenyl, but the total of R 4 and R 5 탄소의 합은 6이하이며, R4와 R5는 합하여 C3-C6 고리를 형성할 수 있으며; The sum of carbons is 6 or less, and R 4 and R 5 may be taken together to form a C 3 -C 6 ring; R6 와 R7은 독립적으로 H, C1-C6알킬, C3-C5시클로알킬, C2-C5알케닐R 6 and R 7 are independently H, C 1 -C 6 alkyl, C 3 -C 5 cycloalkyl, C 2 -C 5 alkenyl 혹은 C2-C5알키닐이나, R6 와 R7중 최소 하나는 H 임을 특징으로 하는 화합물.Or C 2 -C 5 alkynyl, wherein at least one of R 6 and R 7 is H.
제 1항에 있어서, 상기 Z는 0임을 특징으로하는 화합물The compound of claim 1, wherein Z is 0. 제 1항에 있어서, 상기 Z는 0이며, A는 0∼3 헤테로원자 및 0∼2불포화를 함유한 C3-C14 시클로알킬이며, 이는 치환되지 않았거나, 할로겐, 히드록시, C1-C6 알킬, C1-C6할로알킬, 시아노, 니트로, C6 혹은 C10 아로일, C6 혹은 C10 아릴옥시, 헤테로아릴옥시, C1-C6알킬티오, C6 혹은 C10 아릴티오, 헤테로아릴티오, C1-C6알콕시, C1-C6 할로알콕시, C1-C8 아실옥시, C6 혹은 C10 아릴, 헤테로아릴, C1-C6아실, 카보 C6 혹은 C10 아릴옥시, 카보헤테로아릴옥시, C1-C6 카보알콕시 혹은 치환되지 않았거나 1 또는 2의 C1-C6알킬기로 치환된 아미도로 치환될 수 있으며, 상기 치환기중 헤테로아릴부는 하나 또는 그 이상의 헤테로 원자를 갖는 5 혹은 6원자 방향족 고리임을 특징으로 하는 화합물.The compound of claim 1, wherein Z is 0 and A is C 3 -C 14 cycloalkyl containing 0-3 heteroatoms and 0-2 unsaturation, which is unsubstituted, halogen, hydroxy, C 1- C 6 alkyl, C 1 -C 6 haloalkyl, cyano, nitro, C 6 or C 10 aroyl, C 6 or C 10 aryloxy, heteroaryloxy, C 1 -C 6 alkylthio, C 6 or C 10 Arylthio, heteroarylthio, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 8 acyloxy, C 6 or C 10 aryl, heteroaryl, C 1 -C 6 acyl, carbo C 6 Or C 10 aryloxy, carboheteroaryloxy, C 1 -C 6 carboalkoxy or amido unsubstituted or substituted with 1 or 2 C 1 -C 6 alkyl groups, wherein the heteroaryl portion of the substituent is one Or a 5 or 6 membered aromatic ring having more hetero atoms. 제 1항에 있어서, 상기 Z는 0이며, A는 0∼3 헤테로원자 및 0∼2불포화를 함유한 C6-C14 바이(bi)- 혹은 트리(tri)사이클릭 고리 시스템이며, 이는 치환되지 않았거나 혹은 할로겐, 히드록시, C1-C6 알킬, C1-C6할로알킬, 시아노, 니트로, C6 혹은 C10 아로일, C6 혹은 C10 아릴옥시, 헤테로아릴옥시, C1-C6알킬티오, C6 혹은 C10 아릴티오, 헤테로아릴티오, C1-C6알콕시, C1-C6 할로알콕시, C1-C8 아실옥시, C6 혹은 C10아릴, 헤테로아릴, C1-C6아실, 카보 C6 혹은 C10 아릴옥시, 카보헤테로아릴옥시, C1-C6 카보알콕시 혹은 치환되지 않았거나 1 또는 2의 C1-C6알킬기로 치환된 아미도로 치환될수 있으며, 상기 치환기중 헤테로아릴부는 하나 또는 그 이상의 헤테로 원자를 갖는 5 혹은 6원자 방향족 고리임을 특징으로 하는 화합물.The compound of claim 1, wherein Z is 0 and A is a C 6 -C 14 bi- or tricyclic ring system containing 0-3 heteroatoms and 0-2 unsaturated. Unsubstituted or halogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, nitro, C 6 or C 10 aroyl, C 6 or C 10 aryloxy, heteroaryloxy, C 1 -C 6 alkylthio, C 6 or C 10 arylthio, heteroarylthio, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 8 acyloxy, C 6 or C 10 aryl, hetero Aryl, C 1 -C 6 acyl, carbo C 6 or C 10 aryloxy, carboheteroaryloxy, C 1 -C 6 carboalkoxy or unsubstituted or 1 or 2 A compound substituted with amido substituted with a C 1 -C 6 alkyl group, wherein the heteroaryl portion of the substituent is a 5 or 6 membered aromatic ring having one or more heteroatoms. 제 1항에 있어서, Z는 0이며,The compound of claim 1, wherein Z is 0, A는
Figure 112006089133699-pct00201
(여기서 *=부착점이다)임을 특징으로 하는 화합물.
A is
Figure 112006089133699-pct00201
Wherein * is the point of attachment.
단, 여기서 Q1, Q2는 O 또는 S이며;Provided that Q 1 and Q 2 are O or S; W는 0, CH2, CHR6 또는 본드이며, W is 0, CH 2 , CHR 6 or bond, R1은 C1-C8알킬, C2-C8알케닐, C2-C8알키닐, C3-C8시클로알킬, C6 혹은 C10 아릴, 또는 하나 또는 그 이상의 헤테로 원자를 갖는 5 혹은 6원자 방향족 고리인 헤테로아릴이며;R 1 has C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 6 or C 10 aryl, or one or more hetero atoms Heteroaryl which is a 5 or 6 membered aromatic ring; R2는 H, C1-C3알킬, C2-C5알케닐 또는 C2-C5알키닐이며;R 2 is H, C 1 -C 3 alkyl, C 2 -C 5 alkenyl or C 2 -C 5 alkynyl; R3는 H, R1, OR1, OC(O)R1, OC(O)OR1 또는 CO(O)NR1R6이며;R 3 is H, R 1 , OR 1 , OC (O) R 1 , OC (O) OR 1 or CO (O) NR 1 R 6 ; R4와 R5는 독립적으로 H, C1-C6알킬, 또는 C2-C5알케닐이나, R4와 R5의 탄소수의 합은 6이하이며, 또한 R4와 R5는 합하여져 C3-C6고리를 형성할 수 있으며,R 4 and R 5 are independently H, C 1 -C 6 alkyl, or C 2 -C 5 alkenyl, but the sum of the carbon number of R 4 and R 5 is 6 or less, and R 4 and R 5 are combined Can form a C 3 -C 6 ring, R6와 R7은 독립적으로 H, C1-C6알킬, 또는 C3-C6시클로알킬, C2-C5알케닐 또는 C2-C5알키닐이나, R6 와R7중 최소 하나는 H이다. R 6 and R 7 are independently H, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl, C 2 -C 5 alkenyl or C 2 -C 5 alkynyl, but at least of R 6 and R 7 One is H.
청구항 1 및 청구항 35항 내지 41항중 어느 한항의 화합물과 식물학적으로 수용가능한 케리어를 포함하는 살균조성물A bactericidal composition comprising the compound of any one of claims 1 and 35 to 41 and a botanically acceptable carrier. 제 42항에 있어서, 살충제, 살균제, 제초제, 선충구제제, 진드기 박멸제, 절지동물 박멸제, 박테리아 살균제 및 이들의 조합으로 구성되는 그룹에서 선택된 최소 하나의 다른 화합물을 추가로 포함함을 특징으로하는 조성물.43. The method of claim 42, further comprising at least one other compound selected from the group consisting of insecticides, fungicides, herbicides, nematode agents, mite killers, arthropod killers, bacterial fungicides, and combinations thereof. Composition. 살균적으로 유효량의 청구항 1 및 청구항 35항 내지 41항중 어느 한항의 화합물을 균 서식지 또는 감염이 제어되거나 방지될 장소에 적용함을 포함하는 균감염 제어 또는 방지방법.A method of controlling or preventing fungal infection comprising applying a bactericidal effective amount of the compound of any one of claims 1 and 35 to 41 to a bacterial habitat or to a place where the infection is to be controlled or prevented. 청구항 1 및 청구항 35항 내지 41항중 어느 한항의 화합물의 수화물, 염 또는 복합물을 포함하여 구성되는 조성물.42. A composition comprising a hydrate, salt or complex of a compound of any one of claims 1 and 35-41.
KR1020027000678A 1999-08-20 2000-08-04 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation KR100720766B1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14997799P 1999-08-20 1999-08-20
US60/149,977 1999-08-20
US15024899P 1999-08-23 1999-08-23
US60/150,248 1999-08-23
US09/620,662 2000-07-20
US09/620,662 US6521622B1 (en) 1999-07-20 2000-07-20 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation

Publications (2)

Publication Number Publication Date
KR20020040754A KR20020040754A (en) 2002-05-30
KR100720766B1 true KR100720766B1 (en) 2007-05-22

Family

ID=69407330

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027000678A KR100720766B1 (en) 1999-08-20 2000-08-04 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation

Country Status (1)

Country Link
KR (1) KR100720766B1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037472A2 (en) * 1995-05-24 1996-11-28 Novartis Ag Pyridine-microbicides
WO1999040081A1 (en) * 1998-02-06 1999-08-12 Meiji Seika Kaisha, Ltd. Novel antifungal compounds and process for producing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037472A2 (en) * 1995-05-24 1996-11-28 Novartis Ag Pyridine-microbicides
WO1999040081A1 (en) * 1998-02-06 1999-08-12 Meiji Seika Kaisha, Ltd. Novel antifungal compounds and process for producing the same

Also Published As

Publication number Publication date
KR20020040754A (en) 2002-05-30

Similar Documents

Publication Publication Date Title
KR100743262B1 (en) Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
US6706740B2 (en) Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
EP1204643B1 (en) Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
USRE39991E1 (en) Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
EP1516874B1 (en) Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
EP2755960B1 (en) Plant growth regulating compounds
KR100720766B1 (en) Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
EP1486489B1 (en) Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
UA75338C2 (en) Heterocyclic aromatic amides, fungicide composition and a method for control and prevention of invasion

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130419

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20140422

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee